# Patent

## Title
Drug composition antagonistic to both PGD2/TXA2 receptors

## Abstract

A compound of the formula (I):




wherein A is alkylene optionally having an unsaturated bond; R is —C(═O)—R1; R1 is hydroxy or the like; m is 0 or 1; p is 0 or 1; X1 and X3 are each independently optionally substituted aryl or optionally substituted heteroaryl or the like; X2 is a bond, —CH2—, —S—, —SO2—, —CH2—O—, —O—CH2—, —CH2—S—, —S—CH2—, or the like; X4 is —CH2—, —CH2—CH2—, —C(═O)—, or the like, having a dual antagonistic activity against both a thromboxane A2 receptor and a prostaglandin D2 receptor is found.

## Background
This application is a U.S. national stage of International Application No. PCT/JP01/04430 filed May 28, 2001.
TECHNICAL FIELD
This invention relates to a pharmaceutical composition comprising a dual antagonist against thromboxane A2 and prostagrandin D2 receptors and in detail, a compound having a [2.2.1] or [3.1.1.] bicyclo skeleton.
BACKGROUND ART
As a pharmaceutical composition comprising a dual antagonist against PGD2/TXA2 receptors, a compound of the formula:




wherein RX is optionally substituted single ring or fused heterocyclyl; X is hydrogen or alkyl, was described in WO 99/15502. The above mentioned compound has a substituent of the formula: —CH2—CH═CH—CH2—CH2—CH2—COOX wherein X is hydrogen or alkyl, as an α chain and R on an ω chain is a single or fused heterocycl optionally substituted with amino, halogen, hydroxy and the like.

Further, the other compounds having a [2.2.1] bicyclo skeleton similar to the compounds of the present invention have been described in WO97/00853 and the like. In this publication, it is described that the compounds are useful as prostagrandin D2 (PGD2) antagonists.
However, in these publications, almost none of compound having other substituents than those represented by the formula:




wherein X1 and X3 are each independently optionally substituted aryl, optionally substituted heteroaryl or optionally substituted non-aromatic heterocyclyl; X2 is a bond, —CH2—, —S—, —SO2— and the like; X4 is —CH2— and the like; m is 0 or 1; p is 0 or 1 as the ω chain, and furthermore, the formula: —CH2—CH═CH—CH2—CH2—CH2—COOR2 wherein R2 is hydrogen or alkyl, as the α chain of bicyclic ring, has been described.

PGD2 receptor antagonists have a quite different character from that of TXA2 receptor antagonists in the site and mechanism of action and indications thereof.
On the other hand, a compound having a dual antagonistic activity against both a TXA2 receptor and a PGD2 receptor can be useful as therapeutic agents for various diseases caused by TXA2 or PGD2.
For example, in the case of bronchial asthma, it is known that TXA2 cause potent tracheal contraction and respiratory anaphylaxis and PGD2 effects infiltration of eosionophils. From these comprehension, TXA2 and PGD2 are thought to be one of causative substances of the pathopoiesis and advance of asthma, thus the dual antagonistic compounds are expected to be more potent agents for treating asthma than ever known antagonists.
Further, in the case of allergic rhinitis, it is recognized that TXA2 and PGD2 cause the swelling of nasal mucosa through the aggravation of vascular permeability, and PGD2 induces the nasal blockage through the enlargement of vascular volume. Therefore, the dual antagonistic compounds are expected to be more potent agents for treating nasal blockage than ever known antagonists.
These diseases and condition thereof might be treated by administering both a TXA2 receptor antagonist and a PGD2 receptor antagonist at the same time, for example, in combination therapy or as a mixture thereof. But the administration of two or more agents often causes some problems due to the difference of their metabolic rate. For example, when the antagonists are different from each other in the time to reach a maximum blood concentration or the duration of action, they do not always efficiently exhibit each receptor antagonistic effect at the same time, failing to give a desired additive or synergic effect.
It has therefore been desired to develop medicines having a dual antagonistic activity against TXA2/PGD2 receptors, which exhibit new excellent therapeutic effects and can be used for many indications.
On the other hand, it was disclosed that 3-oxa-derivatives were prepared as metabolically stable TXA2/PGH2 receptor antagonists in Bioorganic & Medicinal Chemistry Letters, Vol.2, No.9, pp. 1069–1072, 1992. The active value of the compound was only described but the metabolic stability has not been described in the literature.




wherein, Z is p-fluorophenyl; Rω is benzenesulfonamino and the like.

Furthermore, it was reported in PROSTAGLANDINS, 1986, 31, 95 that ILOPROST, PGI2 mimetics was stabilized metabolically by converting to the 3-oxa-derivative. But, remaining activity of each compound was only compared under a presence of the metabolic enzyme of a rat and the metabolic stability did not mentioned, since there was a possibility of a production of active metabolites
DISCLOSURE OF INVENTION
The present inventors have studied intensively to develop a pharmaceutical composition having a dual antagonistic activity against TXA2/PGD2 receptors and found out new compounds and pharmaceutical compositions comprising them.
The present invention provides:

    (1) a compound of the formula (I):






wherein





    
    
        A is alkylene optionally intervened with a heteroatom, optionally having an oxo group, optionally substituted with halogen and/or optionally having an unsaturated bond;
        R is —C(═O)—R1, —CH2—R1, or tetrazolyl;
        R1 is hydroxy, alkyloxy, or optionally substituted amino;
        m is 0 or 1;
        provided that combinations wherein m is 1, A is —CH═CH—CH2—CH2—CH2— and R is —C(═O)—R1 (R1 is hydroxy or alkyloxy) and wherein A is —CH2—CH═CH—CH2—CH2—CH2— and R is —C(═O)—R1 wherein R1 is hydroxy or alkyloxy are excluded, p is 0 or 1, provided when p=0, X1 is not bonded to X3 via X4;
        X1 and X3 are each independently optionally substituted aryl, optionally substituted heteroaryl or optionally substituted non-aromatic heterocyclyl;
        X2 is a bond, —CH2—, —CH2—CH2—, —C(═O)—, —O—, —S—, —SO—, —SO2—, —NH—, —N(CH3)—, —C(═N—O—CH3)—, —N═N—, —CH═CH—, —(C═O)—NH—, —NH—(C═O)—, —CH2—NH—, —NH—CH2—, —CH2—O—, —O—CH2—, —CH2—, —S—CH2—, —CH2—SO2—, —SO2—CH2—, —SO2—NH—, —NH—SO2—, —C(═CH2)—, —SO2N(Me)—, —CH2NHSO2—, —CH2NH—(C═O)—, —NH—C(═O)—NH or —NH—C(═O)—N(Me)—;
        X4 is —CH2—, —CH2—CH2—, —C(═O)—, —SO—, —SO2—, —(C═O)—NH—, —NH—(C═O)—, —CH2—NH—, —NH—CH2—, —CH2—O—, —O—CH2—, —CH2—S—, —S—CH2—, —CH2—SO2—, —SO2—CH2—, —SO2—NH— or —NH—SO2—,

provided that a combination wherein

    
    






    
    
        A is —CH═CH—CH2—CH2—CH2—, R is —COOH, m is 1, p is 0, X1 and X3 are phenyl, and X2 is —N═N—, is excluded

and provided that when

    
    






    
    
        X1 and X3 are phenyl, X2 is —CH═CH—, —O—, or —S—, m is 0, and p is 0, a compound wherein A is —CH═CH—CH2—CH2—CH2—C(CH3)2— and R is COOH, A is —CH2—C(═O)—CH2—CH2—CH2—CH2— and R is COOH, A is —CH2—CH2—CH2—CH2—CH2— and R is —COOH, or A is —CH═CH—CH2—CH2—CH2— and R is —CH2OH,

is excluded,

a prodrug, a pharmaceutically acceptable salt or a solvate thereof,

    
    
    (2) A compound as described in (1) wherein A is alkylene optionally intervened with a heteroatom, optionally having an oxo group, optionally substituted with halogen and/or optionally having a unsaturated bond;
    
        R is —C(═O)—R1, —CH2—R1, or tetrazolyl;
        R1 is hydroxy, alkyloxy, or optionally substituted amino;
        provided compounds wherein A is —CH═CH—CH2—CH2—CH2— and R is —C(═O)—R1 (R1 is hydroxy or alkyloxy), or A is —CH2—CH═CH—CH2—CH2—CH2— and R is —C(═O)—R1 wherein R1 is hydroxy or alkyloxy are excluded,

a prodrug, a pharmaceutically acceptable salt or a solvate thereof,

    
    
    (3) A compound as described in (1) or (2), wherein A is alkylene intervened with a heteroatom, optionally having an oxo group, optionally substituted with halogen and/or optionally having an unsaturated bond,

a prodrug, a pharmaceutically acceptable salt, or a solvate thereof,

    (4) A compound as described in (1) or (2), wherein A is C1 to C4 or C7 to C9 alkylene optionally intervened with a heteroatom, optionally having an oxo group, optionally substituted with halogen and/or optionally having an unsaturated bond, a prodrug, a pharmaceutically acceptable salt, or a solvate thereof,
    (5) A compound as described in (1) or (2), wherein A is —CH2—CH2—CH2—, —CH2—CH2—CH(F)—, —CH2CH═CH—, —CH2—O—CH2—, —CH2CH═C(F)—, —CH2—CH2—CH2—CH2—, —CH2CH═CH—CH2—, —CH2—CH2—CH═CH—, —CH═CH—CH2—CH2—, —CH2—CH2—O—CH2—, —CH2—CH2—S—CH2—, —CH2—CO—NH—CH2—, —CH2—CH2—CH2—CH2—CH2—, —CH2CH═CH—CH2—CH2—, —CH213 CH2—CH2—CH═CH—, —CH2—CH2—CH2—O—CH2—, —CH2—CH2—CH2—S—CH2—, —CH2—CH2—CO—NH—CH2—, —CH2—CH2—CH2—CH2—CH2—CH2—, —CH2—CH2—CH2—CH2—CH2—CH(Me)—, —CH2—CH2—CH2—CH2—CH2—C(Me)2—, —CH2—CH2—CH2—CH2—CH2—CH(F)—, —CH2—CH═CH—CH2—CH2—CH(Me)—, —CH2—CH═CH—CH2—CH2—C(Me)2—, —CH2—CH═CH—CH2—CH2—CH(F)—, —CH2—CH2—CH2—CH2—CH═CH—, —CH2—CH2—CH2—CH2—CH═C(Me)—, —CH2—CH2—CH2—CH2—C(Me)═CH—, —CH2—CH2—CH2—CH2—CH═C(F)—, —CH2—CH2—CH2—CH2—O—CH2—, —CH2—CH═CH—CH2—O—CH2—, —CH2—CH═CH—CH2—S—CH2—, —CH2—CH═C(F)—CH2—O—CH2—, —CH2—CH2—O—CH2—CH═CH—, —CH2—CH2—CH2—CH2—S—CH2—, —CH2—CH2—CH2—CO—NH—CH2—, —CH2—CH2CH═N—O—CH2—, —CH2—CH2—S—CH2—CH2—CH2—, —CH2—CH2—CH2—CH2—CH2—CH2—CH2—, —CH2—CH═CH—CH2—CH2—CH2—CH2—, —CH2—CH2—CH2—CH2—CH2—O—CH2—, —CH2—CH2—CH2—CH2—CH2—CH2—CH2—, or —CH2—CH═CH—CH2—CH2—CH2—CH2—CH2—,

a prodrug, a pharmaceutically acceptable salt, or a solvate thereof,

    (6) A compound as described in (5), wherein A is —CH2—CH2—CH2—CH2—, —CH2—CH2—CH2—CH2—CH═CH—, —CH2—CH2—CH2—CH2—O—CH2—, —CH2—CH═CH—CH2—O—CH2—, —CH2—CH═CH—CH2—S—CH2—, or —CH2—CH2—CH2—CH2—S—CH2—,

a prodrug, a pharmaceutically acceptable salt, or a solvate thereof,

    (7) A compound as described in (6), wherein A is —CH2—CH2—CH2—CH2—O—CH2—,

a prodrug, a pharmaceutically acceptable salt, or a solvate thereof,

    (8) A compound as described in any one of (1) to (7), wherein X1 and X3 are each independently optionally substituted aryl or optionally substituted heteroaryl,

a prodrug, a pharmaceutically acceptable salt, or a solvate thereof,

    (9) A compound as described in (8), wherein at least one of X1 and X3 is optionally substituted heteroaryl,

a prodrug, a pharmaceutically acceptable salt, or a solvate thereof,

    (10) A compound as described in (9), wherein X1 and X3 are each independently optionally substituted heteroaryl,

a prodrug, a pharmaceutically acceptable salt, or a solvate thereof,

    (11) A compound as described in (9), wherein at least one of X1 and X3 is optionally substituted thienyl or optionally substituted benzothienyl,

a prodrug, a pharmaceutically acceptable salt, or a solvate thereof,

    (12) A compound as described in any one of (1) to (11), wherein X2 is a bond, —CH2—, —S—, —SO2—, —CH2—O—, —O—CH2—, —CH2—S—, —S—CH2—, or —NH—C(═O)—NH—,

a prodrug, a pharmaceutically acceptable salt, or a solvate thereof,

    (13) A compound as described in any one of (1) to (12), wherein m is 0 and p is 0,

a prodrug, a pharmaceutically acceptable salt, or a solvate thereof,

    (14) A compound as described in any one of (1) to (13), wherein R is —C(═O)—R1 and R1 is hydroxy, alkyloxy, or optionally substituted amino,

a prodrug, a pharmaceutically acceptable salt, or a solvate thereof,

    (15) A pharmaceutical composition containing a compound, a prodrug, a pharmaceutically acceptable salt, or a solvate thereof as described in any one of above (1) to (14),
    (16) A pharmaceutical composition having a dual antagonistic activity against PGD2/TXA2 receptors as described in the above (15),
    (17) A pharmaceutical composition as described in the above (15), which is used for treatment of asthma,
    (18) A pharmaceutical composition as described in the above (15), which is used for the treatment of nasal blockage,
    (19) A pharmaceutical composition as described in the above (15), which is used for the treatment of allergic conjunctivitis,
    (20) A pharmaceutical composition as described in the above (15), which is used for the treatment of allergic rhinitis,
    (21) Use of the compound as described in any one of (1) to (14) for the preparation of a pharmaceutical composition for treating asthma, nasal blockage, allergic conjunctivitis or allergic rhinitis,
    (22) A method for treating nasal blockage, allergic conjunctivitis or allergic rhinitis, which comprises administrating a compound as described in any one of (1) to (14),
    (23) A compound of formula: X3—X2—X1—COOH wherein X3 is pyrrolyl optionally substituted with alkyl, alkyloxy or halogen, indolyl optionally substituted with alkyl, alkyloxy or halogen, indolinyl optionally substituted with alkyl, alkyloxy or halogen, or 1,2,3,4-tetrahydroquinolyl optionally substituted with alkyl, alkyloxy or halogen; X2 is —SO2—, —S— or —CH2—; X1 is thienyl, or a salt thereof,
    (24) A compound as described in (23), wherein a substituent of the formula: —X1—X2—X3 is 5-(1-pyrrolylsulfonyl)thiophen-2-yl, 5-[(2-methyl-1-pyrrolyl)sulfonyl]thiophen-2-yl, or 5-[(2,5-dimethyl-1-pyrrolyl)sulfonyl]thiophen-2-yl, or a salt thereof.


BEST MODE FOR CARRYING OUT THE INVENTION
Special feature of a compound in the present invention is

    
    
        (A) a bicyclic ring represented by the Y ring of the above formula (I) is [2.2.1] or [3.1.1] skeleton,
        (B) an ω chain attached to the bicyclic ring, a group represented by the formula:
    
    






    
    
         of the above formula (I), includes —NH—CO—, and X1 and X3 are each independently optionally substituted aryl, optionally substituted heteroaryl or optionally substituted non-aromatic heterocyclyl;
        (C) X1 bonds to X3 via X2,
        (D) an α chain is represented by the formula: —A—R, wherein A is alkylene optionally intervened with a heteroatom, optionally having an oxo group, optionally substituted with halogen and/or optionally having an unsaturated bond; R is —C(═O)—R1, —CH2—R1, or tetrazolyl; R1 is hydroxy, alkyloxy, or optionally substituted amino, and the like.
    
    


Provided that a compound wherein A is —CH2—CH═CH—CH2—CH2—CH2— and R is —C(═O)—R1 (R1 is hydroxy or alkyloxy), is not included in the present invention, since the compound is metabolically unstable coused by oxidizaton of an α-chain at β-position.
Therefore, a compound of the present invention has a special feature at A and R and has an improved metabolic property. Further, a compound of the present invention is a dual antagonistic activity against PGD2/TXA2 receptors having the above mentioned features (A) to (D).
A preferred embodiment is a compound of the formula (I) wherein

    
    
        (1) X1 and X3 are each independently optionally substituted aryl or optionally substituted heteroaryl,
        (2) at least one of X1 and X3 is optionally substituted heteroaryl,
        (3) X1 and X3 are each independently optionally substituted heteroaryl,
        (4) at least one of X1 and X3 is optionally substituted thienyl or optionally substituted benzothienyl,
        (5) X2 is a bond, —CH2—, —S—, —SO2—, —CH2—O—, —O—CH2—, —CH2—S—, —S—CH2— or —NH—C(═O)—NH—,
        (6) m is 0 and p is 0,
        (7) R is —C(═O)—R1, wherein R1 is hydroxy, alkyloxy or optionally substituted amino,
        (8) in a case of a combination of any one of (1) to (4) with (5),
        (9) in a case of a combination of any one of (1) to (4) with (6),
        (10) in a case of a combination of any one of (1) to (4) with (7).
    
    


Each term used herein is defined to have meanings below in either case of a single or a joint use with other terms, unless otherwise noted.
“Alkylene” used herein means a straight chain and branched chain C1 to C9 and refers to methylene, methylmethylene, dimethylmethylene, ethylmethylmethylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, heptamethylene, octamethylene, nonamethylene, and the like. The above mentioned alkylene optionally contains a hetero atom (oxygen atom, sulfur, nitrogen atom or the like), optionally has an oxo group (═O), is optionally substituted with halogen (e.g. F, Cl, Br, I, preferable is F) and/or optionally contains one or more unsaturated bond (double bond or triple bond) on the chain at any position. Examples are —CH2—CH2—CH2—, —CH2—CH2—CH(F)—, —CH2—CH═CH—, —CH2—O—CH2—, —CH2—CH═C(F)—, —CH2—CH2—CH2—CH2—, —CH2—CH═CH—CH2—, —CH2—CH2—CH═CH—, —CH═CH—CH2—CH2—, —CH2—CH2—O2—CH2—, —CH2—CH2—S—CH2—, —CH2—CO—NH—CH2—, —CH2—CH2—CH2—CH2—CH2—, —CH2—CH═CH—CH2—CH2—, —CH2—CH2—CH2—CH═CH—, —CH═CH—CH2—CH2—CH2—, —CH2—CH2—CH2—O—CH2—, —CH2—CH2—CH2—S—CH2—, —CH2—CH2—CO—NH—CH2—, —CH2—CH2—CH2—CH2—CH2—CH2—, —CH2—CH2—CH2—CH2—CH2—CH(Me)—, —CH2—CH2—CH2—CH2—CH2—C(Me)2—, —CH2—CH2—CH2—CH2—CH2—CH(F)—, —CH2—CH═CH—CH2—CH2—CH2—, —CH2—CH═CH—CH2—CH2—CH(Me)—, —CH2—CH═CH—CH2—CH2—C(Me)2—, —CH2—CH═CH—CH2—CH2—CH(F)—, —CH2—CH2—CH2—CH2—CH═CH—, —CH2—CH2—CH2—CH2—CH═C(Me)—, —CH2—CH2—CH2—CH2—C(Me)═CH—, —CH2—CH2—CH2—CH2—CH═C(F)—, —CH2—CH2—CH2—CH2—O—CH2—, —CH2—CH═CH—CH2—O—CH2—, —CH2—CH═CH—CH2—S—CH2—, —CH2—CH═C(F)—CH2—O—CH2—, —CH2—CH2—O—CH2—CH═CH—, —CH2—CH2—CH2—CH2—S—CH2—, —CH2—CH2—CH2—CO—NH—CH2—, —CH2—CH2—CH═N—O—CH2—, —CH2—CH2—S—CH2—CH2—CH2—, —CH2—CH2—CH2—CH2—CH2—CH2—CH2—, —CH2—CH═CH—CH2—CH2—CH2—CH2—, —CH2—CH2—CH2—CH2—CH2—O—CH2—, —CH2—CH2—CH2—CH2—CH2—CH2—CH2—CH2—, —CH2—CH═CH—CH2—CH2—CH2—CH2—, —CH2—CH2—O—CH2—CH2—CH2—, —CH2—CH═CH—CH2—CH═CH2—, and the like.
Especially, the following embodiment is preferred for the above mentioned “alkylene”:

    
    
        1) alkylene intervened with a heteroatom, optionally having an oxo group, optionally substituted halogen and/or optionally containing unsaturated bond(s),
        2) C1 to C4 or C7 to C9 alkylene optionally intervened with a heteroatom, optionally having an oxo group, optionally substituted halogen and/or optionally containing unsaturated bond(s),
        3) —CH2—CH2—CH2—, —CH2—CH2—CH(F)—, —CH2—CH═CH—, —CH2—O—CH2—, —CH2—CH2—CH(F)—, —CH2—CH2—CH2—CH2—, —CH2—CH═CH—CH2—, —CH2—CH2—CH═CH—, —CH═CH—CH2—CH2—, —CH2—CH2—O2—CH2—, —CH2—CH2—S—CH2—, —CH2—CO—NH—CH2—, —CH2—CH2—CH2—CH2—CH2—, —CH2—CH═CH—CH2—CH2—, —CH2—CH2—CH2—CH═CH—, —CH2—CH2—CH2—O—CH2—, —CH2—CH2—CH2—S—CH2—, —CH2—CH2—CO—NH—CH2—, —CH2—CH2—CH2—CH2—CH2—CH2—, —CH2—CH2—CH2—CH2—CH2—CH(Me)—, —CH2—CH2—CH2—CH2—CH2—C(Me)2—, —CH2—CH2—CH2—CH2—CH2—CH(F)—, —CH2—CH═CH—CH2—CH2—CH(Me)—, —CH2—CH═CH—CH2—CH2—C(Me)2—, —CH2—CH═CH—CH2—CH2—CH(F)—, —CH2—CH2—CH2—CH2—CH═CH—, —CH2—CH2—CH2—CH2—CH═C(Me)—, —CH2—CH2—CH2—CH2—C(Me)═CH—, —CH2—CH2—CH2—CH2—CH═C(F)—, —CH2—CH2—CH2—CH2—O—CH2—, —CH2—CH═CH—CH2—O—CH2—, —CH2—CH═CH—CH2—S—CH2—, —CH2—CH═C(F)—CH2—O—CH2—, —CH2—CH2—O—CH2—CH═CH—, —CH2—CH2—CH2—CH2—S—CH2—, —CH2—CH2—CH2—CO—NH—CH2—, —CH2—CH2—CH═N—O—CH2—, —CH2—CH2—S—CH2—CH2—CH2—, —CH2—CH2—CH2—CH2—CH2—CH2—CH2—, —CH2—CH═CH—CH2—CH2—CH2—CH2—, —CH2—CH2—CH2—CH2—CH2—O—CH2—, —CH2—CH2—CH2—CH2—CH2—CH2—CH2—CH2—, or —CH2CH═CH—CH2—CH2—CH2—CH2—CH2—,
        4) —CH2—CH2—CH2—CH2—, —CH2—CH2—CH2—CH2—CH═CH—, —CH2—CH2—CH2—CH2—O—CH2—, —CH2—CH═CH—CH2—O—CH2—, —CH2—CH═CH—CH2—O—CH2—, or —CH2—CH2—CH2—CH2—S—CH2—, and
        5) —CH2—CH2—CH2—CH2—O—CH2—.
    
    


The term “heteroaryl” includes a group which has a bond at any substitutable and which can be converted from a 5- to 7-membered aromatic heterocycle containing one or more oxygen atom, sulfur atom and/or nitrogen atom in the ring, or such an aromatic heterocycle as fused with one or more carbocycle or other aromatic heterocycle. Any one of aromatic heterocycle and aromatic carbocycle may have a bond. “Heteroaryl” may have a bond at a nitrogen atom as well as a carbon atom of aromatic heterocycle or aromatic carbocycle. Examples of “heteroaryl” include pyrrolyl (e.g., 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl), pyridyl (e.g., 2-pyridyl, 3-pyridyl, 4-pyridyl), pyrazolyl (e.g., 1-pyrazolyl, 3-pyrazolyl, 4-pyrazolyl), imidazolyl (e.g., 1-imidazolyl, 2-imidazolyl, 4-imidazolyl), pyrimidinyl (e.g., 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl), pyrazinyl (e.g., 2-pyrazinyl), indolyl (e.g., 1-indolyl, 2-indolyl, 3-indolyl, 4-indolyl, 5-indolyl, 6-indolyl, 7-indolyl), carbazolyl (e.g., 1-carbazolyl, 2-carbazolyl, 3-carbazolyl, 4-carbazolyl, 9-carbazolyl), benzimidazolyl (e.g., 1-benzimidazolyl, 2-benzimidazolyl, 4-benzimidazolyl, 5-benzimidazolyl), indazolyl (e.g., 1-indazolyl, 2-indazolyl, 3-indazolyl, 4-indazolyl, 5-indazolyl, 6-indazolyl, 7-indazolyl), quinolyl (e.g., 2-quinolyl, 3-quinolyl, 4-quinolyl, 5-quinolyl, 6-quinolyl, 7-quinolyl, 8-quinolyl), isoquinolyl (e.g., 1-isoquinolyl, 3-isoquinolyl, 4-isoquinolyl, 5-isoquinolyl, 6-isoquinolyl, 7-isoquinolyl, 8-isoquinolyl), furyl (e.g., 2-furyl, 3-furyl), benzofuryl (e.g., 2-benzofuryl, 3-benzofuryl, 4-benzofuryl, 5-benzofuryl, 6-benzofuryl, 7-benzofuryl), thienyl (e.g., 2-thienyl, 3-thienyl), benzothienyl (e.g., benzo[b]thiophen-2-yl, benzo[b]thiophen-3-yl, benzo[b]thiophen-4-yl, benzo[b]thiophen-5-yl, benzo[b]thiophen-6-yl, benzo[b]thiophen-7-yl), dibenzothienyl (e.g., 2-dibenzothienyl, 3-dibenzothienyl), dibenzofuryl (e.g., 2-dibenzofuryl, 3-dibenzofuryl), naphthothienyl (e.g., naphtho[2,3-b]thiophen-2-yl, naphtho[2,3-b]thiophen-3-yl, naphtho[1.2-b]thiophen-2-yl, naphtho[1.2-b]thiophen-3-yl), oxazolyl (e.g., 2-oxazolyl, 4-oxazolyl, 5-oxazolyl), isoxazolyl (e.g., 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl), thiazolyl (e.g., 2-thiazolyl, 4-thiazolyl, 5-thiazolyl), isothiazolyl (e.g., 3-isothiazolyl, 4-isothiazolyl, 5-isothiazolyl), imidazothiazolyl (e.g., imidazo[2.1-b]thiazol-2-yl, imidazo[2.1-b]thiazol-3-yl), benzoisoxazolyl (e.g., benzo[d]isoxazol-3-yl), benzothiazolyl (e.g., benzo[d]thiazol-2-yl), and the like.
The term of “aromatic carbocycle or other aromatic heterocycle” which may fuse the above “heteroaryl” includes 5- to 7-membered aromatic cycle which may contains one or more oxygen atom, sulfur atom and/or nitrogen atom in the ring, or such an aromatic ring as fused with one or more other aromatic rings.
The term of “aryl” includes mono aromatic carbocyclyl (e.g., phenyl) or fused aromatic carbocyclyl (e.g., 1-naphthyl, 2-naphthyl, 1-anthryl, 9-anthryl, 1-phenanthryl, 10-phenanthryl).
The term of “non-aromatic heterocyclyl” includes a group which has a bond at any substitutable and which can be converted from 3- to 7-membered non-aromatic heterocyclyl which contains one or more oxygen atom, sulfur atom and/or nitrogen atom in the ring, or non-aromatic heterocyclyl which is fused with a carbon ring (e.g. aromatic carbocycle) or other heterocyclyl (e.g. aromatic heterocycle). The substitutable bond may exist not only on the carbon atom but also on the nitrogen atom in the non-aromatic heterocyclyl. Examples are aziridinyl, piperidino, piperidinyl, morphorino, morphorinyl, pyrrolinyl, pyrrolidinyl, imidazolinyl, piperadino, piperadinyl, isooxazolinyl, thiolanyl, tetrahydrofuranyl, dioxanyl, oxathianyl, tetrahydropyranyl, and the like. Preferable is 5- or 6-membered non-aromatic heterocyclyl containing a nitrogen atom. The following groups are exexplified as a group which has a bond at any substitutable and which can be converted from non-aromatic heterocyclyl fused with one or more carbon ring (e.g. aromatic carbocycle) or other heterocyclyl (e.g. aromatic heterocycle):




Furthermore, the substitutable bond may exist at any position of the carbon atom or the nitrogen atom.

“Aryl” or “heteroaryl” may be fused 4- to 7-membered cycloalkane or 4- to 7-membered non-aromatic heterocycle. Examples of cycloalkane include cyclobutane, cyclopentane, cyclohexane, and cycloheptane. Examples of non-aromatic heterocycle include pyrrolidine, piperazine, oxorane, 1,3-dioxorane, 1,4-dioxane, thiorane, or the like. The above “cycloalkane” and “non-aromatic heterocycle” may be fused with other aromatic carbocycle or aromatic heterocycle. Examples of aryl or heteroaryl fused with 4- to 7-membered cycloalkane or 4- to 7-membered non-aromatic heterocycle are illustrated below.




Examples of the substituent on “optionally substituted aryl”, “optionally substituted heteroaryl” or “optionally substituted non-aromatic heterocyclyl” include a group of the formula: —Z1—Z2 wherein Z1 is a bond, —O—, —S—, —NH—, —NH—C(═O)—, —NH—C(═O)—O—, —NH—SO2—, —C(═O)—, —O—C(═O)—, —C(═O)—O—, or —SO2—; and Z2 is alkyl, haloalkyl, alkenyl, alkynyl, aryl optionally substituted with alkyl or halogen, heteroaryl optionally substituted with alkyl or halogen, arylalkyl optionally substituted with alkyl or halogen, heteroarylalkyl optionally substituted with alkyl or halogen, carboxy, halogen (F, Cl, Br, I), hydroxyalkyl, hydroxy, nitro, cyano, mercapto, thioformyl, thioacetyl, thiocarboxy, dithiocarboxy, thiocarbamoyl, sulfino, sulfo, sulfamoyl, sulfoamino, optionally substituted amino, optionally substituted aminoalkyl, hydroxyamino, carbamoyl, or hydorazino. One to three substituents may be at any suitable position on the above aryl, heteroaryl, or non-aromatic heterocyclyl.
“Alkyl” includes a straight or branched C1 to C8 alkyl group or a C3 to C8 cycloalkyl group. Examples are methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, n-hexyl, n-heptyl, n-octyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like.
“Haloalkyl” includes a straight or branched C1 to C8 alkyl or C3 to C8 cycloalkyl group substituted with one or more halogen, for example, chloromethyl, fluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 1,1-difluoroethyl, trichloromethyl, 2,2,2-trichloroethyl, 1,1-dichloroethyl or the like.
“Alkenyl” includes a straight or branched C2 to C8 alkenyl or C3 to C8 cycloalkenyl group having one or more double bond(s), for example, vinyl, 1-propenyl, 2-propenyl, isopropenyl, 2-cyclobuten-1-yl, 2-cyclopenten-1-yl, 3-cyclopenten-1-yl, 2-cyclohexen-1-yl or the like.
“Alkynyl” includes a straight or branched C2 to C8 alkynyl having one or more triple bond(s), for example, ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl or the like.
“Halogen” includes fluoro, chloro, bromo, and iodo.
“Alkyl” used in the term “arylalkyl” or “heteroarylalkyl” have the same meaning of the above “alkyl”, “aryl” used in the term “arylalkyl” have the same meaning of the above “aryl” and “heteroaryl” used in the term “heteroarylalkyl” have the same meaning of the above “heteroaryl”.
“Hydroxy alkyl” includes the above “alkyl” substituted with one or two hydroxy, for example, hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1,2-dihydroxyethyl, 1,2-dihydroxy-n-propyl or the like.
Examples of the substituent of “optionally substituted amino” or “optionally substituted amino alkyl” include the above “alkyl”, the above “arylalkyl”, the above “aryl”, the above “heteroaryl”, the above “heteroarylalkyl” hydroxy. Alkylsulfonyl, or the like. They may be mono- or di-substituted with these substituents. When the substituent is alkyl, alkyl may form a ring together with a nitrogen atom of an amino group.
Example of “optionally substituted amino” includes amino, N,N-dimethylamino, N-ethyl-N-methylamino, N,N-(diethylamino, pyrrolidino, piperidino, N-methyl-N-phenylamino, isopropylamino, diisopropylamino, hydroxyamino, alkylsulfonylamino (e.g., methanesulfonylamino, ethanesulfonylamino, etc.), arylsulfonyl (e.g., benzenesulfonylamino, toluenesulfonylamino, etc.), N-alkyl-N-alkylsulfonylamino (e.g., N-methyl-N-methanesulfonylamino, etc.), halogenated alkylsulfonylamino (e.g., trifluoromethanesulfonylamino, etc.), or the like.
Examples of “optionally substituted aminoalkyl” include N,N-dimethylaminomethyl, N-ethyl-N-methylaminomethyl, N,N-diethylaminomethyl, pyrrolidinomethyl, piperidinomethyl, N-methyl-N-phenylaminomethyl, isopropylaminomethyl, diisopropylaminomethyl or the like.
“A pharmaceutical composition having a dual antagonistic activity against PGD2/TXA2 receptors” means a pharmaceutical composition comprising at least one compound of the formula (I) having an antagonistic activity against both a PGD2 receptor and a TXA2 receptor. In addition to a compound of the formula (I), the other active agents (e.g. antiinflammatory agents, antiallergy agents and the like) and pharmaceutically acceptable admixtures (e.g., binding agent, filler and the like) may be included.
The compound of the present invention has an antagonistic activity against PGD2 receptor and TXA2 receptor and can exhibit antagonistic activities against PGD2 receptor and TXA2 receptor in vivo. For example, even if a compound has both antagonistic activities against receptors in vitro, the compound administered can not always exhibit both of the antagonistic activity in vivo, owing to the preferential binding to the receptor of stronger affinity. Therefore, as a compound of the present invention, preferable is that the compound has antagonistic activities against PGD2 and TXA2 receptors and is 100 times, preferably 50 time and more preferably ca. 10 times in a ratio between affinities against PGD2 and TXA2 receptors. The ratio between affinities against PGD2 and TXA2 receptors can be calculated by the use of IC50 values and the like.
Furthermore, as a compound of the present invention, preferable is less than 0.1 μM in the binding activity against TXA2 receptor using human platelet membrane (IC50 value) and 0.1 μM in the antagonistic activity against PGD2 receptor using human platelet (IC50 value). In particular, the compound is preferable, in which both of the binding activity against TXA2 receptor using human platelet membrane (IC50 value) and the antagonistic activity against PGD2 receptor using human platelet (IC50 value) are less than 0.1 μM. Furthermore, the compound is preferable, in which their ratio is 100 times, preferably 50 time and more preferably ca. 10 times.
The present invention includes a method for treating asthma, nasal blockage, allergic conjunctivitis or allergic rhinitis which comprises administering a compound of the formula (I) and use of a compound of the formula (I) for manufacturing a medicine for asthma, nasal blockage allergic conjunctivitis or allergic rhinitis.
Furthermore, in a compound displayed in formula (I), “α chain” means a group represented by the formula: —A—R1, and “ω chain” means a group represented by the formula:




Preferable is following substituents as the α chain. Furthermore, E and Z mean E-form and Z-form in double bond of each formula, respectively. Each sign in 4A to 9B means an A part of the formula and means the same group in Table 1 to Table 15 in this description.













4A
—CH2CH2CH2—R


4B
—CH2CH2CH(F)—R


 


4C






 


4D






 


4E
—CH2OCH2—R


5A
—CH2CH2CH2CH2—R


 


5B






 


5C






 


5D






 


5E
—CH2CH2OCH2—R


5F
—CH2CH2SCH2—R


5G
—CH2CONHCH2—R


6A
—CH2CH2CH2CH2CH2—R


 


6B






 


6C






 


6D






 


6E
—CH2CH2CH2OCH2—R


6F
—CH2CH2CH2SCH2—R


6G
—CH2CH2CONHCH2—R


7A
—CH2CH2CH2CH2CH2CH2—R


7B
—CH2CH2CH2CH2CH2CH(Me)—R


7C
—CH2CH2CH2CH2CH2C(Me)2—R


7D
—CH2CH2CH2CH2CH2CH(F)—R


 


7E






 


7F






 


7G






 


7H






 


7I






 


7J






 


7K






 


7L






 


7M
—CH2CH2CH2CH2OCH2—R


 


7N






 


7O






 


7P






 


7Q






 


7R
—CH2CH2CH2CH2SCH2—R


7S
—CH2CH2CH2CONHCH2—R2


7T
—CH2CH2CH═N—OCH2—R2


7U
—CH2CH2SCH2CH2CH2—R2


 


7V






 


8A
—CH2CH2CH2CH2CH2CH2CH2—R2


 


8B






 


8C
—CH2CH2CH2CH2CH2OCH2—R2


9A
—CH2CH2CH2CH2CH2CH2CH2CH2—R2


 


9B













R is exemplified by —C(═O)—R1, —CH2—R1, or tetrazolyl and preferable is —C(═O)—R1, wherein, R1 is hydroxy, alkyloxy, or optionally substituted amino. Examples of R are COOH, COOMe, CONH2, CONHSO2Me, CH2OH, CH2OMe, CONHMe, CON(Me)SO2Me, 5-tetrazolyl, CONHSO2Ph, CONHSO2CF3 and the like.
Furthermore, the combination of A and R includes all of the combination and preferable is a combination described in Table 1 to Table 15.
As an ω chain, the following embodiments are preferred in the formula:




    
    
        1) wherein m is 0 and p is 0,
        2) wherein X1 and X3 are each independently optionally substituted aryl or optionally substituted heteroaryl,
        3) wherein at least one of X1 and X3 is optionally substituted heteroaryl,
        4) wherein X1 and X3 are each independently optionally substituted heteroaryl,
        5) wherein at least one of X1 and X3 is optionally substituted thienyl or optionally substituted benzothienyl,
        6) wherein X2 is a bond, —CH2—, —S—, —SO2—, —CH2—O—, —O—CH2—, —CH2—S—, —S—CH2—, or NH—C(═O)—NH—.
    
    


Concretely, preferable is a combination described below for the formula: —X1—X2—X3. Furthermore, each sign of 1 to 513 below means a group shown by the formula: —X1—X2—X3 and the compound number both in Table 1 to Table 15 and in Examples of reference in the present invention means the same group.













—X1—X2—X3

















1






 


2






 


3






 


4






 


5






 


6






 


7






 


8






 


9






 


10






 


11






 


12






 


13






 


14






 


15






 


16






 


17






 


18






 


19






 


20






 


21






 


22






 


23






 


24






 


25






 


26






 


27






 


28






 


29






 


30






 


31






 


32






 


33






 


34






 


35






 


36






 


37






 


38






 


39






 


40






 


41






 


42






 


43






 


44






 


45






 


46






 


47






 


48






 


49






 


50






 


51






 


52






 


53






 


54






 


55






 


56






 


57






 


58






 


59






 


60






 


61






 


62






 


63






 


64






 


65






 


66






 


67






 


68






 


69






 


70






 


71






 


72






 


73






 


74






 


75






 


76






 


77






 


78






 


79






 


80






 


81






 


82






 


83






 


84






 


85






 


86






 


87






 


88






 


89






 


90






 


91






 


92






 


93






 


94






 


95






 


96






 


97






 


98






 


99






 


100






 


101






 


102






 


103






 


104






 


105






 


106






 


107






 


108






 


109






 


110






 


111






 


112






 


113






 


114






 


115






 


116






 


117






 


118






 


119






 


120






 


121






 


122






 


123






 


124






 


125






 


126






 


127






 


128






 


129






 


130






 


131






 


132






 


133






 


134






 


135






 


136






 


137






 


138






 


139






 


140






 


141






 


142






 


143






 


144






 


145






 


146






 


147






 


148






 


149






 


150






 


151






 


152






 


153






 


154






 


155






 


156






 


157






 


158






 


159






 


160






 


161






 


162






 


163






 


164






 


165






 


166






 


167






 


168






 


169






 


170






 


171






 


172






 


173






 


174






 


175






 


176






 


177






 


178






 


179






 


180






 


181






 


182






 


183






 


184






 


185






 


186






 


187






 


188






 


189






 


190






 


191






 


192






 


193






 


194






 


195






 


196






 


197






 


198






 


199






 


200






 


201






 


202






 


203






 


204






 


205






 


206






 


207






 


208






 


209






 


210






 


211






 


212






 


213






 


214






 


215






 


216






 


217






 


218






 


219






 


220






 


221






 


222






 


223






 


224






 


225






 


226






 


227






 


228






 


229






 


230






 


231






 


232






 


233






 


234






 


235






 


236






 


237






 


238






 


239






 


240






 


241






 


242






 


243






 


244






 


245






 


246






 


247






 


248






 


249






 


250






 


251






 


252






 


253






 


254






 


255






 


256






 


257






 


258






 


259






 


260






 


261






 


262






 


263






 


264






 


265






 


266






 


267






 


268






 


269






 


270






 


271






 


272






 


273






 


274






 


275






 


276






 


277






 


278






 


279






 


280






 


281






 


282






 


283






 


284






 


285






 


286






 


287






 


288






 


289






 


290






 


291






 


292






 


293






 


294






 


295






 


296






 


297






 


298






 


299






 


300






 


301






 


302






 


303






 


304






 


305






 


306






 


307






 


308






 


309






 


310






 


311






 


312






 


313






 


314






 


315






 


316






 


317






 


318






 


319






 


320






 


321






 


322






 


323






 


324






 


325






 


326






 


327






 


328






 


329






 


330






 


331






 


332






 


333






 


334






 


335






 


336






 


337






 


338






 


339






 


340






 


341






 


342






 


343






 


344






 


345






 


346






 


347






 


348






 


349






 


350






 


351






 


352






 


353






 


354






 


355






 


356






 


357






 


358






 


359






 


360






 


361






 


362






 


363






 


364






 


365






 


366






 


367






 


368






 


369






 


370






 


371






 


372






 


373






 


374






 


375






 


376






 


377






 


378






 


379






 


380






 


381






 


382






 


383






 


384






 


385






 


386






 


387






 


388






 


389






 


390






 


391






 


392






 


393






 


394






 


395






 


396






 


397






 


398






 


399






 


400






 


401






 


402






 


403






 


404






 


405






 


406






 


407






 


408






 


409






 


410






 


411






 


412






 


413






 


414






 


415






 


416






 


417






 


418






 


419






 


420






 


421






 


422






 


423






 


424






 


425






 


426






 


427






 


428






 


429






 


430






 


431






 


432






 


433






 


434






 


435






 


436






 


437






 


438






 


439






 


440






 


441






 


442






 


443






 


444






 


445






 


446






 


447






 


448






 


449






 


450






 


451






 


452






 


453






 


454






 


455






 


456






 


457






 


458






 


459






 


460






 


461






 


462






 


463






 


464






 


465






 


466






 


467






 


468






 


469






 


470






 


471






 


472






 


473






 


474






 


475






 


476






 


477






 


478






 


479






 


480






 


481






 


482






 


483






 


484






 


485






 


486






 


487






 


488






 


489






 


490






 


491






 


492






 


493






 


494






 


495






 


496






 


497






 


498






 


499






 


500






 


501






 


502






 


503






 


504






 


505






 


506






 


507






 


508






 


509






 


510






 


511






 


512






 


513













A compound of the present invention can be any of the following stereo isomers of [2.2.1] and [3.1.1] bicyclic skeleton.







In these stereo isomers, preferable is a compound having the skeleton of the formula:




The present invention includes all stereo isomers of them and the optional mixtures thereof. Namely, the bond binding to the bicyclic ring is in R configuration or S configuration, and all of the stereo isomers (diastereomer, epimer, enantiomer and the like), racemates, and optional mixture thereof are included in the present invention.
Moreover, the α chain of the compound of the present invention can be in Z configuration or E configuration, thus a compound having any of the configurations and the mixture thereof are included in the present invention.
A prodrug of a compound of the formula (I) is a derivative of the compound of the present invention having a group which can be decomposed chemically or metabolically, and such prodrug is converted to a pharmaceutically active compound of the present invention by means of solvolysis or by placing the compound in vivo under a physiological condition. Method for the selection and process of an appropriate prodrug derivative are described in the literature such as Design of Prodrugs, Elsevier, Amsterdam 1985.
When the compound of the formula (I) has a carboxyl group, an ester derivative prepared by reacting a basal acid compound with a suitable alcohol or an amide derivative prepared by reacting a basal acid compound with a suitable amine is exemplified as a prodrug. A particularly preferred ester derivative as an prodrug is an optionally substituted alkyl ester derivative (e.g., methyl ester, ethyl ester, n-propyl ester, isopropyl ester, n-butyl ester, isobutyl ester, tert-butyl ester, morpholinoethyl ester), an arylalkyl ester derivative (e.g., benzyl ester, phenethyl ester, benzhydryl ester), or the like. A particularly preferred amide derivative as a prodrug is alkyl amide derivative (e.g., N-methyl amide, N-ethyl amide, N-(n-propyl)amide, N-isopropyl amide, N-(n-butyl)amide, N-isobutyl amide, N-(tert-butyl)amide), aryl alkyl amide (e.g., N-benzyl amide, N-phenethyl amide, benzhydryl amide), or the like.
When the compound of the formula (I) has a hydroxy group, an acyloxy derivative prepared by reacting with a suitable acyl halide (e.g., acid chloride, halogenated acid) or a suitable acid anhydride (e.g., mixed acid anhydride) is exemplified as a prodrug. A particularly preferred acyloxy derivative as a prodrug is a derivative substituted with optionally substituted alkylcarbonyloxy (e.g., —OCOC2H5, —OCO(tert-Bu), —OCOC15H31, —OCOCH2CH2COONa, —OCOCH(NH2)CH3, —OCOCH2N(CH3)2—), optionally substituted arylcarbonyloxy (e.g., —OCO(m-COONa-Ph) or the like.
When the compound of the formula (I) has an amino group, an amide derivative prepared by reacting with a suitable acid halide or a suitable acid anhydride is exemplified as a prodrug. A particularly preferred amide derivative as a prodrug is a derivative substituted with optionally substituted alkylcarbonyl (e.g., —NHCO(CH2)20CH3, —NHCOCH(NH2)CH3) or the like.
Examples of a salt of the compound of the formula (I) or its prodrug include alkali metal salts such as lithium salts, sodium salts or potassium salts, alkaline-earth metal salts such as calcium salts, salts with organic bases such as tromethamine, trimethylamine, triethylamine, 2-aminobutane, tert-butylamine, diisopropylethylamine, n-butylmethylamine, cyclohexylamine, dicyclohexylamine, N-isopropylcyclohexylamine, furfurylamine, benzylamine, methylbenzylamine, dibenzylamine, N,N-dimethylbenzylamine, 2-chlorobenzylamine, 4-methoxybenzylamine, 1-naphthylene methylamine, diphenylbenzylamine, triphenylamine, 1-naphthylamine, 1-aminoanthorathene, 2-aminoanthorathene, dehydroabiethylamine, N-methylmorpholine, pyridine), basic amino acid salts such as arginine salts or lysine salts.
A solvate means a solvate with an organic solvent, a hydrate and the like of the compound of the formula (I), its prodrug or its pharmaceutically acceptable salt, for example, monohydrate, dihydrate or the like.
General processes for the preparation of the compounds of the formula (I) are illustrated as follows.




    
    
        A is alkylene optionally intervened with a heteroatom, optionally having an oxo group, optionally substituted with halogen and/or optionally having an unsaturated bond;
        R is —C(═O)—R1, —CH2—R1, or tetrazolyl;
        R1 is hydroxy, alkyloxy, or optionally substituted amino;
        m is 0 or 1;
        provided that when m is 1, A is —CH═CH—CH2—CH2—CH2— and furthermore R is —C(═O)—R1 wherein R1 is hydroxy or alkyloxy, and provided that when A is —CH2—CH═CH—CH2—CH2—CH2— and R is —C(═O)—R1 wherein R1 is hydroxy or alkyloxy, a compound is excluded;
        p is 0 or 1, provided that when p=0, X1 is not bonded to X3 via X4;
        X1 and X3 are each independently optionally substituted aryl, optionally substituted heteroaryl, or optionally substituted non-aromatic heterocyclyl;
        X2 is a bond, —CH2—, —CH2—CH2—, —C(═O)—, —O—, —S—, —SO—, —SO2—, —NH—, —N(CH3)—, —C(═N—O—CH3)—, —N═N—, —CH═CH—, —(C═O)—NH—, —NH—(C═O)—, —CH2—NH—, —NH—CH2—, —CH2—O—, —O—CH2—, —CH2—S—, —S—CH2—, —CH2—SO2—, —SO2—CH2—, —SO2—NH—, —NH—SO2—, —C(═CH2)—, —SO2N(Me)—, —CH2NHSO2—, —CH2NH—(C═O)—, —NH—C(═O)—NH, or —NH—C(═O)—N(Me)—;
        X4 is —C2—, —CH2—CH2—, —C(═O)—, —SO—, —SO2—, —(C═O)—NH—, —NH—(C═O)—, —CH2—NH—, —NH—CH2—, —CH2—O—, —O—CH2—, —CH2—S—, —S—CH2—, —CH2—SO2—, —SO2—CH2—, —SO2—NH— or —NH—SO2—.
    
    


As shown in the above process, the compound of the formula (I) can be prepared by reacting a carboxylic acid of the formula (M-2) or its reactive derivative with an amino compound of the formula (M-1).
The reactive derivatives of carboxylic acid of the formula (M-2) mean the corresponding acid halides (e.g., chloride, bromide, iodide), anhydrides (e.g., mixed anhydride with formic acid or acetic acid), active esters (e.g., N-hydroxysuccinimide ester), and the like, and include acylating agents used for the usual acylation of amino group.
For example, an acid halide is obtained by reacting the compound (M-2) with a thionyl halide (e.g., thionyl chloride), phosphorous halide (e.g., phosphorous trichloride, phosphorous pentachloride), oxalyl halide (e.g., oxalyl chloride), and the like, in accordance with known methods as described in the literatures.
The reaction can be conducted under a condition generally used for the acylation of amino group. For example, in the case of condensation with the acid halide, the reaction is carried out in a solvent such as an ether solvent (e.g., diethyl ether, tetrahydrofuran, dioxane), benzene solvent (e.g., benzene, toluene, xylene), halogenated hydrocarbon solvent (e.g., dichloromethane, dichloroethane, chloroform) as well as ethyl acetate, dimethylformamide, dimethyl sulfoxide, acetonitrile, or the like, if necessary, in the presence of a base (e.g., organic base such as triethylamine, pyridine, N,N-dimethylaminopyridine, N-methylmorpholine; inorganic base such as sodium hydroxide, potassium hydroxide, potassium carbonate, or the like) under cooling, at room temperature, or under heating, preferably at a temperature ranging from −20° C. to ice-cooling temperature, or from room temperature to a refluxing temperature of the reaction system, during several min to several hr, preferably for 0.5 hr to 24 hr, more preferably for 1 hr to 12 hr.
Unless R of a compound represented by the formula (M-1) is a carboxyl group, a free form may be used without converting the carboxy group (M-2) into the reactive derivatives and the reaction may be conducted in the presence of a condensing agent (e.g., dicyclohexylcarbodiimide (DCC), 1-ethyl-3-(3-methylaminopropyl)carbodiimide, N,N′-carbonyldiimidazole, or the like) usually used in the condensation reaction of amine and carboxylic acid.
When “optionally substituted aryl”, “optionally substituted heteroaryl” or “optionally substituted non-aromatic heterocyclyl” in X1 or X3 of the compound of the formula (M-2) is substituted with a hydroxy group or an amino group, such a compound can be used after protection by acetyl group or the like in accordance with the well known method.
In the reaction of the other reactive derivatives or free acid (M-2) with the amine (M-1), the reaction conditions are determined according to the property of each reactive derivative or free acid, in accordance with a known method. The reaction product can be purified in accordance with a conventional purification, such as the extraction with a solvent, chromatography, recrystallization, and the like.
In an object compound of the present invention, various derivatives in which R is —C(═O)—R1, —CH2—R1 or tetrazolyl (R1 is hydroxy, alkyloxy or optionally substituted amino) can be converted from a compound in which R is carboxylic acid. For instance, a derivative of the ester or the amide can be prepared by esterification or amidation, in accordance with the well known method. Furthermore, the ester derivative can be converted by reduction to an alcoholic derivative, which can be derived to an ether derivative by O-alkylation. A compound in which R is 5-tetrazolyl, can be prepared by converting an amide derivative having R; CONH2 to R: CN by dehydration in accordance with the well known method, followed by a reaction with sodium azide (J. Am. Chem. Soc. 1958, 80, 3908) or trimethylsilylazide (J. Org. Chem. 1993, 58, 4139).
In this process, the starting compound (M-1) wherein R1 is —CH2—CH═CH—CH2—CH2—CH2—COOMe, m is 0, Y is [2.2.1]bicyclic skeleton, 7-(3-amino-bicyclo[2.2.1]hept-2-yl)-5-heptenoic acid methyl ester is described in the Japanese Patent Publication (Kokoku) No. 79060/1993. The other starting compounds can be prepared from the aldehyde derivative (Q is a protecting group such as benzyloxycarbonyl, t-butoxycarbonyl and the like) represented by a general formula (M-1a) or (M-1b) by one or more reaction(s) of a yilide compound under a Wittig reaction condition (Org. Reaction, 1965, 14, 270) in combination with other reactions. In a starting compound, various derivatives wherein R is —C(═O)—R1, —CH2—R1 or tetrazolyl (R1 is hydroxy, alkyloxy or optionally substituted amino) can be converted from a compound wherein R is COOH.




For example, the aldehyde (M-1a) is reacted with (3-carboxypropyl)triphenylphosphonium salt under a well known Wittig reaction condition to give a starting material (M-5D), wherein A is —CH2═CH—CH2—CH2—. The compound M-5D is hydrogenated in the presence of palladium, platinum and the like to give a starting material (M-5A), wherein A is —CH2—CH2—CH2—CH2—. Furthermore, after a Wittig reaction using methoxymethyltriphenyl-phosphonium salt, followed by a hydrolysis with hydrochloric acid, formic acid, acetic acid and the like can furnish an aldehyde (M-1b) with one additional carbon atom and moreover a Wittig reaction with 2-(1,3-dioxoran-2-yl)ethyltriphenylphosphonium salt can give a compound represented by a general formula (M-1c). A Jones oxidation (J. Chem. Soc., 1946, 39) of the compound gives a starting material (M-5B) wherein A is —CH2—CH═CHCH2— in the formula (M-1). And by the above similar method, after an aldehyde (M-1d) was obtained by hydrogenation, followed by hydrolysis of the acetal with acid, either a Wittig reaction with a stable yield such as methyl (triphenylphophoranidene)acetate and the like or a Honer-Emmons reaction with methyl dimethylphosphonoacetate can convert to a starting material (M-7I), wherein A is —CH2—CH2—CH2—CH2—CH═CH—. When the above mentioned reaction is applied to an aldehyde (M-1b), a corresponding starting material (M-4B), wherein A is —CH2CH═CH— is obtained and furthermore a corresponding starting material (M-4A) wherein A is —CH2—CH2—CH2— is obtained by a hydrogenation of the double bond. When a starting material wherein A is —CH2—CH2—CH2—CH2—O—CH2— is required, a compound of the formula (M-4A) wherein R is CH2OH can be reacted with halogenated acetic acid or its ester, ether, or amide and the like in the presence of a base in accordance with known methods as described in the literatures.
Amidation with a starting carboxylic acid (M-2) can be accomplished after a deprotection of an amino protecting group Q in a way of conversion to α-chain, if necessary.
When p is 0, the carboxylic acid of the formula (M-2) can be prepared by reacting a carboxylic acid having X1 or its reactive derivative with a compound having X3. A person ordinary skilled in the art can carry out such a reaction by selecting the kinds of reactions and their conditions depending on the kind of X2.
A compound represented by the formula: X3—X2—X1—COOH wherein X3 is pyrrolyl optionally substituted with alkyl, alkyloxy or halogen, indolyl optionally substituted with alkyl, alkyloxy or halogen, indolinyl optionally substituted with alkyl, alkyloxy or halogen or 1,2,3,4-tetrahydroquinolyl optionally substituted with alkyl, alkyloxy or halogen; X2 is —SO2—, —S— or —CH2—; X1 is thienyl, or the pharmaceutically acceptable salt, or especially a substituent represented by the formula: X1—X2—X3 is 5-[(1-pyrrolyl)sulfonyl]thiophen-2-yl, 5-[(2-methyl-1-pyrrolyl)sulfonyl]thiophen-2-yl or 5-[(2,5-dimethyl-1-pyrrolyl)sulfonyl]thiophen-2-yl, or the pharmaceutically acceptable salt is important as an intermediate. Salt refers to lithium salt, sodium salt, potassium salt, calcium salt, triethylammonium salt, pyridinium salt or the like.
When p is 0, a group of the formula: —NHCO—X1—X2—X3 of the compound (I) can be introduced by reacting a carboxylic acid of the formula: X3—X2—X1—COOH (M-2) or its reactive derivative with amine (M-1), or by reacting a carboxylic acid having X1 or its reactive derivatives with amine (M-1) and reacting the obtained compound with a compound having X3.
In case of the introduction of a substituent(s) into the “optionally substituted aryl”, “optionally substituted heteroaryl” or “optionally substituted non-aromatic heterocyclyl”, the change of the functional group can be performed before or after reacting a carboxylic acid or its reactive derivative thereof (M-2) with the amine (M-1).
In an aromatic part such as aryl, heteroaryl and the like, usual methods of introduction or conversion of the functional group known for an aromatic ring can be applied. For example, the compound having an aromatic heterocycle substituted with a nitro group can be prepared through the nitration of the compound with a nitrating acid. Moreover, the compound having an aromatic heterocycle substituted with an amino group can be prepared through the reduction of the above-obtained compound with tin in the presence of hydrochloride. Moreover, the compound having an aromatic heterocycle substituted with hydroxy group can be prepared through the diazonization of the above-obtained compound and the hydrolysis with alkali. On the other hand, the compound having an aromatic heterocycle substituted with an alkoxy group can be prepared through the reaction of the diazonium derivative with alcohol. The compound having an aromatic heterocycle substituted with halogen can be prepared through Sandmeyer reaction, the reaction of the diazonium derivative with a copper salt (e.g., CuCl2, CuBr2). The compound having an aromatic heterocycle substituted with halogen can be also prepared through the direct reaction of the compound having an aromatic heterocycle with chlorine and the like. Using the above-mentioned methods appropriately, halogen can be introduced into a desired position(s). The group of alkyl, alkenyl or acyl group can be directly introduced into an aromatic heterocycle through Friedel Crafts reaction with alkylating agent, an alkenylating agent, or an acylating agent, respectively, in the presence of anhydrous aluminum chloride and the like.
The objective compound (I) of the present invention can be converted into a corresponding ester derivative, if desired. For example, the ester derivative can be prepared by esterification of a carboxylic acid in accordance with a known method.
When using the compound (I) of the present invention in treatment, it can be formulated into ordinary formulations for oral and parenteral administration. A pharmaceutical composition containing the compound (I) of the present invention can be in the form for oral and parenteral administration. Specifically, it can be formulated into formulations for oral administration such as tablets, capsules, granules, powders, syrup, and the like; or those for parenteral administration such as injectable solution or suspension for intravenous, intramuscular, or subcutaneous injection, inhalant, eye drops, nasal drops, suppositories, or percutaneous formulations such as ointment.
In preparing the formulations, carriers, excipients, solvents, and bases known to one having ordinary skill in the art may be used. In case of tablets, they are prepared by compressing or formulating an active ingredient together with auxiliary components. Examples of usable auxiliary components include pharmaceutically acceptable excipients such as binders (e.g., cornstarch), fillers (e.g., lactose, microcrystalline cellulose), disintegrants (e.g., starch sodium glycolate) or lubricants (e.g., magnesium stearate). Tablets may be coated appropriately. In case of liquid formulations such as syrups, solutions, or suspensions, they may contain suspending agents (e.g., methyl cellulose), emulsifiers (e.g., lecithin), preservatives, and the like. In case of injectable formulations, it may be in the form of solution, suspension, or oily or aqueous emulsion, which may contain suspension-stabilizing agents or dispersing agent, and the like. In case of an inhalant, it is formulated into a liquid formulation applicable to an inhaler. In case of eye drops, it is formulated into a solution or a suspension.
Especially, in case of a nasal drug for treating nasal blockage, it can be used as a solution or suspension prepared by a conventional formulating method, or administered as a powder formulated using a powdering agent (e.g., hydroxypropyl cellulose, carbopole) into the nasal cavity. Alternatively, it can be used as an aerosol filled into a special container together with a solvent of low boiling point.
In a case using as an eyewash drug for treating allergic conjunctivitis, it can be used as a solution or suspension of the compound or can be used by solving or suspending the compound before use. A stabilizing agent, solubilizing agent, suspending agent, emulsifier, buffer, preservatives and the like can be included. In a case using as an eyewash drug, aseptic treatment is preferable.
Pharmaceutical preparation of injection, oral agent, inhalation and the like is preferable for treating asthma.
Although an appropriate dosage of the compound (I) varies depending on the administration route, age, body weight, sex, or conditions of the patient, and the kind of drug(s) used together, if any, and should be determined by the physician in the end, in the case of oral administration, the daily dosage can generally be between 0.01–100 mg, preferably 0.01–10 mg, more preferably 0.01–1 mg, per kg body weight. In case of parenteral administration, the daily dosage can generally be between 0.001–100 mg, preferably 0.001–1 mg, more preferably 0.001–0.1 mg, per kg body weight. The daily dosage can be administered in 1–4 divisions.


EXAMPLE
The following examples are provided to further illustrate the present invention and are not to be construed as limiting the scope.
Example 1
Preparation of (I-5A-59a), (I-5A-59b)




Potassium t-butoxide (4.32 g, 38.5 mmol) was added to a suspension of (3-carboxypropyl)triphenylphosphonium bromide (9.42 g, 22.0 mmol) in THF (45 ml) with cooling in ice. The mixture was stirred for 1 h and cooled to −10° C. A solution of compound (I) (3.0 g, 11.0 mmol) in THF (15 ml) was added dropwise over 15 min. The mixture was stirred at the temperature for 1 h, diluted with water, washed twice with toluene, acidified (pH=1) with hydrochloric acid and extracted with ethyl acetate. The extracts were washed with water and brine, dried and concentrated. An excess diazomethane solution in ether was added to a solution of the residue in ethyl acetate (20 ml) with cooling in ice. The mixture was concentrated and purified by silica gel chromatography (hexane-ethyl acetate, 85:15) to give a compound (2) (3.32 g; yield 85%).
Process 2
10% Palladium-carbon (0.32 g) was added to a solution of compound (2) (3.22 g, 9.0 mmol) in methanol (30 ml). The mixture was stirred under a hydrogen atmosphere for 17 h, filtered and concentrated to give a compound (3) (2.05 g; yield 100%)
Process 3
5-(2-Thienylthio)thiophene-2-carboxylic acid (233 mg, 0.96 mmol) and 1-hydroxybenzotriazole (10.8 mg, 0.08 mmol) were added to a solution of compound (3) (180 mg, 0.80 mmol) in THF (8 ml) and 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (149 mg, 0.96 mmol) under cooling in ice. The mixture was stirred at room temperature for 14 h, diluted with ethyl acetate, washed with dilute hydrochloric acid, aq. sodium hydrogencarbonate successively, dried and concentrated. The residue was purified by silica gel chromatography (hexane-ethyl acetate, 5:1) to give a compound (I-5A-59b) (325 mg; yield 90%).
Process 4
1N aq. lithium hydroxide (1.8 ml, 1.8 mmol) was added to a solution of compound (I-5A-59b) (325 mg, 0.72 mmol) in THF (8 ml). The mixture was stirred at room temperature for 14 h, acidified and extracted with ethyl acetate. The extracts were washed with water and brine, successively, dried and concentrated to give a compound (I-5A-59a) (300 mg; yield 96%).
Example 2
Preparation of Compound (I-7M-1a), (I-7N-1a), (I-7N-1b)




Methyl bis(2,2,2-trifluoroethyl)phosphonoacetate (2.94 ml, 13.92 mmol) and 18-crown-6 (5.52 g, 20.88 mmol) in THF (100 ml) were cooled at −60° C. A solution of potassium bis(trimethylsilyl)amide (0.5 M toluene solution, 27.8 ml, 13.9 mmol) was added. The mixture was stirred for 15 h. A solution of compound (4) (2.0 g, 6.96 mmol) in THF (20 ml) was added dropwise during 15 min. The mixture was stirred at the same temperature for 2 h. The temperature was raised to 0° C. and the mixture was diluted with water and extracted with ethyl acetate. The extracts were washed with water and brine, successively, dried, concentrated and purified by silica gel chromatography (hexane-ethyl acetaqte, 5:1) to give a compound (5) (2.10 g; yield 88%).
Process 2
Diisopropylaluminum hydride (1M toluene solution, 13.1 ml, 13.1 mmol) was added dropwise to a solution of compound (5) (1.80 g, 5.24 mmol) in dichloromethane (20 ml)-hexane (20 ml) at −78° C. The mixture was stirred at the temperature for 1 h. Methanol (1 ml) was added. The mixture was warmed to the room temperature. 2N Hydrochloric acid was added. The mixture was extracted with ethyl acetate. The extracts were washed with sodium hydrogencarbonate and brine successively, dried, concentrated and purified by silica gel chromatography (hexane-ethyl acetate, 7:3) to give a compound (6) (5.92 g; yield 96%).
Process 3
A mixture of compound (6) (1.58 g, 5.01 mmol), t-butyl bromoacetate (1.05 ml, 6.50 mmol), tetrabutylammonium hydrogensulfate (170 mg, 0.5 mmol) and 50% sodium hydroxide (4 ml) were vigorously stirred at room temperature for 18 h. The phase of toluene was separated, washed with water and brine successively, dried and concentrated. The residue obtained, trifluoroacetic acid (6.38 ml, 83 mmol) and anisole (3.37 ml. 31 mmol) were stirred at 60° C. for 15 h and concentrated under a reduced pressure. The residue was washed with hexane. Methanol (20 ml) and conc. sulfuric acid (0.44 ml) were added. The mixture was heated under reflux for 2 h. 2N sodium hydroxide was added to be alkaline. The mixture was extracted with ethyl acetate. The extracts were washed with water and brine successively, dried and concentrate to give a compound (7) (461 mg; yield 44%).
Process 4
5-(2-Methyl-1-pyrrolylsulfonyl)thiophene-2-carboxylic acid (21.8 mg, 0.85 mmol) and 1-hydroxybenzotriazole (13 mg, 0.09 mmol) were added to a solution of compound (7) (215 mg, 0.85 mmol) in THF (6 ml). 1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide (137 mg, 1.02 mmol) was further added under cooling in ice. The mixture was stirred at room temperature for 16 h, diluted with ethyl acetate, washed with dilute hydrochloric acid and sodium hydrogencarbonate successively, dried and concentrated. The residue was purified by silica gel chromatography (hexane-ethyl acetate 2:1) to give a compound (I-7N-1b) (328 mg; yield 78%).
Process 5
1 N Sodium hydroxide solution (1.57 ml, 1.57 mmol) was added to a solution of compound (I-7N-1b) (310 mg, 0.63 mmol) in THF (3.2 ml)-methanol (6.3 ml) and the mixture was stirred at room temperature 16 h. 2N Hydrochloric acid was added to acidify and the mixture was extracted with ethyl acetate. The extracts were washed with water and brine successively, dried and concentrated to give a compound (I-7N-1a) (399 mg; yield 73%).
Process 6
10% Palladium-carbon (170 mg, 0.36 mmol) was added to a solution of compound (1-7N-1a) (170 mg, 0.36 mmol) in methanol (5 ml). The mixture was stirred under a hydrogen atmosphere for 17 h and filtered. The filtrate was concentrated to give a compound (I-7M-1a) (162 mg; yield 95%).
Example 3
Preparation of Compounds (I-7I-55a), (II-7I-55b)




Potassium t-butoxide (6.73 g, 60.0 mmol) was added to a suspension of 2-(1,3-dioxolan-2-yl)ethyltriphenylphosphonium bromide (13.28 g, 30.0 mmol) in THF (60 ml) at −30° C. The mixture was stirred at −30° C. to 0° C. for 1 h. A solution of compound (8) (5.62 g, 20.0 mmol) in THF (40 ml) was added dropwise at −25° C. during 15 min. The mixture was warmed to 0° C., stirred for 1.5 h, diluted with water and extracted with ethyl acetate. The extracts were washed with water and brine, dried and concentrated. The residue was purified by silica gel chromatography (hexane-ethyl acetate 85:15) to give a compound (9) (6.27 g, yield 86%)
Process 2
10% Palladium-carbon (0.21 g) was added to a solution of compound (9) (4.10 g, 11.2 mmol) in methanol (41 ml). The mixture was stirred under a hydrogen atmosphere for 2 h and filtered. The filtrate was concentrated to give a residue. Pydidinium p-toluenesulfonate (503 mg, 2.0 mmol) was added to a solution of the residue in acetone-water (4:1, 50 ml). The mixture was heated under reflux for 16 h, diluted with water and extracted with ethyl acetate. The extracts were washed with water and brine, dried and concentrated. A mixture of the residue and methyl (triphenylphosphoraniliden)acetate (2.93 g, 8.76 mmol) in toluene (35 ml) was stirred at room temperature for 18 h, diluted with ethyl acetate, washed with water and brine and concentrated. The residue was purified by silica gel chromatography in (hexane-ethyl acetate 35:15) to give a compound (10) (2.71 g; yield 71%).
Process 3
Trifluoroacetic acid (3.82 ml, 49.5 mmol) was added to a solution of compound (10) (2.35 g, 6.19 mmol) in dicholoromethane (38 ml) and the mixture was stirred at room temperature for 3 h and concentrated under a reduced pressure. The residue was dissolved in toluene (50 ml) and water (10 ml). 2N Sodium hydroxide was added to be alkaline in the aq. layer. The toluene phase was separated, washed with water and brine, dried and concentrated to give a compound (11) (1.70 g; yield 98%).
Process 4
1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide (252 mg, 1.62 mmol) was added to a mixture of a compound (11) (433 mg, 1.55 mmol), 5-(2-methyl-1-pyrrolylsulfonyl)thiophen-2-carboxylic acid (400 mg, 1.47 mmol) and 1-hydroxybenzotriazole (20 mg, 0.15 mmol) in THF (6 ml) with cooling in ice. The mixture was stirred at room temperature for 16 h, diluted with ethyl acetate, washed with dilute hydrochloric acid and aq. sodium hydrogencarbonate successively, dried and concentrated. The residue was purified by silica gel chromatography (hexane-ethyl acetate, 4:1) to give a product (II-7I-55b) (585 mg; yield 74%).
Process 5
2N Lithium hydroxide (1.58 ml, 3.15 mmol) was added to a solution of compound (II-7I-55b) (560 mg, 1.05 mmol) in THF (8 ml). A mixture was stirred at room temperature for 48 h, acidified with 2N Hydrochloric acid and extracted with ethyl acetate. The extracts were washed with water and brine successively, dried and concentrated. The residue was purified by silica gel chromatography (hexane-ethyl acetate, 1:3) to give a compound (II-7I-55a) (399 mg; yield 73%).
Example 4
Preparation of Compounds (I-7A-1e), (I-7E-1e)




Oxalyl chloride (0.236 ml, 2.71 mmol) and N,N-dimethylformamide (a drop) were added to a solution compound (12) (840 mg, 2.26 mmol) in dichloromethane (20 ml) with cooling in ice. The mixture was stirred for 30 min and concentrated under a reduced pressure. The residue was dissolved in dichloromethane (20 ml). Methanesulfonamide (258 mg, 2.71 mmol) and 1,8-diazabicyclo[5.4.0]-7-undecene (0.744 ml, 4.97 mmol) were added. The mixture was stirred for 2.5 h, diluted with ethyl acetate, washed with dilute hydrochloric acid, aq. sodium hydrogencarbonate and brine successively, dried and concentrated. Trifluoroacetic acid (25 ml) and anisole (2 ml, 18.40 mmol) were added to the residue. The mixture was stirred at 50° C. for 13 h and concentrated under a reduced pressure. The oily residue was washed with hexane to give a compound (13) (0.776 g; yield 65%).
Process 2
Oxalyl chloride (0.081 ml, 0.929 mmol) and N,N-dimethylformamide (a drop) were added to a solution 5-(1-pyrrolylsulfonyl)thiophene-2-carboxylic acid (209 mg, 0.812 mmol) in dichloromethane (4 ml) with cooling in ice. The mixture was stirred for 20 min and at room temperature for 40 min and concentrated under a reduced pressure. The residue was dissolved in dichloromethane (4 ml). A solution of compound (13) (0.42, 0.774 mmol) in dichloromethane (4 ml)-THF (3 ml) and triethylamine (0.486 ml, 3.49 mmol) were added to the solution with cooling in ice. The mixture was stirred for 1.5 h and at room temperature for 19 h, diluted with ethyl acetate, washed with dilute hydrochloric acid, aq. sodium hydrogencarbonate and brine successively, dried and concentrated. The residue was purified by silica gel chromatography (hexane-ethyl acetate-acetic acid, 1:1:0.003) to give a compound (I-7E-1e) (157 mg; yield 37%).
Process 3
20% Palladium hydroxide-carbon (64 mg) was added to a solution of compound (I-7E-1e) (116 mg, 0.21 mmol) in methanol (3 ml). The mixture was stirred under a hydrogen atmosphere for 20 h and filtered. The filtrate was concentrated to give a compound (I-7A-1e) (109 mg; yield 94%).
Example 5
Preparation of Compound (Formula: X3—X2—X1—COOH)




5-Bromothiophene-2-sulfonyl chloride was reacted directly with a pyrrole derivative or the acid chloride was converted to the sulfonamide followed by condensation with 2,5-dimethoxytetrahydro-derivative to give a sulfonylpyrrole derivative. Then, the product was converted to the organolithium or the organomagnesium compound by a halogen-metal exchange reaction, followed by reacting with carbon dioxide to give a desired compound.
5-(1-Pyrrolylsulfonyl)-2-thiophenecarboxylic acid
mp 191–194° C.; 1H-NMR (CDCl3) δ6.36 (2H, t, J=2.4 Hz), 7.18 (2H, t, J=2.4 Hz), 7.61 (1H, d, J=4.2 Hz), 7.74 (1H, d, J=4.2 Hz).
5-(2-Methyl-1-pyrrolylsulfonyl)-2-thiophenecarboxylic acid
mp 159–160° C.; 1H-NMR (CDCl3) δ2.40 (3H, d, J=0.9 Hz), 6.01 (1H, m), 6.23 (1H, t, J=3.0 Hz), 7.20 (1H, dd, J=1.8, 3.6 Hz), 7.58 (1H, d, J=4.2 Hz), 7.76 (1H, d, J=4.2 Hz).
5-(2,5-Dimethyl-1-pyrrolylsulfonyl)-2-thiophenecarboxylic acid
mp 167–171° C.; 1H-NMR (CDCl3) δ2.43 (6H, s), 5.90 (2H, s), 7.52 (1H, d, J=3.9 Hz), 7.75 (1H, d, J=3.9 Hz).
The structure and physical property of the compound prepared in accordance with the above examples are shown below. Each sign used for —X1—X2—X3 and A in Tables means the sign represented before.







TABLE 1













 












Compd. No..
—X1—X2—X3
A
R
















I-4A-1a
1
4A
CO2H



I-4B-1a
1
4B
CO2H



I-4C-1a
1
4C
CO2H



I-4D-1a
1
4D
CO2H



I-4E-1a
1
4E
CO2H



I-4F-1a
1
4F
CO2H



I-5A-1a
1
5A
CO2H



I-5A-1b
1
5A
CO2Me



I-5A-31a
31
5A
CO2H



I-5A-47a
47
5A
CO2H



I-5A-55a
55
5A
CO2H



I-5A-59a
59
5A
CO2H



I-5A-59b
59
5A
CO2Me



I-5A-80a
80
5A
CO2H



I-5A-88a
88
5A
CO2H



I-5A-88b
88
5A
CO2Me



I-5A-104a
104
5A
CO2H



I-5A-126a
126
5A
CO2H



I-5A-143a
143
5A
CO2H



I-5A-197a
197
5A
CO2H



I-5B-1a
1
5B
CO2H



I-5B-47a
47
5B
CO2H



I-5B-59a
59
5B
CO2H



I-5C-1a
1
5C
CO2H



I-5C-1b
1
5C
CO2Me



I-5C-55a
55
5C
CO2H



I-5C-31a
31
5C
CO2H



I-5C-47a
47
5C
CO2H



I-5C-88a
88
5C
CO2H



I-5D-1a
1
5D
CO2H



I-5E-1a
1
5E
CO2H



I-5E-55a
55
5E
CO2H



I-5F-1a
1
5F
CO2H



I-5F-47a
47
5F
CO2H



I-5G-47a
47
5G
CO2H



I-6A-1a
1
6A
CO2H



I-6A-31a
31
6A
CO2H



I-6A-55a
55
6A
CO2H



I-6A-88a
88
6A
CO2H



I-6B-1a
1
6B
CO2H



I-6B-31a
31
6B
CO2H



I-6B-88a
88
6B
CO2H



I-6C-1a
1
6C
CO2H

















TABLE 2













 










Compd. No..
—X1—X2—X3
A
R













I-6D-1a
1
6D
CO2H


I-6E-1a
1
6E
CO2H


I-6E-59a
59
6E
CO2H


I-6F-1a
1
6E
CO2H


I-6G-1a
1
6G
CO2H


I-7A-1a
1
7A
CO2H


I-7A-1b
1
7A
CO2Me


I-7A-1c
1
7A
CONH2


I-7A-1e
1
7A
CONHSO2Me


I-7A-1h
1
7A
CH2OH


I-7A-1i
1
7A
CH2OMe


I-7A-31a
31
7A
CO2H


I-7A-47a
47
7A
CO2H


I-7A-47i
47
7A
CH2OMe


I-7A-55a
55
7A
CO2H


I-7A-59a
59
7A
CO2H


I-7A-80a
80
7A
CO2H


I-7A-88a
88
7A
CO2H


I-7A-88e
88
7A
CONHSO2Me


I-7A-88h
88
7A
CH2OH


I-7A-88i
88
7A
CH2OMe


I-7A-104a
104
7A
CO2H


I-7A-143a
143
7A
CO2H


I-7A-197a
197
7A
CO2H


I-7A-315a
315
7A
CO2H


I-7A-316a
316
7A
CO2H


I-7B-1a
1
7B
CO2H


I-7C-1a
1
7C
CO2H


I-7D-1a
1
7D
CO2H


I-7E-1c
1
7E
CONH2


I-71-1d
1
7E
CONHMe


I-71-1e
1
7E
CONHSO2Me


I-71-1f
1
7E
CON(Me)SO2Me


I-7E-1g
1
7E
5-tetrazolyl


I-7E-1h
1
7E
CH2OH


I-71-1i
1
7E
CH2OMe


I-71-47c
47
7E
CONH2


I-71-47i
47
7E
CH2OMe


I-7E-88e
88
7E
CONHSO2Me


I-7E-88h
88
7E
CH2OH


I-71-88i
88
71
CH2OMe


I-7F-1a
1
7F
CO2H
















TABLE 3













 










Compd. No..
—X1—X2—X3
A
R













I-7F-31a
31
7F
CO2H


I-7F-47a
47
7F
CO2H


I-7F-88a
88
7F
CO2H


I-7F-143a
143
7F
CO2H


I-7G-1a
1
7G
CO2H


I-7G-88a
88
7G
CO2H


I-7G-126a
126
7G
CO2H


I-7I-1a
1
7H
CO2H


I-7I-1a
1
7I
CO2H


I-7I-1b
1
7I
CO2Me


I-7I-1c
1
7I
CONH2


I-7I-1e
1
7I
CONHSO2Me


I-7I-31a
31
7I
CO2H


I-7I-47a
47
7I
CO2H


I-7I-55a
55
7I
CO2H


I-7I-59a
59
7I
CO2H


I-7I-80a
80
7I
CO2H


I-7I-88a
88
7I
CO2H


I-7I-93a
93
7I
CO2H


I-7I-126a
126
7I
CO2H


I-7I-143a
143
7I
CO2H


I-7I-197a
197
7I
CO2H


I-7I-270a
270
7I
CO2H


I-7I-307a
307
7I
CO2H


I-7I-327a
327
7I
CO2H


I-7I-332a
332
7I
CO2H


I-7I-343a
343
7I
CO2H


I-7I-385a
385
7I
CO2H


I-7I-389a
389
7I
CO2H


I-7I-391a
391
7I
CO2H


I-7J-1a
1
7J
CO2H


I-7J-31a
31
7J
CO2H


I-7K-1a
1
7K
CO2H


I-7K-47a
47
7K
CO2H


I-7K-59a
59
7K
CO2H


I-7K-143a
143
7K
CO2H


I-7L-1a
1
7L
CO2H


I-7M-1a
1
7M
CO2H


I-7M-1b
1
7M
CO2Me


I-7M-1c
1
7M
CONH2


I-7M-1e
1
7M
CONHSO2Me


I-7M-31a
31
7M
CO2H


I-7M-40a
40
7M
CO2H
















TABLE 4













 










Compd. No..
—X1—X2—X3
A
R













I-7M-43a
43
7M
CO2H


I-7M-47a
47
7M
CO2H


I-7M-55a
55
7M
CO2H


I-7M-59a
59
7M
CO2H


I-7M-80a
80
7M
CO2H


I-7M-88a
88
7M
CO2H


I-7M-88e
88
7M
CONHSO2Me


I-7M-88h
88
7M
CH2OH


I-7M-88i
88
7M
CH2OMe


I-7M-104a
104
7M
CO2H


I-7M-126a
126
7M
CO2H


I-7M-143a
143
7M
CO2H


I-7M-197a
197
7M
CO2H


I-7M-270a
270
7M
CO2H


I-7M-307a
307
7M
CO2H


I-7M-315a
315
7M
CO2H


I-7M-316a
316
7M
CO2H


I-7M-317a
317
7M
CO2H


I-7M-318a
318
7M
CO2H


I-7M-327a
327
7M
CO2H


I-7M-329a
329
7M
CO2H


I-7M-330a
330
7M
CO2H


I-7M-331a
331
7M
CO2H


I-7M-332a
332
7M
CO2H


I-7M-333a
333
7M
CO2H


I-7M-334a
334
7M
CO2H


I-7M-336a
336
7M
CO2H


I-7M-337a
337
7M
CO2H


I-7M-342a
342
7M
CO2H


I-7M-343a
343
7M
CO2H


I-7M-385a
385
7M
CO2H


I-7M-389a
389
7M
CO2H


I-7M-390a
390
7M
CO2H


I-7M-391a
391
7M
CO2H


I-7M-392a
392
7M
CO2H


I-7M-393a
393
7M
CO2H


I-7M-396a
396
7M
CO2H


I-7M-412a
412
7M
CO2H


I-7M-424a
424
7M
CO2H


I-7M-446a
446
7M
CO2H


I-7M-447a
447
7M
CO2H


I-7M-448a
448
7M
CO2H


I-7N-1a
1
7N
CO2H
















TABLE 5













 










Compd. No..
—X1—X2—X3
A
R













I-7N-1b
1
7N
CO2Me


I-7N-55a
55
7N
CO2H


I-7N-88a
88
7N
CO2H


I-7N-143a
143
7N
CO2H


I-70-1a
1
7O
CO2H


I-7P-1a
1
7P
CO2H


I-7P-1e
1
7P
CONHSO2Me


I-7Q-1a
1
7Q
CO2H


I-7R-1a
1
7R
CO2H


I-7R-59a
59
7R
CO2H


I-7R-88a
88
7R
CO2H


I-7R-270a
270
7R
CO2H


I-7R-307a
307
7R
CO2H


I-7S-1a
1
7S
CO2H


I-7T-1a
1
7T
CO2H


I-8A-1a
1
8A
CO2H


I-8A-47a
47
8A
CO2H


I-8A-88a
88
8A
CO2H


I-8B-1a
1
8B
CO2H


I-8B-47a
47
8B
CO2H


I-8B-88a
88
8B
CO2H


I-8C-1a
1
8C
CO2H


I-8C-88a
88
8C
CO2H


I-9A-1a
1
9A
CO2H


I-9A-47a
47
9A
CO2H


I-9A-88a
88
9A
CO2H


I-9B-1a
1
9B
CO2H


I-9B-47a
47
9B
CO2H


I-9B-88a
88
9B
CO2H
















TABLE 6













 












Compd. No..
—X1—X2—X3
A
R
















II-4A-55a
55
4A
CO2H



II-4B-55a
55
4B
CO2H



II-4C-55a
55
4C
CO2H



II-4D-55a
55
4D
CO2H



II-4E-55a
55
4E
CO2H



II-4F-55a
55
4F
CO2H



II-5A-1a
1
5A
CO2H



II-5A-1b
1
5A
CO2Me



II-5A-31a
31
5A
CO2H



II-5A-47a
47
5A
CO2H



II-5A-55a
55
5A
CO2H



II-5A-55c
55
5A
CONH2



II-5A-55g
55
5A
5-tetrazolyl



II-5A-59a
59
5A
CO2H



II-5A-80a
80
5A
CO2H



II-5A-88a
88
5A
CO2H



II-5A-88b
88
5A
CO2Me



II-5A-104a
104
5A
CO2H



II-5A-126a
126
5A
CO2H



II-5A-143a
143
5A
CO2H



II-5A-197a
197
5A
CO2H

















TABLE 7













 












Compd. No..
—X1—X2—X3
A
R
















Il-5B-1a
1
5B
CO2H



II-5B-47a
47
5B
CO2H



II-5B-55a
55
5B
CO2H



II-5C-1a
1
5C
CO2H



II-5C-1b
1
5C
CO2Me



II-5C-55a
55
5C
CO2H



II-5C-88a
88
5C
CO2H



II-5D-1a
1
5D
CO2H



II-5E-1a
1
5E
CO2H



II-5E-55a
55
5E
CO2H



II-5F-31a
31
5F
CO2H



II-5F-47a
47
5F
CO2H



II-5F-55a
55
5F
CO2H



II-5F-88a
88
5F
CO2H



II-5G-47a
47
5G
CO2H



Il-6A-1a
1
6A
CO2H



II-6A-31a
31
6A
CO2H



II-6A-55a
55
6A
CO2H



II-6A-88a
88
6A
CO2H



Il-6B-1a
1
6B
CO2H



II-6B-31a
31
6B
CO2H



II-6B-55a
55
6B
CO2H



II-6B-88a
88
6B
CO2H

















TABLE 8













 












Compd. No..
—X1—X2—X3
A
R
















II-6C-31a
31
6C
CO2H



Il-6D-1a
1
6D
CO2H



II-6E-1a
1
6E
CO2H



II-6E-59a
59
6E
CO2H



II-6F-1a
1
6F
CO2H



II-6G-1a
1
6G
CO2H



II-7A-1a
1
7A
CO2H



II-7A-1b
1
7A
CO2Me



II-7A-1c
1
7A
CONH2



II-7A-31a
31
7A
CO2H



II-7A-47a
47
7A
CO2H



II-7A-55a
55
7A
CO2H



II-7A-55e
55
7A
CONHSO2Me



II-7A-55g
55
7A
5-tetrazolyl



II-7A-59a
59
7A
CO2H



II-7A-80a
80
7A
CO2H



II-7A-88a
88
7A
CO2H



II-7A-88e
88
7A
CONHSO2Me



II-7A-88h
88
7A
CH2OH



II-7A-88i
88
7A
CH2OMe



II-7A-104a
104
7A
CO2H



II-7A-143a
143
7A
CO2H



II-7A-197a
197
7A
CO2H



II-7A-315a
315
7A
CO2H



II-7A-316a
316
7A
CO2H



II-7B-55a
55
7B
CO2H



II-7C-1a
1
7C
CO2H



II-7D-1a
1
7D
CO2H



II-7E-1c
1
7E
CONH2



II-7E-1d
1
7E
CONHMe



II-7E-1e
1
7E
CONHSO2Me



II-7E-1f
1
7E
CON(Me)SO2Me



II-7E-1g
1
7E
5-tetrazolyl



II-7E-1h
1
7E
CH2OH



II-7E-1i
1
7E
CH2OMe



II-7E-47c
47
7E
CONH2



II-7E-55c
55
7E
CONH2



II-7E-55e
55
7E
CONHSO2Me



II-7E-55g
55
7E
5-tetrazolyl



II-7E-88e
88
7E
CONHSO2Me



II-7E-88h
88
7E
CH2OH



II-7E-88i
88
7E
CH2OMe



II-7F-1a
1
7F
CO2H

















TABLE 9













 












Compd. No..
—X1—X2—X3
A
R
















II-7F-47a
47
7F
CO2H



II-7F-55a
55
7F
CO2H



II-7F-88a
88
7F
CO2H



I1-7F-143a
143
7F
CO2H



II-7G-1a
1
7G
CO2H



II-7H-1a
1
7H
CO2H



II-7I-1a
1
7I
CO2H



II-7I-1b
1
7I
CO2Me



II-7I-1c
1
7I
CONH2



II-7I-1e
1
7I
CONHSO2Me



II-7I-31a
31
7I
CO2H



I1-7I-47a
47
7I
CO2H



1I-7I-55a
55
7I
CO2H



II-7I-55b
55
7I
CO2Me



II-7I-59a
59
7I
CO2H



II-7I-80a
80
7I
CO2H



II-7I-88a
88
7I
CO2H



II-7I-104a
104
7I
CO2H



II-7I-126a
126
7I
CO2H



II-7I-197a
197
7I
CO2H



II-7I-239a
239
7I
CO2H



II-7I-270a
270
7I
CO2H



II-7I-327a
327
7I
CO2H



II-7I-332a
332
7I
CO2H



II-7I-343a
343
7I
CO2H



II-7I-389a
389
7I
CO2H



II-7I-391a
391
7I
CO2H



II-7J-1a
1
7I
CO2H



II-7J-55a
55
7I
CO2H



II-7K-1a
1
7K
CO2H



II-7K-47a
47
7K
CO2H



II-7K-55a
55
7K
CO2H



II-7K-59a
59
7K
CO2H



II-7K-143a
143
7K
CO2H



II-7L-1a
1
7L
CO2H



II-7L-55a
55
7L
CO2H



II-7M-1a
1
7M
CO2H



II-7M-1b
1
7M
CO2Me



II-7M-1c
1
7M
CONH2



II-7M-1e
1
7M
CONHSO2Me



II-7M-1k
1
7M
CONHSO2Ph



II-7M-31a
31
7M
CO2H



II-7M-40a
40
TM
CO2H

















TABLE 10













 












Compd. No..
—X1—X2—X3
A
R
















II-7M-43a
43
7M
CO2H



II-7M-47a
47
7M
CO2H



II-7M-55a
55
7M
CO2H



II-7M-59a
59
7M
CO2H



II-7M-80a
80
7M
CO2H



II-7M-88a
88
7M
CO2H



II-7M-88e
88
7M
CONHSO2Me



II-7M-88h
88
7M
CH2OH



II-7M-88i
88
7M
CH2OMe



II-7M-104a
104
7M
CO2H



II-7M-126a
126
7M
CO2H



II-7M-143a
143
7M
CO2H



II-7M-197a
197
7M
CO2H



II-7M-239a
239
7M
CO2H



II-7M-270a
270
7M
CO2H



II-7M-307a
307
7M
CO2H



II-7M-327a
327
7M
CO2H



II-7M-329a
329
7M
CO2H



II-7M-330a
330
7M
CO2H



II-7M-331a
331
7M
CO2H



II-7M-332a
332
7M
CO2H



II-7M-333a
333
7M
CO2H



II-7M-334a
334
7M
CO2H



II-7M-336a
336
7M
CO2H



II-7M-343a
343
7M
CO2H



II-7M-385a
385
7M
CO2H



II-7M-389a
389
7M
CO2H



II-7M-390a
390
7M
CO2H



II-7M-391a
391
7M
CO2H



II-7M-392a
392
7M
CO2H



II-7M-393a
393
7M
CO2H



II-7N-1a
1
7N
CO2FI



II-7N-55a
55
7N
CO2H



II-7N-88a
88
7N
CO2H



II-7N-143a
143
7N
CO2H



II-70-55a
55
7O
CO2H



II-7P-55a
55
7P
CO2H



II-7P-55e
55
7P
CONHSO2Me



II-7P-55j
55
7P
CONHSO2CF3



II-7Q-1a
1
7Q
CO2H



II-7Q-55a
55
7Q
CO2H



II-7R-55a
55
7R
CO2H



II-7R-88a
88
7R
CO2H

















TABLE 11













 












Compd. No..
—X1—X2—X3
A
R
















II-7R-270a
270
7R
CO2H



II-7S-1a
1
7S
CO2H



II-7S-47a
47
7S
CO2H



II-7S-55a
55
7S
CO2H



II-7T-55a
55
7T
CO2H



II-7U-31a
31
7U
CO2H



II-7U-55a
55
7U
CO2H



II-7U-88a
88
7U
CO2H



II-7V-55a
55
7V
CO2H



II-8A-1a
1
8A
CO2H



II-8A-47a
47
8A
CO2H



II-8A-88a
88
8A
CO2H



II-8B-1a
1
8B
CO2H



II-8B-47a
47
8B
CO2H



II-8B-88a
88
8B
CO2H



II-8C-55a
55
8C
CO2H



II-8C-88a
88
8C
CO2H



II-9A-1a
1
9A
CO2H



II-9A-47a
47
9A
CO2H



II-9A-88a
88
9A
CO2H



II-9B-1a
1
9B
CO2H



II-9B-47a
47
9B
CO2H



II-9B-88a
88
9B
CO2H

















TABLE 12













 












Compd. No..
—X1—X2—X3
A
R
















III-5A-1a
1
5A
CO2H



III-5A-47a
47
5A
CO2H



III-5A-55a
55
5A
CO2H



III-5A-80a
80
5A
CO2H



III-7A-1a
1
7A
CO2H



III-7A-47a
47
7A
CO2H



III-7A-55a
55
7A
CO2H



III-7A-80a
80
7A
CO2H

















TABLE 13













 












Compd. No..
—X1—X2—X3
A
R
















IV-5A-1a
1
5A
CO2H



IV-5A-47a
47
5A
CO2H



IV-7A-1a
1
7A
CO2H



IV-7A-47a
47
7A
CO2H

















TABLE 14













 












Compd. No..
—X1—X2—X3
A
R
















V-5A-88a
88
5A
CO2H



V-7A-88a
88
7A
CO2H

















TABLE 15













 












Compd. No..
—X1—X2—X3
A
R
















VI-6A-1a
1
6A
CO2H



VI-6A-31a
31
6A
CO2H



VI-6A-40a
40
6A
CO2H



VI-6A-47a
47
6A
CO2H



VI-6A-55a
55
6A
CO2H



VI-6A-80a
80
6A
CO2H



VI-6A-88a
88
6A
CO2H



VI-6A-104a
104
6A
CO2H



VI-6A-122a
122
6A
CO2H



VI-6A-123a
123
6A
CO2H



VI-6A-124a
124
6A
CO2H



VI-6A-133a
133
6A
CO2H

















TABLE 16













 












Compd. No..
—X1—X2—X3
A
R
















VII-6A-1a
1
6A
CO2H



VII-6A-47a
47
6A
CO2H



VII-6A-88a
88
6A
CO2H


















TABLE 17





Compd.



No..
Physical property







I-4B-1a
1H-NMR(CD3OD) δ 1.24–2.33(11H, m), 2.46(1H, m),



3.69–3.76(2H, m), 6.11(1H, dt, J=7.8and33.3Hz),



6.36(2H, m), 7.23(2H, m), 7.71(2H, m), 8.54(1H, br);



IR(CHCl3)3442, 2877, 1741, 1657, 1529, 1504, 1456,



1383, 1167, 1076, 1057, 1036cm−1; [α]D25+37.7±0.7°



(c=1.05, MeOH)


I-4E-1a
1H-NMR(CDCl3) δ 1.26–1.76(7H, m), 2.10(1H, m), 2.47



(1H, m), 3.35(1H, dd, J=8.4and9.0Hz), 3.58(1H, dd, J=



6.3and8.4Hz), 3.98(1H, d, J=16.2Hz), 4.08(1H, m),



4.13(1H, d, J=16.2Hz), 6.27(1H, d, J=8.1Hz), 6.34



(2H, d, J=4.8Hz), 7.15(2H, d, J=4.8Hz), 7.37(1H, d,



J=4.2Hz), 7.58(1H, d, J=4.2Hz); IR(CHCl3)3440,



2958, 2879, 1753, 1734, 1655, 1533, 1508, 1477, 1456,



1427, 1383, 1315, 1167, 1122, 1057, 1034cm−1; [α]D24+



41.7±0.8°(c=1.00, CHCl3)Anal.(C19H22N2O6S2·0.6H2O)



Calcd.(%): C, 50.79; H, 5.20; N, 6.23; S, 14.27Found(%): 



C, 50.76; H, 5.00; N, 6.26; S, 14.09


I-4F-1a
mp126–128°C.; 1H-NMR(CD3OD) δ 1.26–1.66(8H, m),



2.03(1H, m), 2.48(1H, m), 2.57(1H, m), 3.76(1H, m),



5.69(1H, dt, J=8.1and21.3Hz), 6.36(2H, m), 7.23



(2H, m), 7.72(2H, m), 8.53(1H, d, J=5.4Hz); IR



(CHCl3)3417, 3322, 2958, 2877, 1730, 1653, 1535, 1508,



1456, 1427, 1379, 1302, 1167, 1128, 1057, 1036cm−1;



[α]D25+68.3±1.0°(c=1.04, MeOH)Anal.



(C20H21FN2O5S2·0.9H2O)Calcd.(%): C, 51.52; H, 4.90; N,



5.98; F, 4.05; S, 13.68Found(%): C, 51.46; H, 4.62; N,



5.72; F, 3.72; S, 12.93


I-5A-1a
1H-NMR(CDCl3) δ 1.02(1H, m), 1.23–1.44(8H, m),



1.54–1.65(4H, m), 2.00(1H, m), 2.29–2.36(2H, m), 2.49



(1H, brs), 3.80(1H, m), 6.17(1H, d, J=7.5Hz), 6.33–6.34



(2H, m), 7.15–7.16(2H, m), 7.35(1H, d, J=3.9Hz),



7.55(1H, d, J=3.9Hz); IR(CHCl3)3516, 3442, 1709,



1658, 1529, 1504, 1456, 1383, 1192, 1167, 1057, 1034cm−1;



[α]D27+48.7±0.9°(c=1.006, MeOH)Anal.



(C21H26N2O5S2)Calcd.(%): C, 55.98; H, 5.82; N, 6.22; S,



14.23Found(%): C, 56.10; H, 5.81; N, 6.08; S, 13.77


I-5A-31a
1H-NMR(CDCl3) δ 0.95(1H, m), 1.16–1.70(12H, m), 1.97



(1H, m), 2.32(2H, t, J=7.2Hz), 2.48(1H, m), 3.81(1H,



m), 4.14(2H, s), 5.83(1H, d, J=6.6Hz), 6.77(1H, d, J=



3.3Hz), 7.21–7.37(6H, m); IR(CHCl3)3514, 3446, 3427,



1709, 1643, 1543, 1506, 1456cm−1; [α]D24.0+46.9±0.9°



(c=1.011, MeOH)Anal.(C24H29NO3S·0.5H2O)Calcd.(%): 



C, 68.54; H, 7.19; N, 3.33; S, 7.62Found(%): C, 68.62;



H, 7.03; N, 3.47; S, 7.54

















TABLE 18





Compd.



No..
Physical property







I-5A-47a
1H-NMR(CDCl3) δ 1.03(1H, m), 1.18–1.70(12H, m), 1.98



(1H, m), 2.32(2H, dt, J=8.1, 2.1Hz), 2.50(1H, m), 3.81



(1H, m), 6.19(1H, d, J=7.8Hz), 7.11 



(1H, dd, J=5.1, 3.9Hz),



7.39(1H, d, J=3.9Hz), 7.61(1H, d, J=3.9Hz),



7.70(1H, dd, J=5.1, 1.2Hz), 7.75(1H, dd, J=3.9, 1.2Hz);



IR(CHCl3)3512, 3442, 3375, 2679, 1709, 1655,



1529, 1504, 1402, 1336, 1153, 1095, 1022cm−1; [α]D24.0+



48.6±0.9°(c=1.009, MeOH)Anal.



(C21H25NO5S3·0.2H2O)Calcd.(%): C, 53.53; H, 5.43; N,



2.97; S, 20.41Found(%): C, 53.56; H, 5.32; N, 2.92; S,



20.17


I-5A-55a
1H-NMR(CDCl3) δ 1.02(1H, m), 1.25–1.48(8H, m),



1.55–1.66(4H, m), 2.01(1H, m), 2.32



(2H, dt, J=2.1, 7.5Hz),



2.38(3H, s), 2.50(1H, brs), 3.80(1H, m), 5.99(1H,



m), 6.07(1H, brd, J=5.7Hz), 6.20(1H, t, J=3.3Hz),



7.18(1H, dd, J=1.8, 3.3Hz), 7.35(1H, d, J=3.9Hz),



7.54(1H, d, J=3.9Hz); IR(CHCl3)3514, 3442, 3149,



3101, 1709, 1657, 1529, 1504, 1375, 1182, 1161, 1053cm−1;



[α]D24+47.1±0.9°(c=1.003, MeOH)Anal.



(C22H28N2O5S2)Calcd.(%): C, 56.87; H, 6.07; N, 6.03; S,



13.80Found(%): C, 56.59; H, 6.06; N, 5.91; S, 13.52


I-5A-59a
1H-NMR(CDCl3) δ 0.97(1H, m), 1.16–1.68(12H, m), 1.98



(1H, d, J=3.9Hz), 2.31(2H, t, J=7.5Hz), 2.47(1H, m),



3.79(1H, m), 5.86(1H, d, J=4.5Hz), 7.01(1H, dd, J=



5.4, 3.6Hz), 7.04(1H, d, J=3.6Hz), 7.28(1H, dd, J=



3.6, 1.2Hz), 7.31(1H, d, J=3.6Hz), 7.42(1H, dd, J=



5.4, 1.2Hz); IR(CHCl3)3516, 3444, 3425, 2671, 1709,



1645, 1531, 1498, 1421cm−1; [α]D25.0+49.1±0.9°(c=1.003,



MeOH)Anal.(C21H25NO3S3·0.1H2O)Calcd.(%): C, 57.66;



H, 5.81; N, 3.20; S, 21.99Found(%): C, 57.47; H, 5.81;



N, 3.23; S, 22.21


I-5A-59b
1H-NMR(CDCl3) δ 0.96(1H, m), 1.16–1.66(12H, m), 1.98



(1H, d, J=3.6Hz), 2.27(2H, dt, J=7.2, 1.8Hz), 2.49



(1H, m), 3.62(3H, s), 3.77(1H, m), 5.85(1H, d, J=6.9Hz),



7.01(1H, dd, J=5.4, 3.6Hz), 7.04(1H, d, J=4.2Hz),



7.29(1H, dd, J=3.6, 1.2Hz), 7.31(1H, d, J=4.2Hz),



7.43(1H, dd, J=5.4, 1.2Hz)


I-5A-88a
1H-NMR(CDCl3) δ 0.96(1H, m), 1.16–1.70(12H, m), 1.99



(1H, d, J=3.6Hz), 2.32(2H, t, J=7.5Hz), 2.50(1H, m),



3.82(1H, m), 4.16(2H, s), 5.85(1H, d, J=8.1Hz), 6.79



(1H, d, J=3.6Hz), 6.96(1H, dd, J=5.1, 1.5Hz), 7.05



(1H, m), 7.28(1H, dd, J=5.1, 3.0Hz), 7.35(1H, d, J=



3.6Hz); IR(CHCl3)3516, 3446, 3427, 1709, 1641, 1545,



1506, 1458cm−1; [α]D24.0+44.9±0.9°(c=1.003, MeOH)



Anal.(C22H27NO3S2·0.1H2O)Calcd.(%): C, 63.00; H, 6.54;



N, 3.34; S, 15.29Found(%): C, 63.06; H, 6.53; N, 3.43; S,



15.01

















TABLE 19





Compd.



No..
Physical property







I-5A-104a
1H-NMR(CDCl3) δ 0.99(1H, m), 1.18–1.70(12H, m), 1.99



(1H, m), 2.33(2H, t, J=7.5Hz), 2.50(1H, m), 3.82(1H,



m), 4.10(2H, s), 5.88(1H, d, J=8.4Hz), 6.70(1H, d, J=



3.6Hz), 6.95(1H, dd, J=5.4, 3.6Hz), 7.04(1H, dd, J=



3.6, 1.2Hz), 7.28(1H, d, J=3.6Hz), 7.36(1H, dd, J=5.4,



1.2Hz); IR(CHCl3)3514, 3446, 2669, 1709, 1643, 1543,



1506, 1458cm−1; [α]D25.0+44.5±1.3°



(c=0.670, MeOH)Anal.



(C22H27NO3S3·0.2H2O)Calcd.(%): C, 58.30; H, 6.09; N,



3.09; S, 21.22Found(%): C, 58.34; H, 6.09; N, 3.25; S,



21.10


I-5A-143a
1H-NMR(CDCl3) δ 1.01(1H, m), 1.16–1.72(12H, m), 2.00



(1H, m), 2.33(2H, t, J=7.5Hz), 2.57(1H, m), 3.93(1H,



m), 4.24(2H, s), 6.03(1H, d, J=7.5Hz), 7.18–7.34(6H, m),



7.42(1H, t, J=7.8Hz), 7.80



(1H, s), 8.17(1H, d, J=7.8Hz);



IR(CHCl3)3514, 3438, 1709, 1651, 1516, 1495cm−1;



[α]D24.0+41.4±0.8°(c=1.000, MeOH)Anal.(C28H31NO3S·



0.3H2O)Calcd.(%): C, 72.01; H, 6.82; N, 3.00; S, 6.87



Found(%): C, 72.05; H, 6.81; N, 3.02; S, 6.75


I-5A-197a
1H-NMR(CDCl3) δ 0.96(1H, m), 1.18–1.68(12H, m), 1.97



(1H, d, J=3.9Hz), 2.32(2H, t, J=7.5Hz), 2.48(1H, m),



3.22(2H, t, J=8.7Hz), 3.80(1H, m), 4.07(2H, s), 4.57



(2H, t, J=8.7Hz), 5.83(1H, d, J=7.8Hz), 6.79(1H, t, J=



7.5Hz), 6.81(1H, d, J=3.9Hz), 6.97(1H, d, J=7.5Hz),



7.09(1H, d, J=7.5Hz), 7.33(1H, d, J=3.9Hz); IR



(CHCl3)3516, 3446, 3427, 2679, 1709, 1641, 1543, 1506,



1458cm−1; [α]D25.0+14.7±0.5°



(c=1.009, MeOH)Anal.



(C26H31NO4S·0.6H2O)Calcd.(%): C, 67.24; H, 6.99; N, 3.01;



S, 6.90Found(%): C, 67.14; H, 6.85; N, 3.03; S, 6.64


I-5B-1a
1H-NMR(CDCl3) δ 1.08–1.70(7H, m),



2.04(1H, m), 2.10–2.18



(2H, m), 2.53(1H, brs), 3.14(1H, d, J=6.0Hz), 3.81



(1H, m), 5.52–5.67(2H, m), 6.25



(1H, d, J=6.9Hz), 6.33–6.34



(2H, m), 7.14–7.16(2H, m), 7.35(1H, d, J=3.9Hz),



7.54(1H, d, J=3.9Hz); IR(CHCl3)3512, 3440, 1712,



1658, 1531, 1504, 1456, 1383, 1192, 1167, 1057, 1034cm−1;



[α]D27+61.4±1.0°(c=1.008, MeOH)Anal.



(C21H24N2O5S2·0.3H2O)Calcd.(%): C, 55.56; H, 5.46; N,



6.17; S, 14.13Found(%): C, 55.47; H, 5.42; N, 6.54; S,



14.26


I-5C-1a
mp149–152°C.; 1H-NMR(CDCl3) δ 1.07(1H, m),



1.24–1.32(2H, m), 1.41–1.48(2H, m),



1.53–1.69(4H, m), 2.01(1H, m),



2.23–2.30(2H, m), 2.49(1H, brs), 3.87(1H, m), 5.78(1H, d,



J=15.6Hz), 6.15(1H, d, J=7.2Hz), 6.33–6.34(2H, m),



7.02(1H, dt, J=15.6and7.2Hz), 7.15–7.17(2H, m), 7.37



and7.56(each1H, eachd, eachJ=4.2Hz); IR(CHCl3)



3523, 3440, 2679, 1695, 1655, 1529, 1504, 1456, 1383,



1192, 1167, 1057, 1034cm−1; [α]D24+38.7±0.8°(c=1.001,



MeOH)Anal.(C21H24N2O5S2·0.2H2O)Calcd.(%): C, 55.78;



H, 5.44; N, 6.20; S, 14.18Found(%): C, 55.70; H, 5.36; N,



6.20; S, 14.08

















TABLE 20





Compd.



No..
Physical property







I-5C-31a
1H-NMR(CDCl3) δ 0.99(1H, m), 1.22–1.29(2H, m),



1.42–1.49(2H, m), 1.53–1.69(4H, m), 1.99(1H, m),



2.18–2.33(2H, m), 2.49(1H, brs), 3.88(1H, m), 4.14(2H,



s), 5.79(1H, d, J=15.6Hz), 5.85(1H, d, J=7.8Hz), 6.78



(1H, d, J=3.6Hz), 7.03(1H, dt, J=6.9and15.6Hz),



7.23–7.33(5H, m), 7.36(1H, d, J=3.6Hz); IR(CHCl3)



3523, 3446, 3427, 2679, 1695, 1649, 1543, 1506, 1456,



1308, 1282cm−1; [α]D24+41.2±0.8°



(c=1.011, MeOH)



Anal.(C24H27NO3S·0.2H2O)Calcd.(%): C, 69.77; H, 6.68;



N, 3.39; S, 7.76Found(%): C, 69.72; H, 6.55; N, 3.40; S,



7.65


I-5C-47a
1H-NMR(CDCl3) δ 1.09(1H, m), 1.25–1.31(2H, m),



1.42–1.47(2H, m), 1.56–1.64(4H, m), 2.00(1H, m),



2.24–2.31(2H, m), 2.49(1H, brs), 3.88(1H, m), 5.78(1H,



d, J=15.6Hz), 6.25(1H, d, J=8.1Hz), 7.02(1H, dt, J=



15.6and6.8Hz), 7.12(1H, dd, J=3.6and4.8Hz), 7.42



and7.61(each1H, eachd, eachJ=3.9Hz), 7.70(1H, dd,



J=1.5and4.8Hz), 7.75(1H, dd, J=1.5and3.6Hz); IR



(CHCl3)3523, 3440, 3373, 2681, 1695, 1653, 1529, 1504,



1335, 1402, 1153, 1095, 1020cm−1;



[α]D24+39.1±0.8°



(c=1.000, MeOH)Anal. 



(C21H33NO5S3·0.3H2O)Calcd.(%): 



C, 53.55; H, 5.05; N, 2.97; S, 20.42Found(%): C, 53.58;



H, 4.97; N, 3.04; S, 20.17


I-5C-88a
1H-NMR(CDCl3) δ 1.00(1H, m), 1.23–1.30(2H, m),



1.43–1.48(2H, m), 1.53–1.69(4H, m), 2.00(1H, m),



2.19–2.33(2H, m), 2.50(1H, brs), 3.88(1H, m), 4.16(2H,



s), 5.79(1H, dt, J=15.6and1.5Hz),



5.90(1H, d, J=8.1Hz),



6.79(1H, d, J=3.6Hz), 6.95–7.08(3H, m), 7.28(1H,



dd, J=2.7and4.8Hz), 7.36(1H, d, J=3.6Hz); IR



(CHCl3)3523, 3446, 3427, 2679, 1695, 1649, 1543, 1506,



1458, 1284cm−1; [α]D24+39.9±0.8°



(c=1.011, MeOH)



Anal.(C24H27NO3S·0.2H2O)Calcd.(%): C, 63.04; H, 6.11;



N, 3.34; S, 15.30Found(%): C, 63.12; H, 5.96; N, 3.44; S,



15.22


I-5D-1a
mp150–152°C.; 1H-NMR(CDCl3) δ 1.32–1.66(6H, m),



1.96(1H, m), 2.12–2.46(5H, m), 2.61(1H, brs), 3.87



(1H, m), 5.28(1H, m), 5.41(1H, dd, J=9.6, 10.5Hz),



6.33(2H, t, J=2.4Hz), 6.68(1H, br d, J=7.2Hz), 7.15



(2H, t, J=2.4Hz), 7.44(1H, d, J=3.9Hz), 7.48(1H, d, J=



3.9Hz); IR(CHCl3)3510, 3390, 3145, 3101, 2673,



1709, 1655, 1531, 1506, 1456, 13811192, 1167, 1057,



1034cm−1; [α]D25+9.2±0.5°



(c=1.011, MeOH)Anal.



(C21H24N2O5S2)Calcd.(%): C, 56.23; H, 5.39; N, 6.25; S,



14.30Found(%): C, 56.20; H, 5.44; N, 6.23; S, 14.23

















TABLE 21





Compd. 



No..
Physical property







I-5E-1a
mp155–159°C.; 1H-NMR(CDCl3) δ 1.18–1.82(9H, m),



2.00(1H, m), 2.61(1H, m), 3.50–3.59(2H, m), 3.79(1H,



m), 3.99and4.10(each1H, Abq, J=17.1Hz), 5.54–5.70



(2H, m), 6.32–6.34(2H, m), 6.47(1H, d, J=6.3Hz),



7.14–7.17(2H, m), 7.39(1H, d, J=4.2Hz), 7.54(1H, d, J=



4.2Hz); IR(CHCl3)3423, 1764, 1730, 1655, 1531,



1506, 1456, 1383, 1192, 1167, 1057cm−1; [α]D23+



28.9±0.7°(c=1.011, MeOH)Anal.(C20H26N2O6S2)



Calcd.(%): C, 53.08; H, 5.35; N, 6.19; S, 14.17Found(%): 



C, 53.44; H, 5.62; N, 6.00; S, 13.70


I-6A-1a
mp109–111°C.; 1H-NMR(CDCl3) δ 1.02(1H, m),



1.24–1.56



(14H, m), 1.98(1H, brs), 2.29(2H, t, J=7.2Hz),



2.48(1H, brs), 3.79(1H, m), 6.28(1H, d, J=7.2Hz),



6.33(2H, t, J=2.4Hz), 7.15(2H, t, J=2.4Hz), 7.38 and



7.55(each1H, eachd, eachJ=4.2Hz); IR(KBr)3352,



1709, 1624, 1541, 1512, 1456, 1377, 1192, 1167, 1057,



1036cm−1; [α]D24.5+47.7±0.9°



(c=1.003, MeOH)Anal.



(C22H28N2O5S2·0.2H2O)Calcd.(%): C, 56.44; H, 6.11; N,



5.98; S, 13.70Found(%): C, 56.50; H, 6.11; N, 6.18; S,



13.51


I-6B-1a
1H-NMR(CDCl3) δ 1.08(1H, m), 1.21–1.31(2H, m),



1.40–1.45(2H, m), 1.58–1.66(2H, m), 2.03–2.19(3H, m),



2.32–2.46(4H, m), 2.52(1H, brs), 3.80(1H, m), 5.33–5.45



(2H, m), 6.24(1H, d, J=7.8Hz), 6.32–6.34(2H, m),



7.15–7.16(2H, m), 7.36(1H, d, J=3.9Hz), 7.55(1H, d, J=



3.9Hz); IR(CHCl3)3514, 3440, 1711, 1657, 1531,



1504, 1456, 1383, 1192, 1167, 1057, 1034cm−1; [α]D24.5+



69.8±1.1°(c=1.006, MeOH)Anal.



(C22H26N2O5S2·0.2H2O)Calcd.(%): C, 56.68; H, 5.71; N,



6.01; S, 13.76Found(%): C, 56.67; H, 5.70; N, 6.14; S,



13.89


I-6B-31a
1H-NMR(CDCl3) δ 1.04(1H, m), 1.17–1.28(2H, m),



1.41–1.46(2H, m), 1.55–1.66(2H, m), 2.00(1H, m),



2.04–2.24(2H, m), 2.31–2.44(4H, m), 2.51(1H, brs), 3.82



(1H, m), 4.13(2H, s), 5.32–5.44(2H, m), 5.96(1H, d, J=



6.6Hz), 6.76(1H, dt, J=3.6and0.9Hz), 7.22–7.35(5H,



m), 7.36(1H, d, J=3.6Hz); IR(CHCl3)3514, 3444,



3427, 2671, 1711, 1643, 1545, 1506, 1454, 1309, 1279cm−1;



[α]D24+67.7±1.1°(c=1.002, MeOH)Anal.



(C25H29NO3S)Calcd.(%): C, 70.89; H, 6.90; N, 3.31; S,



7.57Found(%): C, 70.67; H, 6.95; N, 3.36; S, 7.42


I-6D-1a
1H-NMR(CDCl3) δ 1.26–1.34(2H, m), 1.43–1.48(2H, m),



1.55–1.76(4H, m), 1.96–2.13(4H, m),



2.32(2H, t, J=7.2Hz),



2.59(1H, br s), 3.92(1H, m), 5.28–5.44(2H, m), 6.33



(2H, t, J=2.1Hz), 6.69(1H, br d, J=6.6Hz), 7.15(2H,



t, J=2.1Hz), 7.39(1H, d, J=4.2Hz), 7.53(1H, d, J=



4.2Hz); IR(CHCl3)3512, 3368, 1706, 1654, 1532, 1506,



1455, 1382, 1212, 1132, 1106, 1075, 1016cm−1; Anal.



(C22H26N2O5S2)Calcd.(%): C, 57.12; H, 5.67; N, 6.06; S,



13.86Found(%): C, 56.91; H, 5.71; N, 6.18; S, 13.75

















TABLE 22





Compd.



No..
Physical property







I-7A-1a
mp114–117°C.;



1H-NMR(CDCl3) δ 1.05(1H, m), 1.18–1.70



(16H, m), 2.00(1H, m), 2.32(2H, t, J=6.9Hz), 2.49



(1H, m), 3.80(1H, m), 6.05(1H, d, J=7.2Hz), 6.32–6.35



(2H, m), 7.15–7.18(2H, m), 7.35(1H, d, J=3.9Hz), 7.57



(1H, d, J=3.9Hz); IR(CHCl3)3442, 1708, 1657, 1529,



1504, 1456, 1383, 1192, 1167, 1057, 1034cm−1; [α]D24+



45.9±0.9°(c=1.004, MeOH)Anal.(C23H30N2O5S2)



Calcd.(%): C, 57.72; H, 6.32; N, 5.85; S, 13.40Found



(%): C, 57.56; H, 6.44; N, 5.82; S, 13.11


I-7A-1e
1H-NMR(CDCl3) δ 1.01(1H, m), 1.29–1.67(16H, m), 1.99



(1H, m), 2.30(2H, t, J=7.2Hz), 2.45(1H, m), 3.28(3H,



s), 3.84(1H, m), 6.14(1H, d, J=7.8Hz), 6.34(2H, d, J=



4.5Hz), 7.16(2H, d, J=4.5Hz), 7.40(1H, d, J=3.9Hz),



7.58(1H, d, J=3.9Hz); IR(CHCl3)3386, 2954, 2929,



2877, 2858, 1720, 1651, 1531, 1506, 1456, 1425, 1398,



1385, 1342, 1167, 1076, 1067, 1034cm−1; [α]D25+



38.5±0.8°(c=1.01, MeOH)Anal.



(C24H33N3O6S3·0.8MeOH)Calcd.(%): C, 51.24; H, 6.28; N,



7.23; S, 16.55Found(%): C, 51.59; H, 6.17; N, 7.40; S,



16.22


I-7A-1h
mp134–136°C.;



1H-NMR(CDCl3) δ 0.97(1H, m), 1.28–1.69



(18H, m), 2.01(1H, m), 2.49(1H, brs), 3.61(2H, t, J=



6.6Hz), 3.81(1H, m), 6.05(1H, d, J=7.8Hz), 6.33–6.35



(2H, m), 7.16–7.17(2H, m), 7.35and7.57(each1H,



eachd, eachJ=3.9Hz); IR(Nujol)3357, 3244, 1621,



1554, 1371, 1186, 1169, 1061, 1038cm−1; [α]D24+



47.8±0.9°(c=1.005, MeOH)Anal.



(C23H32N2O4S2·0.2AcOEt)Calcd.(%): C, 59.27; H, 7.02;



N, 5.81; S, 13.30Found(%): C, 59.53; H, 7.09; N, 5.92; S,



13.29


I-7A-1i
mp82–84°C.;



1H-NMR(CDCl3) δ 0.95(1H, m), 1.26–1.65



(18H, m), 2.01(1H, m), 2.49(1H, brs), 3.32(3H, s), 3.34



(2H, t, J=6.6Hz), 3.80(1H, m), 5.97(1H, d, J=7.5Hz),



6.33–6.34(2H, m), 7.16–7.17(2H, m), 7.33and7.58(each



1H, eachd, eachJ=3.9Hz); IR(CHCl3)3442, 1658,



1529, 1504, 1456, 1385, 1192, 1167, 1113, 1057, 1034cm−1;



[α]D25+43.9±0.8°(c=1.003, MeOH)Anal.



(C24H34N2O4S2)Calcd.(%): C, 60.22; H, 7.16; N, 5.85; S,



13.40Found(%): C, 60.27; H, 7.14; N, 5.79; S, 13.29


I-7A-31a
1H-NMR(CDCl3) δ 0.92(1H, m), 1.18–1.66(16H, m), 1.96



(1H, m), 2.31(2H, t, J=7.5Hz), 2.48(1H, m), 3.81(1H,



m), 4.13(2H, s), 5.83(1H, d, J=8.1Hz), 6.77(1H, d, J=



3.9Hz), 7.21–7.36(6H, m); IR(CHCl3)3516, 3446, 3427,



1709, 1643, 1543, 1506, 1456cm−1;



[α]D24.0+41.0±0.8°



(c=1.006, MeOH)Anal.(C26H33NO3S·0.2H2O)Calcd.(%): 



C, 70.46; H, 7.60; N, 3.16; S, 7.23Found(%): C, 70.43;



H, 7.66; N, 3.21; S, 7.07

















TABLE 23





Compd.



No..
Physical property







I-7A-47a
1H-NMR(CDCl3) δ 0.98(1H, m), 1.16–1.70(16H, m), 1.99



(1H, m), 2.31(2H, t, J=7.5Hz), 2.49(1H, m), 3.80(1H,



m), 6.05(1H, d, J=7.8Hz), 7.10(1H, dd, J=4.8, 3.6Hz),



7.39(1H, d, J=3.9Hz), 7.64(1H, d, J=3.9Hz), 7.69(1H,



dd, J=4.8, 1.2Hz), 7.75(1H, dd, J=3.6, 1.2Hz); IR



(CHCl3)3514, 3442, 3375, 2677, 1709, 1655, 1529, 1504,



1402, 1336, 1153, 1095, 1022cm−1;



[α]D24.0+45.7±0.9°



(c=1.010, MeOH)Anal.(C23H29NO5S3·0.2H2O)Calcd.(%): 



C, 55.33; H, 5.94; N, 2.80; S, 19.26Found(%): C, 55.42; H,



6.04; N, 2.86; S, 19.03


I-7A-47i
1H-NMR(CDCl3) δ 0.96(1H, m),



1.26–1.35(11H, m), 1.40–1.46



(2H, m), 1.51–1.67(5H, m), 2.01(1H, m), 2.50(1H,



brs), 3.32(3H, s), 3.34(2H, t, J=6.9Hz), 3.80(1H, m),



6.03(1H, d, J=7.5Hz), 7.11(1H, dd, J=3.9and4.8Hz),



7.38and7.65(each1H, eachd, eachJ=3.9Hz), 7.70(1H,



dd, J=1.5and4.8Hz), 7.76(1H, dd, J=1.5and3.9Hz);



IR(CHCl3)3442, 1657, 1529, 1504, 1402, 1336, 1153, 1113,



1095, 1020cm−1; [α]D25+43.7±0.8°



(c=1.008, MeOH)Anal.



(C24H33NO4S3·0.1H2O)Calcd.(%): C, 57.94; H, 6.73; N,



2.82; S, 19.34Found(%): C, 57.81; H, 6.68; N, 2.90; S,



19.42


I-7A-59a
1H-NMR(CDCl3) δ 0.93(1H, m), 1.16–1.68(16H, m), 1.98



(1H, d, J=3.6Hz), 2.31(2H, t, J=7.2Hz), 2.47(1H, m),



3.78(1H, m), 5.87(1H, d, J=7.5Hz), 7.00(1H, dd, J=5.7,



3.9Hz), 7.04(1H, d, J=3.6Hz),



7.28(1H, dd, J=3.9, 1.2Hz),



7.31(1H, d, J=3.6Hz), 7.42(1H, dd, J=5.7, 1.2Hz);



IR(CHCI3)3516, 3444, 3427, 2671, 1709, 1645, 1529, 1498,



1421cm−1; [δ ]D25.0+41.2±0.8°



(c=1.003, MeOH)Anal.



(C23H29NO3S3)Calcd.(%): C, 59.58; H, 6.30; N, 3.02; S,



20.75Found(%): C, 59.70; H, 6.27; N, 3.03; S, 20.56


I-7A-88a
1H-NMR(CDCl3) δ 0.93(1H, m), 1.16–1.68(16H, m), 1.98



(1H, d, J=3.6Hz), 2.31(2H, t, J=7.5Hz), 2.49(1H, m),



3.81(1H, m), 4.15(2H, s), 5.86(1H, d, J=7.5Hz), 6.79



(1H, d, J=3.6Hz), 6.96(1H, dd, J=4.8, 1.2Hz), 7.05(1H,



dd, J=3.0, 1.2Hz), 7.28(1H, dd, J=4.8, 3.0Hz), 7.35(1H,



d, J=3.6Hz); IR(CHCl3)3516, 3446, 3427, 1709, 1641,



1545, 1506, 1458cm−1; [α]D24.0+40.2±0.8°



(c=1.007, MeOH)



Anal.(C24H31NO3S2·0.1H2O)Calcd.(%): C, 64.42; H, 7.03;



N, 3.13; S, 14.33Found(%): C, 64.52; H, 7.00; N, 3.18; S,



14.04


I-7A-88h
mp92–93°C.; 1H-NMR(CDCl3) δ 0.94(1H, m), 1.20–1.34



(11H, m), 1.42–1.47(2H, m), 1.48–1.63(5H, m), 1.98(1H,



m), 2.49(1H, brs), 3.61(2H, t, J=6.6Hz), 3.83(1H, m),



4.16(2H, s), 5.86(1H, d, J=8.1Hz), 6.79(1H, d, J=



3.6Hz), 6.97(1H, dd, J=1.2and4.8Hz), 7.06(1H, m), 7.29



(1H, dd, J=3.0and4.8Hz), 7.35(1H, d, J=3.6Hz); IR



(Nujol)3315, 3259, 1599, 1549, 1527, 1317cm−1; [α]D24+



45.0±0.9°(c=1.001, MeOH)Anal.(C24H33NO2S2)



Calcd.(%): C, 66.78; H, 7.71; N, 3.24; S, 14.86Found(%): 



C, 66.85; H, 7.71; N, 3.37; S, 14.57

















TABLE 24





Compd.



No..
Physical property







I-7A-88i
mp47–48°C.; 1H-NMR(CDCl3) δ 0.93(1H, m),



1.23–1.32



(11H, m), 1.41–1.46(2H, m), 1.51–1.63(5H, m), 1.98(1H,



m), 2.50(1H, brs), 3.31(3H, s), 3.34(2H, t, J=6.6Hz),



3.81(1H, m), 4.16(2H, s), 5.81(1H, d, J=7.2Hz), 6.79



(1H, d, J=3.9Hz), 6.97(1H, dd, J=0.9and4.8Hz), 7.06



(1H, m), 7.29(1H, dd, J=3.0and4.8Hz), 7.34(1H, d, J=



3.9Hz); IR(CHCl3)3446, 3426, 1643, 1543, 1506, 1460,



1113cm−1; [α]D25.5+43.0±0.8°



(c=1.008, MeOH)Anal.



(C25H35NO2S2)Calcd.(%): C, 67.37; H, 7.92; N, 3.14; S,



14.39Found(%): C, 67.32; H, 7.91; N, 3.19; S, 14.32


I-7A-104a
1H-NMR(CDCl3) δ 0.95(1H, m), 1.18–1.70(16H, m), 2.00



(1H, d, J=3.6Hz), 2.32(2H, t, J=7.5Hz), 2.50(1H, m),



3.82(1H, m), 4.10(2H, s), 5.87(1H, d, J=7.2Hz), 6.70



(1H, d, J=3.6Hz), 6.95(1H, dd, J=5.4, 3.6Hz), 7.04(1H,



dd, J=3.6, 1.2Hz),



7.28(1H, d, J=3.6Hz), 7.36(1H, dd, J=



5.4, 1.2Hz); IR(CHCl3)3516, 3446, 3427, 2671, 1709,



1643, 1543, 1506, 1458cm−1;



[α]D25.0+39.4±0.8°.(c=1.004,



MeOH)Anal.(C24H31NO3S3)Calcd.(%): C, 60.34; H, 6.54;



N, 2.93; S, 20.14Found(%): C, 60.12; H, 6.51; N, 3.05; S,



19.95


I-7A-143a
1H-NMR(CDCl3) δ 0.97(1H, m), 1.16–1.70(16H, m), 2.00



(1H, m), 2.31(2H, t, J=7.5Hz), 2.58(1H, m), 3.93(1H,



m), 4.24(2H, s), 6.01(1H, d, J=7.2Hz), 7.18–7.32(6H, m),



7.42(1H, t, J=7.8Hz), 7.80(1H, s),



8.18(1H, d, J=7.2Hz);



IR(CHCl3)3516, 3438, 1709, 1651, 1516, 1495cm−1;



[α]D24.0+41.9±0.8°(c=1.006, MeOH)Anal.



(C30H35NO3S·



0.2H2O)Calcd.(%): C, 73.05; H, 7.23; N, 2.84; S, 6.50



Found(%): C, 73.10; H, 7.13; N, 2.86; S, 6.39


I-7A-197a
1H-NMR(CDCl3) δ 0.93(1H, m), 1.18–1.68(16H, m), 1.97



(1H, d, J=3.9Hz), 2.31(2H, t, J=7.5Hz), 2.48(1H, m),



3.22(2H, t, J=9.0Hz), 3.81(1H, m), 4.07(2H, s), 4.57



(2H, t, J=9.0Hz), 5.82(1H, d, J=7.5Hz), 6.79(1H, t, J=



7.2Hz), 6.80(1H, d, J=7.2Hz), 6.96(1H, d, J=7.2Hz),



7.09(1H, d, J=7.2Hz), 7.33(1H, d, J=7.2Hz); IR



(CHCl3)3516, 3446, 3427, 2671, 1709, 1641, 1543, 1506,



1458cm−1; [α]D25.0+37.9±0.8°



(c=1.003, MeOH)Anal.



(C28H35NO4S·0.3H2O)Calcd.(%): C, 69.05; H, 7.39; N, 2.88;



S, 6.58Found(%): C, 69.11; H, 7.24; N, 2.99; S, 6.61


I-7A-315a
1H-NMR(CDCl3) δ 1.00(1H, m), 1.23–1.63(16H, m), 2.00



(1H, m), 2.31(2H, t, J=7.2Hz), 2.58(1H, m), 3.94(1H,



m), 4.26(2H, s), 6.06(1H, d, J=7.8Hz), 7.00–7.18(5H, m),



7.42(1H, m), 7.82(1H, s), 8.18(1H, d, J=7.2Hz); 



IR(CHCl3)3516, 3438, 2954, 2927, 2875, 2856, 1709, 1653,



1516, 1492, 1456, 1396, 1298, 1271cm−1;



[α]D25.5+39.0±0.8°



(c=1.04, MeOH)Anal.(C30H34FNO3S·0.5MeOH)Calcd.(%): 



C, 69.95; H, 6.93; N, 2.67; F, 3.63; S, 6.12Found(%): C,



70.24; H, 6.80; N, 2.98; F, 3.19; S, 6.08

















TABLE 25





Compd.



No..
Physical property







I-7A-316a
1H-NMR(CDCl3) δ 0.98(1H, m), 1.22–1.63(16H, m), 2.00



(1H, m), 2.31(2H, t, J=7.5Hz), 2.58(1H, m), 3.82(3H,



s), 3.92(1H, m), 4.23(2H, s), 6.03(1H, d, J=8.1Hz),



6.85–6.91(2H, m), 7.02–7.23(3H, m), 7.39(1H, m), 7.83



(1H, s), 8.14(1H, d, J=8.4Hz); IR(CHCl3)3518, 3438,



2954, 2929, 1709, 1653, 1601, 1516, 1493, 1464, 1439,



1394, 1246cm−1; [α]D26.0+35.2±0.7°(c=1.03, MeOH)



Anal.(C31H37NO4S·0.2H2O)Calcd.(%): C, 71.15; H, 7.20;



N, 2.68; S, 6.13Found(%): C, 71.03; H, 7.35; N, 2.86; S,



5.99


I-7B-1a
1H-NMR(CDCl3) δ 0.98–2.49(20H, m), 1.14(3H, d, J=



6.9Hz), 3.80(1H, m), 6.05(1H, d, J=5.2Hz), 6.33(2H,



d, J=4.2Hz), 7.16(2H, d, J=4.2Hz), 7.35(1H, m), 7.57



(1H, m); IR(CHCl3)3442, 2954, 2929, 2877, 2858, 1705,



1657, 1529, 1504, 1456, 1383, 1167, 1057, 1034cm−1;



[α]D24.5+41.6±1.6°(c=0.50, CHCl3)Anal.



(C24H32N2O5S2·0.4MeOH)Calcd.(%): C, 57.98; H, 6.70; N,



5.54; S, 12.69Found(%): C, 58.27; H, 6.47; N, 5.50; S,



12.33


I-7D-1a
1H-NMR(CDCl3) δ 0.98(1H, m), 1.22–2.33(17H, m), 2.48



(1H, m), 3.79(1H, m), 4.92(1H, dt, J=6.0and44.1Hz),



6.07(1H, d, J=7.2Hz), 6.33(2H, d, J=4.8Hz), 7.16



(2H, d, J=4.8Hz), 7.36(1H, d, J=3.6Hz), 7.57(1H, d,



J=3.6Hz); IR(CHCl3)3440, 2956, 2875, 1732, 1657,



1531, 1504, 1456, 1383, 1167, 1057, 1034cm−1; [α]D25+



30.2±0.7°(c=1.02, MeOH)Anal.



(C23H29FN2O5S2·0.3MeOH)Calcd.(%): C, 55.28; H, 6.01;



N, 5.53; F, 3.75; S, 12.67Found(%): C, 55.58; H, 6.14; N,



5.61; S, 12.05


I-7E-1c
1H-NMR(CDCl3) δ 1.18–1.30(3H, m), 1.40–1.45(2H, m),



1.57–1.82(5H, m), 1.95–2.28(6H, m), 2.54(1H, br s),



3.75(1H, m), 5.26(1H, br), 5.30–5.46(2H, m), 5.89(1H,



br), 6.33(2H, t, J=2.4Hz), 6.69(1H, br d, J=6.0Hz),



7.17(2H, t, J=2.4Hz), 7.48(1H, d, J=3.9Hz), 7.57



(1H, d, J=3.9Hz); IR(CHCl3)3527, 3485, 3442, 3411,



3340, 1674, 1531, 1504, 1456, 1383, 1192, 1167, 1057,



1034cm−1; [α]D24+79.9±1.2°(c=1.002, MeOH)Anal.



(C23H29N3O4S2·0.3H2O)Calcd.(%): C, 57.43; H, 6.20; N,



8.74; S, 13.33Found(%): C, 57.55; H, 6.50; N, 8.76; S,



13.28


I-7E-1d
1H-NMR(CDCl3) δ 1.19–1.27(3H, m), 1.40–1.45(2H, m),



1.56–1.82(5H, m), 1.97–2.20(6H, m), 2.56(1H, br s), 2.75



(3H, d, J=4.8Hz), 3.73(1H, m), 5.29–5.42(2H, m), 5.90



(1H, br), 6.33(2H, t, J=2.1Hz), 6.79(1H, br d, J=7.8Hz),



7.16(2H, t, J=2.1Hz), 7.54and7.57(each1H,



ABq, J=3.9Hz); [α]D24+76.1±1.2°(c=1.006, MeOH)



Anal.(C24H31N3O4S2·0.3H2O)Calcd.(%): C, 58.23; H,



6.43; N, 8.49; S, 12.95Found(%): C, 58.22; H, 6.64; N,



8.45; S, 12.81

















TABLE 26





Compd.



No..
Physical property







I-7E-1e
1H-NMR(CDCl3) δ 1.16–2.24(13H, m), 2.32(2H, d, J=



7.2Hz), 2.57(1H, m), 3.27(3H, s), 3.74(1H, m), 5.25–5.32



(2H, m), 6.14(1H, d, J=7.5Hz), 6.35(2H, d, J=4.8Hz),



7.18(2H, d, J=4.8Hz), 7.46(1H, d, J=3.9Hz),



7.60(1H, d, J=3.9Hz), 9.96(1H, s); IR(CHCl3)2956,



2879, 1716, 1645, 1533, 1506, 1456, 1385, 1342, 1167,



1122, 1057, 1034cm−1; [α]D24+90.4±1.3°



(c=1.00, CHCl3)



Anal.(C24H31N3O6S3·0.8MeOH)Calcd.(%): C, 51.41; H,



5.95; N, 7.25; S, 16.60Found(%): C, 51.77; H, 5.70; N,



7.53; S, 16.22


I-7E-1f
1H-NMR(CDCl3) δ 1.07–2.19(13H, m), 2.51(1H, m), 2.58



(2H, t, J=7.5Hz), 3.22(3H, s), 3.27(3H, s), 3.84(1H,



m), 5.32–5.43(2H, m), 6.26(1H, d, J=7.8Hz), 6.33(2H,



d, J=4.5Hz), 7.17(2H, d, J=4.5Hz), 7.39(1H, d, J=



4.2Hz), 7.58(1H, d, J=4.2Hz); IR(CHCl3)3394, 2956,



2877, 1699, 1655, 1531, 1504, 1456, 1381, 1354, 1167,



1057, 1034cm−1; [α]D24.5+47.4±0.9°



(c=1.00, CHCl3)



Anal.(C25H33N3O6S3·0.2H2O)Calcd.(%): C, 52.55; H,



5.89; N, 7.35; S, 16.84Found(%): C, 52.85; H, 5.81; N,



7.26; S, 16.45


I-7E-1g
1H-NMR(CDCl3) δ 1.12–1.86(9H, m), 2.01–2.10(5H, m),



2.55(1H, br s), 2.96–3.04(2H, m), 3.57(1H, m), 5.27–5.40



(2H, m), 6.36(2H, t, J=2.1Hz), 7.17(2H, t, J=2.1Hz),



7.46(1H, d, J=3.9Hz), 7.60(1H, d, J=3.9Hz); IR



(CHCl3)3462, 3336, 1657, 1531, 1506, 1456, 1383, 1192,



1167, 1057, 1036cm−1; 



[α]D25+74.0±1.1°(c=1.000,



MeOH)Anal.(C23H28N6O3S2·0.4Et2O)Calcd.(%): C,



55.72; H, 6.08; N, 15.85; S, 12.09Found(%): C, 55.45; H,



6.10; N, 15.85; S, 11.84


I-7E-1h
mp123–125°C.; 1H-NMR(CDCl3) δ 1.09(1H, m), 1.16–1.75



(10H, m), 1.99–2.20(5H, m), 2.52(1H, brs), 3.63



(2H, t, J=6.5Hz), 3.81(1H, m), 5.28–5.44(2H, m), 6.24



(1H, d, J=7.2Hz), 6.33–6.34(2H, m), 7.15–7.17(2H, m),



7.37and7.57(each1H, eachd, eachJ=3.9Hz); IR



(Nujol)3388, 3255, 1618, 1552, 1373, 1190, 1163, 1057,



1039cm−1; [α]D25+80.1±1.2°



(c=1.014, MeOH)Anal.



(C23H30N2O4S2)Calcd.(%): C, 59.71; H, 6.54; N, 6.06; S,



13.86Found(%): C, 59.59; H, 6.50; N, 6.08; S, 13.82


I-7E-1i
1H-NMR(CDCl3) δ 1.06(1H, m), 1.19–1.31(2H, m),



1.34–1.44(4H, m), 1.52–1.65(4H, m), 2.01–2.13(5H, m),



2.53(1H, brs), 3.32(3H, s), 3.37(2H, t, J=6.3Hz), 3.82



(1H, m), 5.28–5.44(2H, m), 6.15(1H, d, J=7.5Hz),



6.32–6.34(2H, m), 7.15–7.17(2H, m), 7.35and7.57(each



1H, eachd, eachJ=4.2Hz); IR(CHCl3)3442, 1658,



1529, 1504, 1456, 1382, 1192, 1167, 1115, 1057, 1034cm−1;



[α]D24+73.8±1.1°(c=1.006, MeOH)Anal.



(C24H32N2O4S2·0.2H2O)Calcd.(%): C, 60.02; H, 6.80; N,



5.83; S, 13.35Found(%): C, 60.09; H, 6.75; N, 5.79; S,



13.19

















TABLE 27





Compd.



No..
Physical property







I-7E-47i
1H-NMR(CDCl3) δ 1.08(1H, m), 1.21–1.31(2H, m),



1.21–1.31(2H, m), 1.37–1.46(4H, m), 2.01–2.13(5H, m),



2.53(1H, brs), 3.32(3H, s), 3.37(2H, t, J=6.6Hz), 3.82



(1H, m), 5.28–5.43(2H, m), 6.19(1H, d, J=7.2Hz), 6.19



(1H, d, J=7.2Hz), 7.11(1H, dd, J=3.9and5.1Hz),



7.39and7.63(each1H, eachd, eachJ=3.9Hz), 7.69



(1H, dd, J=1.5and5.1Hz), 7.75



(1H, dd, J=1.5and3.9Hz);



IR(CHCl3)3442, 1657, 1529, 1504, 1402, 1336,



1153, 1115, 1097, 1020cm−1; [α]D24+76.3±1.2°(c=1.011,



MeOH)Anal.(C24H31NO4S3·0.5H2O)Calcd.(%): C, 57.34;



H, 6.42; N, 2.79; S, 19.14Found(%): C, 57.25; H, 6.25;



N, 2.83; S, 19.25


I-7E-88e
1H-NMR(CDCl3) δ 1.11–1.66(9H, m), 1.93–2.34(7H, m),



2.59(1H, m), 3.24(3H, s), 3.70(1H, m), 4.17(2H, s),



5.21–5.31(2H, m), 5.92(1H, d, J=9.6Hz), 6.84(1H, d,



J= 3.6Hz), 6.98(1H, dd, J=1.5and4.8Hz), 7.08(1H,



dd, J=1.2and1.8Hz), 7.30(1H, m),



7.50(1H, d, J=3.6Hz),



10.78(1H, s); IR(CHCl3)3444, 3425, 2954, 2877,



1714, 1630, 1545, 1510, 1456, 1408, 1342, 1169, 1122cm−1;



[α]D24+66.0±2.1°(c=0.50, MeOH)Anal.



(C25H32N2O4S3·0.3H2O)Calcd.(%): C, 57.07; H, 6.25; N,



5.32; S, 18.28Found(%): C, 57.38; H, 6.34; N, 5.52; S,



17.92


I-7E-88h
1H-NMR(CDCl3) δ 1.04(1H, m), 1.19–1.75(10H, m),



2.02–2.24(5H, m), 2.53(1H, brs), 3.63(2H, t, J=6.6Hz),



3.83(1H, m), 4.16(2H, s), 5.30–5.44(2H, m), 5.90(1H, d,



J=6.9Hz), 6.79(1H, d, J=3.6Hz), 6.96(1H, dd, J=1.5



and4.8Hz), 7.05(1H, dd, J=1.5and3.0Hz), 7.28(1H,



dd, J=3.0and4.8Hz), 7.35(1H, d, J=3.6Hz); IR



(CHCl3)3624, 3446, 3429, 1643, 1545, 1506cm−1; [α]D24+



74.7±1.1°(c=1.009, MeOH)Anal.



(C24H31NO2S2·0.2H2O)Calcd.(%): C, 66.54; H, 7.31; N,



3.23; S, 14.80Found(%): C, 66.55; H, 7.26; N, 3.38; S,



14.57


I-7E-88i
1H-NMR(CDCl3) δ 1.03(1H, m), 1.18–1.29(2H, m),



1.34–1.47(4H, m), 1.53–1.67(4H, m), 2.01–2.14(5H, m),



2.54(1H, brs), 3.32(3H, s), 3.36(2H, t, J=6.6Hz), 3.84



(1H, m), 4.16(2H, s), 5.29–5.43(2H, m), 5.90(1H, d, J=



7.5Hz), 6.79(1H, dt, J=3.9and0.9Hz), 6.96(1H, dd, J=



1.5and5.1Hz), 7.06(1H, m), 7.29(1H, dd, J=3.0and



5.1Hz), 7.35(1H, d, J=3.9Hz); IR(CHCl3)3446, 3429,



1643, 1543, 1506, 1458, 1115cm−1; [α]D25+68.1±1.1°



(c=1.019, MeOH)Anal.(C25H33NO2S2·0.2H2O)Calcd.(%): 



C, 67.13; H, 7.53; N, 3.13; S, 14.34Found(%): C, 67.10;



H, 7.53; N, 3.21; S, 14.32

















TABLE 28





Compd.



No..
Physical property







I-7F-1a
1H-NMR(CDCl3) δ 1.09–2.51(16H, m), 1.17(3H, m), 3.80



(1H, s), 5.28–5.42(2H, m), 6.24(1H, m), 6.33(2H, d, J=



4.5Hz), 7.15(2H, d, J=4.5Hz), 7.39(1H, d, J=4.2Hz),



7.56(1H, d, J=4.2Hz); IR(CHCl3)3442, 2956, 2877,



1705, 1657, 1531, 1504, 1456, 1383, 1167, 1057, 1034cm−1;



[α]D24+49.0±0.9°(c=1.00, CHCl3)Anal.



(C24H30N2O5S2·0.7H2O)Calcd.(%): C, 57.28; H, 6.29; N,



5.57; S, 12.74Found(%): C, 57.49; H, 6.11; N, 5.66; S,



12.46


I-7G-1a
1H-NMR(CDCl3) δ 1.06–2.18(14H, m), 1.21(6H, s), 2.51



(1H, m), 2.75(1H, m), 5.27–5.43(2H, m), 6.17(1H, d, J=



6.9Hz), 6.33(2H, dd, J=4.5and2.4Hz), 7.16(2H, dd, J=



4.5and2.4Hz), 7.37(1H, d, J=4.2Hz), 7.57(1H, d, J=



4.2Hz); IR(CHCl3)3442, 2956, 2877, 1728, 1699,



1657, 1531, 1504, 1475, 1456, 1383, 1167, 1074, 1057,



1034cm−1; [α]D25+43.4±0.8°(c=1.00, CHCl3)


I-7G-88a
1H-NMR(CDCl3) δ 1.04–2.24(14H, m), 1.20(3H, s), 1.21



(3H, s), 2.50(1H, m), 3.85(1H, m), 4.16(2H, s), 5.29–5.43



(2H, m), 5.97(1H, d, J=7.5Hz), 6.79(1H, d, J=3.9Hz),



6.96(1H, dd, J=5.1and1.2Hz), 7.05(1H, d, J=



1.2Hz), 7.29(1H, m), 7.37(1H, J=3.9Hz); IR(CHCl3)



3446, 3427, 2956, 2877, 1728, 1699, 1743, 1545, 1506,



1475, 1458, 1282, 1024cm−1; [α]D26+48.6±0.9°(c=1.02,



CHCl3)Anal.(C26H33NO3S2·0.3H2O)Calcd.(%): C, 65.46;



H, 7.10; N, 2.94; S, 13.44Found(%): C, 65.66; H, 6.96;



N, 3.12; S, 13.05


I-7G-126a
1H-NMR(CDCl3) δ 0.95(1H, d, J=9.9Hz), 1.08(3H, s),



1.17(3H, s), 1.90(3H, s), 1.21(3H, s), 1.53–2.51(12H,



m), 3.84(3H, s), 4.12(2H, s), 4.24(1H, m), 5.39–5.43(2H,



m), 6.04(1H, d, J=8.7Hz), 6.77(1H, d, J=2.7Hz),



6.86–6.92(2H, m), 7.14–7.23(2H, m),



7.31(1H, d, J=3.6Hz);



IR(CHCl3)3450, 3431, 2924, 1728, 1699, 1641,



1601, 1543, 1506, 1471, 1406, 1387, 1367, 1319, 1288,



1126, 1049, 1030cm−1; [α]D25+29.7±0.7°(c=1.00, CHCl3)



Anal.(C31H41NO4S·0.3H2O)Calcd.(%): C, 70.37; H, 7.92;



N, 2.65; S, 6.06Found(%): C, 70.50; H, 8.03; N, 2.78; S,



5.84


I-7I-1a
1H-NMR(CDCl3) δ 0.98(1H, m), 1.19–1.49(10H, m),



1.54–1.67(2H, m), 2.00(1H, m), 2.16–2.24(2H, m), 2.48



(1H, brs), 3.81(1H, m), 5.79(1H, d, J=15.6Hz), 6.12



(1H, d, J=7.2Hz), 6.33–6.34(2H, m), 7.03(1H, dt, J=



15.6and7.2Hz), 7.15–7.17(2H, m), 7.35and7.56(each



1H, eachd, eachJ=3.9Hz); IR(CHCl3)3523, 3442,



2681, 1695, 1655, 1529, 1504, 1456, 1425, 1383, 1192,



1167, 1057, 1034cm−1; [α]D24.5+40.1±0.8°(c=1.003,



MeOH)Anal.(C23H28N2O5S2·0.3H2O)Calcd.(%): C,



57.31; H, 5.98; N, 5.81; S, 13.30Found(%): C, 57.59; H,



5.98; N, 5.86; S, 14.04

















TABLE 29





Compd.



No..
Physical property







I-7I-31a
mp134–136°C.; 1H-NMR(CDCl3) δ 0.94(1H, m), 1.18–1.46



(10H, m), 1.54–1.68(2H, m), 1.98(1H, m), 2.16–2.23



(2H, m), 2.48(1H, brs), 3.83(1H, m), 4.14(2H, s), 5.79



(1H, dt, J=15.6and1.5Hz), 5.83(1H, d, J=6.9Hz),



6.78(1H, d, J=3.3Hz), 7.03(1H, dt, J=6.8and15.6Hz),



7.23–7.33(5H, m), 7.35(1H, d, J=3.3Hz); IR(KBr)



3329, 1695, 1649, 1616, 1549, 1527, 1454, 1319, 1288cm−1;



[α]D25+35.6±0.8°(c=1.004, MeOH)Anal.



(C26H31NO3S)Calcd.(%): C, 71.36; H, 7.14; N, 3.20; S,



7.33Found(%): C, 71.15; H, 7.14; N, 3.28; S, 7.22


I-7I-47a
1H-NMR(CDCl3) δ 1.00(1H, m), 1.26–1.46(10H, m),



1.55–1.65(2H, m), 2.00(1H, m), 2.17–2.24(2H, m), 2.49



(1H, brs), 3.82(1H, m), 5.79(1H, d, J=15.6Hz), 6.16



(1H, d, J=7.5Hz), 7.03(1H, dt, J=15.6and7.1Hz),



7.11(1H, dd, J=3.6and4.8Hz), 7.40and7.63(each1H,



eachd, eachJ=3.9Hz), 7.70(1H, dd, J=1.2and4.8Hz),



7.75(1H, dd, J=1.2and3.6Hz); IR(CHCl3)3523,



3442, 3375, 2681, 1695, 1653, 1529, 1504, 1402, 1336,



1402, 1153, 1095, 1022cm−1; [α]D24+40.3±0.80°(c=1.015,



MeOH)Anal.(C23H27NO5S3·0.2H2O)Calcd.(%): C, 55.55;



H, 5.55; N, 2.82; S, 19.35Found(%): C, 55.52; H, 5.46;



N, 2.92; S, 19.31


I-7I-88a
1H-NMR(CDCl3) δ 0.95(1H, m), 1.21–1.46(10H, m),



1.55–1.68(2H, m), 1.98(1H, m), 2.16–2.33(2H, m), 2.49



(1H, brs), 3.83(1H, m), 4.16(2H, s), 5.79(1H, d, J=15.6Hz),



5.88(1H, d, J=7.5Hz), 6.79(1H, d, J=3.6Hz),



6.95–7.08(3H, m), 7.28(1H, dd, J=3.0and4.8Hz), 7.35



(1H, d, J=3.6Hz); IR(CHCl3)3523, 3446, 3427, 2679,



1695, 1647, 1545, 1506, 1458, 1300, 1281cm−1; [α]D24+



34.7±0.70°(c=1.004, MeOH)Anal.(C24H29NO3S2)



Calcd.(%): C, 64.98; H, 6.59; N, 3.16; S, 14.46Found(%): 



C, 64.71; H, 6.61; N, 3.24; S, 14.17


I-7I-93a
mp116–120°C.; 1H-NMR(CDCl3) δ 0.95(1H, m), 1.21–1.68



(12H, m), 1.98(1H, m), 2.17–2.23(2H, m), 2.48(1H,



brs), 3.84(1H, m), 4.34(2H, s), 5.80(1H, br d, J=15.6Hz),



5.84(1H, d), 6.85(1H, br d, J=3.3Hz), 6.90(1H,



m), 6.95(1H, dd, J=3.6, 5.1Hz), 7.02(1H, dt, J=15.9,



6.9Hz), 7.19(1H, dd, J=1.2, 5.1Hz), 7.35(1H, d, J=



3.3Hz); IR(Nujol)3032, 1695, 1648, 1542, 1506, 1458,



1223, 1213cm−1; [α]D26.0+37.6±0.80°(c=1.015, MeOH)



Anal.(C24H29NO3S2·0.1H2O)Calcd.(%): C, 64.72; H, 6.61;



N, 3.14; S, 14.40Found(%): C, 64.64; H, 6.58; N, 3.24; S,



14.50

















TABLE 30





Compd.



No..
Physical property







I-7I-126a
1H-NMR(CDCl3) δ 0.93(1H, m),



1.20–1.48(10H, m), 1.54–1.64



(2H, s), 1.97(1H, d, J=3.6Hz), 2.19(2H, dd, J=13.8,



6.9Hz), 2.47(1H, m), 3.84(3H, s), 4.12(2H, s), 5.80(1H, 



dt, J=15.6, 1.5Hz), 5.81(1H, d, J=6.9Hz),



6.78(1H, d, J=3.9Hz),



6.86–6.93(2H, m), 7.01(1H, dt, J=15.6, 6.9Hz), 7.16



(1H, d, J=7.2Hz), 7.22(1H, d, J=7.2Hz), 7.31(1H, d, J=



3.9Hz); IR(Nujol)3276, 3079, 3058, 2678, 1691, 1604, 



1552, 1456, 1319, 1247cm−1;



[α]D27.0+34.3±0.70°



(c=1.010, MeOH)



Anal.(C27H33NO4S)Calcd.(%): C, 69.35; H, 7.11; N, 3.00; 



S, 6.86Found(%): C, 69.19; H, 7.10; N, 3.12; S, 6.62


I-7I-143a
1H-NMR(CDCl3) δ 1.00(1H, m), 1.21–1.50(10H, m),



1.59–1.65(2H, m), 2.00(1H, m),



2.17–2.21(2H, m), 2.57(1H, brs),



3.94(1H, m), 4.24(2H, s), 5.79(1H, d, J=15.6Hz), 6.07



(1H, d, J=7.8Hz), 7.03(1H, dt, J=15.6and7.2Hz),



7.18–7.30(6H, m), 7.42(1H, t, J=7.8Hz),



7.81(1H, s), 8.18(1H, d, J=



7.8Hz); IR(CHCl3)3523, 3438, 2683, 1695,



1651, 1516, 1495cm−1;



[α]D24+41.7±0.80°(c=1.002, MeOH)Anal.



(C30H33NO3S)



Calcd.(%): C, 73.62; H, 6.84; N, 2.86; S, 6.55Found(%): C,



73.54; H, 6.77; N, 2.92; S, 6.49


I-7I-270a
1H-NMR(CDCl3) δ 0.99(1H, m), 1.18–1.70(12H, m), 2.01



(1H, brd), 2.17–2.24(2H, m), 2.42(6H, s), 2.48(1H, brs), 



3.81(1H, m), 5.79(1H, dt, J=15.6, 1.5Hz), 5.88(2H, s), 



6.05(1H, d, J=7.5Hz), 7.03(1H, dt, J=15.6, 6.9Hz),



7.35(1H, d, J=



3.9Hz), 7.50(1H, d, J=3.9Hz); IR(CHCl3)3525, 3442,



2677, 1695, 1655, 1529, 1504, 1375, 1180, 1119cm−1;



[α]D25+37.7±0.8°(c=1.009, MeOH)Anal.



(C25H32N2O5S2·0.3H2O)



Calcd.(%): C, 58.87; H, 6.44; N, 5.49; S, 12.57 



Found(%): C, 58.99; H, 6.39; N, 5.51; S, 12.48


I-7I-307a
mp171–173°C.; 1H-NMR(CDCl3) δ 0.91(1H, m),



1.17–1.41(10H, m), 1.50–1.59(2H, m),



1.93(1H, m), 2.12–2.19(2H, m),



2.44(1H, m), 3.78(1H, m), 3.97(3H, s), 4.59(2H, s), 5.77



(1H, d, J=15.6Hz), 5.81(1H, d, J=7.2Hz), 6.75(1H, d, 



J=3.6Hz), 7.01(1H, dt, J=15.6, 7.1Hz),



7.28(1H, d, J=3.6Hz),



7.25–7.36(3H, m), 7.46(1H, m), 7.78–7.82(1H, m), 7.92



(1H, d, J=8.7Hz); IR(Nujol)3365, 3059, 2638, 1689, 1622,



1552, 1527, 1516, 1464, 1263, 1252, 1092cm−1;



[α]D25.5+



31.6±0.7°(c=1.001, MeOH)Anal.



(C31H35NO4S)Calcd.(%): 



C, 71.92; H, 6.81; N, 2.71; S, 6.19Found(%): C, 71.62; H,



6.90; N, 2.79; S, 6.20


I-7I-327a
mp176–179°C.; 1H-NMR(CDCl3)



δ 0.98(1H, m), 1.20–1.70



(12H, m), 2.00(1H, d, J=3.6Hz), 2.16–2.24(2H, m), 2.47



(1H, brs), 3.00(2H, t, J=8.4Hz), 3.80(1H, m), 3.98



(2H, t, J=8.4Hz), 5.79(1H, dt, J=1.8, 15.3Hz),



6.01(1H, d, J=7.8Hz),



6.97–7.24(4H, m), 7.33(1H, d, J=4.2Hz), 7.46(1H, d, J=



4.2Hz), 7.58(1H, d, J=8.4Hz); IR(Nujol)3332, 2925,



2854, 1689, 1608, 1554, 1479, 1460, 1365, 1238, 1161cm−1;



[α]D26+36.3±0.8°(c=1.012%, MeOH);



Anal.(C27H32N2O5S2)



Calcd.(%)C, 61.34; H, 6.10; N, 5.30; S, 12.13Found(%)C,



61.08; H, 6.22; N, 5.24; S, 11.82

















TABLE 31





Compd.



No..
Physical property







I-7I-332a
mp136–139°C.; 1H-NMR(CDCl3)



δ 0.98(1H, m), 1.20–1.82



(14H, m), 2.01(1H, d, J=3.0Hz), 2.21(2H, q, J=



6.9Hz), 2.48(1H, brs), 2.53(2H, t, J=6.6Hz), 3.53



(2H, t, J=6.3Hz), 3.79–3.87(3H, m), 5.79(1H, dt, J=



1.5, 15.6Hz), 6.01(1H, d, J=7.2Hz), 6.97–7.26(5H, m),



7.31(1H, d, J=3.9Hz), 7.77(1H, dd, J=0.9, 7.8Hz); IR



(Nujol)3371, 3325, 2922, 1728, 1693, 1614, 1549, 1342,



1163cm−1; [α]D24+35.4±0.8°



(c=1.009%, MeOH); Anal.



(C28H34N2O5S2)Calcd.(%)C, 61.97; H, 6.31; N, 5.16; S,



11.82Found(%)C, 61.94; H, 6.47; N, 5.14; S, 11.69


I-7I-343a
1H-NMR(CDCl3) δ 1.07(1H, m), 1.22–1.62(12H, m), 1.98



(1H, m), 2.22(1H, m), 2.54(1H, m), 3.94(1H, m), 5.80



(1H, d, J=15.6Hz), 6.27(1H, d, J=8.1Hz), 7.02(1H,



m), 7.45–7.60(5H, m), 7.89(1H, s), 7.99–8.05(3H, m),



8.59(1H, d, J=8.1Hz); IR(KBr)3381, 3292, 3066,



2949, 2927, 2873, 1685, 1655, 1620, 1558, 1477, 1446,



1385, 1319, 1308, 1284, 1244, 1230, 1209cm−1;



[α]D26.0+32.6±1.5°



(c=0.50, DMSO)Anal.(C29H31NO5S2·0.4H2O)



Calcd.(%): C, 63.92; H, 5.88; N, 2.57; S, 11.77Found(%): 



C, 64.07; H, 5.82; N, 2.75; S, 11.41


I-7I-385a
1H-NMR(CDCl3) δ 1.03(1H, m), 1.20–1.74(12H, m), 2.04



(1H, m), 2.14–2.26(2H, m), 2.57(1H, m), 3.97(1H, m),



5.77(1H, d, J=15.6Hz), 6.27(2H, t, J=2.4Hz), 6.37



(1H, d, J=8.4Hz), 7.02(1H, dt, J=15.6, 6.9Hz), 7.22



(2H, t, J=2.4Hz), 7.57(1H, t, J=7.8Hz), 7.67(1H, d, J=



7.8Hz), 8.37(1H, d, J=7.8Hz), 8.44(1H, s); IR



(CHCl3)3452, 3023, 2954, 2877, 1695, 1650, 1516, 1456,



1373, 1282, 1188, 1163, 1057cm−1;



[α]D22.0+39.4 ±0.8°



(c=1.017, MeOH)Anal.(C27H30N2O5S2·0.1H2O)



Calcd.(%): C, 61.36; H, 5.76; N, 5.30; S, 12.14Found(%): 



C, 61.26; H, 5.89; N, 5.11; S, 11.95


I-7I-389a
mp140–143°C.; 1H-NMR(CDCl3) δ 0.96(1H, m), 



1.21–1.46(10H, m), 1.54–1.64(2H, m),



1.99(1H, m), 2.23(3H,



s)+2.16–2.23(2H, m), 2.48(1H, m), 3.21(2H, t, 



J=8.7Hz), 3.81(1H, m), 4.62(2H, t, J=8.7Hz), 5.79(1H,



d, J=15.6Hz), 5.88(1H, d, J=7.8Hz), 6.89(1H, s), 6.96



(1H, s), 7.02(1H, dd, J=15.6, 6.9Hz),



7.08(1H, d, J=3.9Hz),



7.35(1H, d, J=3.9Hz); IR(Nujol)3294, 3066,



2675, 1695, 1649, 1604, 1550, 1512, 1327, 1203cm−1;



[α]D25+29.2±0.7°(c=1.013, MeOH)Anal.



(C28H33NO4S2)Calcd.(%): C, 65.72; H, 650; N, 2.74; S,



12.53Found(%): C, 65.57; H, 6.62; N, 2.62; S, 12.37

















TABLE 32





Compd.



No..
Physical property







I-7I-391a
mp204–207°C.; 1H-NMR(CDCl3)



δ 1.01(1H, m), 1.25–1.46



(10H, m), 1.54–1.64(2H, m), 2.00(1H, m), 2.17–2.23(2H,



m), 2.31(3H, s), 2.48(1H, m), 3.18(2H, t, J=8.7Hz), 3.81



(1H, m), 4.71(2H, t, J=8.7Hz), 5.79(1H, d, J=15.6Hz),



6.20(1H, d, J=7.8Hz), 7.02(1H, dt, J=15.6, 6.9Hz), 7.21



(1H, s), 7.41(1H, d, J=3.9Hz), 7.50(1H, s), 7.70(1H, d, 



J=3.9Hz); IR(Nujol)3398, 3197, 3086, 1716, 1689, 1639,



1541, 1313, 1151cm−1;



[α]D25+37.9±0.8°(c=1.005, MeOH)



Anal.(C28H33NO6S2)Calcd.(%): C, 61.85; H,



6.12; N, 2.58; S, 11.80Found(%): C, 61.61; H, 6.08; N,



2.50; S, 11.69


I-7J-1a
mp116–118°C.; 1H-NMR(CDCl3) δ 0.99(1H, m),



1.19–1.82(12H, m), 1.79(3H, d, J=1.2Hz), 2.01(1H, m),



2.17(2H, brq, J=7.8Hz), 2.48(1H, m),



3.82(1H, m), 6.00(1H, d, J=



7.8Hz), 6.32–6.35(2H, m), 6.85(1H, m), 7.15–7.17(2H,



m), 7.33(1H, d, J=3.9Hz), 7.63(1H, d, J=3.9Hz), 7.57



(1H, d, J=3.9Hz); IR(Nujol)3354, 3141, 3099, 3076,



2669, 2557, 1682, 1641, 1624, 1539, 1390, 1375, 1302,



1190, 1167cm−1;



[α]D2637.1±0.6°(c=1.002, MeOH)Anal.



(C24H30N2O5S2)Calcd.(%): C, 58.75; H, 6.16;



N, 5.71; S, 13.07Found(%): 



C, 58.55; H, 6.14; N, 5.70; S, 12.89


I-7K-1a
mp168–171°C.; 1H-NMR(CDCl3)



δ 0.99(1H, m), 1.20–1.82



(12H, m), 2.01–2.20(3H, m), 2.12(3H, d, J=0.9Hz), 2.48



(1H, m), 3.82(1H, m), 4.05(2H, s), 5.65(1H, s), 5.97(1H,



d, J=7.5Hz), 6.33–6.35(2H, m), 7.16–7.18(2H, m), 7.33



(1H, d, J=3.9Hz), 7.63(1H, d, J=3.9Hz), 7.58(1H, d, J=



3.9Hz); IR(Nujol)3330, 3086, 1693, 1633, 1614, 1544,



1456, 1377, 1250, 1194, 1169, 1057cm−1;



[α]D26+34.0±1.5°



(c=0.509, MeOH)Anal.



(C24H30N2O5S2·0.6CHCl3)



Calcd.(%): C, 52.55; H, 5.49; N, 4.98; S, 11.41; Cl, 11.35



Found(%): C, 52.62; H, 5.19; N, 4.93; S, 11.11; Cl, 10.53


I-7M-1a
1H-NMR(CDCl3) δ 1.00–1.70(13H, m), 2.01(1H, m), 2.47



(1H, m), 3.52(2H, t, J=6.6Hz), 3.82(1H, m), 4.04(2H, s),



5.54–5.70(2H, m), 6.13(1H, d, J=7.2Hz), 6.32–6.35(2H,



m), 7.15–7.18(2H, m), 7.37(1H, d, J=4.2Hz), 7.57(1H, d,



J=4.2Hz); IR(CHCl3)3440, 1778, 1731, 1655, 1531, 1504,



1456, 1383, 1192, 1167, 1128, 1057, 1034cm−1; [α]D24+



40.9±0.8°(c=1.007, MeOH)Anal.



(C22H28N2O6S2·0.4H2O)



Calcd.(%): C, 54.17; H, 5.95; N, 5.74; S, 13.15Found(%): 



C, 54.51; H, 6.00; N, 5.58; S, 12.76


I-7M-1e
1H-NMR(CDCl3) δ 1.02–1.70(13H, m), 2.02(1H, m), 2.48



(1H, m), 3.31(3H, s), 3.50(2H, t, J=6.6Hz), 3.85(1H, m),



3.99(2H, s), 6.05(1H, d, J=8.1Hz), 6.34(2H, m), 7.16



(2H, m), 7.36(1H, d, J=3.9Hz), 7.58(1H, d, J=3.9Hz),



8.88(1H, s); IR(CHCl3)3442, 3352, 2956, 2877, 1730,



1657, 1531, 1504, 1456, 1423, 1402, 1385, 1350, 1167,



1076, 1057, 1034cm−1;



[α]D25.5+35.6±0.8°(c=1.00, MeOH)



Anal.(C23H31N3O7S3·0.8MeOH)Calcd.(%): 



C, 48.29; H, 5.74; N, 7.34; S, 16.81Found(%): 



C, 48.00; H, 5.68; N, 7.74; S, 17.12

















TABLE 33





Compd.



No..
Physical property







I-7M-40a
1H-NMR(CDCl3) δ 1.03(1H, m), 1.22–1.74(12H, m), 2.01



(1H, m), 2.51(1H, brs), 3.54(2H, dt, J=1.5, 6.3Hz), 3.91



(1H, m), 4.05(2H, s), 6.03(1H, d, J=8.1Hz), 7.25–7.64



(7H, m); IR(CHCl3)2954, 1780, 1732, 1643, 1541, 1510,



1491, 1454, 1219, 1213, 1132cm−1;



[α]D25+50.9±0.9°



(c=1.013%, MeOH); Anal.(C24H29NO4S·0.5H2O)Calcd.(%)



C, 66.03; H, 6.93; N, 3.21; S, 7.34Found(%)C, 66.14; H,



6.92; N, 3.26; S, 7.22


I-7M-43a
mp132–134°C.; 1H-NMR(CDCl3) δ 1.01(1H, m), 1.20–1.75



(12H, m), 2.01(1H, d, J=3.0Hz), 2.47(1H, brs), 3.53(2H,



t, J=6.0Hz), 3.79–3.96(5H, m),



4.05(2H, s), 6.06(1H, d, J=



7.8Hz), 6.85(1H, dd, J=1.5, 8.1Hz), 6.96(1H, m), 7.11



(1H, m), 7.29(1H, d, J=4.2Hz), 7.34(1H, d, J=4.2Hz),



7.83(1H, dd, J=1.5, 8.1Hz); IR(Nujol)3325, 3084, 2924,



1730, 1612, 1562, 1491, 1460, 1369,



1250, 1236, 1165, 1138cm−1;



[α]D26+53.6±0.9°



(c=1.009%, MeOH); Anal.



(C22H27NO4S2)Calcd.(%)C, 60.94; H, 6.28; N, 3.23; S,



14.79Found(%)C, 60.77; H, 6.32; N, 3.38; S, 14.51


I-7M-47a
mp116–118°C.; 1H-NMR(CDCl3) δ 1.06(1H, m),



1.19–1.70(12H, m), 2.00(1H, m), 2.49(1H, m),



3.52(2H, t, J=6.3Hz),



3.84(1H, m), 4.05(2H, s), 6.21(1H, d, J=7.8Hz),



7.11(1H, dd, J=3.9, 4.5Hz), 7.42(1H, d, J=3.9Hz), 7.63



(1H, d, J=3.9Hz), 7.70(1H, dd, J=0.9, 4.8Hz), 7.75(1H,



dd, J=0.9, 3.9Hz); IR(Nujol)3319, 3097, 2557, 1732,



1618, 1566, 1444, 1432, 1321, 1232, 1151, 1031cm−1;



[α]D24+



44.4±0.8°(c=1.009, MeOH)Anal.(C22H27NO6S3)



Calcd.(%): C, 53.10; H, 5.47; N, 2.81; S, 19.33Found(%): 



C, 52.90; H, 5.37; N, 2.91; S, 19.10


I-7M-59a
mp103–104°C.; 1H-NMR(CDCl3) δ 0.99(1H, m),



1.20–1.70(12H, m), 1.99(1H, d, J=3.3Hz),



2.45(1H, m), 3.23(2H, t,



J=8.7Hz), 3.48–3.55(2H, m), 3.84(1H, m), 4.04(2H, s),



5.89(1H, d, J=8.1Hz), 7.01(1H, dd, J=3.6, 5.1Hz), 7.04



(1H, d, J=3.9Hz), 7.29(1H, dd, J=1.5, 3.6Hz), 7.33(1H,



d, J=3.9Hz), 7.43(1H, dd, J=1.5, 5.1Hz); IR(Nujol)



3332, 2922, 2854, 1930, 1601, 1564, 1458, 1439, 1331,



1230, 1134cm−1;



[α]D26+40.0±0.8°(c=1.004%, MeOH);



Anal.(C22H27NO4S3)Calcd.(%)C, 56.75; H, 5.84; N, 3.01;



S, 20.66Found(%)C, 56.59; H, 5.81; N, 3.04; S, 20.65


I-7M-88a
mp90–91.5°C.; 1H-NMR(CDCl3) δ 1.00(1H, m),



1.18–1.70



(12H, m), 1.99(1H, m), 2.46(1H, m), 3.52(2H, dt, J=1.8,



8.7Hz), 387(1H, m), 4.04and4.16(each2H, s), 4.58(1H,



brs), 5.91(1H, d, J=8.7Hz), 6.80(1H, d, J=3.6Hz), 6.96



(1H, dd, J=1.2, 5.1Hz), 7.06(1H, m), 7.29(1H, dd, J=



3.0, 4.8Hz), 7.37(1H, d, J=3.9Hz); IR(Nujol)3332, 3095,



3080, 2553, 1735, 1597, 1562, 1537, 1435, 1325, 1304,



1228, 1146cm−1; [α]D24+39.8±0.8°(c=1.002,



MeOH)Anal.



(C23H29NO4S2)Calcd.(%): C, 61.72; H, 6.53; N, 3.13; S,



14.33Found(%): C, 61.60; H, 6.20; N, 3.24; S, 14.01

















TABLE 34





Compd.



No..
Physical property







I-7M-126a
1H-NMR(CDCl3) δ 0.96(1H, m),



1.23–1.26(2H, m), 1.38–1.46



(6H, m), 1.54–1.63(4H, s), 1.97(1H, d, J=3.6Hz),



2.45(1H, m), 3.48–3.53(2H, m), 3.83(3H, s), 3.85(1H, m),



4.03(2H, s), 4.12(2H, s), 5.88(1H, d, J=7.8Hz), 6.77(1H,



d, J=3.6Hz), 6.86–6.90(2H, m),



7.16(1H, dd, J=4.5, 1.8Hz),



7.21(1H, dd, J=7.8, 1.8Hz), 7.33(1H, d, J=3.6Hz);



IR(CHCl3)3427, 2875, 1639, 1504, 1460, 1248, 1221cm−1;



[α]D27.0+36.8±1.5°(c=0.508, MeOH)Anal.



(C26H33NO5S·0.3H2O)Calcd.(%): C, 65.47; H, 7.10; N, 2.94;



S, 6.72Found(%): C, 65.30; H, 7.01; N, 3.02; S, 6.54


I-7M-143a
mp123–125°C.;



1H-NMR(CDCl3) δ 1.04(1H, m), 1.20–1.75



(12H, m), 2.01(1H, brs), 2.55(1H, brs), 3.53(2H, dt, J=



1.8, 6.0Hz), 3.98(1H, m), 4.02and4.24(2H, s), 6.08(1H,



d, J=7.8Hz), 7.17–7.45(7H, m), 7.83(1H, s), 8.16(1H, d,



J=7.8Hz); IR(Nujol)3280, 2924, 1722, 1612, 1566, 1454,



1242, 1228, 1137cm−1;



[α]D26+39.2±0.6°(c=1.012%,



MeOH); Anal.(C29H33NO4S)Calcd.(%)C, 70.85; H, 6.77;



N, 2.85; S, 6.52Found(%)C, 70.58;



H, 6.70; N, 2.94; S, 6.40


I-7M-197a
1H-NMR(CDCl3) δ 0.98(1H, m), 1.20–1.70(12H, m), 1.98



(1H, d, J=3.3Hz), 2.45(1H, m), 3.23(2H, t, J=8.7Hz),



3.49–3.54(2H, m), 3.86(1H, m), 4.03and4.08(2H, s), 4.58



(2H, t, J=8.7Hz), 5.88(1H, d, J=8.4Hz), 6.20(1H, t, J=



3.6Hz), 6.77–6.82(2H, m), 6.96(1H, d, J=7.2Hz), 7.10



(1H, d, J=7.2Hz), 7.35(1H, d, J=3.6Hz); IR(CHCl3)



2954, 1732, 1641, 1545, 1506, 1477, 1458, 1254, 1225,



1221, 1213, 1207, 1130cm−1;



[α]D26+37.2±0.8°(c=1.008%,



MeOH); Anal.(C27H33NO5S·0.3H2O)Calcd.(%)C,



66.31; H, 6.93; N, 2.86; S, 6.56Found(%)C,



66.24; H, 6.91; N, 2.92; S, 6.52


I-7M-270a
mp.141–143°C.;



1H-NMR(CDCl3) δ 1.02(1H, br), 1.18–1.70



(12H, m), 2.01(1H, brd), 2.42(6H, s), 2.48(1H, brs), 3.53



(2H, dt, J=0.9, 6.6Hz), 3.83(1H, m), 4.06(2H, s), 5.88



(2H, s), 6.11(1H, d, J=7.8Hz), 7.36(1H, d, J=3.9Hz),



7.50(1H, d, J=3.9Hz); IR(Nujol)3327, 3097, 3084, 2555,



1732, 1616, 1556, 1234, 1219, 1176, 1134, 1113cm−1;



[α]D26+



40.5±0.8°(c=1.014, MeOH)Anal.(C24H32N2O6S2)



Calcd.(%): C, 56.67; H, 6.37; N, 5.51; S, 12.61Found(%): 



C, 56.56; H, 6.10; N, 5.48; S, 12.38


I-7M-307a
mp131–132°C.;



1H-NMR(CDCl3) δ 0.94(1H, m), 1.20–1.23



(2H, m), 1.34–1.39(6H, m),



1.51–1.63(4H, m), 1.94(1H, m),



2.42(1H, m), 3.45–3.49(2H, m), 3.81(1H, m), 3.98(3H, s),



4.01(2H, s), 4.59(2H, s), 5.85(1H, d, J=7.5Hz), 6.75(1H,



d, J=3.3Hz), 7.28–7.36(3H, m,), 7.47(1H, t, J=7.7Hz),



7.79(1H, d, J=3.9Hz), 7.82(1H, d, J=4.8Hz), 7.92(1H,



d, J=8.4Hz);



IR(Nujol)3340, 3068, 2744, 2546, 1738,



1604, 1560, 1435, 1250, 1236, 1146cm−1;



[α]D25.5+36.1±0.8°



(c=1.000, MeOH)Anal.(C30H35NO5S)Calcd.(%): C, 69.07;



H, 6.76; N, 2.68; S, 6.15Found(%): C, 68.99; H, 6.87; N,



2.74; S, 6.05

















TABLE 35





Compd.



No..
Physical property







I-7M-315a
1H-NMR(CDCl3) δ 1.04(1H, m), 1.26–1.64(12H, m), 2.03



(1H, m), 2.55(1H, m), 3.54(2H, t, J=5.1Hz), 3.99 



(1H, m), 4.03(2H, s), 4.26(2H, s),



6.07–6.10(1H, d, J=7.5Hz),



7.00–7.23(5H, m), 7.43(1H, m), 7.85(1H, s),



8.16(1H, d, J=



8.1Hz); IR(CHCl3)3508, 3437, 2954, 2875, 



1780, 1732, 1651, 1518, 1477, 1456, 1396,



1363cm−1; [α]D24.0+38.1±0.8°



(c=1.03, MeOH)Anal.(C29H32FNO4S·0.6MeOH)Calcd.(%): 



C, 67.22; H, 6.56; N, 2.65;F, 3.59; S, 6.06Found(%): C,



67.31; H, 6.57; N, 2.92;F, 3.21; S, 6.09


I-7M-316a
1H-NMR(CDCl3) δ 1.04(1H, m),



1.23–1.68(11H, m), 2.01



(1H, m), 2.55(2H, m), 3.54(2H, t, J=6.6Hz), 3.82(3H, s),



3.99(1H, m), 4.02(2H, s),



4.23(2H, s), 6.09(1H, d, J=8.1Hz),



6.83–6.91(2H, m), 7.05–7.23(3H, m), 7.39(1H, m),



7.85(1H, s), 8.12(1H, d, J=8.1Hz); IR(CHCl3)3437,



2954, 2875, 1780, 1732, 1651, 1601, 1516, 1493, 1464,



1394, 1363, 1246cm−1;



[α]D26.0+35.2±1.5°(c=0.50, MeOH)



Anal.(C30H35NO5S·0.2H2O)Calcd.(%): C,



68.60; H, 6.79; N,



2.67; S, 6.10Found(%): C, 68.56; H, 6.89; N, 2.86; S, 5.93


I-7M-317a
1H-NMR(CDCl3) δ 1.03(1H, m), 1.22–1.65(11H, m), 2.02



(1H, m), 2.57(1H, m), 3.54(2H, d, J=6.0Hz), 4.00(1H,



m), 4.03(3H, s), 4.35(2H, s), 6.10(1H, d, J=7.8Hz),



7.08–7.24(4H, m), 7.39–7.44(2H, m), 7.85(1H, s), 



8.18(1H, d, J=8.4Hz);



IR(CHCl3)3508, 3437, 2954, 2875,



1780, 1732, 1651, 1568, 1518, 1495, 1475,



1444, 1394, 1363cm−1;



[α]D26.0+34.9±0.8°(c=1.00, MeOH)Anal.



(C29H32ClNO4S)Calcd.(%): C, 66.21; H, 6.13; N, 2.66; Cl,



6.74; S, 6.10Found(%): C, 66.01; H, 6.32; N, 2.89; Cl, 6.03;



S, 5.91


I-7M-318a
1H-NMR(CDCl3) δ 1.05(1H, m), 1.22–1.64(12H, m), 2.01



(1H, m), 2.56(1H, m), 3.49–3.52(2H, m), 3.97(2H, s), 3.50



(1H, m), 4.24(2H, s), 6.12(1H, d, J=6.3Hz), 6.81–6.91



(2H, m), 7.11–7.18(3H, m), 7.39(1H, m), 7.84(1H, s), 8.12



(1H, d, J=7.8Hz); IR(CHCl3)3597, 3435, 2954, 2875,



1780, 1730, 1649, 1518, 1496, 1456, 1394, 1363, 1327cm−1;



[α]D27.0+36.9±0.8°



(c=1.01, MeOH)Anal.



(C29H33NO5S·1.2H2O)Calcd.(%): C, 65.81; H, 6.74; N, 2.65;



S, 6.06Found(%): C, 65.74;



H, 6.59; N, 2.79; S, 5.90


I-7M-327a
mp137–139°C.; 1H-NMR(CDCl3) δ 1.01(1H, m),



1.20–1.70(12H, m), 2.00(1H, d, J=3.0Hz),



2.46(1H, brs), 3.01(2H,



t, J=8.7Hz), 3.52(2H, t, J=6.3Hz), 3.81(1H, m), 3.98



(2H, t, J=8.4Hz), 4.04(2H, s), 6.11(1H, d, J=7.5Hz),



6.98–7.24(3H, m), 7.35(1H, d, J=3.9Hz), 7.46(1H, d, J=



3.9Hz), 7.57(1H, d, J=8.1Hz); IR(Nujol)3325, 2924,



1730, 1616, 1566, 1460, 1444, 1373, 1236, 1163, 1138cm−1;



[α]D26+39.2±0.8°(c=1.006%, MeOH); Anal.



(C26H32N2O6S2·0.2H2O)Calcd.(%)C, 58.23; H, 6.09; N,



5.22; S, 11.96Found(%)C, 58.19; H, 6.14; N, 5.22; S,



11.85

















TABLE 36





Compd.



No..
Physical property







I-7M-329a
mp137–139°C.; 1H-NMR(d6-DMSO) δ 1.14–1.60(13H,



m), 1.91(1H, d, J=3.0Hz), 2.29(1H, brs), 3.05(2H, t, J=



8.4Hz), 3.37(2H, t, J=6.3Hz), 3.57(1H, m), 3.91(2H,



s), 4.01(2H, t, J=8.4Hz), 6.91(1H, m), 7.27–7.37(2H,



m), 7.78(1H, d, J=3.9Hz), 7.93(1H, d, J=3.9Hz), 8.53



(1H, d, J=6.9Hz); IR(Nujol)3325, 2924, 1730, 1618,



1566, 1460, 1444, 1435, 1375, 1234, 1165, 1138, 1070cm−1;



[α]D25+38.2±0.8°(c=1.015%, MeOH); Anal.



(C26H31FN2O6S2)Calcd.(%)C, 56.71; H, 5.67;F, 3.45; N,



5.09; S, 11.65Found(%)C, 56.61; H, 5.47;F, 3.32; N,



5.12; S, 11.54


I-7M-330a
mp158–160°C.; 1H-NMR(d6-DMSO) δ 1.13–1.58(13H,



m), 1.91(1H, d, J=3.0Hz), 2.29(1H, brs), 2.97(2H, t, J=



8.4Hz), 3.37(2H, t, J=6.9Hz), 3.57(1H, m), 3.91(2H,



s), 3.97(2H, t, J=8.4Hz), 7.10(1H, d, J=8.7Hz), 7.43



(1H, dd, J=4.5, 8.4Hz), 7.72(1H, d, J=3.9Hz), 7.92



(1H, d, J=3.9Hz), 8.52(1H, d, J=6.9Hz); IR(Nujol)



3325, 3095, 2924, 1732, 1618, 1566, 1481, 1460, 1444,



1373, 1236, 1221, 1167, 1140, 1038cm−1; [α]D25+



38.2±0.8°(c=1.009%, MeOH); Anal.(C26H31FN2O6S2)



Calcd.(%)C, 56.71; H, 5.67;F, 3.45; N, 5.09; S, 11.65



Found(%)C, 56.51; H, 5.74;F, 3.30; N, 5.09; S, 11.57


I-7M-331a
mp152–154°C.; 1H-NMR(d6-DMSO) δ 1.14–1.60(13H,



m), 1.92(1H, d, J=2.7Hz),



2.29(1H, brs), 2.98(2H, t, J=



8.4Hz), 3.37(2H, t, J=6.6Hz), 3.58(1H, m), 3.91(2H,



s), 3.99(2H, t, J=8.4Hz),



6.88(1H, ddd, J=2.4, 8.1, 9.0Hz),



7.16–7.26(2H, m), 7.82(1H, d, J=4.2Hz), 7.94(1H,



d, J=4.2Hz), 8.54(1H, d, J=7.5Hz); IR(Nujol)3317,



3091, 2924, 1734, 1616, 1568, 1491, 1460, 1446, 1435,



1371, 1261, 1234, 1221, 1176, 1163, 1142, 1092, 1036cm−1;



[α]D25+38.7±0.8°(c=1.012%, MeOH); Anal.



(C26H31FN2O6S2)Calcd.(%)C,



56.71; H, 5.67; F, 3.45; N,



5.09; S, 11.65Found(%)C, 56.49; H, 5.36;F, 3.34; N,



5.10; S, 11.27


I-7M-332a
mp100–103°C.; 1H-NMR(CDCl3) δ 1.01(1H, m),



1.20–1.82(14H, m), 2.01(1H, d, J=3.3Hz),



2.47(1H, brs),



2.53(2H, t, J=6.6Hz), 3.53(2H, t, J=6.3Hz), 3.79–3.88



(3H, m), 4.05(2H, s), 6.07(1H, d, J=7.8Hz),



7.03–7.23(4H, m), 7.32(1H, d, J=3.9Hz), 7.78(1H, dd,



J=0.9, 8.1Hz); IR(Nujol)3329, 2925, 1730, 1614, 1562,



1458, 1363, 1346, 1234, 1159cm−1; [α]D24+37.7±0.8°



(c=1.018%, MeOH); Anal.(C27H34N2O6S2·0.4H2O)



Calcd.(%)C, 58.55; H, 6.33; N, 5.06; S, 11.58Found(%)



C, 58.84; H, 6.41; N, 5.02; S, 11.30

















TABLE 37





Compd. No..
Physical property







I-7M-333a
mp 125–128° C.; 1H-NMR(CDCl3) δ 1.01(1H, m), 1.20–



1.75(12H, m), 2.01(1H, d, J=3.0Hz), 2.47(1H, brs),



3.53(2H, t, J=6.0Hz), 3.79–3.96(5H, m), 4.05(2H, s),



6.06(1H, d, J=7.8Hz), 6.85(1H, dd, J=1.5, 8.1Hz),



6.96(1H, m), 7.11(1H, m), 7.29(1H, d, J=4.2Hz), 7.34



(1H, d, J=4.2Hz), 7.83(1H, dd, J=1.5, 8.1Hz); IR



(Nujol) 3325, 3084, 2924, 1730, 1612, 1562, 1491, 1460,



1369, 1250, 1236, 1165, 1138cm−1; [α]D26+36.4±0.8°



(c=1.008%, MeOH); Anal.(C26H32N2O7S2.0.3H2O)



Calcd.(%) C, 56.36; H, 5.93; N, 5.06; S, 11.57 Found(%)



C, 56.36; H, 5.72; N, 5.08; S, 11.53


I-7M-334a
mp 127–129° C.; 1H-NMR(CDCl3) δ 1.02(1H, m), 1.20–



1.70(12H, m), 2.01(1H, d, J=3.3Hz), 2.48(1H, brs),



3.05(2H, dd, J=5.7, 9.0Hz), 3.53(2H, t, J=6.3Hz),



3.82(1H, m), 4.03–4.07(4H, m), 6.08(1H, d, J=8.1Hz),



7.07–7.33(5H, m), 7.67(1H, m); IR(Nujol) 3315, 2924,



1761, 1728, 1616, 1550, 1467, 1363, 1165cm−1;



[α]D24+37.1±0.8°(c=1.010%, MeOH); Anal.



(C26H32N2O6S3.0.1Hexane) Calcd.(%) C, 55.72; H, 5.87;



N, 4.89; S, 16.78 Found(%) C, 55.86; H, 5.94; N, 4.84; S,



16.61


I-7M-336a
mp 209–212° C.; 1H-NMR(d6-DMSO) δ 1.11–1.56(13H,



m), 1.91(1H, m), 2.29(1H, brs), 3.37(2H, t, J=6.3Hz),



3.58(1H, m), 3.91(2H, s), 4.63(4H, s), 7.20–7.35(4H,



m), 7.77(1H, d, J=3.9Hz), 7.96(1H, d, J=3.9Hz), 8.51



(1H, d, J=7.5Hz); IR(Nujol) 3332, 2924, 1736, 1616,



1562, 1468, 1354, 1240, 1165, 1140, 1092cm−1; Anal.



(C26H32N2O6S2) Calcd.(%) C, 58.62; H, 6.06; N, 5.26; S,



12.04 Found(%) C, 58.38; H, 5.98; N, 5.25; S, 11.82


I-7M-337a
1H-NMR(CDCl3) δ 1.04(1H, m), 1.23–1.32(3H, m),



1.43–1.69(8H, s), 2.02(1H, m), 2.52–2.54(2H, m), 3.53



(2H, t, J=6.3Hz), 4.01(1H, m), 4.03(2H, s), 4.28(2H,



s), 6.06(1H, d, J=8.1Hz), 7.01–7.07(2H, m), 7.15–7.31



(4H, m), 7.65(1H, dd, J=7.5, 0.9Hz), 8.17(1H, s); IR



(CHCl3) 3323, 2656, 2548, 1728, 1621, 1562, 1456, 1234,



1130cm−1; [α]D27.0+26.7±0.7°(c=1.001, MeOH) Anal.



(C29H32FNO5.0.5H2O) Calcd.(%): C, 69.31; H, 6.62; N,



2.79; F, 3.58 Found(%): C, 69.19; H, 6.67; N, 2.82; F,



3.28


I-7M-342a
1H-NMR(CDCl3) δ 1.05(1H, m), 1.22–1.63(12H, m), 2.01



(1H, m), 2.55(1H, m), 3.49–3.53(2H, m), 3.99(1H, m),



4.01(2H, s), 6.14(1H, br), 7.18–7.26(5H, m), 7.43–7.54



(2H, m), 7.85(1H, s), 8.32(1H, d, J=7.8Hz); IR(CHCl3)



3438, 2954, 2875, 1780, 1730, 1649, 1583, 1516, 1477,



1456, 1375cm−1; [α]D26.0+38.5±0.8°(c=1.03, MeOH)

















TABLE 38





Compd. No..
Physical property







I-7M-343a
1H-NMR(CDCl3) δ 1.05(1H, m), 1.24–1.63(12H, m), 2.05



(1H, m), 2.54(1H, m), 3.54(2H, t, J=8.1Hz), 3.94(1H,



m), 4.03(2H, s), 6.17(1H, d, J=7.5Hz), 7.45–7.63(4H,



m), 7.94(1H, s), 8.01–8.11(3H, m), 8.62(1H, d, J=8.4Hz);



IR(CHCl3) 3437, 3375, 2954, 2875, 1780, 1730,



1518, 1383, 1315, 1309cm−1; [α]D25.0+33.3±0.7°(c=1.04,



MeOH)


I-7M-385a
1H-NMR(CDCl3) δ 1.07(1H, m), 1.20–1.72(12H, m), 2.04



(1H, m), 2.56(1H, m), 3.52(2H, dt, J=6.3, 1.8Hz), 3.97



(1H, s), 4.03(2H, s), 6.27(2H, t, J=2.4Hz), 6.42(1H, d,



J=7.2Hz), 7.21(2H, t, J=2.4Hz), 7.56(1H, t, J=7.8Hz),



7.68(1H, d, J=7.8Hz), 8.38(1H, dd, J=7.8, 1.2Hz),



8.43(1H, s); IR(CHCl3) 3450, 3103, 3022, 2954,



2875, 1732, 1651, 1518, 1456, 1373, 1221, 1188, 1163,



1057cm−1; [α]D22.0+39.9±0.8°(c=1.006, MeOH) Anal.



(C26H30N2O6S2.0.1H2O) Calcd.(%): C, 58.65; H, 5.72; N,



5.26; S, 12.04 Found(%): C, 58.40; H, 5.82; N, 5.08; S,



11.88


I-7M-389a
mp 94–96° C.; 1H-NMR(CDCl3) δ 0.99(1H, m), 1.21–1.27



(2H, m), 1.38–1.46(6H, m), 1.55–1.68(4H, m), 1.99(1H,



m), 2.23(3H, s), 2.46(1H, m), 3.21(2H, t, J=8.7Hz),



3.46–3.57(2H, m), 3.83(1H, m), 4.05(2H, s), 4.62(2H, t,



J=8.7Hz), 5.95(1H, d, J=7.8Hz), 6.90(1H, s), 6.96



(1H, s), 7.07(1H, d, J=3.9Hz), 7.37(1H, d, J=3.9Hz);



IR(Nujol) 3327, 3074, 2750, 2650, 2613, 2551, 1728,



1604, 1562, 1234, 1223, 1136cm−1; [α]D23+35.5±0.7°



(c=1.014, MeOH) Anal.(C27H33NO5S2) Calcd.(%): C,



62.88; H, 6.45; N, 2.72; S, 12.44 Found(%): C, 62.96; H,



6.46; N, 2.68; S, 12.33


I-7M-390a
mp 99–101° C.; 1H-NMR(CDCl3) δ 0.99(1H, m), 1.20–



1.27(2H, m), 1.37–1.45(6H, m), 1.54–1.63(4H, m), 1.98



(1H, m), 2.39(3H, s), 2.46(1H, m), 3.46–3.56(2H, m), 3.83



(1H, m), 4.04(2H, s), 5.95(1H, d, J=7.8Hz), 6.72(1H,



d, J=2.1Hz), 7.09(1H, m), 7.18(1H, d, J=3.9Hz), 7.33



(1H, m), 7.39(1H, d, J=3.9Hz), 7.63(1H, d, J=2.1Hz);



IR(CHCl3) 3508, 3444, 3425, 2667, 2567, 1780,



1732, 1645, 1531, 1500, 1421, 1321, 1130cm−1;



[α]D24+36.1±0.8°(c=1.008, MeOH) Anal.



(C27H31NO5S2.0.2H2O) Calcd.(%): C, 62.69; H, 6.12; N,



2.71; S, 12.40 Found(%): C, 62.54; H, 5.98; N, 2.68; S,



12.55

















TABLE 39





Compd. No..
Physical property







I-7M-391a
1H-NMR(CDCl3) δ 1.06(1H, m), 1.24–1.29(2H, m), 1.38–1.47



(6H, m), 1.55–1.59(4H, m), 2.00(1H, m), 2.32(3H, s),



2.48(1H, m), 3.19(2H, t, J=8.7Hz), 3.52(2H, t, J=6.3Hz),



3.83(1H, m), 4.05(2H, s), 4.72(2H, t, J=8.7Hz), 6.26(1H, d,



J=7.8Hz), 7.22(1H, s), 7.43(1H, d, J=3.9Hz), 7.50(1H, s),



7.70(1H, d, J=3.9Hz); IR(CHCl3) 3508, 3440, 3423, 3377,



2567, 2463, 1778, 1732, 1653, 1529, 1504, 1481, 1327, 1151cm−1;



[α]D25+40.6±0.8°(c=1.004, MeOH) Anal.



(C27H33NO7S2.0.5H2O) Calcd.(%): C, 58.25; H, 6.16; N, 2.52; S, 11.52



Found(%): C, 58.18; H, 6.07; N, 2.45; S, 11.55


I-7M-392a
mp 136–140° C.; 1H-NMR(CDCl3+CD3OD) δ 1.09(1H, m),



1.22–1.29(2H, m), 1.33–1.43(5H, m), 1.52–1.58(4H, m), 1.96



(1H, m), 2.48–2.51(2H, m)+2.51(3H, s), 3.42–3.53(2H, m),



3.75(1H, m), 4.01(2H, s), 6.68(1H, d, J=7.2Hz), 6.78(1H,



d, J=2.1Hz), 7.48(1H, d, J=3.9Hz), 7.64(1H, s), 7.74(1H,



d, J=2.1Hz), 7.76(1H, s), 7.82(1H, d, J=3.9Hz); IR



(Nujol) 3280, 3141, 3114, 3084, 2750, 2650, 2548, 1732,



1618, 1566, 1460, 1323, 1223, 1153, 1126cm−1; [α]D25+



40.5±0.8°(c=1.004, MeOH) Anal.(C27H31NO7S2.0.2H2O)



Calcd.(%): C, 59.04; H, 5.76; N, 2.55; S, 11.68 Found(%): C,



59.01; H, 5.77; N, 2.51; S, 11.50


I-7M-393a
mp 104–107° C.; 1H-NMR(CDCl3) δ 0.90(3H, t, J=7.4Hz),



0.98(1H, m), 1.21–1.64(16H, m), 1.99(1H, m), 2.46–2.51(3H,



m), 3.23(2H, t, J=8.7Hz), 3.49–3.55(2H, m), 3.84(1H, m),



4.05(2H, s), 4.62(2H, t, J=8.7Hz), 5.92(1H, d, J=7.8Hz),



6.93(1H, s), 6.98(1H, s), 7.07(1H, d, J=3.6Hz), 7.36(1H, d,



J=3.6Hz); IR(CHCl3) 3444, 3425, 2569, 1780, 1732, 1643,



1531, 1498, 1479, 1464, 1419, 1317, 1132cm−1; [α]D24+



33.3±0.7°(c=1.009, MeOH) Anal.(C30H39NO5S2.0.2H2O)



Calcd.(%): C, 64.19; H, 7.07; N, 2.50; S, 11.42 Found(%): C,



64.09; H, 6.95; N, 2.55; S, 11.36


I-7M-396a
1H-NMR(CDCl3) δ 1.06(1H, m), 1.26–1.69(12H, m), 2.03



(1H, m), 2.56(1H, m), 3.55(2H, t, J=5.1Hz), 4.00(1H, m),



4.04(2H, s), 6.11(1H, d, J=8.1Hz), 6.88(1H, d, J=7.5Hz),



7.07–7.19(3H, m), 7.34–7.42(3H, m), 7.89(1H, s), 8.03(1H,



d, J=8.1Hz); IR(KBr) 3383, 3076, 2949, 2929, 2868, 2520,



1736, 1604, 1550, 1487, 1466, 1390, 1298, 1281, 1248, 1213,



1134cm−1; [α]D25.0+35.4±3.0°(c=0.26, MeOH) Anal.



(C28H31NO5S.0.5H2O) Calcd.(%): C, 66.91; H, 6.42; N, 2.79; S,



6.38 Found(%): C, 66.98; H, 6.35; N, 2.85; S, 6.29


I-7M-412a
1H-NMR(CDCl3) δ 1.05(1H, m), 1.22–1.70(12H, m), 2.01



(1H, d, J=3.3Hz), 2.50(1H, brs), 3.53(2H, t, J=6.3Hz),



3.92(1H, m), 4.05(2H, s), 6.11(1H, d, J=7.8Hz), 7.27–7.62



(6H, m), 7.79(1H, d, J=1.8Hz); IR(CHCl3) 3444, 2954,



1780, 1732, 1649, 1547, 1514, 1491, 1219, 1213, 1128cm−1;



[α]D24+49.9±0.9°(c=1.008%, MeOH); Anal.



(C24H29NO4S.0.3H2O) Calcd.(%) C, 66.58; H, 6.89; N, 3.24; S,



7.41Found(%) C, 66.73; H, 6.90; N, 3.35 S, 7.29

















TABLE 40





Compd. No..
Physical property







I-7M-424a
1H-NMR(CDCl3) δ 1.00(1H, m), 1.22–1.64(12H, m), 1.98



(1H, m), 2.55(1H, m), 3.48(2H, t, J=6.9Hz), 3.94(1H,



m), 3.99(2H, s), 4.15(2H, s), 6.13(1H, d, J=8.1Hz),



6.84(1H, d, J=2.1Hz), 7.20–7.30(5H, m), 7.74(1H, s),



7.79(1H, d, J=2.1Hz); IR(KBr) 3433, 3246, 3024,



2954, 2875, 1730, 1639, 1599, 1518, 1495, 1475, 1454,



1421, 1352cm−1; [α]D26.0+34.0±0.7°(c=1.00, MeOH)



Anal.(C29H33NO5S.0.6H2O) Calcd.(%): C, 67.18; H, 6.65;



N, 2.70; S, 6.18 Found(%): C, 67.21; H, 6.66; N, 2.71; S,



5.99


I-7M-446a
1H-NMR(CDCl3) δ 1.00(1H, m), 1.22–1.64(12H, m),



1.98(1H, m), 2.55(1H, m), 3.47(2H, t, J=6.3Hz), 3.96



(1H, m), 3.98(2H, s), 4.17(2H, s), 6.16(1H, d, J=8.1Hz),



6.82(1H, d, J=2.4Hz), 6.99–7.22(4H, m), 7.76(1H,



s), 7.82(1H, d, J=2.4Hz); IR(CHCl3) 3593, 3433, 3244,



2954, 2875, 1728, 1639, 1599, 1518, 1491, 1456, 1421,



1362cm−1; [α]D22.0+31.2±0.7°(c=1.01, MeOH) Anal.



(C29H32FNO5S.0.9H2O) Calcd.(%): C, 64.28; H, 6.29; N,



2.58; F, 3.51; S, 5.92 Found(%): C, 64.39; H, 6.29; N,



2.52; F, 3.40; S, 5.72


I-7M-447a
1H-NMR(CDCl3) δ 1.04(1H, m), 1.22–1.69(12H, m), 2.03



(1H, m), 2.55(1H, m), 3.55(2H, t, J=6.6Hz), 3.96(1H,



m), 4.04(2H, s), 6.08(1H, d, J=7.8Hz), 7.16(1H, dd, J=



8.7 and 2.7Hz), 7.25–7.35(5H, m), 7.88(1H, s), 8.03



(1H, dd, J=9.6 and 2.7Hz); IR(CHCl3) 3510, 3438,



2954, 2875, 1780, 1732, 1655, 1591, 1558, 1514, 1477,



1441, 1383cm−1; [α]D24.0+38.1±0.8°(c=1.01, MeOH)



Anal.(C28H30FNO4S2.0.9H2O) Calcd.(%): C, 61.83; H,



5.89; N, 2.58; F, 3.49; S, 11.79 Found(%): C, 61.91; H,



5.73; N, 2.65; F, 3.56; S, 11.67


I-7M-448a
1H-NMR(CDCl3) δ 1.05(1H, m), 1.22–1.63(12H, m), 2.00



(1H, m), 2.53(1H, m), 3.54(2H, m), 3.90(1H, m), 4.04



(2H, s), 6.19(1H, d, J=7.8Hz), 7.47–7.83(3H, m), 7.85



(1H, dd, J=7.8 and 2.4Hz), 8.00–8.05(3H, m), 8.38(1H,



dd, J=9.3 and 2.4Hz); IR(CHCl3) 3437, 3386, 2954,



2875, 1780, 1730, 1655, 1601, 1518, 1477, 1446, 1396,



1325, 1309cm−1; [α]D24.0+31.5±0.7°(c=1.01, MeOH)



Anal.(C28H30FN6S2.0.9H2O) Calcd.(%):



C, 58.40; H, 5.57; N, 2.43; F, 3.30; S, 11.14 Found(%):



C, 58.43; H, 5.54; N, 2.38; F, 3.16; S, 10.78


I-7N-1a
1H-NMR(CDCl3) δ 1.10–1.70(7H, m), 2.00–2.32(3H, m),



2.51(1H, m), 3.83(1H, m), 4.07–4.21(4H, m), 5.54–5.70



(2H, m), 6.26(1H, d, J=7.5Hz), 6.32–6.35(2H, m),



7.15–7.18(2H, m), 7.38(1H, d, J=4.2Hz), 7.57(1H, d, J=



4.2Hz); IR(CHCl3) 3440, 1732, 1655, 1531, 1506,



1456, 1383, 1192, 1167, 1057, 1034cm−1;



[α]D24+67.3±1.1°(c=1.005, MeOH) Anal.



(C22H26N2O6S2.0.3H2O) Calcd.(%): C, 54.60; H, 5.54; N,



5.79; S, 13.25 Found(%): C, 54.58; H, 5.50; N, 5.65; S,



13.15

















TABLE 41





No. fo Compd.
Physical property







I-7N-1b
1H-NMR(CDCl3) δ 1.16–1.70(7H, m), 2.04(1H, m), 2.12–2.18(2H, m),



2.56(1H, brs), 3.72(3H, s), 3.78(1H, m),



4.05–4.16(4H, m), 5.57–5.76(2H, m), 6.32–6.34(2H, m),



6.39(1H, d, J=6.6Hz), 7.15–7.17(2H, m), 7.40(1H, d, J=



3.9Hz), 7.56(1H, d, J=3.9Hz)


I-7P-1a
1H-NMR(CD3OD) δ 1.28–1.64(8H, m), 2.02–2.13(3H, m),



2.47(1H, m), 3.71(1H, m), 3.98(2H, s), 4.25(2H, d, J=



22.2Hz), 5.30(1H, dt, J=8.4 and 22.2Hz), 6.36(2H, m),



7.23(2H, m), 7.70(1H, d, J=3.9Hz), 7.75(1H, d, J=3.9Hz);



IR(CHCl3) 3419, 2956, 1635, 1604, 1537, 1508, 1456,



1431, 1381, 1167, 1076, 1057, 1036cm−1; [α]D25+45.7±0.8°



(c=1.02, MeOH)


I-7P-1e
1H-NMR(CDCl3) δ 1.10–1.72(7H, m), 2.06–2.26(3H, m),



2.51(1H, m), 3.29(3H, s), 3.84(1H, m), 4.01–4.31(4H, m),



5.36(1H, dt, J=9.0 and 20.7Hz), 6.15(1H, d, J=6.6Hz),



6.34(2H, m), 7.16(2H, m), 7.38(1H, d, J=4.2Hz), 7.58



(1H, d, J=4.2Hz), 9.26(1H, s); IR(CHCl3) 3442, 3352,



2956, 2829, 1728, 1655, 1531, 1506, 1456, 1452, 1402,



1383, 1348, 1167, 1109, 1057, 1034cm−1; [α]D25+51.8±0.9°



(c=1.03, MeOH) Anal.(C23H28FN3O7S30.5MeOH)



Calcd.(%): C, 47.86; H, 5.13; N, 7.13; F, 3.22; S, 16.31



Found(%): C, 48.09; H, 5.02; N, 7.38; F, 3.12; S, 16.12


I-7R-1a
1H-NMR(CDCl3) δ 1.02(1H, m), 1.23–1.72(12H, m), 2.02



(1H, d, J=3.9Hz), 2.48(1H, brs), 2.63(2H, t, J=7.2Hz),



3.21(2H, s), 3.83(1H, m), 6.17(1H, d, J=7.5Hz), 6.32–6.35



(2H, m), 7.15–7.17(2H, m), 7.37(1H, d, J=3.9Hz),



7.57(1H, d, J=3.9Hz); IR(Nujol) 3348, 2924, 1711,



1641, 1622, 1550, 1541, 1456, 1375, 1290, 1190, 1167, 1057cm−1;



[α]D25+42.8±0.8°(c=1.005%, MeOH); Anal.



(C22H28N2O5S3) Calcd.(%) C, 53.20; H, 5.68; N, 5.64; S,



19.37 Found(%) C, 53.41; H, 5.58; N, 5.54; S, 19.08


I-7R-88a
1H-NMR(CDCl3) δ 0.99(1H, m), 1.21–1.72(12H, m), 1.98



(1H, d, J=3.9Hz), 2.47(1H, brs), 2.64(2H, t, J=7.2Hz),



3.20(2H, s), 3.87(1H, m), 4.16(2H, s), 5.96(1H, d, J=7.5Hz),



6.79(1H, d, J=3.6Hz), 6.96(1H, d, J=4.8Hz), 7.06



(1H, d, J=2.1Hz), 7.26–7.30(2H, m), 7.37(1H, d, J=3.9Hz);



IR(CHCl3) 2877, 1711, 1641, 1545, 1508, 1458, 1298,



1282, 1225, 1205cm−1; [α]D25+42.8±0.8°(c=1.005%,



MeOH); Anal.(C23H29NO3S3.0.2H2O) Calcd.(%) C, 59.12;



H, 6.34; N, 3.00; S, 20.59 Found(%) C, 59.18; H, 6.01; N,



3.04; S, 20.28


I-7R-270a
1H-NMR(CDCl3) δ 1.03(1H, br), 1.18–1.70(12H, m), 2.01



(1H, brd), 2.41(6H, s), 2.46(1H, brs), 2.62(2H, t, J=7.2Hz),



3.21(2H, s), 3.82(1H, m), 5.88(2H, s), 6.23(1H, d, J=



7.2Hz), 7.36(1H, d, J=3.9Hz), 7.49(1H, d, J=3.9Hz);



IR(CHCl3) 3508, 3442, 2673, 1709, 1657, 1531, 1504, 1375,



1180, 1119cm−1; [α]D26+39.2±0.8°(c=1.010, MeOH) Anal.



(C24H32N2O5S3.0.3H2O) Calcd.(%): C, 54.94; H, 6.15; N,



5.34; S, 18.33 Found(%): C, 54.44; H, 6.04; N, 5.28; S,



18.08

















TABLE 42





Compd. No..
Physical property







I-7R-307a
1H-NMR(CDCl3) δ 0.93(1H, m), 1.17–1.22(2H, m), 1.34–1.41(6H, m),



1.52–1.58(4H, m), 1.94(1H, m), 2.43(1H, m), 2.59



(2H, t, J=7.2Hz), 3.16(2H, s), 3.79(1H, m), 3.97(3H, s),



4.59(2H, s), 5.90(1H, d, J=7.8Hz), 6.74(1H, d, J=3.9Hz),



7.29(1H, d, J=3.9Hz), 7.29–7.36(2H, m,), 7.46(1H, m),



7.78–7.83(2H, m), 7.92(1H, d, J=8.4Hz); IR(CHCl3) 3446,



3425, 3062, 2877, 2673, 1711, 1639, 1597, 1542, 1512, 1265,



1254cm−1; [α]D25.5+35.8±0.8°(c=1.007, MeOH) Anal.



(C30H35NO4S2.0.2H2O) Calcd.(%): C, 66.56; H, 6.59; N, 2.59; S, 11.85



Found(%): C, 66.53; H, 6.70; N, 2.65; S, 11.78


I-8B-1a
1H-NMR(CDCl3) δ 1.06(1H, m), 1.19–1.30(2H, m), 1.34–1.44



(4H, m), 1.54–1.68(4H, m), 2.04–2.12(5H, m), 2.35(2H, t, J=



7.5Hz), 2.51(1H, brs), 3.82(1H, m), 5.29–5.42(2H, m), 6.21



(1H, d, J=6.9Hz), 6.32–6.34(2H, m), 7.15–7.17(2H, m), 7.35



and 7.56(each 1H, each d, each J=3.9Hz); IR(CHCl3) 3512,



3442, 2679, 1707, 1657, 1529, 1504, 1456, 1383, 1192, 1167,



1057, 1034cm−1; [α]D24+69.7±1.1°(c=1.004, MeOH) Anal.



(C24H30N2O5S2.0.2H2O) Calcd.(%): C, 58.32; H, 6.20; N, 5.67;



S, 12.98 Found(%): C, 58.30; H, 6.07; N, 5.67; S, 12.84


I-8C-1a
1H-NMR(CDCl3) δ 1.01(1H, m), 1.25–1.45(10H, m), 1.53–1.66



(4H, m), 2.00(1H, m), 2.48(1H, m), 3.52(2H, t, J=7.1Hz),



3.80(1H, m), 4.08(2H, s), 6.22(1H, d, J=7.5Hz),



6.33–6.34(2H, m), 7.15–7.17(2H, m), 7.38(1H, d, J=3.9Hz),



7.57(1H, d, J=3.9Hz); IR(CHCl3) 3440, 3145, 2578,



1780, 1730, 1657, 1529, 1383, 1192, 1167, 1057cm−1; [α]D25.0+



45.0±0.8°(c=1.010, MeOH) Anal.(C23H30N2O6S2.0.4H2O)



Calcd.(%): C, 55.05; H, 6.19; N, 5.58; S, 12.78 Found(%): C,



55.09; H, 6.08; N, 5.61; S, 12.74


I-8C-88a
1H-NMR(CDCl3) δ 0.97(1H, m), 1.23–1.47(10H, m), 1.55–1.61



(4H, m), 1.97(1H, m), 2.48(1H, m), 3.52(2H, t, J=6.6Hz),



3.83(1H, m), 4.06(2H, s), 4.16(2H, s), 5.93(1H, d, J=



7.8Hz), 6.79(1H, dt, J=3.9, 0.9Hz), 6.96(1H, dd, J=5.1, 1.2Hz),



7.06(1H, m), 7.29(1H, dd, J=5.1, 3.0Hz), 7.37(1H, d, J=



3.9Hz); IR(CHCl3) 3444, 3427, 3107, 3022, 2954, 2875,



1780, 1732, 1643, 1545, 1506, 1221, 1211, 1128cm−1; [α]D25.0+



39.6±0.8°(c=1.016, MeOH) Anal.(C24H31NO4S2.0.3H2O)



Calcd.(%): C, 61.72; H, 6.82; N, 3.00; S, 13.73 Found(%): C,



61.79; H, 6.69; N, 3.11; S, 13.59


I-9B-1a
1H-NMR(CDCl3) δ 1.06(1H, m), 1.22–1.45(8H, m), 1.59–1.67



(4H, m), 2.03–2.13(5H, m), 2.33(2H, t, J=7.5Hz), 2.52(1H,



brs), 3.82(1H, m), 5.26–5.42(2H, m), 6.18(1H, d, J=7.2Hz),



6.33–6.34(2H, m), 7.15–7.17(2H, m), 7.36 and 7.57(each 1H,



each d, each J=3.9Hz); IR(CHCl3) 3514, 3442, 2677, 1709,



1657, 1529, 1504, 1456, 1383, 1192, 1167, 1057, 1034cm−1;



[α]D24.5+72.2±1.1°(c=1.006, MeOH) Anal.(C25H32N2O5S2)



Calcd.(%): C, 59.50; H, 6.39; N, 5.55; S, 12.71 Found(%): C,



59.24; H, 6.48; N, 5.60; S, 12.46

















TABLE 43





Compd. No..
Physical property







II-4A-55a
1H-NMR(CDCl3) δ 0.90(1H, d, J=10.2Hz), 1.09 and



1.22(3H, s), 1.40–2.40(12H, m), 2.38(3H, s), 4.17(1H,



m), 4.56(1H, brs), 5.98(1H, m), 6.19(1H, t, J=3.0Hz),



6.24(1H, d, J=8.7Hz), 7.17(1H, dd, J=1.5, 3.3Hz),



7.31(1H, d, J=3.9Hz), 7.51(1H, d, J=3.9Hz); IR



(CHCl3) 3446, 1709, 1657, 1529, 1504, 1375, 1182, 1161,



1144, 1053cm−1; [α]D23+28.9±0.7°(c=1.011, MeOH)



Anal.(C23H30N2O5S2.0.4H2O) Calcd.(%): C, 56.86 H,



6.39; N, 5.77; S, 13.20 Found(%): C, 57.24; H, 6.36; N,



5.73; S, 12.72.


II-4B-55a
1H-NMR(CDCl3) δ 0.90(1H, d, J=10.5Hz), 1.10(3H, s),



1.23(3H, s), 1.43–2.35(10H, m), 2.38(3H, s), 4.20(1H,



m), 4.96(1H, dt, J=11.4 and 49.2Hz), 5.98(1H, m),



6.19–6.21(2H, m), 7.17(1H, m), 7.29(1H, d, J=3.9Hz),



7.51(1H, d, J=3.9Hz); IR(CHCl3) 3446, 2925, 2870,



1730, 1657, 1529, 1504, 1471, 1375, 1159, 1144, 1053,



1022cm−1; [α]D24+24.6±0.6°(c=1.04, MeOH) Anal.



(C23H29FN2O5S2.0.6MeOH) Calcd.(%): C, 54.95;



H, 6.14; N, 5.43; F, 3.68; S, 12.43 Found(%): C, 54.94;



H, 5.97; N, 5.65; F, 3.55; S, 12.24


II-4C-55a
1H-NMR(CDCl3) δ 0.92(1H, d, J=10.5Hz), 1.10 and



1.24(3H, s), 1.56(1H, ddd, J=2.7, 5.7, 12.0Hz), 1.96–2.70



(8H, m), 2.37(3H, s), 4.25(1H, m), 5.88(1H, brd, J=



15.9Hz), 5.99(1H, m), 6.17–6.21(2H, m), 7.03(1H, dt,



J=7.2, 15.9Hz), 7.17(1H, dd, J=1.5, 3.3Hz), 7.27(1H,



d, J=3.9Hz), 7.47(1H, d, J=3.9Hz); IR(CHCl3) 3446, 1697,



1655, 1529, 1504, 1375, 1182, 1161, 1144, 1053cm−1;



[α]D23+5.4±0.5°(c=1.002, MeOH) Anal.



(C23H28N2O5S2.0.4H2O) Calcd.(%):C, 57.10; H, 6.00; N,



5.79; S, 13.26 Found(%): C, 57.14; H, 5.89; N, 5.78; S,



13.01.


II-4D-55a
1H-NMR(CDCl3) δ 0.97(1H, d, J=10.5Hz), 1.09 and



1.23(3H, s), 1.60(1H, ddd, J=2.7, 5.7, 10.8Hz), 1.96–2.40



(6H, m), 2.39(3H, s), 2.72–3.01(2H, m), 4.25(1H,



m), 5.85(1H, brd, J=11.7Hz), 5.98(1H, m), 6.17–6.21



(2H, m), 6.40(1H, dt, J=7.8, 11.7Hz), 7.18(1H, dd, J=



1.8, 3.3Hz), 7.32(1H, d, J=4.2Hz), 7.54(1H, d, J=4.2Hz);



IR(CHCl3) 3519, 3446, 1697, 1658, 1529, 1504,



1375, 1182, 1161, 1144, 1053cm−1; [α]D23+63.6±1.0°



(c=1.006, MeOH) Anal.(C23H328N2O5S2.0.3H2O)



Calcd.(%): C, 57.31; H, 5.98; N, 5.81; S, 13.30 Found(%):



C, 57.48; H, 5.93; N, 5.75; S, 12.90

















TABLE 44





Compd. No..
Physical property







II-4F-55a
1H-NMR(CDCl3) δ 0.94(1H, d, J=10.5Hz), 1.09(3H, s),



1.24(3H, s), 1.59(1H, m), 2.03–2.34(5H, m), 2.39(3H,



s), 2.62(1H, m), 2.92(1H, m), 4.26(1H, m), 5.99(1H, m),



6.06(1H, dt, J=8.4 and 21.0Hz), 6.20(1H, m), 7.18



(1H, m), 7.28(1H, m), 7.33(1H, d, J=3.9Hz), 7.53(1H,



d, J=3.9Hz); IR(CHCl3) 33446, 2925, 2870, 1711, 1658,



1529, 1504, 1442, 1375, 1161, 1070, 1053, 1018cm−1;



[α]D25+52.9±0.9°(c=1.02, MeOH)



Anal. (C23H27FN2O5S2.0.8MeOH) Calcd.(%):



C, 54.95; H, 5.85; N, 5.38; F, 3.65; S, 12.33 Found(%):



C, 54.72; H, 5.61; N, 5.67; F, 3.43; S, 12.16


II-5A-1a
1H-NMR(CDCl3) δ 0.91(1H, d, J=10.5Hz), 1.08(3H, s),



1.22(3H, s), 1.33–2.38(14H, m), 4.18(2H, s), 6.08(1H,



d, J=9.0Hz), 6.34(2H, t, J=2.4Hz), 7.16(2H, t, J=2.4Hz),



7.28(1H, d, J=3.9Hz), 7.57(1H, d, J=3.9Hz); IR



(CHCl3) 3512, 3446, 1709, 1657, 1504, 1456, 1385, 1192,



1167, 1057, 1034cm−1; [α]D25.0+26.2±0.7°(c=1.008,



MeOH) Anal.(C23H30N2O5S2.0.6H2O.0.3AcOEt)



Calcd.(%): C, 56.33; H, 6.65; N, 5.45; S, 12.40 Found(%):



C, 56.31; H, 6.35; N, 5.64; S, 12.08


II-5A-31a
1H-NMR(CDCl3) δ 0.90(1H, d, J=10.2Hz), 1.08(3H, s),



1.20(3H, s), 1.30–2.38(14H, m), 4.13(2H, s), 4.18(1H,



m), 5.93(1H, d, J=10.2Hz), 6.77(1H, d, J=3.6Hz),



7.20–7.38(6H, m); IR(CHCl3) 3512, 3450, 3431, 1709,



1643, 1543, 1506, 1456cm−1; [α]D24.0+20.4±0.6°



(c=1.011, MeOH) Anal.(C26H33NO3S.0.6H2O) Calcd.(%):



C, 71.04; H, 7.57; N, 3.19; S, 7.29 Found(%): C, 69.33;



H, 7.65; N, 3.31; S, 7.11


II-5A-47a
1H-NMR(CDCl3) δ 0.91(1H, d, J=10.8Hz), 1.08(3H, s),



1.21(3H, s), 1.30–2.38(14H, m), 4.19(1H, m), 6.08(1H,



d, J=9.3Hz), 7.11(1H, dd, J=5.1, 3.9Hz), 7.32(1H, d,



J=3.9Hz), 7.64(1H, d, J=3.9Hz), 7.69(1H, dd, J=



5.1, 1.2Hz), 7.75(1H, dd, J=3.6, 1.2Hz); IR(CHCl3)



3516, 3446, 2679, 1709, 1655, 1529, 1504, 1402, 1336,



1153, 1095, 1074, 1024cm−1; [α]D24.0+23.5±0.6°



(c=1.004, MeOH) Anal.(C23H29NO5S3.0.5H2O)



Calcd.(%): C, 54.74; H, 5.99; N, 2.78; S, 19.06 Found(%):



C, 54.90; H, 5.76; N, 2.85; S, 18.81


II-5A-55a
1H-NMR(CDCl3) δ 0.91(1H, d, J=10.2Hz), 1.09 and



1.22(3H, s), 1.22–2.30(12H, m), 2.33(2H, t, J=7.5Hz),



2.39(3H, s), 4.19(1H, m), 5.99(1H, m), 6.09(1H, d, J=



8.7Hz), 6.20(1H, t, J=3.3Hz), 7.19(1H, dd, J=1.8, 6.3Hz),



7.29(1H, d, J=3.9Hz), 7.55(1H, d, J=3.9Hz); IR



(CHCl3) 3446, 1709, 1657, 1529, 1504, 1375, 1205, 1182,



1161, 1053cm−1; [α]D24+25.3±0.7°(c=1.002, MeOH)



Anal.(C24H32N2O5S2) Calcd.(%): C, 58.51; H, 6.55; N,



5.69; S, 13.02 Found(%): C, 58.21; H, 6.53; N, 5.69; S,



12.93

















TABLE 45





Compd. No..
Physical property







II-5A-55c
1H-NMR(CDCl3) δ 0.89(1H, d, J=10.5Hz), 1.08(3H, s),



1.22(3H, s), 1.36–2.36(14H, m), 2.39(3H, s), 4.16(1H,



m), 5.24(1H, brs), 5.50(1H, brs), 5.99(1H, m), 6.20(1H,



t, J=3.3Hz), 6.20(1H, brs), 7.19(1H, m), 7.32(1H, d, J=



4.2Hz), 7.56(1H, d, J=4.2Hz); IR(CHCl3) 3529,



3446, 3411, 3348, 1678, 1591, 1529, 1504, 1375, 1182,



1161, 1144, 1053cm−1; [α]D26.0+23.0±0.6°(c=1.016,



MeOH) Anal.(C24H33N3O4S2.0.4H2O) Calcd.(%): C,



57.78; H, 6.83; N, 8.42; S, 12.86 Found(%): C, 57.79; H,



6.81; N, 8.37; S, 12.68


II-5A-55g
1H-NMR(CDCl3) δ 0.89(1H, d, J=10.5Hz), 1.12(3H, s),



1.25(3H, s), 1.33–2.35(12H, m), 2.39(3H, s), 2.95–3.11



(2H, m), 4.19(1H, m), 6.00(1H, m), 6.21(1H, t, J=3.3Hz),



6.45(1H, d, J=8.7Hz), 7.18(1H, dd, J=3.3, 1.5Hz),



7.38(1H, d, J=3.9Hz), 7.54(1H, d, J=3.9Hz); IR



(CHCl3) 3149, 2624, 1641, 1533, 1508, 1375, 1205, 1182,



1160cm−1; [α]D25.0+17.9±0.6°(c=1.018, MeOH) Anal.



(C24H32N6O3S2.0.4CHCl3) Calcd.(%): C, 51.62;



H, 5.79; N, 14.89; S, 11.36 Found(%): C, 51.53; H, 5.99;



N, 14.82; S, 11.09


II-5A-59a
1H-NMR(CDCl3) δ 0.90(1H, d, J=10.2Hz), 1.07(3H, s),



1.21(3H, s), 1.28–2.36(14H, m), 4.17(1H, m), 5.91(1H,



d, J=8.4Hz), 7.00(1H, dd, J=5.4, 3.6Hz), 7.05(1H, d,



J=3.9Hz), 7.25(1H, d, J=3.9Hz), 7.28(1H, dd, J=



3.6, 1.2Hz), 7.42(1H, dd, J=5.4, 1.2Hz); IR(CHCl3)



3516, 3450, 3431, 2671, 1709, 1645, 1529, 1500, 1471,



1421cm−1; [α]D25.0+23.3±0.6°(c=1.013, MeOH) Anal.



(C23H29NO3S3.0.2H2O) Calcd.(%): C, 59.12; H, 6.34; N,



3.00; S, 20.58 Found(%): C, 59.12; H, 6.30; N, 3.07; S,



20.84


II-5A-88a
1H-NMR(CDCl3) δ 0.91(1H, d, J=10.2Hz), 1.09(3H, s),



1.21(3H, s), 1.18–2.33(14H, m), 4.15(2H, s), 4.19(1H,



m), 5.94(1H, d, J=9.6Hz), 6.79(1H, d, J=3.6Hz),



6.96(1H, dd, J=5.1, 1.2Hz), 7.05(1H, dd, J=1.8, 1.2Hz),



7.28(1H, dd, J=5.1, 1.8Hz), 7.30(1H, d, J=3.6Hz);



IR(CHCl3) 3516, 3450, 3431, 1709, 1641, 1545,



1506, 1471cm−1; [α]D24.0+19.6±0.6°(c=1.009, MeOH)



Anal.(C24H31NO3S2.0.3H2O) Calcd.(%):



C, 63.91; H, 7.06; N, 3.11; S, 14.22 Found(%): C, 63.89;



H, 6.89; N, 3.31; S, 14.28


II-5A-104a
1H-NMR(CDCl3) δ 0.92(1H, d, J=10.2Hz), 1.10(3H, s),



1.22(3H, s), 1.28–2.38(14H, m), 4.10(2H, s), 4.20(1H,



m), 5.97(1H, d, J=9.6Hz), 6.70(1H, d, J=3.6Hz),



6.95(1H, m), 7.04(1H, dd, J=3.3, 1.2Hz), 7.24(1H, d, J=



3.6Hz), 7.37(1H, dd, J=5.1, 1.2Hz); IR(CHCl3) 3516,



3450, 2669, 1709, 1643, 1543, 1508, 1471cm−1; [α]D25.0+



20.8±0.6°(c=1.015, MeOH) Anal.(C24H31NO3S3.



0.3H2O) Calcd.(%): C, 59.67; H, 6.59; N, 2.90; S, 19.91



Found(%): C, 59.65; H, 6.49; N, 3.13; S, 20.18

















TABLE 46





Compd. No..
Physical property







II-5A-143a
1H-NMR(CDCl3) δ 0.95(1H, d, J=9.9Hz), 1.04(3H, s),



1.23(3H, s), 1.32–2.40(14H, m), 4.24(2H, s), 4.32(1H,



m), 6.11(1H, d, J=9.0Hz), 7.16–7.32(6H, m), 7.42(1H,



dd, J=8.1, 7.2Hz), 7.76(1H, s), 8.18(1H, d, J=8.1Hz);



IR(CHCl3) 3516, 3442, 1709, 1651,



1513, 1495, 1471cm−1;



[α]D24.0+31.6±0.7°(c=1.000, MeOH) Anal.



(C30H35NO3S.0.3H2O) Calcd.(%): C, 72.78; H, 7.25; N,



2.83; S, 6.48 Found(%): C, 72.79; H, 7.27; N, 2.87; S,



6.44


II-5A-197a
1H-NMR(CDCl3) δ 0.90(1H, d, J=9.9Hz), 1.08(3H, s),



1.20(3H, s), 1.30–2.36(14H, m), 3.22(2H, t, J=9.0Hz),



4.07(2H, s), 4.18(1H, m), 4.57(2H, t, J=9.0Hz), 5.92



(1H, d, J=8.4Hz), 6.78(1H, t, J=7.5Hz), 6.80(1H, d, J=



3.9Hz), 6.95(1H, d, J=7.5Hz), 7.09(1H, d, J=7.5Hz),



7.28(1H, d, J=3.9Hz); IR(CHCl3) 3516, 3450,



3431, 1709, 1641, 1543, 1506, 1458cm−1; [α]D25.0+



41.1±0.8°(c=1.002, MeOH) Anal.(C28H35NO4S.0.3H2O)



Calcd.(%): C, 69.05; H, 7.37; N, 2.88; S, 6.58 Found(%):



C, 69.05; H, 7.20; N, 3.06; S, 6.51


II-5B-55a
1H-NMR(CDCl3) δ 0.93(1H, d, J=10.5Hz), 1.08 and



1.23(3H, s), 1.55(1H, m), 1.91–2.42(7H, m), 2.39(3H,



s), 3.18(2H, d, J=6.6Hz), 4.20(1H, m), 5.56–5.73(2H,



m), 5.99(1H, m), 6.18–6.23(2H, m), 7.19(1H, dd, J=1.5,



3.3Hz), 7.30(1H, d, J=3.9Hz), 7.54(1H, d, J=3.9Hz);



IR(CHCl3) 3446, 1711, 1657, 1529, 1504, 1375, 1182,



1161, 1144, 1053cm−1;



[α]D25+38.8±0.8°(c=1.001,



MeOH) Anal.(C24H39N2O5S2.0.3H2O) Calcd.(%):



C, 58.11; H, 6.22; N, 5.65; S, 12.93 Found(%): C, 58.13;



H, 6.09; N, 5.68; S, 12.73.


II-5C-1a
1H-NMR(CDCl3) δ 0.95(1H, d, J=10.5Hz), 1.08(3H, s),



1.23(3H, s), 1.42–2.33(10H, m), 4.22(1H, m), 5.78(1H,



d, J= 15.9Hz), 6.07(1H, d, J=8.1Hz), 6.33(2H, t, J=



2.4Hz), 7.03(1H, dt, J=15.9, 6.9Hz), 7.16(2H, t, J=



2.4Hz), 7.28(2H, d, J=4.2Hz), 7.57(1H, d, J=4.2Hz);



IR(CHCl3) 3523, 3446, 1697, 1655, 1529, 1504, 1456,



1385, 1192, 1167, 1057, 1034cm−1; [α]D25.0+29.7±0.7°



(c=1.005, MeOH) Anal.(C23H28N2O5S2.0.2H2O)



Calcd.(%): C, 57.52; H, 5.96; N, 5.83; S, 13.35 Found(%):



C, 57.51; H, 5.89; N, 5.88; S, 13.31


II-5C-55a
1H-NMR(CDCl3) δ 0.92(1H, d, J=10.5Hz), 1.09 and



1.23(3H, s), 1.48–2.40(10H, m), 2.39(3H, s), 4.24(1H,



m), 5.79(1H, d, J=15.6Hz), 5.99(1H, m), 6.09(1H, d, J=



8.7Hz), 6.20(1H, t, J=3.6Hz), 7.03(1H, dt, J=6.9,



15.6Hz), 7.19(1H, dd, J=1.8, 3.3Hz), 7.29(1H, d, J=



4.2Hz), 7.55(1H, d, J=4.2Hz).; IR(CHCl3) 3446, 1697,



1655, 1529, 1504, 1375, 1182, 1161, 1144, 1053cm−1;



[α]D26.5+27.9±0.7°(c=1.005, MeOH) Anal.



(C24H39N2O5S2.0.3H2O) Calcd.(%): C, 58.11; H, 6.22; N,



5.65; S, 12.93 Found(%): C, 58.12; H, 6.22; N, 5.62; S,



12.91.

















TABLE 47





Compd.



No..
Physical property







II-5E-1a
mp 154–155° C.; 1H-NMR(CDCl3) δ 0.90(1H, d, J=10.2Hz),



1.10 and 1.23(3H, s), 1.51(1H, ddd, J=2.1, 5.1, 12.9Hz),



1.72–2.40(7H, m), 3.58–3.64(2H, m), 3.98 and 4.07(each 1H,



Abq, J=16.8Hz), 4.23(1H, m), 6.27(1H, d, J=8.7Hz),



6.32–6.35(2H, m), 7.15–7.17(2H, m), 7.31(1H, d, J=3.9Hz),



7.55(1H, d, J=3.9Hz); IR(CHCl3) 3444, 1730, 1655, 1529,



1504, 1456, 1385, 1192, 1167, 1057, 1034cm−1; [α]D24



−2.2±0.4°(c=1.009, MeOH) Anal.(C22H28N2O6S2)



Calcd.(%): C, 54.98 H, 5.87; N, 5.83; S, 13.34 Found(%):



C, 54.97; H, 5.92; N, 5.89; S, 13.12


II-5E-55a
1H-NMR(CDCl3) δ 0.90(1H, d, J=9.9Hz), 1.10 and 1.23



(3H, s), 1.51(1H, ddd, J=2.7, 4.8, 12.6Hz), 1.74–2.40(7H,



m), 2.39(3H, s), 3.58–3.64(2H, m), 3.98 and 4.07(each 1H,



Abq, J=17.1Hz), 4.23(1H, m), 5.99(1H, m), 6.20(1H, t, J=



3.6Hz), 6.29(1H, d, J=8.1Hz), 7.19(1H, dd, J=1.5, 3.3Hz),



7.33(1H, d, J=3.9Hz), 7.53(1H, d, J=3.9Hz); IR



(CHCl3) 3444, 1729, 1655, 1529, 1504, 1375, 1182, 1161,



1142, 1053cm−1; [α]D24 −2.8±0.4°(c=1.013, MeOH) Anal.



(C23H30N2O6S2.1.2H2O) Calcd.(%): C, 53.51;



H, 6.33; N, 5.43; S, 12.42



Found(%): C, 53.53; H, 5.93; N, 5.45; S, 12.55


II-5F-31a
1H-NMR(CDCl3) δ 0.90(1H, d, J=10.2Hz), 1.09 and 1.22



(3H, s), 1.47(1H, ddd, J=2.4, 4.8, 12.9Hz), 1.74(1H, m),



1.91–2.38(6H, m), 2.61–2.80(2H, m), 3.49(2H, s), 4.13(2H,



s), 4.21(1H, m), 6.07(1H, d, J=8.4Hz), 6.77(1H, dt, J=0.9,



3.6Hz), 7.22–7.35(6H, m); IR(CHCl3) 2924, 1711, 1641,



1543, 1508, 1471, 1454, 1286, 1257, 1227,



1223cm−1; [α]D26+



30.7±1.4°(c=0.512%, MeOH);



Anal.(C25H31NO3S2.0.3H2O)



Calcd.(%) C, 64.85; H, 6.88; N, 3.02; S, 13.85 Found(%) C,



64.73; H, 6.81; N, 3.13; S, 13.81


II-5F-55a
1H-NMR(CDCl3) δ 0.90(1H, d, 10.2Hz), 1.10 and 1.23(3H,



s), 1.49(1H, ddd, J=2.7, 5.7, 13.5Hz), 1.64–2.38(7H, m),



2.39(3H, s), 2.60–2.80(2H, m), 3.21(2H, ABq, J=15.0Hz),



4.19(1H, m), 5.98(1H, m), 6.20(1H, t, J=3.0Hz), 6.25(1H,



d, J=8.4Hz), 7.18(1H, m), 7.33(1H, d, J=4.2Hz), 7.53



(1H, d, J=4.2Hz); IR(CHCl3) 2925,



1710, 1657, 1529, 1504,



1375, 1227, 1213, 1207, 1182, 1161cm−1;



[α]D26+29.6±1.4°



(c=0.503%, MeOH);



Anal.(C23H30N2O5S3.0.4H2O) Calcd.(%)



C, 53.34; H, 5.99; N, 5.41; S, 18.57 Found(%) C, 53.41; H,



6.01; N, 5.47; S, 18.65


II-5F-88a
1H-NMR(CDCl3) δ 0.91(1H, d, 10.2Hz), 1.10 and 1.22(3H,



s), 1.48(1H, m), 1.67–2.38(7H, m), 2.60–2.80(2H, m), 3.21



(2H, br s), 4.18(2H, d, J=0.9Hz), 4.22(1H, m), 6.08(1H, d,



J=8.4Hz), 6.79(1H, dt, J=0.9, 3.6Hz), 6.96(1H, dd, J=



1.5, 5.1Hz), 7.05(1H, m), 7.27–7.33(2H, m);



IR(CHCl3) 2923, 1710, 1643, 1543, 1508, 1471,



1286, 1221, 1205cm−1;



[α]D26+30.3±1.4°(c=0.508%, MeOH); Anal.



(C23H29NO3S3.0.2H2O)



Calcd.(%) C, 59.12; H, 6.34; N, 3.00; S,



20.59 Found(%) C, 59.10; H, 6.31; N, 3.09; S, 20.47

















TABLE 48





Compd.



No..
Physical property







II-6A-55a
1H-NMR(CDCl3) δ 0.88(1H, d, J=10.2Hz), 1.08 and



1.21(3H, s), 1.22–2.36(16H, m), 2.38(3H, s), 4.16(1H,



m), 5.98(1H, m), 6.19(1H, t, J=3.3Hz), 6.30(1H, d, J=



8.7Hz), 7.17(1H, dd, J=1.8, 3.3Hz), 7.33(1H, d, J=



4.2Hz), 7.52(1H, d, J=4.2Hz); IR(CHCl3) 3446, 1709,



1657, 1529, 1504, 1375, 1182, 1161, 1144, 1053cm−1;



[α]D25+22.7±0.6°(c=1.002, MeOH) Anal.



(C25H34N2O5S2.0.3H2O) Calcd.(%): C, 58.64; H, 6.81; N,



5.47; S, 12.52 Found(%): C, 58.73; H, 6.68; N, 5.45; S,



11.93.


II-6B-55a
1H-NMR(CDCl3) δ 0.94(1H, d, J=10.5Hz), 1.08 and



1.22(3H, s), 1.55(1H, ddd, J=2.4, 5.7, 13.2Hz), 1.84–2.50



(11H, m), 2.39(3H, s), 4.20(1H, m), 5.37–5.52(2H,



m), 5.99(1H, m), 6.17–6.21(2H, m), 7.18(1H, dd, J=1.8,



6.3Hz), 7.31(1H, d, J=4.2Hz), 7.54(1H, d, J=4.2Hz);



IR(CHCl3) 3446, 1711, 1657, 1529, 1504, 1392, 1375,



1182, 1161, 1144, 1053cm−1; [α]D25+44.6±0.8°(c=1.004,



MeOH) Anal.(C25H32N2O5S2) Calcd.(%): C, 59.50; H,



6.39; N, 5.55; S, 12.71 Found(%): C, 59.16; H, 6.27; N;



5.54; S, 12.44


II-7A-31a
1H-NMR(CDCl3) δ 0.91(1H, d, J=9.9Hz), 1.08(3H, s),



1.20(3H, s), 1.22–2.34(18H, m), 4.13(2H, s), 4.19(1H,



m), 5.92(1H, d, J= 9.0Hz), 6.77(1H, d, J=3.6Hz),



7.22–7.35(6H, m); IR(CHCl3) 3516, 3450, 3431, 1709,



1641, 1545, 1506, 1469, 1456cm−1; [α]D24.0+20.4±0.6°



(c=1.000, MeOH) Anal.(C28H37NO3S.0.2H2O) Calcd.(%):



C, 71.36; H, 8.00; N, 2.97; S, 6.80 Found(%): C, 71.44;



H, 7.99; N, 3.02; S, 6.69


II-7A-47a
1H-NMR(CDCl3) δ 0.91(1H, d, J=10.5Hz), 1.09(3H, s),



1.21(3H, s), 1.22–2.33(18H, m), 4.19(1H, m), 6.06(1H,



d, J= 9.0Hz), 7.11(1H, dd, J=5.1, 3.9Hz), 7.33(1H, d,



J=3.9Hz), 7.65(1H, d, J=3.9Hz), 7.70(1H, dd, J=



5.1, 1.5Hz), 7.76(1H, dd, J=3.6, 1.5Hz); IR(CHCl3)



3516, 3446, 2679, 1709, 1657, 1529, 1504, 1402, 1336,



1153, 1095, 1022cm−1; [α]D24.0 30 25.3±0.7°(c=1.004,



MeOH) Anal.(C25H33NO5S3.0.3H2O) Calcd.(%): C, 56.75;



H, 6.40; N, 2.65; S, 18.07 Found(%): C, 56.88; H, 6.43;



N, 2.68; S, 17.79


II-7A-55a
1H-NMR(CDCl3) δ 0.90(1H, d, J=10.2Hz), 1.08 and



1.22(3H, s), 1.22–2.32(18H, m), 2.39(3H, s), 4.18(1H,



m), 4.65(1H, br s), 5.99(1H, m), 6.12(1H, d, J=9.0Hz),



6.20(1H, t, J=3.6Hz), 7.03(1H, dt, J=6.9, 15.6Hz),



7.19(1H, dd, J=1.8, 3.3Hz), 7.30(1H, d, J=4.2Hz),



7.54(1H, d, J=3.9Hz); IR(CHCl3) 3446, 1708, 1657,



1529, 1504, 1375, 1182, 1161, 1144, 1053cm−1;



[α]D25+25.1±0.6°(c=1.009, MeOH) Anal.



(C26H36N2O5S2.0.2H2O) Calcd.(%): C, 59.56; H, 7.00; N,



5.34; S, 12.23 Found(%): C, 59.59; H, 7.01; N, 5.33; S,



11.85.

















TABLE 49





Compd.



No..
Physical property







II-7A-55e
1H-NMR(CDCl3) δ 0.93(1H, d, J=10.2Hz), 1.10(3H, s),



1.23(3H, s), 1.32–2.34(16H, m), 2.29(2H, d, J=7.5Hz),



2.39(3H, s), 3.28(3H, s), 4.21(1H, m), 6.00(1H, m),



6.17(1H, d, J=9.3Hz), 6.21(1H, m), 7.19(1H, m), 7.36



(1H, d, J=3.9Hz), 7.56(1H, d, J=3.9Hz), 8.76(1H,



br); IR(CHCl3) 3386, 2927, 2862, 1718, 1651, 1531,



1506, 1398, 1375, 1344, 1159, 1053, 1020cm−1;



[α]D24+20.8±0.6°(c=1.00, MeOH) Anal.



(C27H39N3O6S3.0.5MeOH) Calcd.(%): C, 53.81; H, 6.73; N,



6.85; S, 15.67 Found(%): C, 53.91; H, 6.64; N, 7.13; S,



15.29


II-7A-55g
1H-NMR(CDCl3) δ 0.94(1H, d, J=10.5Hz), 1.13(3H, s),



1.25(3H, s), 1.26–2.40(16H, m), 2.38(3H, s), 2.93–3.00



(2H, m), 4.28(1H, m), 6.00(1H, m), 6.21(1H, t, J=3.3Hz),



6.43(1H, d, J=8.7Hz), 7.17(1H, dd, J=3.3, 1.5Hz),



7.42(1H, d, J=3.9Hz), 7.56(1H, d, J=3.9Hz); IR



(CHCl3) 3426, 2626, 1639, 1533, 1508, 1375, 1222, 1216,



1205, 1184, 1160cm−1; [α]D24.0+22.7±0.6°(c=1.002,



MeOH) Anal.(C26H36N6O3S2.0.6H2O) Calcd.(%): C,



56.21; H, 6.75; N, 15.03; S, 11.43 Found(%): C, 56.32; H,



6.52; N, 14.80; S, 11.13


II-7A-59a
1H-NMR(CDCl3) δ 0.90(1H, d, J=10.2Hz), 1.07(3H, s),



1.20(3H, s), 1.24–2.33(18H, m), 4.17(1H, m), 5.91(1H,



d, J= 9.0Hz), 7.00(1H, dd, J=5.4, 3.6Hz), 7.05(1H, d,



J=3.6Hz), 7.26(1H, d, J=3.6Hz), 7.28(1H, dd, J=



3.6, 1.2Hz), 7.42(1H, dd, J=5.4, 1.2Hz); IR(CHCl3)



3516, 3450, 3431, 2673, 1709, 1645, 1529, 1500, 1471,



1421cm−1; [α]D25.0+20.1±0.6°(c=1.010, MeOH) Anal.



(C25H33NO3S3) Calcd.(%): C, 61.06; H, 6.76; N, 2.85; S,



19.56 Found(%): C, 60.86; H, 6.87; N, 2.93; S, 19.29


II-7A-88a
1H-NMR(CDCl3) δ 0.91(1H, d, J=10.2Hz), 1.09(3H, s),



1.21(3H, s), 1.24–2.33(18H, m), 4.15(2H, s), 4.19(1H,



m), 5.94(1H, d, J= 9.0Hz), 6.79(1H, d, J=3.6Hz), 6.96



(1H, dd, J=5.1, 1.2Hz), 7.05(1H, m), 7.27(1H, dd, J=



4.8, 1.2Hz), 7.30(1H, d, J=3.6Hz); IR(CHCl3) 3518,



3450, 3431, 1709, 1641, 1545, 1506, 1469cm−1;



[α]D24.0+19.2±0.6°(c=1.012, MeOH) Anal.



(C26H35NO3S2.0.1H2O) Calcd.(%): C, 65.67; H, 7.46; N,



2.95; S, 13.09 Found(%): C, 65.81; H, 7.43; N, 2.94; S,



12.99


II-7A-
1H-NMR(CDCl3) δ 0.92(1H, d, J=10.5Hz),


104a
1.10(3H, s), 1.22(3H, s), 1.25–2.34(18H, m), 4.10(2H, s),



4.20(1H, m), 5.95(1H, d, J=8.7Hz), 6.70(1H, d, J=3.3Hz),



6.95(1H, dd, J=5.1, 3.9Hz), 7.04(1H, dd, J=3.9, 1.2Hz),



7.25(1H, d, J=3.3Hz), 7.36(1H, dd, J=5.1, 1.2Hz);



IR(CHCl3) 3516, 3450, 3431, 1709, 1643, 1543,



1506, 1471cm−1; [α]D25.0+19.8±0.6°(c=1.009, MeOH)



Anal.(C26H35NO3S3.0.1H2O) Calcd.(%): C, 61.53, H, 6.99,



N, 2.76; S, 18.95 Found(%): C, 61.42; H, 6.85; N, 2.86; S,



18.89

















TABLE 50





Compd.



No..
Physical property







II-7A-143a
1H-NMR(CDCl3) δ 0.96(1H, d, J=10.2Hz), 1.10(3H, s),



1.23(3H, s), 1.26–2.38(18H, m), 4.24(2H, s), 4.32(1H,



m), 6.11(1H, d, J= 8.7Hz), 7.19–7.28(6H, m), 7.42(1H,



dd, J=8.1, 7.2Hz), 7.76(1H, s), 8.19(1H, d, J=8.1Hz);



IR(CHCl3) 3516, 3442, 1709, 1651,



1514, 1495, 1469cm−1;



[α]D24.0+34.1±0.7°(c=1.004, MeOH) Anal.



(C32H39NO3S.0.2H2O) Calcd.(%): C, 73.73; H, 7.62; N,



2.69; S, 6.15 Found(%): C, 73.72; H, 7.68; N, 2.65; S,



5.88


II-7A-197a
1H-NMR(CDCl3) δ 0.91(1H, d, J=9.9Hz), 1.08(3H, s),



1.20(3H, s), 1.24–2.33(18H, m), 3.22(2H, t, J=8.7Hz),



4.05(2H, s), 4.19(1H, m), 4.57(2H, t, J=8.7Hz), 5.92



(1H, d, J=9.3Hz), 6.79(1H, t, J=7.2Hz), 6.80(1H, d, J=



3.9Hz), 6.96(1H, d, J=7.2Hz), 7.09(1H, d, J=7.2Hz),



7.28(1H, d, J=3.9Hz); IR(CHCl3) 3516, 3450,



3431, 2671, 1709, 1639, 1543, 1506, 1458cm−1; [α]D25.0+



17.4±0.6°(c=1.001, MeOH) Anal.(C30H39NO4S.0.3H2O)



Calcd.(%): C, 69.95; H, 7.75; N, 2.72; S, 6.22 Found(%):



C, 69.86; H, 7.65; N, 2.80; S, 6.08


II-7A-315a
1H-NMR(CDCl3) δ 0.96(1H, d, J=9.9Hz), 1.11(3H, s),



1.24(3H, s), 1.33–2.36(16H, m), 2.3(2H, t, J=7.2Hz),



4.26(2H, s), 4.33(1H, m), 6.12(1H, d, J=9.3Hz),



7.00–7.23(5H, m), 7.42(1H, m), 7.78(1H, s), 8.20(1H, d,



J=7.5Hz); IR(CHCl3) 3516, 3442, 2925, 2858, 1709,



1651, 1585, 1570, 1514, 1492, 1469, 1396cm−1;



[α]D25.5+33.4±0.7°(c=1.00, MeOH) Anal.



(C32H38FNO3S.0.5MeOH) Calcd.(%):



C, 70.75; H, 7.31; N,



2.54; F, 3.44; S, 5.81 Found(%): C, 70.85; H, 7.34; N,



2.80; F, 3.06; S, 5.66


II-7A-316a
1H-NMR(CDCl3) δ 0.96(1H, d, J=10.2Hz), 1.11(3H, s),



1.24(3H, s), 1.32–2.36(16H, m), 2.30(2H, t, J=7.2Hz),



3.82(3H, s), 4.23(2H, s), 4.33(1H, m), 6.12(1H, d, J=



9.0Hz), 6.82–6.91(2H, m), 7.05–7.22(3H, m), 7.39(1H,



m), 7.78(1H, s), 8.14(1H, d, J=8.1Hz); IR(CHCl3)



3516, 3442, 2925, 2858, 1709, 1651, 1601, 1514, 1493,



1468, 1439, 1394, 1246cm−1; [α]D26.0+31.4±0.7°(c=1.04,



MeOH) Anal.(C33H41NO4S.0.1H2O) Calcd.(%): C, 72.12;



H, 7.56; N, 2.55; S, 5.23 Found(%): C, 71.93; H, 7.73; N,



2.77; S, 5.60


II-7B-55a
1H-NMR(CDCl3) δ 0.91(1H, d, J=10.2Hz), 1.08(3H, s),



1.15(3H, d, J=7.2Hz), 1.22(3H, s), 1.29–2.45(17H, m),



2.39(3H, s), 4.19(1H, m), 5.98(1H, d, J=2.4Hz), 6.06



(1H, d, J=9.0Hz), 6.20(1H, dd, J=3.3 and 3.6Hz),



7.19(1H, dd, J=2.4 and 3.3Hz), 7.29(1H, d, 3.9Hz),



7.55(1H, d, J=3.9Hz); IR(CHCl3) 3448, 2927, 2860,



1739, 1705, 1657, 1529, 1504, 1469, 1375, 1281, 1161,



1144, 1070, 1053, 1022cm−1; [α]D24+21.4±0.6°(c=1.02,



MeOH) Anal.(C27H38N2O5S2.0.3H2O) Calcd.(%): C,



60.04; H, 7.20; N, 5.19; S, 11.87 Found(%): C, 60.26; H,



7.22; N, 5.28; S, 11.50

















TABLE 51





Compd.



No..
Physical property







II-7E-55c
1H-NMR(CDCl3) δ 0.93(1H, d, J=10.5Hz), 1.08(3H, s),



1.21(3H, s), 1.50–2.40(14H, m), 2.39(3H, s), 4.14(1H, m),



5.24(1H, brs), 5.33–5.50(2H, m), 5.99(1H, m), 5.99(1H,



brs), 6.20(1H, t, J=3.3Hz), 6.48(1H, d, J=7.2Hz), 7.19



(1H, m), 7.39(1H, d, J=4.2Hz), 7.55(1H, t, J=4.2Hz);



IR(CHCl3) 3527, 3485, 3448, 3411, 3348, 1676, 1591, 1529,



1504, 1375, 1182, 1161, 1144, 1053cm−1;



[α]D26.0+55.5±1.0°



(c=1.010, MeOH) Anal.(C26H35N3O4S2.0.3H2O)



Calcd.(%): C, 59.70; H, 6.86; N, 8.03; S, 12.26 Found(%):



C, 59.79; H, 6.75; N, 8.05; S, 12.14


II-7E-55e
mp 70–72° C.; 1H-NMR(CDCl3) δ 0.96(1H, d, J=10.8Hz),



1.09(3H, s), 1.22(3H, s), 1.60–2.37(14H, m), 2.41(3H, s),



3.25(3H, s), 4.10(1H, m), 5.28–5.47(2H, m), 6.00(1H, m),



6.06(1H, d, J=8.7Hz), 6.22(1H, dd, J=3.3 and 3.6Hz),



7.19(1H, dd, J=1.8 and 3.3Hz), 7.41(1H, d, J=3.9Hz),



7.57(1H, d, J=3.9Hz); IR(CHCl3 ) 3427, 3386, 2927,



1714, 1647, 1531, 1506, 1454, 1375, 1342, 1161, 1120,



1053, 1020cm−1; [α]D24+50.0±0.9°(c=1.00, MeOH) Anal.



(C27H37N3O6S3.0.4H2O) Calcd.(%): C, 53.78; H, 6.32; N,



6.97; S, 15.95 Found(%): C, 53.89; H, 6.28; N, 7.05; S,



15.57


II-7E-55g
1H-NMR(CDCl3) δ 0.76(1H, d, J=10.8Hz), 1.10(3H, s),



1.24(3H, s), 1.44–2.31(12H, m), 2.40(3H, s), 2.92–3.08



(2H, m), 3.98(1H, m), 5.37–5.39(2H, m), 6.01(1H, m), 6.22



(1H, t, J=3.3Hz), 6.30(1H, d, J=8.4Hz), 7.19(1H, dd, J=



3.3, 1.8Hz), 7.41(1H, d, J=3.9Hz), 7.58(1H, d, J=3.9Hz);



IR(CHCl3) 3151, 1639, 1533, 1508, 1375, 1184, 1160cm−1;



[α]D25.0+40.9±0.8°(c=1.010, MeOH) Anal.



(C26H34N6O3 S2.1.3H2O) Calcd.(%): C, 55.16; H, 6.52; N,



14.44; S, 10.43 Found(%): C, 55.44; H, 6.42; N, 14.17; S,



10.66


II-7F-55a
1H-NMR(CDCl3) δ 0.94(1H, d, J=9.9Hz), 1.08(3H, s),



1.16 or 1.18(3H, d, J=4.2Hz), 1.22(3H, s), 1.47–2.52



(13H, m), 2.39(3H, s), 4.20(1H, m), 5.38–5.41(2H, m),



5.99(1H, m), 6.14–6.21(2H, m), 7.19(1H, m), 7.31(1H, m),



7.54(1H, m); IR(CHCl3) 3446, 2925, 2870, 1738, 1705,



1657, 1529, 1504, 1469, 1375, 1182, 1161, 1144, 1070,



1053, 1022cm−1; [α]D24+49.8±0.9°(c=1.02, MeOH) Anal.



(C27H36N2O5S2.0.4H2O) Calcd.(%): C, 60.06; H, 6.87; N,



5.19; S, 11.88 Found(%): C, 60.03; H, 6.71; N, 5.31; S,



11.76


II-7I-1a
mp 111–115° C.; 1H-NMR(CDCl3) δ 0.91(1H, d, J=10.5Hz),



1.09 and 1.22(3H, s), 1.22–2.40(12H, m), 4.19(1H,



m), 5.79(1H, br d, J=15.6Hz), 6.06(1H, d, J=9.3Hz),



6.32–6.35(2H, m), 7.03(1H, dt, J=7.8, 15.6Hz), 7.15–7.17



(2H, m), 7.27(1H, d, J=3.9Hz), 7.57(1H, d, J=3.9Hz);



IR(CHCl3) 3446, 1695, 1654, 1529, 1504, 1456, 1385, 1192,



1167, 1057, 1034cm−1; [α]D25+20.5±0.6°(c=1.007, MeOH)



Anal.(C25H32N2O5S2) Calcd.(%): C, 59.50; H, 6.39; N, 5.55;



S, 12.71 Found(%): C, 59.19; H, 6.39; N, 5.48; S, 12.39

















TABLE 52





Compd.



No..
Physical property







II-7I-47a
1H-NMR(CDCl3) δ 0.91(1H, d, J=10.8Hz), 1.09 and



1.22(3H, s), 1.22–2.40(12H, m), 4.20(1H, m), 5.79(1H,



br d, J=15.6Hz), 5.99(1H, m), 6.08(1H, d, J=9.0Hz),



7.03(1H, dt, J=7.2, 15.6Hz), 7.11(1H, dd, J=3.9, 5.1Hz),



7.33(1H, d, J=3.9Hz), 7.65(1H, d, J=3.9Hz) 7.70



(1H, dd, J=1.2, 6.0Hz), 7.76(1H, dd, J=1.2, 3.9Hz);



IR(CHCl3) 3446, 2680, 1695, 1655, 1529, 1504, 1336,



1153, 1022cm−1; [α]D24+20.2±0.6°(c=1.000, MeOH)



Anal.(C25H31NO5S3.0.3H2O) Calcd.(%): C, 56.96; H, 6.04;



N, 2.66; S, 18.25 Found(%):C, 57.07; H, 6.12; N, 2.72; S,



17.88


II-7I-55a
1H-NMR(CDCl3) δ 0.91(1H, d, J=10.5Hz), 1.09 and



1.22(3H, s), 1.22–2.40(12H, m), 2.39(3H, s), 4.20(1H,



m), 5.79(1H, br d, J=15.6Hz), 5.99(1H, m), 6.06(1H,



d, J=9.0Hz), 6.20(1H, t, J=3.6Hz), 7.03(1H, dt, J=



6.9, 15.6Hz), 7.19(1H, dd, J=1.8, 3.3Hz), 7.29(1H, d,



J=3.9Hz), 7.55(1H, d, J=3.9Hz); IR(CHCl3) 3448,



1695, 1655, 1529, 1504, 1375, 1182, 1161, 1144, 1053cm−1;



[α]D25+19.7±0.6°(c=1.007, MeOH) Anal.



(C26H34N2O5S2.0.2H2O) Calcd.(%): C, 59.79; H, 6.64; N,



5.36; S, 12.28 Found(%): C, 59.83; H, 6.40; N, 5.42; S,



12.10.


II-7I-55b
1H-NMR(CDCl3) δ 0.91(1H, d, J=9.9Hz), 1.09 and 1.22



(3H, s), 1.27–1.78(8H, m), 1.99–2.38(6H, m), 2.39(3H,



s), 3.72(3H, s), 4.19(1H, m), 5.79(1H, dt, J=15.6, 1.5Hz),



5.98(1H, m), 6.03(1H, d, J=9.0Hz), 6.20(1H, t, J=



3.3Hz), 6.93(1H, dt, J=15.6, 6.9Hz), 7.19(1H, dd, J=



1.8, 3.3Hz), 7.28(1H, d, J=3.9Hz), 7.55(1H, d, J=



3.9Hz).


II-7I-59a
mp 143–145° C.; 1H-NMR(CDCl3) δ 0.90(1H, d, J=10.2Hz),



1.08 and 1.21(3H, s), 1.24–2.40(14H, m), 4.18(1H,



m), 5.79(1H, br d, J=15.6Hz), 5.91(1H, d, J=9.0Hz),



6.98–7.08(3H, m), 7.26(1H, d, J=3.6Hz), 7.29(1H, dd,



J=1.2, 3.6Hz), 7.42(1H, dd, J=1.2, 5.4Hz); IR(Nujol)



3419, 3184, 1705, 1670, 1626, 1525, 1500, 1180cm−1;



[α]D26+12.7±0.6°(c=1.007%, MeOH) Anal.(C25H31NO3S3)



Calcd.(%): C, 61.31; H, 6.38; N, 2.86; S, 19.64 Found(%):



C, 61.11; H, 6.41; N, 2.92; S, 19.42


II-7I-88a
1H-NMR(CDCl3) δ 0.91(1H, d, J=10.2Hz), 1.09(3H, s),



1.21(3H, s), 1.26–2.34(14H, m), 4.15(2H, s), 4.20(1H,



m), 5.79(1H, dt, J=15.6, 1.2Hz), 5.94(1H, d, J=9.3Hz),



6.79(1H, d, J=3.6Hz), 6.97(1H, dd, J=4.8, 1.5Hz),



7.05(1H, m), 7.25–7.33(3H, m); IR(CHCl3) 3523,



3450, 3431, 2679, 1695, 1647, 1545, 1506, 1471cm−1;



[α]D26.5+12.7±0.5°(c=1.002, MeOH) Anal.



(C26H33NO3S2.0.4H2O) Calcd.(%): C, 65.21; H, 6.92; N,



3.92; S, 13.39 Found(%): C, 65.16; H, 6.63; N, 3.76; S,



13.48

















TABLE 54





Compd.



No..
Physical property







II-7I-104a
1H-NMR(CDCl3) δ 0.92(1H, d, J=10.2Hz), 1.10(3H, s),



1.22(3H, s), 1.28–2.36(14H, m), 4.10(2H, s), 4.21(1H,



m), 5.79(1H, dt, J=15.9, 1.5Hz), 5.96(1H, d, J=9.0Hz),



6.70(1H, d, J=3.6Hz), 6.95(1H, dd, J=5.1, 3.6Hz),



7.03(1H, dt, J=15.9, 3.6Hz), 7.04(1H, dd, J=3.6,



1.2Hz), 7.25(1H, d, J=3.6Hz), 7.37(1H, dd, J=5.1,



1.2Hz); IR(CHCl3) 3523, 3450, 3431, 2679, 1695, 1649,



1543, 1506cm−1; [α]D25.0+11.0±0.7°(c=0.709, MeOH)



Anal.(C26H33NO3S3.0.5H2O) Calcd.(%): C, 60.99; H,



6.68; N, 2.73; S, 19.06 Found(%): C, 60.69; H, 6.45; N,



3.12; S, 19.32


II-7I-126a
1H-NMR(CDCl3) δ 0.90(1H, d, J=10.2Hz), 1.08(3H, s),



1.21(3H, s), 1.27–2.31(14H, m), 3.83(3H, s), 4.12(2H,



m), 4.20(1H, m), 5.79(1H, dt, J=15.6, 1.5Hz), 5.92



(1H, d, J=9.3Hz), 6.77(1H, d, J=3.6Hz), 6.86–6.92



(2H, m), 7.02(1H, dt, J=15.6, 6.9Hz), 7.16(1H, d, J=



7.5Hz), 7.22(1H, dd, J=7.5, 1.8Hz), 7.27(1H, d, J=



3.6Hz); IR(CHCl3) 3451, 3433, 2679, 1695, 1647, 1504,



1288, 1248, 1223, 1213cm−1; [α]D27.0+14.0±0.5°(c=1.001,



MeOH) Anal.(C29H37NO4S.0.2H2O) Calcd.(%): C, 69.76;



H, 7.55; N, 2.81; S, 6.42 Found(%): C, 69.50; H, 7.50; N,



2.88; S, 6.36


II-7I-197a
1H-NMR(CDCl3) δ 0.90(1H, d, J=10.2Hz), 1.08(3H, s),



1.20(3H, s), 1.26–2.36(14H, m), 3.22(2H, t, J=8.7Hz),



4.07(2H, s), 4.19(1H, m), 4.57(2H, t, J=8.7Hz), 5.79



(1H, dt, J=15.6Hz, 1.5Hz), 5.92(1H, d, J=9.0Hz),



6.79(1H, t, J=7.2Hz), 6.80(1H, d, J=3.6Hz), 6.96



(1H, d, J=7.2Hz), 7.01(1H, dt, J=15.6, 6.9Hz), 7.10



(1H, dd, J=7.2, 1.5Hz), 7.29(1H, d, J=3.6Hz); IR



(CHCl3) 3525, 3450, 3431, 2679, 1695, 1647, 1543, 1506,



1458cm−1; [α]D25.0+13.0±0.5°(c=1.002, MeOH) Anal.



(C30H37NO4S.0.2H2O) Calcd.(%): C, 70.47; H, 7.37; N,



2.74; S, 6.27 Found(%): C, 70.48; H, 7.33; N, 2.74; S,



6.29


II-7I-239a
mp 138–140° C.; 1H-NMR(CDCl3) δ 0.87(1H, d, J=10.2Hz),



1.07(3H, s), 1.19(3H, s), 1.26–2.31(12H, m), 4.09



(2H, s), 4.20(1H, m), 5.73(1H, d, J=15.6Hz), 6.08(1H,



d, J=9.0Hz), 6.79(1H, d, J=3.6Hz), 6.81–6.86(2H, m),



6.96(1H, dt, J=15.6, 6.9Hz), 7.29(1H, d, J=3.6Hz),



7.45(1H, s); IR(CHCl3) 3342, 3246, 1720, 1701, 1593,



1545, 1520, 1456, 1377, 1203cm−1; [α]D25.0+13.8±0.5°



(c=1.011, MeOH) Anal.(C30H35NO5S) Calcd.(%): C,



69.07; H, 6.76; N, 2.68; S, 6.15 Found(%): C, 68.91; H,



6.77; N, 2.75; S, 5.99

















TABLE 54





Compd.



No..
Physical property







II-7I-270a
1H-NMR(CDCl3) δ 0.91(1H, d, J=10.5Hz), 1.09(3H, s),



1.23(3H, s), 1.26–1.55(6H, m), 1.62–1.82(2H, m), 1.96–2.38



(6H, m), 2.42(6H, s), 4.20(1H, m), 5.79(1H, dt, J=



15.6, 1.5Hz), 5.88(2H, s), 6.06(1H, d, J=9.0Hz), 7.03



(1H, dt, J=15.6, 6.6Hz), 7.27(1H, d, J=3.9Hz), 7.50



(1H, d, J=3.9Hz); IR(CHCl3) 3525, 3448, 2679, 1695,



1655, 1529, 1504, 1375, 1180, 1119cm−1; [α]D25+19.4±0.6°



(c=1.008, MeOH) Anal.(C27H36N2O5S2.0.2H2O) Calcd.(%):



C, 60.47; H, 6.84; N, 5.22; S, 11.96 Found(%): C, 60.41; H,



6.77; N, 5.25; S, 11.90


II-7I-327a
1H-NMR(CDCl3) δ 0.90(1H, d, J=10.5Hz), 1.07 and 1.21



(3H, s), 1.25–2.38(12H, m), 3.00(2H, t, J=8.4Hz), 3.99



(2H, t, J=8.4Hz), 4.17(1H, m), 5.78(1H, dt, J=1.8, 15.9Hz),



6.02(1H, d, J=8.7Hz), 6.97–7.24(4H, m), 7.27(1H,



d, J=4.2Hz), 7.47(1H, d, J=4.2Hz), 7.58(1H, d, J=8.1Hz);



IR(CHCl3) 2927, 1695, 1653, 1529, 1504, 1479, 1367,



1165cm−1; [α]D26+21.3±0.6°(c=1.008%, MeOH); Anal.



(C29H36N2O5S2.0.4H2O) Calcd.(%) C, 61.76; H, 6.58; N,



4.97; S, 11.37 Found(%) C, 61.68; H, 6.43; N, 5.02; S,



11.40


II-7I-332a
1H-NMR(CDCl3) δ 0.91(1H, d, J=10.2Hz), 1.07 and 1.22



(3H, s), 1.30–2.40(16H, m), 2.54(2H, t, J=7.2Hz), 3.84–3.89



(2H, m), 4.19(1H, m), 5.79(1H, br d, J=14.4Hz),



6.01(1H, d, J=8.7Hz), 6.97–7.27(5H, m), 7.78(1H, d, J=



8.4Hz); IR(CHCl3) 2929, 1695, 1653, 1529, 1502, 1363,



1211, 1161cm−1; [α]D24+19.4±0.6°(c=1.010%, MeOH);



Anal.(C30H38N2O5S2.0.3H2O) Calcd.(%) C, 62.54; H, 6.75;



N, 4.86; S, 11.13 Found(%) C, 62.56; H, 6.76; N, 4.87; S,



10.90


II-7I-343a
1H-NMR(CDCl3) δ 0.94(1H, d, J=10.2Hz), 1.11(3H, s),



1.22(3H, s), 1.39–2.39(14H, m), 4.29(1H, m), 5.78(1H, d,



J=15.6Hz), 6.15(1H, d, J=9.0Hz), 7.02(1H, m), 7.44–7.64



(4H, m), 7.85(1H, s), 8.02–8.12(3H, m), 8.65(1H, d, J=



6.9Hz); IR(CHCl3) 3523, 3444, 2925, 2862, 1695, 1653,



1516, 1493, 1471, 1446, 1419, 1383, 1315cm−1; [α]D25.0+



34.8±0.7°(c=1.03, MeOH) Anal.(C31H35NO5S2.0.4H2O)



Calcd.(%): C, 64.99; H, 6.30; N, 2.44; S, 11.19 Found(%):



C, 64.97; H, 6.26; N, 2.62; S, 10.86


II-7I-389a
mp 119–121° C.; 1H-NMR(CDCl3) δ 0.90(1H, d, J=10.5Hz),



1.09(3H, s), 1.21(3H, s), 1.33–1.50(6H, m), 1.63–1.78



(2H, m), 1.98(1H, m), 2.18(1H, m), 2.23(3H, s),



2.12–2.32(5H, m), 3.21(2H, t, J=8.7Hz), 4.18(1H, m),



4.62(2H, t, J=8.7Hz), 5.79(1H, d, J=15.6Hz), 5.95(1H,



d, J=9.3Hz), 6.90(1H, s), 6.95(1H, s), 7.02(1H, dd, J=



15.6, 6.9Hz), 7.09(1H, d, J=3.6Hz), 7.30(1H, d, J=3.6Hz);



IR(Nujol) 3361, 2671, 1695, 1649, 1604, 1583, 1533,



1504, 1415, 1323, 1203cm−1; [α]D25+9.7±0.5°(c=1.012,



MeOH) Anal.(C30H37NO4S2.0.1H2O) Calcd.(%): C, 66.54;



H, 6.92; N, 2.59; S, 11.84 Found(%): C, 66.42; H, 6.99; N,



2.52; S, 11.92

















TABLE 55





Compd. No..
Physical property







II-7I-391a
1H-NMR(CDCl3) δ 0.91(1H, d, J=10.5Hz), 1.09(3H, s),



1.22(3H, s), 1.33–1.52(6H, m), 1.67–1.77(2H, m), 2.00(1H, m), 2.12(1H,



m), 2.18–2.25(3H, m), 2.32(3H, s)+2.32(1H,



m), 3.19(2H, t, J=8.7Hz), 4.20(1H, m), 4.73(2H, t, J=8.7Hz),



5.79(1H, dt, J=15.6, 1.5Hz), 6.89(1H, d, J=9.0Hz),



7.03(1H, dt, J=15.6, 7.1Hz), 7.21(1H, s), 7.35(1H, d, J=



3.9Hz), 7.51(1H, s), 7.74(1H, d, J=3.9Hz); IR(CHCl3)



3523, 3448, 2681, 1695, 1652, 1527, 1502, 1481, 1329cm−1;



[α]D25+17.1±0.6°(c=1.016, MeOH) Anal.



(C30H37NO6S2.0.5H2O) Calcd.(%): C, 62.04; H, 6.60; N, 2.41; S, 11.07



Found(%): C, 62.16; H, 6.52; N, 2.37; S, 10.85


II-7J-55a
1H-NMR(CDCl3) δ 0.91(1H, d, J=10.2Hz), 1.08(3H, s),



1.22(3H, s), 1.24–2.34(14H, m), 1.78(3H, d, J=1.2Hz), 2.38



(3H, d, J=1.2Hz), 4.19(1H, s), 5.98(1H, m), 6.04(1H, d, J=



9.0Hz), 6.19(1H, t, J=3.3Hz), 6.85(1H, dt, J=7.2, 1.2Hz),



7.19(1H, dd, J=3.3Hz, 1.2Hz), 7.28(1H, d, J=3.9Hz),



7.55(1H, d, J=3.9Hz); IR(CHCl3) 3525, 3446, 2667, 1685,



1657, 1529, 1504, 1375, 1281, 1182, 1161, 1053cm−1; [α]D24.0+



11.5±0.5°(c=1.000, MeOH) Anal.(C27H36N2O5S2.0.4H2O)



Calcd.(%): C, 60.06; H, 6.87; N, 5.19; S, 11.67 Found(%): C,



60.15; H, 6.56; N, 5.00; S, 11.37


II-7K-55a
1H-NMR(CDCl3) δ 0.92(1H, d, J=10.5Hz), 1.08(3H, s),



1.22(3H, s), 1.24–2.40(14H, m), 2.12(3H, d, J=1.2Hz), 2.39



(3H, d, J=1.2Hz), 4.20(2H, s), 5.64(1H, d, J=1.2Hz), 5.99



(1H, m), 6.04(1H, d, J=9.0Hz), 6.20(1H, t, J=3.3Hz), 7.19



(1H, dd, J=3.3, 1.8Hz), 7.28(1H, d, J=4.2Hz), 7.55(1H, d,



J=4.2Hz); IR(CHCl3) 3523, 3446, 2575; 1689, 1655, 1530,



1504, 1375, 1182, 1161, 1053, 1022cm−1; [α]D26.5+18.3±0.6°



(c=1.009, MeOH) Anal.(C27H36N2O5S2.0.3H2O) Calcd.(%): C,



60.27; H, 6.86; N, 5.20; S, 11.92 Found(%): C, 60.23; H, 6.66;



N, 5.17; S, 11.73


II-7L-55a
1H-NMR(CDCl3) δ 0.90(1H, d, J=10.2Hz), 1.00(3H, s),



1.22(3H, s), 1.26–2.61(14H, m), 2.39(3H, s), 4.18(1H, m),



5.95–6.08(2H, m), 6.16–6.21(2H, m), 7.19(1H, m), 7.32(1H,



d, J=4.2Hz), 7.55(1H, d, J=4.2Hz); IR(CHCl3) 3510,



3446, 2927, 2862, 1709, 1658, 1529, 1504, 1441, 1375cm−1;



[α]D25.0+18.4±0.6°(c=1.00, MeOH) Anal.



(C26H33FN2O5S2.0.5H2O) Calcd.(%): C, 57.23; H, 6.28; N,



5.13; F, 3.48; S, 11.75 Found(%): C, 57.44; H, 6.31; N, 5.10;



F, 3.28; S, 11.27


II-7M-1a
1H-NMR(CDCl3) δ 0.92(1H, d, J=10.2Hz), 1.09 and 1.23



(3H, s), 1.35–2.40(12H, m), 3.54(2H, t, J=6.0Hz), 4.04(2H,



s), 4.21(1H, m), 6.10(1H, d, J=9.6Hz), 6.32–6.35(2H, m),



7.15–7.18(2H, m), 7.29(1H, d, J=3.9Hz), 7.57(1H, d, J=



3.9Hz); IR(CHCl3) 3446, 3431, 1780, 1732, 1657, 1529,



1504, 1456, 1385, 1192, 1167, 1124, 1057, 1034cm−1; [α]D25.5+



22.0±0.6°(c=1.000, MeOH) Anal.(C24H32N2O6S2.0.3H2O)



Calcd.(%): C, 56.08 H, 6.39; N, 5.45; S, 12.48 Found(%):C,



56.19; H, 6.39; N, 5.48; S, 12.33

















TABLE 56





Compd.



No..
Physical property







II-7M-1e
1H-NMR(CDCl3) δ 0.92(1H, d, J=10.2Hz), 1.10(3H, s),



1.23(3H, s), 1.26–2.34(12H, m), 3.32(3H, s), 3.51(2H, d, J=



6.3Hz), 3.99(2H, s), 4.20(1H, m), 6.11(1H, d, J=9.3Hz),



6.34(2H, m), 7.17(2H, m), 7.29(1H, d, J=3.9Hz),



7.58(1H, d, J=3.9Hz), 8.90(1H, s); IR(CHCl3) 3448,



3352, 2925, 2870, 1730, 1657, 1529, 1504, 1471, 1456,



1423, 1402, 1387, 1354, 1167, 1151, 1120, 1057, 1034cm−1;



[α]D26 +18.7±1.1°(c=0.52, MeOH) Anal.



(C25H35N3O7S3.0.7MeOH) Calcd.(%): C, 50.75; H, 6.26; N,



6.91; S, 15.82 Found(%): C, 50.76; H, 5.68; N, 6.94; S,



15.49


II-7M-1k
1H-NMR(CDCl3) δ 0.93(1H, d, J=10.2Hz), 1.11(3H, s),



1.23(3H, s), 1.39–2.33(12H, m), 3.46(2H, t, J=6.6Hz),



3.85(2H, s), 4.22(1H, m), 6.12(1H, d, J=9.0Hz), 6.33



(2H, m), 7.15(2H, m), 7.29(1H, m), 7.52–7.66(4H, m), 8.09



(2H, d, J=7.8Hz), 9.03(1H, s); IR(CHCl3) 3446, 3350,



2924, 2870, 1732, 1657, 1529, 1504, 1473, 1450, 1415,



1385, 1167, 1120, 1088, 1057, 1034cm−1; [α]D26+14.9±0.6°



(c=1.00, MeOH) Anal.(C30H37N3O7S3.0.6H2O) Calcd.(%):



C, 54.71; H, 5.85; N, 6.38; S, 14.61 Found(%): C, 54.81; H,



5.76; N, 6.60; S, 14.29


II-7M-31a
1H-NMR(CDCl3) δ 0.92(1H, d, J=10.2Hz), 1.09 and 1.21



(3H, s), 1.39–2.37(12H, m), 3.52(2H, t, J=6.3Hz), 4.03



and 4.14(2H, s), 4.23(1H, m), 6.00(1H, d, J=8.4Hz),



6.77(1H, d, J=3.6Hz), 7.20–7.37(6H, m); IR(CHCl3)



2923, 1780, 1732, 1641, 1545, 1508, 1471, 1456, 1365,



1248, 1219, 1211, 1207, 1124cm−1; [α]D25+14.9±1.1°



(c=0.509%, MeOH); Anal.(C27H35NO4S2.0.3H2O) Calcd.(%)



C, 68.27; H, 7.55; N, 2.95; S, 6.75 Found(%) C, 68.25; H,



7.62; N, 3.02; S, 6.76


II-7M-40a
1H-NMR(CDCl3) δ 0.94(1H, d, J=10.2Hz), 1.15 and 1.25



(3H, s), 1.21–2.38(12H, m), 3.54(2H, t, J=6.3Hz), 4.05



(2H, s), 4.28(1H, m), 6.11(1H, d, J=9.0Hz), 7.25–7.64



(7H, m); IR(CHCl3) 2924, 1780, 1732, 1641, 1541, 1510,



1491, 1471, 1454, 1219, 1211cm−1; [α]D 25+15.7±0.6°



(c=1.010%, MeOH); Anal.(C26H33NO4S.0.3H2O) Calcd.(%)



C, 67.74; H, 7.35; N, 3.04; S, 6.96 Found(%) C, 67.68; H,



7.26; N, 3.107; S, 6.75


II-7M-43a
mp 95–97° C.; 1H-NMR(CDCl3) δ 0.94(1H, d, J=10.2Hz),



1.14 and 1.24(3H, s), 1.24–2.38(12H, m), 3.54(2H, t, J=



6.3Hz), 4.05(2H, s), 4.27(1H, m), 6.07(1H, d, J=8.7Hz),



7.04(1H, dd, J=3.9, 4.8Hz), 7.11(1H, d, J=3.9Hz), 7.24



(1H, dd, J=1.2, 3.6Hz), 7.28(1H, dd, J=1.2, 5.1Hz), 7.37



(1H, d, 3.9Hz); IR(Nujol) 3346, 2927, 1759, 1728, 1612,



1525, 1504, 1458, 1377, 1132cm−1; [α]D26+18.7±0.6°



(c=1.011%, MeOH); Anal.(C24H31NO4S2.0.8H2O)



Calcd.(%) C, 60.55; H, 6.90; N, 2.94; S, 13.47 Found(%) C,



60.35; H, 6.61; N, 3.07; S, 13.43

















TABLE 57





Compd.



No..
Physical property







II-7M-47a
1H-NMR(CDCl3) δ 0.91(1H, d, J=10.5Hz), 1.10 and 1.22



(3H, s), 1.36–2.40(12H, m), 3.53(2H, t, J=6.0Hz), 4.05



(2H, s), 4.21(1H, m), 6.14(1H, d, J=9.3Hz), 7.12(1H, dd,



J=0.9, 4.8Hz), 7.35(1H, d, J=3.9Hz), 7.64(1H, d, J=



3.9Hz), 7.70(1H, dd, J=1.2, 5.1Hz), 7.76(1H, dd, J=1.2,



3.9Hz); IR(CHCl3) 3446, 3429, 1780, 1732, 1655, 1529,



1504, 1336, 1153, 1124, 1074, 1024cm−1; [α]D24+22.5±0.6°



(c=1.013, MeOH) Anal.(C24H31NO6S3.0.4H2O) Calcd.(%):



C, 54.09 H, 6.01; N, 2.63; S, 18.05 Found(%): C, 54.29; H,



5.90; N, 2.81; S, 17.77


II-7M-55a
1H-NMR(CDCl3) δ 0.92(1H, d, J=10.2Hz), 1.09 and 1.23



(3H, s), 1.35–2.40(12H, m), 2.39(3H, s),



3.53(2H, t, J=6.3Hz),



4.04(2H, s), 4.21(1H, m), 5.99(1H, m), 6.12(1H, d, J=



9.6Hz), 6.20(1H, t, J=3.3Hz), 7.19(1H, dd, J=1.5, 3.3Hz),



7.32(1H, d, J=3.9Hz), 7.55(1H, d, J=3.9Hz); I IR



(CHCl3) 3446, 1780, 1731, 1656, 1529, 1504, 1375, 1182,



1161, 1142, 1053cm−1; [α]D24+20.9±0.6°(c=1.005, MeOH)



Anal.(C25H34N2O6S2.0.3H2O) Calcd.(%): C, 56.86 H, 6.60;



N, 5.30; S, 12.14 Found(%):, 56.88; H, 6.60; N, 5.31; S,



11.76


II-7M-59a
1H-NMR(CDCl3) δ 0.91(1H, d, J=10.2Hz), 1.09 and 1.22



(3H, s), 1.36–2.38(12H, m), 3.53(2H, t, J=6.0Hz), 4.04



(2H, s), 4.21(1H, m), 5.98(1H, d, J=8.7Hz), 7.01(1H, dd,



J=3.6, 5.4Hz), 7.05(1H, d, J=3.9Hz), 7.27(1H, d, J=



4.2Hz), 7.29(1H, dd, J=1.2, 3.6Hz), 7.43(1H, dd, J=1.5,



5.4Hz); IR(CHCl3) 3448, 3429, 1780, 1732, 1645, 1529,



1500, 1471, 1458, 1124cm−1; [α]D26+17.1±0.9°(c=0.608%,



MeOH) Anal.(C24H31NO4S3.0.3H2O) Calcd.(%): C, 57.75 H,



6.38; N, 2.81; S, 19.27 Found(%): C, 57.86; H, 6.39; N,



2.89; S, 19.18


II-7M-88a
1H-NMR(CDCl3) δ 0.92(1H, d, J=10.2Hz), 1.11 and 1.22



(3H, s), 1.42–2.38(12H, m), 3.53(2H, t, J=6.0Hz), 4.03



and 4.16(2H, s), 4.24(1H, m), 6.01(1H, d, J=9.0Hz),



6.79(1H, d, J=2.7Hz), 6.96(1H, dd, J=1.2, 5.1Hz), 7.05



(1H, m), 7.26–7.33(2H, m); IR(CHCl3) 2924, 1780, 1732,



1641, 1545, 1508, 1471, 1221, 1219, 1211, 1207, 1124cm−1;



[α]D25+15.5±1.1°(c=0.505%, MeOH);



Anal. (C25H33NO4S2.0.3H2O)



Calcd.(%) C, 62.42; H, 7.04; N, 2.91;



S, 13.33 Found(%) C, 62.57; H, 7.03; N, 2.98; S, 13.15


II-7M-
1H-NMR(CDCl3) δ 0.91(1H, d, J=10.2Hz), 1.09(3H, s),


126a
1.21(3H, s), 1.45–2.33(12H, m), 3.51(2H, t, J=6.3Hz),



3.84(3H, s), 4.02(2H, s), 4.11(2H, s), 4.22(1H, m), 5.99



(1H, d, J=9.0Hz), 6.77(1H, d, J=3.9Hz), 6.86–6.92(2H,



m), 7.15(1H, dd, J=7.2, 1.8Hz), 7.22(1H, dd, J=4.8, 1.8Hz),



7.29(1H, d, J=3.9Hz); IR(CHCl3) 3431, 1669, 1506,



1463, 1247, 1128cm−1; [α]D27.0+14.4±0.5°(c=1.009, MeOH)



Anal.(C28H37NO5S.0.2H2O) Calcd.(%): C, 66.82; H, 7.49; N,



2.78; S, 6.37 Found(%): C, 66.59; H, 7.41; N, 2.82; S, 6.17

















TABLE 58





Compd.



No..
Physical property







II-7M-197a
1H-NMR(CDCl3) δ 0.92(1H, d, J=10.2Hz), 1.10 and



1.21(3H, s), 1.39–2.38(12H, m), 3.22(2H, t, J=9.0Hz),



3.52(2H, t, J=6.3Hz), 4.02 and 4,07(2H, s), 4.23(1H,



m), 4.58(2H, t, J=9.0Hz), 6.00(1H, d, J=8.4Hz),



6.80–7.12(4H, m), 7.30(1H, d, J=3.6Hz); IR(CHCl3)



2923, 1780, 1732, 1639, 1545, 1506, 1477, 1458, 1441,



1365, 1254, 1205, 1126cm−1; [α]D26+13.4±1.1°



(c=0.506%, MeOH); Anal.(C29H37NO5S.0.4H2O)



Calcd.(%) C, 67.13; H, 7.34; N, 2.70; S, 6.18 Found(%) C,



67.19; H, 7.21; N, 2.75; S, 6.18


II-7M-239a
mp 179–180° C.;



1H-NMR(d6-DMSO) δ 0.78(1H, d, J=9.6Hz),



1.05(3H, s), 1.13(3H, s), 1.20–2.30(12H, m),



3.40(2H, t, J=6.3Hz), 3.84(1H, m), 3.93(2H, s),



4.17(2H, s), 6.73(1H, dd, J=8.7, 2.4Hz), 6.79(1H, d, J=



2.4Hz), 6.95(1H, d, J=3.6Hz), 7.34(1H, d, J=8.7Hz),



7.66(1H, d, J=3.6Hz), 7.79(1H, d, J=6.9Hz),



7.82(1H, s); IR(KBr) 3338, 3244, 2602, 1739, 1606,



1557, 1550, 1525, 1458, 1367, 1261, 1211cm−1; [α]D25.0+



14.0±0.5°(c=1.009, MeOH) Anal.(C29H35NO6.0.3H2O)



Calcd.(%): C, 65.59; H, 6.76; N, 2.36; S, 6.04 Found(%):



C, 65.62; H, 6.82; N, 2.81; S, 5.92


II-7M-270a
mp.147–149° C.;



1H-NMR(CDCl3) δ 0.92(1H, d, J=10.2Hz),



1.09(3H, s), 1.23(3H, s), 1.34–2.38(12H, m), 2.42



(6H, s), 3.54(2H, t, J=6.3Hz), 4.05(2H, s), 4.21(1H,



m), 5.88(2H, s), 6.12(1H, d, J=9.0Hz), 7.28(1H, d, J=



3.9Hz), 7.49(1H, d, J=3.9Hz); IR(Nujol) 3267, 3099,



2549, 1726, 1610, 1562, 1230,



1211, 1176, 1126, 1113cm−1;



[α]D26+19.8±0.6°(c=1.010, MeOH) Anal.



(C26H36N2O6S2) Calcd.(%): C, 58.18; H, 6.76; N, 5.22; S,



11.95 Found(%): C, 58.05; H, 6.74; N, 5.16; S, 11.71


II-7M-307a
1H-NMR(CDCl3) δ 0.90(1H, d, J=10.5Hz), 1.06(3H, s),



1.19(3H, s), 1.38–1.79(8H, m), 1.96(1H, m), 2.06(1H,



m), 2.15–2.31(2H, m), 3.49(2H, t, J=6.6Hz), 3.99(3H,



s), 4.20(1H, m), 4.60(2H, s), 5.95(1H, d, J=9.0Hz),



6.74(1H, brd, J=3.6Hz), 7.22(1H, d, J=3.6Hz), 7.32



(1H, d, J=9.3Hz), 7.34(1H, ddd, J=1.5, 6.9, 8.4Hz),



7.47(1H, ddd, J=1.5, 6.9, 8.4Hz), 7.80(1H, brd, J=8.4Hz),



7.82(1H, d, J=9.3Hz), 7.93(1H, brd, J=8.4Hz);



IR(Nujol) 3450, 3060, 1780, 1732, 1639, 1597, 1510,



1471, 1265, 1252, 1217cm−1; [α]D26+16.1±0.6°(c=1.005,



MeOH) Anal.(C32H39NO5S.0.4H2O) Calcd.(%): C, 69.01;



H, 7.20; N, 2.51; S, 5.76 Found(%): C, 68.97; H, 7.13; N,



2.56; S, 5.62

















TABLE 59





Compd.



No..
Physical property







II-7M-327a
1H-NMR(CDCl3) δ 0.91(1H, d, J=10.5Hz), 1.07 and



1.21(3H, s), 1.36–2.35(12H, m), 3.01(2H, t, J=8.4Hz),



3.52(2H, t, J=6.6Hz), 3.99(2H, t, J=8.4Hz), 4.03(2H,



s), 4.19(1H, m), 6.09(1H, d, J=8.7Hz), 6.99–7.24(3H,



m), 7.29(1H, d, J=3.9Hz), 7.47(1H, d, J=3.9Hz), 7.58



(1H, d, J=8.1Hz); IR(CHCl3) 2924, 1780, 1732, 1655,



1529, 1504, 1479, 1460, 1367, 1240, 1225, 1213, 1205,



1165, 1122, 1105cm−1; [α]D26+22.2±0.6°(c=1.009%,



MeOH); Anal.(C28H36N2O6S2.0.5H2O) Calcd.(%) C,



59.03; H, 6.55; N, 4.92; S, 11.26 Found(%) C, 58.93; H,



6.75; N, 5.14; S, 11.27


II-7M-329a
1H-NMR(CDCl3) δ 0.91(1H, d, J=10.5Hz), 1.08 and



1.22(3H, s), 1.36–2.38(12H, m), 3.04(2H, t, J=8.4Hz),



3.53(2H, t, J=6.3Hz), 4.04(2H, s), 4.04(2H, t, J=8.4Hz),



4.20(1H, m), 6.11(1H, d, J=8.7Hz), 6.75(1H, m),



7.20(1H, m), 7.30(1H, d, J=3.9Hz), 7.37(1H, brd, J=



7.5Hz), 7.49(1H, d, J=3.9Hz); IR(CHCl3) 2924, 1780,



1732, 1655, 1626, 1529, 1504, 1473, 1460, 1369, 1244,



1223, 1213, 1167cm−1; [α]D26+21.4±0.6°(c=1.009%,



MeOH); Anal.(C28H35FN2O6S2.0.4H2O) Calcd.(%) C,



57.40; H, 6.16; F, 3.24; N, 4.78; S, 10.95 Found(%) C,



57.37; H, 5.82; F, 3.06; N, 4.86; S, 10.80


II-7M-330a
1H-NMR(CDCl3) δ 0.91(1H, d, J=10.5Hz), 1.08 and



1.22(3H, s), 1.36–2.39(12H, m), 2.97(2H, t, J=8.4Hz),



3.53(2H, t, J=6.3Hz), 4.02(2H, t, J=8.7Hz), 4.04(2H,



s), 4.19(1H, m), 6.10(1H, d, J=8.4Hz), 6.82–6.94(2H,



m), 7.44(1H, d, J=3.9Hz), 7.53(1H, dd, J=4.5, 8.7Hz);



IR(CHCl3) 2924, 1780, 1732, 1655, 1529, 1504,



1481, 1367, 1225, 1165cm−1; [α]D26+21.7±0.6°



(c=1.008%, MeOH); Anal.(C28H35FN2O6S2.0.5H2O)



Calcd.(%) C, 57.22; H, 6.17; F, 3.23; N, 4.77; S, 10.91



Found(%) C, 57.26; H, 6.14; F, 3.19; N, 4.85; S, 10.76


II-7M-331a
1H-NMR(CDCl3) δ 0.91(1H, d, J=10.5Hz), 1.08 and



1.22(3H, s), 1.36–2.38(12H, m), 3.04(2H, t, J=8.4Hz),



3.53(2H, t, J=6.3Hz), 4.04(2H, s), 4.04(2H, t, J=8.4Hz),



4.20(1H, m), 6.11(1H, d, J=8.7Hz), 6.75(1H, m),



7.20(1H, m), 7.30(1H, d, J=3.9Hz), 7.37(1H, brd, J=



7.5Hz), 7.49(1H, d, J=3.9Hz); IR(CHCl3) 2924, 1780,



1732, 1655, 1606, 1529, 1492, 1369, 1261, 1227, 1205,



1165, 1142, 1095cm−1; [α]D25+21.4±0.6°(c=1.009%,



MeOH); Anal.(C28H35FN2O6S2.0.3H2O) Calcd.(%) C,



57.57; H, 6.14; F, 3.25; N, 4.80; S, 10.98 Found(%) C,



57.28; H, 5.85; F, 3.20; N, 4.86; S, 10.97

















TABLE 60





Compd.



No..
Physical property







II-7M-
1H-NMR(CDCl3) δ 0.92(1H, d, J=10.2Hz), 1.08 and 1.23


332a
(3H, s), 1.36–2.40(14H, m), 2.55(2H, t, J=6.6Hz), 3.53



(2H, t, J=6.6Hz), 3.84–3.87(2H, m), 4.05(2H, s), 4.20



(1H, m), 6.05(1H, d, J=9.0Hz), 7.04–7.27(5H, m), 7.78



(1H, dd, J=0.9, 8.1Hz); IR(CHCl3) 2925, 1780, 1732,



1655, 1529, 1504, 1489, 1363, 1236, 1225, 1213, 1207,



1161, 1122cm−1; [α]D24+19.5±0.6°(c=1.015%, MeOH);



Anal.(C29H38N2O6S2.0.4H2O) Calcd.(%) C, 59.85; H, 6.72;



N, 4.81; S, 11.02 Found(%) C, 59.84; H, 6.75; N, 4.92; S,



11.16


II-7M-
1H-NMR(CDCl3) δ 0.91(1H, d, J=10.2Hz), 1.08 and 1.23


333a
(3H, s), 1.36–2.40(12H, m), 3.53(2H, t, J=6.3Hz), 3.87–3.96



(4H, m), 4.05(2H, s), 4.20(1H, m), 6.09(1H, d, J=9.0Hz),



6.85(1H, dd, J=1.5, 8.4Hz), 6.96(1H, m), 7.11(1H,



m), 7.26–7.30(2H, m), 7.83(1H, dd, J=1.5, 8.1Hz); IR



(CHCl3) 2924, 1780, 1732, 1655, 1529, 1502, 1491, 1367,



1248, 1215, 1207, 1165, 1126cm−1; [α]D26+20.5±0.6°



(c=1.004%, MeOH); Anal.(C28H36N2O7S2.0.4H2O)



Calcd.(%) C, 57.59; H, 6.35; N, 4.80; S, 10.98 Found(%)



C, 57.59; H, 6.24; N, 4.89; S, 10.78


II-7M-
1H-NMR(CDCl3) δ 0.91(1H, d, J=10.2Hz), 1.08 and 1.23


334a
(3H, s), 1.36–2.40(12H, m), 3.05(2H, dd, J=5.4, 9.0Hz),



3.54(2H, t, J=6.3Hz), 4.03–4.07(4H, m), 4.21(lH, m),



6.07(1H, d, J=8.7Hz), 7.09–7.27(5H, m), 7.67(1H, m); IR



(CHCl3) 2924, 1780, 1732, 1655, 1529, 1504, 1473, 1363,



1161cm−1; [α]D24+24.4±0.6°(c=1.013%, MeOH); Anal.



(C28H36N2O6S3.0.4H2O) Calcd.(%) C, 56.05; H, 6.18; N,



4.67; S, 16.03 Found(%) C, 56.18; H, 6.09; N, 4.69; S,



15.74


II-7M-
mp 166–168° C.;



1H-NMR(d6-DMSO) δ 0.79(1H, d, J=9.6Hz),


336a
1.03 and 1.22(3H, s), 1.22–1.58(8H, m), 1.91(1H, m),



2.08–2.30(4H, m), 3.39(2H, t, J=6.0Hz), 3.85(1H, m),



3.92(2H, s), 4.63(4H, s), 7.20–7.35(4H, m), 7.77(1H, d, J=



3.9Hz), 7.94(1H, d, J=3.9Hz), 8.24(1H, d, J=6.9Hz);



IR(Nujol) 3369, 3093, 2924, 1730, 1612, 1541, 1516, 1466,



1377, 1344, 1215, 1165, 1126, 1084cm−1; [α]D25+19.0±0.6°



(c=1.003%, MeOH); Anal.(C28H36N2O6S2.0.7H2O)



Calcd.(%) C, 58.66; H, 6.57; N, 4.89; S, 11.19 Found(%) C,



58.38; H, 6.40; N, 4.99; S, 11.48


II-7M-
1H-NMR(CDCl3) δ 0.94(1H, d, J=10.2Hz), 1.11(3H, s),


343a
1.23(3H, s), 1.44–2.36(12H, m), 3.49(2H, t, J=6.9Hz),



3.99(2H, t, J=6.9Hz), 4.29(1H, m), 6.27(1H, d, J=9.3Hz),



7.44–7.63(4H, m), 7.89(1H, s), 8.01–8.11(3H, m), 8.63



(1H, d, J=7.5Hz); IR(CHCl3) 3442, 2924, 2870, 1780,



1730, 1653, 1518, 1417, 1446, 1383, 1317cm−1; [α]D26.0+



24.3±0.6°(c=1.01, MeOH) Anal.(C30H35NO6S2.1.7H2O)



Calcd.(%): C, 60.02; H, 6.45; N, 2.33; S, 10.68 Found(%):



C, 60.14; H, 6.18; N, 2.40; S, 10.3

















TABLE 61





Compd.



No..
Physical property







II-7M-385a
1H-NMR(CDCl3) δ 0.96(1H, d, J=10.2Hz), 1.16(3H, s),



1.23(3H, s), 1.37–2.39(12H, m), 3.52(2H, t, J=6.3Hz),



4.02(2H, s), 4.35(1H, m), 6.26(2H, t, J=2.4Hz), 6.48



(1H, d, J=7.8Hz), 7.21(2H, t, J=2.4Hz), 7.57–7.59



(2H, m), 8.39(1H, m), 8.44(1H, s); IR(CHCl3) 3456,



3103, 3022, 2924, 1732, 1651, 1516, 1371, 1221, 1188,



1163, 1057cm−1; [α]D22.0+42.9±0.8°(c=1.008, MeOH)



Anal.(C28H34N2O6S2.0.1H2O) Calcd.(%): C, 60.00; H,



6.15; N, 5.00; S, 11.44 Found(%): C, 59.85; H, 6.29; N,



4.82; S, 11.28


II-7M-389a
mp 112–114° C.;



1H-NMR(CDCl3) δ 0.91(1H, d, J=10.5Hz),



1.09(3H, s), 1.21(3H, s), 1.39–1.52(4H, m), 1.59–1.81



(4H, m), 1.98(1H, m), 2.11(1H, m), 2.23(3H, s) +



2.18–2.34(2H, m), 3.21(2H, t, J=8.7Hz), 3.52(2H, t, J=



6.5Hz), 4.05(2H, s), 4.20(1H, m), 4.62(2H, t, J=8.7Hz),



6.00(1H, d, J=9.0Hz), 6.90(1H, s), 6.96(1H, s),



7.08(1H, d, J=4.2Hz), 7.32(1H, d, J=4.2Hz); IR



(Nujol) 3406, 3338, 2729, 1757, 1738, 1614, 1583, 1533,



1503, 1203, 1124cm−1; [α]D23+12.2±0.5°(c=1.013,



MeOH) Anal.(C29H37NO5S2.0.2H2O) Calcd.(%): C, 63.64;



H, 6.89; N, 2.56; S, 11.72 Found(%): C, 63.68; H, 6.83;



N, 2.55; S, 11.54


II-7M-390a
mp 120–122° C.;



1H-NMR(CDCl3) δ 0.91(1H, d, J=10.2Hz),



1.08(3H, s), 1.21(3H, s), 1.38–1.52(4H, m), 1.56–1.78



(4H, m), 1.98(1H, m), 2.10(1H, m), 2.17–2.33(2H,



m), 2.39(3H, s), 3.52(2H, t, J=6.3Hz), 4.04(2H, s),



4.20(1H, m), 6.00(1H, d, J=9.0Hz), 6.72(1H, d, J=2.1Hz),



7.09(1H, m), 7.18(1H, d, J=3.9Hz), 7.33(1H, m) +



7.34(1H, d, J=3.9Hz), 7.63(1H, d, J=2.1Hz) ; IR



(CHCl3) 3508, 3448, 3429, 2667, 2568, 1780, 1732, 1645,



1529, 1500, 1471, 1421, 1323, 1246, 1130,cm−1;



[α]D24+12.5±0.5°(c=1.008, MeOH) Anal.



(C29H35NO5S2.0.3H2O) Calcd.(%): C, 63.66; H, 6.56; N,



2.56; S, 11.72 Found(%): C, 63.74; H, 6.44; N, 2.54; S,



11.78


II-7M-391a
mp 177–179° C.;



1H-NMR(CDCl3) δ 0.91(1H, d, J=10.2Hz),



1.10(3H, s), 1.22(3H, s), 1.40–1.53(4H, m), 1.57–1.71



(3H, m), 1.79(1H, m), 2.00(1H, m), 2.11(1H, m),



2.19–2.35(2H, m)+2.32(3H, s), 3.19(2H, t, J=8.7Hz),



3.53(2H, t, J=6.5Hz), 4.05(2H, s), 4.21(1H, m), 4.73



(2H, t, J=8.7Hz), 6.17(1H, d, J=9.0Hz), 7.21(1H, s),



7.36(1H, d, J=3.9Hz), 7.51(1H, s), 7.74(1H, d, J=3.9Hz);



IR(Nujol) 3249, 2754, 2677, 2553, 1736, 1622,



1564, 1331, 1225, 1196, 1155, 1134cm−1;



[α]D25+17.1±0.6°(c=1.006, MeOH) Anal.



(C29H37NO7S2.0.2H2O) Calcd.(%): C, 60.12; H, 6.51; N,



2.42; S, 11.07 Found(%): C, 60.09; H, 6.47; N, 2.32; S,



11.06

















TABLE 62





Compd.



No..
Physical property







II-7M-392a
mp 155–156° C.;



1H-NMR(CDCl3) δ 0.89(1H, d, J=9.9Hz),



1.08(3H, s), 1.20(3H, s), 1.36–1.52(4H, m), 1.55–1.69



(3H, m), 1.78(1H, m), 1.99(1H, m), 2.10(1H, m),



2.17–2.34(2H, m), 2.51(3H, s), 3.51(2H, t, J=6.5Hz),



4.04(2H, s), 4.19(1H, m), 6.17(1H, d, J=8.7Hz), 6.78



(1H, d, J=2.1Hz), 7.36(1H, d, J=3.9Hz), 7.64(1H, m),



7.75(1H, d, J=2.1Hz), 7.77(1H, m), 7.83(1H, d, J=3.9Hz);



IR(Nujol) 3323, 1734, 1624, 1536, 1321, 1153,



1126cm−1; [α]D25+20.4±0.6°(c=1.006, MeOH) Anal.



(C29H35NO7S2.0.6H2O) Calcd.(%): C, 59.59; H, 6.24; N,



2.40; S, 10.97 Found(%): C, 59.57; H, 6.12; N, 2.37; S,



10.77


II-7M-393a
1H-NMR(CDCl3) δ 0.90(3H, t, J=7.2Hz), 0.91(1H, d, J=



9.3Hz), 1.09(3H, s), 1.21(3H, s), 1.25–1.79(12H, m),



1.98(1H, m), 2.10(1H, m), 2.17–2.34(2H, m), 2.47(2H,



t, J=7.7Hz), 3.23(2H, t, J=8.7Hz), 3.52(2H, t, J=6.3Hz),



4.04(2H, s), 4.21(1H, m), 4.62(2H, t, J=8.7Hz),



5.99(1H, d, J=9.0Hz), 6.93(1H, s), 6.98(1H, s), 7.07



(1H, d, J=3.9Hz), 7.31(1H, d, J=3.9Hz); IR(CHCl3)



3058, 3448, 3429, 1780, 1732, 1643, 1529, 1500, 1466,



1419, 1248, 1124cm−1; [α]D24+12.7±0.5°(c=1.014,



MeOH) Anal.(C32H43NO5S2.0.2H2O) Calcd.(%): C, 65.21;



H, 7.42; N, 2.38; S, 10.88 Found(%): C, 65.09; H, 7.37;



N, 2.35; S, 11.02


II-7N-55a
1H-NMR(CDCl3) δ 0.92(1H, d, J=10.5Hz), 1.08 and



1.23(3H, s), 1.56(1H, ddd, J=2.7, 6.0, 13.5Hz), 1.90–2.46



(7H, m), 2.39(3H, s), 4.11(2H, d, J=1.2Hz), 4.14–4.19



(3H, m), 5.57–5.76(2H, m), 5.99(1H, m), 6.17–6.21



(2H, m), 7.19(1H, dd, J=1.8, 3.3Hz), 7.34(1H, d, J=3.9Hz),



7.55(1H, d, J=3.9Hz); IR(CHCl3) 3446, 1732,



1657, 1529, 1504, 1375, 1182, 1161,



1142, 1119, 1053cm−1;



[α]D24+40.4±0.8°(c=1.001, MeOH) Anal.



(C25H32N2O6S2.0.3H2O) Calcd.(%): C, 57.08 H, 6.25; N,



5.32; S, 12.19 Found(%): C, 57.07; H, 6.18; N, 5.39; S,



11.91


II-7O-55a
1H-NMR(CDCl3) δ 0.92(1H, d, J=10.2Hz), 1.09 and



1.23(3H, s), 1.55(1H, ddd, J=2.7, 5.7, 13.5Hz), 1.85–2.40



(7H, m), 2.39(3H, s), 3.93–4.05(4H, m), 4.25(1H,



m), 5.58–5.79(2H, m), 6.00(1H, m), 6.11(1H, d, J=9.0Hz),



6.20(1H, t, J=3.3Hz), 7.19(1H, dd, J=1.5, 3.3Hz),



7.32(1H, d, J=4.2Hz), 7.55(1H, d, J=4.2Hz); IR



(CHCl3) 3444, 1778, 1732, 1657, 1529, 1504, 1375, 1182,



1161, 1144, 1053cm−1; [α]D24.5+15.8±0.6°(c=1.008,



MeOH) Anal.(C25H32N2O6S2.0.4H2O) Calcd.(%): C, 56.88



H, 6.26; N, 5.31; S, 12.15 Found(%): C, 56.91; H, 6.17;



N, 5.30; S, 12.14

















TABLE 63





Compd.



No..
Physical property







II-7P-55a
1H-NMR(CDCl3) δ 0.89(1H, d, J=10.2Hz), 1.09(3H, s),



1.23(3H, s), 1.54(1H, m), 1.95–2.35(7H, m), 2.39(3H, s),



4.14–4.31(5H, m), 5.39(1H, dt, J=7.8Hz and 20.7Hz),



5.99(1H, m), 6.20(1H, m), 6.29(1H, d, J=5.4Hz), 7.18



(1H, m), 7.36(1H, d, J=3.9Hz), 7.53(1H, d, J=3.9Hz);



IR(CHCl3) 3446, 2925, 1732, 1655, 1531, 1504, 1375, 1161,



1142, 1053, 1022cm−1; [α]D24+30.1±0.7°(c=1.01, MeOH)



Anal.(C25H31FN2O6S2.0.7MeOH) Calcd.(%): C, 55.01; H,



6.07; N, 4.99; F, 3.39; S, 11.43 Found(%): C, 55.21; H,



5.92; N, 5.11; F, 3.49; S, 11.16


II-7P-55e
1H-NMR(CDCl3) δ 0.91(1H, d, J=10.2Hz), 1.10(3H, s),



1.25(3H, s), 1.97–2.37(8H, m), 2.39(3H, s), 3.28(3H, s),



3.99–4.28(5H, m), 5.41(1H, dt, J=8.7 and 20.4Hz), 5.99



(1H, m), 6.13(1H, d, J=8.4Hz), 6.20(1H, m), 7.19(1H,



m), 7.33(1H, d, J=4.2Hz), 7.55(1H, d, J=4.2Hz); IR



(CHCl3) 3448, 3352, 2925, 1728, 1657, 1529, 1504, 1425,



1402, 1375, 1348, 1157, 1053, 1020cm−1; [α]D24+32.7±1.5°



(c=0.49, MeOH) Anal.(C26H34FN3O7S3.0.45MeOH)



Calcd.(%): C, 50.41; H, 5.73; N, 6.67; F, 3.01; S, 15.26



Found(%): C, 50.80; H, 5.81; N, 6.63; F, 2.85; S, 14.87


II-7P-55j
1H-NMR(CDCl3) δ 0.90(1H, d, J=10.2Hz), 1.09(3H, s),



1.24(3H, s), 1.51–2.37(8H, m), 2.39(3H, s), 3.97(2H, s),



4.17–4.25(3H, m), 5.39(1H, dt, J=9.0 and 20.7Hz), 5.99



(1H, m), 6.20(1H, m), 6.37(1H, d, J=8.1Hz), 6.71(1H, s),



7.19(1H, m), 7.39(1H, d, J=3.9Hz), 7.55(1H, d, J=3.9Hz);



IR(CHCl3) 3519, 3402, 2925, 2870, 1745, 1689, 1657,



1574, 1529, 1504, 1471, 1448, 1375, 1161, 1144, 1092,



1053, 1022cm−1; [α]D25+40.8±1.6°(c=0.51, MeOH)


II-7Q-55a
1H-NMR(CDCl3) δ 0.90(1H, d, J=10.2Hz), 1.11 and 1.23



(3H, s), 1.53(1H, ddd, J=2.1, 5.7, 13.5Hz), 1.70–2.38(7H,



m), 2.38(3H, s), 3.52(2H, t, J=6.3Hz), 3.96–4.13(2H, m),



4.23(1H, m), 5.97–6.04(2H, m), 6.14(1H, d, J=9.3Hz),



6.20(1H, t, J=3.6Hz), 6.96(1H, dt, J=4.2, 15.6Hz), 7.18



(1H, m), 7.27(1H, d, J=3.9Hz), 7.54(1H, d, J=3.9Hz);



IR(CHCl3) 2925, 1701, 1657, 1529, 1504, 1375, 1215, 1182,



1161, 1142cm−1; [α]36526 −42.1±0.8°(c=1.001%, MeOH);



Anal.(C25H32N2O6S2.0.4H2O) Calcd.(%) C, 56.88; H, 6.26;



N, 5.31; S, 12.15 Found(%) C, 56.95; H, 6.11; N, 5.35; S,



12.11


II-7R-55a
1H-NMR(CDCl3) δ 0.92(1H, d, J=10.2Hz), 1.09 and 1.22



(3H, s), 1.35–2.40(12H, m), 2.39(3H, s),



2.64(2H, t, J=7.2Hz),



3.20(2H, s), 4.20(1H, m), 4.52(1H, brs), 5.99(1H,



m), 6.16(1H, d, J=8.7Hz), 6.20(1H, t, J=3.3Hz), 7.19



(1H, dd, J=1.8, 3.3Hz), 7.31(1H, d, J=3.9Hz), 7.55(1H,



d, J=3.9Hz); IR(CHCl3) 3446, 2675, 2565, 1711, 1657,



1529, 1504, 1375, 1182, 1161, 1144, 1053cm−1; [α]D24+



23.5±0.6°(c=1.007, MeOH) Anal.(C25H34N2O5S3.0.3H2O)



Calcd.(%): C, 55.18; H, 6.41; N, 5.15; S, 17.68 Found(%): C,



55.29; H, 6.31; N, 5.12; S, 17.46

















TABLE 64





Compd.



No..
Physical property







II-7R-88a
1H-NMR(CDCl3) δ 0.93(1H, d, J=10.2Hz), 1.10 and



1.22(3H, s), 1.36–2.40(12H, m), 2.65(2H, t, J=6.9Hz),



3.17 and 3.22(each 1H, ABq, J=14.7Hz), 4.16(2H, s),



4.23(1H, m), 4.60(1H, brs), 6.04(1H, d, J=9.3Hz),



6.79(1H, brd, J=3.9Hz), 6.96(1H, dd, J=1.5, 5.1Hz),



7.05(1H, m), 7.28(1H, dd, J=3.0, 4.8Hz), 7.32(1H, d, J=



3.6Hz); IR(CHCl3) 3450, 3430, 1711, 1641, 1545,



1508, 1471, 1460, 1294, 1263, 1126cm−1; [α]D24+



18.0±0.6°(c=1.003, MeOH) Anal.



(C25H33NO3S3.0.3H2O) Calcd.(%): C, 60.40; H, 6.81; N,



2.82; S, 19.35 Found(%): C, 60.42; H, 6.60; N, 2.99; S,



19.47


II-7R-270a
mp.150–152° C.;



1H-NMR(CDCl3) δ 0.92(1H, d, J=10.5Hz),



1.09(3H, s), 1.23(3H, s), 1.34–2.38(12H, m), 2.42



(6H, s), 2.64(2H, t, J=7.2Hz), 3.20(2H, s), 4.21(1H,



m), 5.88(2H, s), 6.15(1H, d, J=9.0Hz), 7.29(1H, d, J=



3.9Hz), 7.49(1H, d, J=3.9Hz); IR(Nujol) 3365, 3084,



1709, 1622, 1549, 1367, 1176, 1126cm−1; [α]D27+



22.7±0.6°(c=1.001, MeOH) Anal.



(C26H36N2O5S3.0.2(C6H14O))



Calcd.(%): C, 57.31; H, 6.86;



N, 4.91; S, 16.88 Found(%): C, 57.18; H, 6.78; N, 4.89; S,



16.95


II-7S-47a
1H-NMR(CDCl3) δ 0.86(1H, d, J=10.2Hz), 1.08 and



1.20(each 3H, s), 1.38–2.40(10H, m), 3.89–4.20(4H, m),



6.68–6.72(2H, d, m), 7.11(1H, dd, J=3.6, 4.8Hz), 7.44



(1H, d, J=4.2Hz), 7.59(1H, d, J=4.2Hz), 7.71(1H, dd,



J=3.6, 5.1Hz), 7.74(1H, dd, J=1.2, 3.9Hz); IR(CHCl3)



3346, 3097, 1730, 1649, 1533, 1506, 1402, 1335, 1153,



1024cm−1; [α]D24+27.5±0.7°(c=1.003, MeOH) Anal.



(C24H30N2O6S3.0.5H2O) Calcd.(%): C, 52.63; H, 5.70; N,



5.11; S, 17.56 Found(%): C, 52.45; H, 5.39; N, 5.211; S,



17.62


II-7S-55a
mp 99–101° C.;



1H-NMR(CDCl3) δ 0.87(1H, d, J=10.2Hz),



1.08 and 1.21(each 3H, s), 1.40–2.40(10H, m), 2.38



(3H, s), 3.91–4.20(3H, m), 5.99(1H, m), 6.20(1H, t, J=



3.6Hz), 6.53–6.60(2H, d, m), 7.17(1H, dd, J=1.8, 3.3Hz),



7.41(1H, d, J=4.2Hz), 7.53(1H, d, J=4.2Hz); IR



(Nujol) 3321, 3089, 1736, 1709, 1660, 1633, 1550, 1377,



1236, 1184, 1159, 1051cm−1; [α]D24+28.5±0.7°(c=1.006,



MeOH) Anal.(C25H33N3O6S2) Calcd.(%): C, 56.05; H,



6.21; N, 7.84; S, 11.97 Found(%): C, 55.74; H, 6.17; N,



7.71; S, 11.81

















TABLE 65





Compd.



No..
Physical property







II-7T-55a
1H-NMR(CDCl3) δ 0.86(1H×1/2, d, J=10.5Hz), 0.90



(1H×1/2, d, J=10.5Hz), 1.05, 1.08, 1.20 and 1.22(each



3H×1/2, s), 1.40–2.57(10H, m), 2.39(3H, s), 4.18(1H, m),



4.47 and 4.57(each 1H×1/2, ABq, J=17.1Hz), 4.49 and



4.59(each 1H×1/2, ABq, J=17.1Hz), 5.99(1H, m), 6.20



(1H, m), 6.36(1H, m), 6.73(1H×1/2, t, J=6.0Hz), 7.18



(1H, m), 7.32(1H×1/2, d, J=3.9Hz), 7.38(1H×1/2, d, J=



3.9Hz), 7.46(1H×1/2, t, J=6.0Hz), 7.53(1H, d, J=3.9Hz);



IR(CHCl3) 3446, 1765, 1732, 1655, 1531, 1504, 1375,



1182, 1161, 1144, 1053, 1022cm−1; [α]D25 −4.2±0.4°



(c=1.008, MeOH) Anal.(C24H31N3O6S2) Calcd.(%): C, 55.26;



H, 5.99; N, 8.06; S, 12.29 Found(%): C, 55.20; H, 5.88; N,



7.81; S, 11.94


II-7U-31a
1H-NMR(CDCl3) δ 0.91(1H, d, J=10.2Hz), 1.10 and 1.22



(3H, s), 1.47(1H, m), 1.64–2.63(12H, m), 4.13(2H, s), 4.20



(1H, m), 6.07(1H, d, J=8.4Hz), 6.77(1H, d, J=3.9Hz),



7.22–7.36(6H, m); IR(CHCl3) 2924, 1709, 1643, 1543,



1506, 1471, 1454, 1284, 1223, 1213, 1205cm−1; [α]D26+



25.1±1.3°(c=0.507%, MeOH); Anal.



(C27H35NO3S2.0.3H2O)



Calcd.(%) C, 66.03; H, 7.31; N, 2.83;



S, 13.06 Found(%) C, 66.03; H, 7.37; N, 2.96; S, 13.09


II-7U-55a
1H-NMR(CDCl3) δ 0.89(1H, d, J=10.2Hz), 1.10 and 1.22



(3H, s), 1.48(1H, ddd, J=2.4, 5.4, 13.2Hz), 1.65–2.60



(12H, m), 2.40(3H, s), 4.18(1H, m), 5.99(1H, m), 6.20(1H,



t, J=3.3Hz), 6.23(1H, d, J=8.4Hz), 7.19(1H, dd, J=1.8,



3.3Hz), 7.33(1H, d, J=4.2Hz), 7.55(1H, d, J=4.2Hz);



IR(CHCl3) 2925, 1741, 1709, 1657, 1529, 1504, 1375, 1221,



1211, 1207, 1182, 1161, 1144cm−1;



[α]D25+29.1±0.7°



(c=1.008%, MeOH);



Anal.(C25H34N2O5S3.0.3H2O) Calcd.(%)



C, 55.18; H, 6.41; N, 5.15; S, 17.68 Found(%) C, 55.20; H,



6.25; N, 5.21; S, 17.71


II-7U-88a
1H-NMR(CDCl3) δ 0.91(1H, d, J=10.2Hz), 1.11 and 1.22



(3H, s), 1.47(1H, m), 1.64–2.63(12H, m), 4.16(2H, s), 4.21



(1H, m), 6.08(1H, d, J=8.7Hz), 6.79(1H, d, J=3.9Hz),



6.96(1H, dd, J=1.2, 5.1Hz), 7.05(1H, m), 7.27–7.34(3H,



m); IR(CHCl3) 2924, 1709, 1643, 1543, 1508, 1471, 1284,



1238, 1217cm−1; [α]D25+24.9±0.6°(c=1.014%, MeOH);



Anal.(C25H33NO3S3.0.4H2O) Calcd.(%) C, 60.18; H, 6.83;



N, 2.81; S, 19.28 Found(%) C, 60.20; H, 6.77; N, 2.94; S,



19.34


II-7V-55a
1H-NMR(CDCl3) δ 0.92(1H, d, J=10.8Hz), 1.09(3H, s),



1.23(3H, s), 1.26–2.34(14H, m), 2.39(3H, s), 4.20(1H, m),



5.99–6.07(2H, m), 6.13–6.29(2H, m), 7.19(1H, m), 7.29



(1H, d, J=3.9Hz), 7.55(1H, d, J=3.9Hz); IR(CHCl3)



3512, 3446, 2927, 2862, 2553, 1711, 1658, 1529, 1504,



1431, 1375, 1279cm−1; [α]D26.0+16.0±1.1°(c=0.50, MeOH)



 (C26H33FN2O5S2.0.6MeOH) Calcd.(%): C, 57.47; H,



6.42; N, 5.04; F, 3.42; S, 11.5 Found(%): C, 57.77; H, 6.28;



N, 4.95; F, 3.33; S, 11.15

















TABLE 66





Compd.



No..
Physical property







II-8C-55a
1H-NMR(d6-DMSO) δ 0.77(1H, d, J=9.6Hz), 1.03(3H, s),



1.12(3H, s), 1.13–1.52(9H, m), 1.89(1H, m), 2.06–2.30



(4H, m), 2.32(3H, s), 3.39(2H, m), 3.62(2H, s), 3.84(1H,



m), 6.10(1H, m), 6.27(1H, t, J=3.3Hz), 7.25(1H, dd, J=



3.3, 1.5Hz), 7.87(1H, d, J=3.9Hz), 7.98(1H, d, J=3.9Hz),



8.45(1H, d, J=7.2Hz); IR(Nujol) 3332, 1623, 1536,



1457, 1375, 1182, 1160cm−1; [α]D24.0+15.1±0.6°(c=1.006,



DMSO) Anal.(C26H36N2O6S2.2.0H2O) Calcd.(%): C, 53.52;



H, 7.04; N, 4.89; S, 11.10 Found(%): C, 53.38; H, 6.74; N,



4.82; S, 10.88


II-8C-88a
1H-NMR(d6-DMSO) δ 0.77(1H, d, J=9.3Hz), 1.05(3H, s),



1.13(3H, s), 1.14–1.66(8H, m), 1.86–2.28(6H, m), 3.38



(2H, m), 3.60(2H, s), 3.85(1H, m), 4.13(2H, s), 6.88(1H,



d, J=3.6Hz), 6.99(1H, dd, J=5.1, 0.9Hz), 7.28(1H, m),



7.48(1H, dd, J=5.1, 3.0Hz), 7.67(1H, d, J=3.6Hz), 7.82



(1H, d, J=7.2Hz);



IR(Nujol) 3413, 1623, 1508, 1459, 1091cm−1;



[α]D24.0+12.6±1.1°(c=0.500, DMSO) Anal.



(C26H35NO4S2.2.0H2O) Calcd.(%): C, 58.40; H, 7.28; N,



2.66; S, 12.00 Found(%): C, 58.43; H, 7.01; N, 2.73; S,



11.73


VI-6A-1a
1H-NMR(CDCl3) δ 0.86(1H, m), 1.04–1.66(15H, m),



1.95(1H, m), 2.15(1H, brs), 2.33(2H, t, J=7.5Hz), 3.26



(1H, m), 3.49(1H, m), 6.11(1H, brt), 6.33(2H, t, J=2.4Hz),



7.16(2H, t, J=2.4Hz), 7.33 and 7.57(each 1H, each



d, each J=4.2Hz); IR(CHCl3) 3514, 3446, 2679, 1709,



1658, 1535, 1509, 1456, 1385, 1274, 1192, 1192, 1167,



1057, 1034cm−1; [α]D26+8.7±0.5°(c=1.002, MeOH) Anal.



(C23H30N2O5S2.0.1H2O) Calcd.(%): C, 57.50; H, 6.34; N,



5.83; S, 13.35 Found(%): C, 57.56; H, 6.46; N, 5.91; S,



13.04


VI-6A-47a
1H-NMR(CDCl3) δ 0.87(1H, m), 1.04–1.66(15H, m), 1.95



(1H, m), 2.16(1H, brs), 2.33(2H, t, J=7.5Hz), 3.27(1H,



m), 3.49(1H, m), 6.24(1H, brt), 7.11(1H, dd, J=3.6 and



4.8Hz), 7.39 and 7.63(each 1H, each d, each J=3.9Hz),



7.70(1H, dd, J=1.2 and 4.8Hz), 7.75(1H, dd, J=1.2 and



3.6Hz); IR(CHCl3) 3514, 3446, 1709, 1657, 1533, 1506,



1402, 1336, 1153, 1097, 1024cm−1; [α]D26+7.4±0.5°



(c=1.014, MeOH) Anal.(C23H29NO5S3.0.4H2O) Calcd.(%): 



C, 55.93; H, 5.97; N, 2.79; S, 19.13 Found(%): C, 55.08; H,



6.09; N, 2.93; S, 19.03


VI-6A-88a
1H-NMR(CDCl3) δ 0.87(1H, m), 1.04–1.68(15H, m), 1.94



(1H, m), 2.17(1H, brs), 2.33(2H, t, J=7.5Hz), 3.20(1H,



m), 3.53(1H, m), 4.15(2H, s), 5.87(1H, brt), 6.78(1H, m),



6.96(1H, dd, J=1.2 and 5.1Hz), 7.05(1H, m), 7.28(1H,



dd, J=3.0 and 5.1Hz), 7.34(1H, d, J=3.6Hz); IR(CHCl3)



3516, 3452, 1709, 1645, 1547, 1513, 1462cm−1; [α]D26+



8.4±0.5°(c=1.015, MeOH) Anal.(C24H31NO3S2.0.2H2O)



Calcd.(%): C, 64.17; H, 7.04; N, 3.12; S, 14.28 Found(%): 



C, 64.16; H, 7.13; N, 3.18; S, 14.09

















TABLE 67





Compd. No..
Physical property







VII-GA-1a
1H-NMR (CDCl3) δ 0.86 (1H, m), 1.08–1.60 (15H, m),



1.95(1H, m), 2.15 (1H, brs), 2.33 (2H, t, J=7.5 Hz), 3.26



(1H, m), 3.49 (1H, m), 6.15 (1H, brt, J=5.1 Hz), 6.33



(2H, t, J=2.4 Hz), 7.16 (2H, t, J=2.4 Hz), 7.33 and 7.57



(each 1H, each d, each J=3.9 Hz); IR (CHCl3) 3514,



3446, 2677, 1709, 1660, 1533, 1508, 1456, 1385, 1275,



1192, 1167, 1057, 1034 cm−1; [α]D24 − 7.6 ± 0.5° (c=1.006



MeOH) Anal. (C23H30N2O5S2·0.3H2O) Calcd.(%): C,



57.07; H, 6.37; N, 5.79; S, 13.25 Found (%): C, 57.16; H,



6.27; N, 5.81; S, 13.19


VII-6A-47a
1H-NMR (CDCl3) δ 0.87 (1H, m), 1.10–1.63 (15H, m),



1.95 (1H, m), 2.16 (1H, brs), 2.33 (2H, t, J=7.5 Hz),



3.27 (1H, m), 3.49 (1H, m), 6.23 (1H, brt, J=5.6 Hz),



7.11 (1H, dd, J=3.9 and 5.1 Hz), 7.38 and 7.63 (each 1H,



each d, each J=3.9 Hz), 7.70 (1H, dd, J=1.5 and 5.1 Hz),



7.75 (1H, dd, J=1.5 and 3.9 Hz); IR (CHCl3) 3514,



3446, 1709, 1657, 1533, 1506, 1402, 1336, 1275, 1153,



1097, 1024 cm−1; [α]D24 − 8.1 ± 0.5° (c=1.008, MeOH)



Anal. (C23H29NO5S3·0.3H2O) Calcd.(%): C, 55.13; H,



5.95; N, 2.80; S, 19.20 Found (%): C, 55.15; H, 5.94;



N, 3.06; S, 19.14


VII-6A-88a
1H-NMR (CDCl3) δ 0.86 (1H, m), 1.09–1.61 (15H, m),



1.94 (1H, m), 2.17 (1H, brs), 2.32 (2H, t, J=7.5 Hz),



3.21 (1H, m), 3.52 (1H, m), 4.15 (2H, s), 5.89 (1H, brt,



J=5.4 Hz), 6.78 (1H, d, J=3.6 Hz), 6.96 (1H, dd,



J=1.8 and 5.1 Hz), 7.05 (1H, m), 7.28 (1H, dd, J=3.0



and 5.1 Hz), 7.34 (1H, d, J=3.6 Hz); IR (CHCl3) 3517,



3450, 1709, 1645, 1547, 1514, 1462 cm−1;



[α]D24 − 9.4 ± 0.5° (c=1.012, MeOH)



Anal. (C24H31NO3S2) Calcd.(%): C, 64.68; H, 7.01; N,



3.14; S, 14.39 Found (%): C, 64.51; H, 6.90; N, 3.17; S,



14.53









The structure and physical property of the compound prepared as the example of reference are shown below. A compound with a beginning number “I-” means a compound of the formula:




A compound with a beginning number “II-” means a compound of the formula:





A compound with a beginning number “III-” means a compound of the formula:





A compound with a beginning number “IV-” means a compound of the formula:





A compound with a beginning number “V-” means a compound of the formula:





A compound with a beginning number “VI-” means a compound of the formula:





Furthermore, a number following the number (I, II, III, IV, V, and VI) represents a structure of the group of the formula: —X1—X2—X3 and each number is the same meaning as that used in the list of the structure of the formula: —X1—X2—X3.

Compound Number I-1

mp.113–114° C.; 1H-NMR(CDCl3) δ: 1.09(1H, m), 1.17–1.32(2H, m), 1.34–1.52(2H, m), 1.56–1.75(4H, m), 2.00–2.18(5H, m), 2.35 (2H, t, J=7.2 Hz), 2.52(1H, m), 3.80(1H, m), 5.31–5.43(2H, m), 6.22(1H, d, J=6.0 Hz), 6.35 and 7.17(each 2H, each t, each J=2.1 Hz), 7.37 and 7.56(each 1H, each d, each J=3.9 Hz). IR(Nujol): 3369, 3143, 3124, 3068, 2678, 1710, 1626, 1593, 1374, 1200, 1171 cm−1. [α]D26.5+75.5±1.2°(c=1.004, MeOH) Anal. (C23H28N2O5S2) Calcd.(%): C, 57.96.; H, 5.92; N, 5.88; S, 13.45. Found(%): C, 57.99; H, 5.88; N, 5.66; S, 13.50.
Compound Number I-3
1H-NMR (CDCl3-CD3OD) δ: 1.23(1H, m), 1.28–1.32(2H, m), 1.44–1.53(2H, m), 1.57–1.74(4H, m), 2.03–2.14(5H, m), 2.32(2H, t, J=7.2 Hz), 2.56(1H, m), 3.82(1H, m), 5.33–5.47(2H, m), 6.80(1H, m), 7.09–7.12(2H, m), 7.22(1H, t, J=8.1 Hz), 7.63 and 7.86(each 1H, each d, each J=8.1 Hz). IR(CHCl3): 3593 3442, 3111, 1710, 1644, 1519, 1449 cm−1. [α]D25+77.6±1.20°(c=1.010, MeOH) Anal. (C25H29NO4S.0.2H2O) Calcd.(%): C, 67.76; H, 6.69; N, 3.16; S, 7.23. Found(%): C, 67.64; H, 6.77; N, 3.17; S, 7.18.
Compound Number I-4
1H-NMR(CDCl3) δ: 1.06(1H, m), 1.17–1.32(2H, m), 1.40–1.50(2H, m), 1.56–1.80 (4H, m), 2.00–2.22(5H, m), 2.33(2H, t, J=7.2 Hz), 2.53(1H, m), 3.84 (3H, s), 3.85(1H, m), 5.29–5.42(2H, m), 6.18(1H, d, J=6.9 Hz), 6.93, 7.10, 7.44 and 7.59 (each 2H, each d-like). IR(CHCl3): 3516, 3448, 1708, 1650, 1594, 1514, 1494, 1483, 1288, 1248, 1032 cm−1. [α]D26+82.8±1.2°(c=1.000, MeOH) Anal. (C28H33NO4S.0.2H2O) Calcd.(%): C, 69.59; H, 6.97; N, 2.90; S, 6.64. Found(%): C, 69.69; H, 6.93; N, 3.20; S, 6.57.
Compound Number I-5
1H-NMR(CDCl3) δ: 1.06(1H, m), 1.16–1.32(2H, m), 1.36–1.50(2H, m), 1.54–1.80 (4H, m), 2.00–2.22(5H, m), 2.34(2H, t, J=7.2 Hz), 2.53(1H, m), 3.82 (1H, m), 3.83(3H, s), 5.29–5.42(2H, m), 6.14(1H, d, J=7.2 Hz), 6.92 (2H, d-like), 7.20–7.30(2H, m), 7.41–7.51(4H, m). IR(CHCl3): 3509, 3444, 2666, 1708, 1654, 1592, 1570, 1510, 1494, 1468, 1288, 1247, 1082 cm−1. [α]D26+58.4±1.4°(c=0.704, MeOH) Anal. (C28H33NO4S.0.2H2O) Calcd.(%): C, 69.59; H, 6.97; N, 2.90; S, 6.64. Found(%): C, 69.55; H, 6.93; N, 3.03; S, 6.57.
Compound Number I-6
1H-NMR(CDCl3) δ: 1.11(1H, m), 1.20–1.34(2H, m), 1.42–1.52(2H, m), 1.56–1.78(4H, m), 2.00–2.23(5H, m), 2.35(2H, t, J=7.2 Hz), 2.57(1H, m), 3.89 (1H, m), 5.31–5.45(2H, m), 6.30(1H, d, J=7.2 Hz), 6.37 and 7.12(each 2H, each 2H, each J=2.1 Hz), 7.42 and 7.83(each 2H, each d-like). IR(CHCl3): 3518, 3448, 2662, 1708, 1653, 1609, 1499, 1334 cm−1. [α]D23+94.9±1.3°(c=1.005, MeOH) Anal. (C25H30N2O3.0.1H2O) Calcd.(%): C, 73.54; H, 7.45; N, 6.86. Found(%): C, 73.43; H, 7.46; N, 7.01.
Compound Number I-7
1H-NMR(CDCl3) δ: 1.12–1.76(9H, m), 1.96–2.24(5H, m), 2.33(2H, t, J=7.2 Hz), 2.53(1H, m), 3.86(1H, m), 5.30–5.47(2H, m), 6.60(1H, d, J=6.9 Hz), 7.05–7.23(5H, m), 7.55(1H, brs), 7.67 and 7.74(each 2H, each d, each J=8.7 Hz). IR(CHCl3): 3516, 3439, 3368, 1708, 1653, 1600, 1519, 1496, 1487, 1401, 1347, 1165 cm−1. [α]D25+69.9±1.1°(c=1.019, MeOH) Anal. (C27H34N2O5S.0.1H2O) Calcd.(%): C, 64.80; H, 6.89; N, 5.60; S, 6.41. Found(%): C, 64.73; H, 6.56; N, 5.74; S, 6.41.
Compound Number I-8
1H-NMR(CDCl3) δ: 1.19–1.27(3H, m), 1.35–1.43(2H, m), 1.55–1.80(4H, m), 1.90–2.08(3H, m), 2.11–2.21(2H, m), 2.34(2H, t, J=7.2 Hz), 2.53(1H, m), 3.74 (1H, m), 5.29–5.48(2H, m), 6.44(1H, d, J=6.9 Hz), 7.15(1H, d, J=1.5 Hz), 7.46(2H, t, J=7.8 Hz), 7.57(1H, m), 7.60(1H, d, J=1.5 Hz), 7.76–7.78 (2H, m), 7.89(1H, s). IR(CHCl3): 3440, 3360, 3107, 1708, 1637, 1518, 1448, 1329, 1163 cm−1. [α]D20+55.5±1.0°(c=1.003, MeOH) Anal. (C25H30N2O5S2.0.2H2O) Calcd.(%): C, 59.31; H, 6.05; N, 5.53; S, 12.67. Found(%): C, 59.19; H, 6.12; N, 5.66; S, 12.50.
Compound Number I-9
mp.193–194° C.; 1H-NMR (d6-DMSO) δ: 1.18–1.59 (9H, m), 1.93 (1H, d, J=2.4 Hz), 1.99–2.07(4H, m), 2.21(2H, t, J=7.2 Hz), 2.36(1H, m), 5.30–5.40(2H, m), 7.25(1H, d, J=1.5 Hz), 7.54–7.63(3H, m), 7.69(1H, d, J=1.5 Hz), 7.99–8.02 (3H, m), 11.6(1H, s), 12.00(1H, brs). IR(Nujol): 3367, 3221, 3186, 3091, 3055, 2654, 1711, 1631, 1566, 1541, 1321 cm−1. [α]D21+74.6±1.1°(c=1.006, MeOH) Anal. (C26H30N2O4S) Calcd.(%): C, 66.93; H, 6.48; N, 6.00; S, 6.87. Found(%): C, 66.76; H, 6.44; N, 5.88; S, 6.76.
Compound Number I-10
1H-NMR(CDCl3) δ: 1.08(1H, m), 1.18–1.34(2H, m), 1.40–1.50(2H, m), 1.56–1.77(4H, m), 2.00–2.20(5H, m), 2.35(2H, t, J=7.2 Hz), 2.55(1H, m), 3.86 (1H, m), 5.31–5.54(2H, m), 6.26(1H, d, J=7.8 Hz), 6.31 and 7.14(each 2H, each t, each J=2.1 Hz), 7.84 and 7.88(each 2H, each d, each J=8.4 Hz). IR(CHCl3): 3515, 3441, 3144, 2669, 1708, 1662, 1515, 1486, 1455, 1376 cm−1. [α]D22+77.4±1.2°(c=1.004, MeOH) Anal. (C25H30N2O5S.0.2H2O) Calcd.(%): C, 63.32; H, 6.46; N, 6.91; S, 6.76. Found(%): C, 63.23; H, 6.49; N, 5.88; S, 6.67.
Compound Number I-11
1H-NMR(CDCl3) δ: 1.06(1H, m), 1.18–1.29(2H, m), 1.42–1.46(2H, m), 1.56–1.79 (4H, m), 2.03–2.20(5H, m), 2.34(2H, t, J=7.2 Hz), 2.52(1H, m), 3.82(1H, m), 4.12(2H, s), 5.29–5.43(2H, m), 6.04(1H, d, J=7.5 Hz), 7.09(1H, d, J=1.5 Hz), 7.22–7.34(5H, m), 7.67(1H, d, J=1.5 Hz). IR (CHCl3): 3517, 3446, 2669, 1708, 1647, 1549, 1508, 1454 cm−1. [α]D21.5+68.8±1.1°(c=1.016, MeOH) Anal. (C26H31NO3S.0.1H2O) Calcd.(%): C, 71.07; H, 7.16; N, 3.19; S, 7.30. Found(%): C, 71.05; H, 7.11; N, 3.38; S, 7.33.
Compound Number I-12
1H-NMR(CDCl3) δ: 1.09(1H, m), 1.10–1.30(2H, m), 1.40–1.46(2H, m), 1.56–1.77 (4H, m), 2.00–2.22(5H, m), 2.33(2H, t, J=7.2 Hz), 2.52(1H, m), 3.83(1H, m), 5.28–5.42 (2H, m), 6.26(1H, d, J=6.9 Hz), 7.15 and 7.63(each 2H, each d, each J=8.7 Hz), 7.53(1H, m), 7.78–7.82(2H, m). IR(CHCl3): 3515, 3446, 3371, 3138, 1708, 1648, 1610, 1496, 1163 cm−1. [α]D22.5+66.5±1.1°(c=1.004, MeOH) Anal. (C27H34N2O5S.0.4H2O) Calcd.(%): C, 64.11; H, 6.93; N, 5.54; S, 6.34. Found(%): C, 64.05; H, 6.63; N, 5.56; S, 6.12.
Compound Number I-13
1H-NMR(CDCl3) δ: 1.19–1.31(3H, m), 1.36–1.44(2H, m), 1.55–1.78(4H, m), 1.85–2.02(2H, m), 2.05(1H, m), 2.13–2.47(4H, m), 2.57(1H, m), 3.71(1H, m), 5.31–5.54(2H, m), 6.53(1H, d, J=6.9 Hz), 7.14–7.32(5H, m), 7.47(1H, br), 8.05 and 8.13 (each 1H, each d, each J=1.5 Hz). IR(CHCl3): 3509, 3360, 3262, 1709, 1649, 1542, 1496, 1349, 1160 cm−1. [α]D23+59.1±1.1°(c=1.001, MeOH) Anal. (C25H30N2O5S2.0.2H2O) Calcd.(%): C, 59.31; H, 6.05; N, 5.53; S, 12.67. Found(%): C, 59.17; H, 6.01; N, 5.49; S, 12.37.
Compound Number I-14
1H-NMR(CDCl3) δ: 1.18–1.32(3H, m), 1.38–1.47(2H, m), 1.55–1.78(4H, m), 1.90–2.08(3H, m), 2.15–2.31(2H, m), 2.32–2.49(2H, m), 2.59(1H, m), 3.74 (1H, m), 5.33–5.53(2H, m), 6.35 and 7.17(each 2H, each t, each J=2.4 Hz), 6.47(1H, d, J=6.3 Hz), 8.21 and 8.22(each 1H, each d, each J=1.5 Hz). IR(CHCl3): 3506, 3412, 3144, 3107, 1727, 1709, 1656, 1540, 1504, 1456, 1382, 1166 cm−1. [α]D23+63.8±1.0°(c=1.005, MeOH) Anal. (C23H28N2O5S2.0.2H2O) Calcd.(%): C, 57.53; H, 5.96; N, 5.83; S, 13.35. Found(%): C, 57.44; H, 5.96; N, 6.00; S, 13.35.
Compound Number I-15
mp.128–130° C.; 1H-NMR(CDCl3) δ: 1.16–1.34(3H, m), 1.40–1.81(6H, m), 2.37 (2H, t, J=7.2 Hz), 2.57(1H, m), 3.89(1H, m), 5.35–5.51(2H, m), 6.37 and 7.20 (each 2H, each d, each J=2.4 Hz), 7.23(1H, d, J=8.7 Hz). IR (Nujol): 3371, 3097, 2662, 1716, 1703, 1671, 1652, 1530, 1367, 1361, 1187, 1162 cm−1. [α]D25+47.5±0.9°(c=1.003, MeOH) Anal. (C23H28N2O5S2) Calcd.(%): C, 57.96; H, 5.92; N, 5.88; S, 13.45. Found(%): C, 58.05; H, 5.91; N, 5.83; S, 13.38.
Compound Number I-16
1H-NMR(CDCl3) δ: 1.09(1H, m), 1.20–1.32(2H, m), 1.42–1.47(2H, m), 1.58–1.75(4H, m), 2.01(3H, d, J=2 Hz), 2.00–2.16(5H, m), 2.35(2H, t, J=7.2 Hz), 2.55(1H, m), 3.86(1H, m), 5.31–5.44(2H, m), 6.14(1H, dd, J=1.5 and 3.0 Hz), 6.29(1H, d, J=7.5 Hz), 6.86(1H, m), 7.04(1H, t, J=3.0 Hz), 7.84 (4H, s). IR(CHCl3): 3517, 3441, 2667, 1708, 1661, 1515, 1485, 1375, 1260, 1178 cm−1. [α]D25+73.8±1.1°(c=1.001, MeOH) Anal. (C26H32N2O5S.0.1H2O) Calcd.(%): C, 64.20; H, 6.67; N, 5.76; S, 6.59. Found(%): C, 64.14; H, 6.65; N, 5.85; S, 6.86.
Compound Number I-17
1H-NMR(CDCl3) δ: 1.20–1.31(3H, m), 1.40–1.47(2H, m), 1.57–1.80(4H, m), 2.00–2.30(5H, m), 2.37(2H, t, J=6.9 Hz), 2.60(1H, m), 3.84(1H, m), 5.32–5.50(2H, m), 6.32(2H, t, J=2.4 Hz), 6.63(1H, d, J=6.6 Hz), 7.16(2H, t, J=2.4 Hz), 7.55(1H, t, J=8.0 Hz), 7.89(1H, m), 8.06(1H, d, J=7.8 Hz), 8.30(1H, t, J=1.7 Hz). IR(CHCl3): 3394, 3145, 1726, 1709, 1659, 1374 cm−1. [α]D25+60.3±1.0°(c=1.000, MeOH) Anal. (C25H30N2O5S.0.2H2O) Calcd.(%): C, 63.32; H, 6.46; N, 5.91; S, 6.76. Found(%): C, 63.39; H, 6.50; N, 6.16; S, 6.80.
Compound Number I-18
1H-NMR(CDCl3) δ: 1.10(1H, m), 1.20–1.32(2H, m), 1.45(2H, t, J=6.9 Hz), 1.58–1.74(4H, m), 2.04–2.16(5H, m), 2.28(3H, s), 2.35(2H, t, J=6.9 Hz), 2.55 (1H, m), 3.87(1H, m), 5.31–5.44(2H, m), 5.96(1H, m), 6.18(1H, t, J=3.3 Hz), 6.32 (1H, d, J=7.5 Hz), 7.25(1H, dd, J=1.8 and 3.3 Hz), 7.78 and 7.85(each 2H, each d, each J=8.7 Hz). IR(CHCl3): 3514, 3441, 1708, 1661, 1515, 1487, 1368, 1164 cm−1. [α]D25+74.0±1.1°(c=1.004, MeOH) Anal. (C26H32N2O5S.0.2H2O) Calcd.(%): C, 63.96; H, 6.69; N, 5.74; S, 6.57. Found(%): C, 63.97; H, 6.69; N, 5.98; S, 6.54.
Compound Number I-19
1H-NMR(CDCl3) δ: 1.07(1H, m), 1.18–1.31(2H, m), 1.41–1.49(2H, m), 1.56–1.76(4H, m), 2.00–2.21(5H, m), 2.34(2H, t, J=7.2 Hz), 2.55(1H, m), 3.86 (1H, m), 5.09(2H, s), 5.29–5.43(2H, m), 6.19(2H, t, J=2.1 Hz), 6.25(1H, d, J=7.5 Hz), 6.67(2H, t, J=2.1 Hz), 7.13 and 7.70(each 2H, each d, each J=8.4 Hz). IR(CHCl3): 3517, 3446, 3103, 2667, 1708, 1653, 1523, 1497 cm−1. [α]D25+57.7±1.0°(c=1.010, MeOH) Anal. (C26H32N2O3) Calcd.(%): C, 73.63; H, 7.70; N, 6.60. Found(%): C, 73.72; H, 7.77; N, 6.76.
Compound Number I-20
1H-NMR(CDCl3) δ: 1.05(1H, m), 1.15–1.30(2H, m), 1.36–1.45(2H, m), 1.55–1.72 (4H, m), 2.00–2.14(5H, m), 2.32(2H, t, J=7.2 Hz), 2.51(1H, m), 3.82 (1H, m), 5.28–5.42(2H, m), 6.22(2H, d, J=7.5 Hz), 6.68(1H, d, J=3.6 Hz), 7.22–7.34(2H, m), 7.52–7.55(2H, m), 7.76 and 7.88(each 2H, each d, each J=8.7 Hz), 7.97(1H, d, J=8.1 Hz). IR(CHCl3): 3510, 3480, 3440, 3145, 3117, 1708, 1661, 1516, 1485, 1445, 1377, 1130 cm−1. [α]D25+65.9±1.1°(c=1.010, MeOH) Anal. (C29H32N2O5S.0.3H2O) Calcd.(%): C, 66.21; H, 6.25; N, 5.33; S, 6.10. Found(%): C, 66.34; H, 6.30; N, 5.63; S, 5.84.
Compound Number I-21
1H-NMR(CDCl3) δ: 1.13(1H, m), 1.20–1.31(2H, m), 1.44(2H, t, J=6.8 Hz), 1.59–1.72(4H, m), 2.03–2.20(5H, m), 2.32(2H, t, J=7.2 Hz), 2.54(1H, m), 3.83 (1H, m), 4.62(2H, s), 5.31–5.45(2H, m), 6.25–6.26(2H, m), 6.57(1H, d, J=7.2 Hz), 7.25(1H, m), 7.81(4H, s). IR(CHCl3): 3581, 3518, 3440, 3149, 1708, 1660, 1517, 1486, 1371, 1150 cm−1. [α]D27+72.2±1.1°(c=1.007, MeOH) Anal. (C26H32N2O6S) Calcd.(%): C, 62.38; H, 6.44; N, 5.60; S, 6.40. Found(%): C, 62.17; H, 6.52; N, 5.71; S, 6.40.
Compound Number I-22
1H-NMR(d6-DMSO) δ: 1.18–1.33(3H, m), 1.43–1.60(6H, m), 1.92–2.30(5H, m), 2.20(2H, t, J=7.5 Hz), 2.38(1H, m), 3.67(1H, m), 5.30–5.36(2H, m), 6.85 (1H, d, J=4.8 Hz), 7.27(1H, d, J=4.8 Hz), 7.86 and 7.94(each 2H, each d, each J=8.7 Hz), 8.37(1H, d, J=6.9 Hz). IR(KBr): 3360, 3151, 3103, 1707, 1635, 1569, 1530, 1328, 1284, 1140 cm−1. [α]D27+67.4±1.1°(c=1.007, DMSO) Anal. (C24H29N3O5S2.0.3H2O) Calcd.(%): C, 56.62; H, 5.86; N, 8.24; S, 12.60. Found(%): C, 56.74; H, 5.96; N, 8.30; S, 12.31.
Compound Number I-23
mp.231–232° C.; 1H-NMR(d6-DMSO) δ: 1.19–1.61(9H, m), 1.95–2.08(5H, m), 2.21(2H, t, J=7.2 Hz), 2.40(1H, m), 3.71(1H, m), 5.34–5.37(2H, m), 7.31 and 7.59(each 1H, each d, each J=3.6 Hz), 7.98 and 8.16(each 2H, each d, each J=8.7 Hz), 8.41(1H, d, J=7.2 Hz). IR(KBr): 3336, 3185, 2541, 1675, 1631, 1548, 1324, 1295, 1163 cm−1. [α]D27+84.5±1.3°(c=1.000, DMSO) Anal. (C24H29N3O4S) Calcd.(%):.C, 64.22; H, 6.25; N, 8.99; S, 6.86. Found(%): C, 64.13; H, 6.10; N, 8.92; S, 7.08.
Compound Number I-24
1H-NMR(CDCl3) δ: 1.14(1H, m), 1.22–1.35(2H, m), 1.44–1.53(2H, m), 1.58–1.78 (4H, m), 2.02–2.28(5H, m), 2.36(2H, t, J=7.2 Hz), 2.58(1H, m), 3.87(1H, m), 5.15–5.48(2H, m), 6.29 and 7.18(each 2H, each t, J=2.4 Hz), 6.38(1H, d, J=7.2 Hz), 7.77(1H, dd, J=1.8 and 8.7 Hz), 7.82(1H, s), 7.91(1H, d, J=8.7 Hz), 8.34(1H, d, J=1.8 Hz). IR(CHCl3): 3512, 3441, 3423, 3144, 2670, 1708, 1530, 1501, 1374, 1164 cm−1. [α]D26+96.1±1.4°(c=1.006, MeOH) Anal. (C27H30N2O5S2.0.2H2O) Calcd.(%): C, 61.16; H, 5.78; N, 5.28; S, 12.09. Found(%): C, 61.17; H, 5.74; N, 5.35; S, 12.12.
Compound Number I-25
1H-NMR(CDCl3) δ: 1.06(1H, m), 1.17–1.31(2H, m), 1.39–1.48(2H, m), 1.56–1.77(4H, m), 1.99–2.20(5H, m), 2.34(2H, t, J=7.2 Hz), 2.53(1H, m), 3.84 (1H, m), 5.29–5.42(2H, m), 6.20(1H, d, J=7.2 Hz), 7.10–7.17(3H, m), 7.32 (1H, dd, J=1.2 and 3.6 Hz), 7.54(1H, dd, J=1.2 and 5.4 Hz), 7.60–7.64 (2H, m). IR(CHCl3): 3518, 3447, 2669, 1708, 1651, 1596, 1515, 1483 cm−1. [α]D26+84.7±1.2°(c=1.003, MeOH) Anal. (C25H29NO3S2.0.1H2O) Calcd.(%): C, 65.64; H, 6.43; N, 3.06; S, 14.02. Found(%): C, 65.58; H, 6.41; N, 3.10; S, 13.82.
Compound Number I-26
1H-NMR(CDCl3) δ: 1.13(1H, m), 1.20–1.33(2H, m), 1.41–1.50(2H, m), 1.56–1.77(4H, m), 2.00–2.21(5H, m), 2.37(2H, t, J=7.2 Hz), 2.55(1H, m), 3.87(1H, m), 5.31–5.45(2H, m), 6.48(1H, d, J=7.2 Hz), 7.10(1H, dd, J=3.9 and 5.1 Hz), 7.68(1H, dd, J=1.2 and 5.1 Hz), 7.69(1H, dd, J=1.2 and 3.9 Hz), 7.84–7.88 and 7.95–7.99(each 2H, each m). IR(CHCl3): 3518, 3441, 3382, 1708, 1659, 1515, 1329, 1158 cm−1. [α]D26+75.7±1.2°(c=1.000, MeOH) Anal. (C25H29NO5S2) Calcd.(%): C, 61.58; H, 5.99; N, 2.87; S, 13.15. Found(%): C, 61.36; H, 6.05; N, 2.91; S, 13.13.
Compound Number I-27
mp.213–215° C.; 1H-NMR(d6-DMSO) δ: 1.18–1.61(9H, m), 1.95–2.10 (5H, m), 2.21(2H, t, J=7.5 Hz), 2.40(1H, m), 3.71(1H, m), 5.33–5.38(2H, m), 7.19(1H, m), 7.87(1H, m), 7.96 and 8.10(each 2H, each d, each J=8.2 Hz), 8.21(1H, d, J=8.6 Hz), 8.40(1H, m), 10.92(1H, s), 12.05(1H, brs). IR (Nujol): 3337, 3249, 3205, 3132, 2524, 1678, 1632, 1545, 1433, 1305 cm−1. [α]D23+85.2±2.5°(c=0.505, MeOH) Anal. (C27H31N3O4.0.3H2O) Calcd.(%): C, 69.72; H, 6.80; N, 9.03. Found(%): C, 69.76; H, 6.75; N, 8.76.
Compound Number I-28
1H-NMR(CDCl3) δ: 1.07(1H, m), 1.18–1.32(2H, m), 1.40–1.50(2H, m), 1.56–1.78(4H, m), 2.00–2.21(5H, m), 2.34(2H, t, J=7.2 Hz), 2.54(1H, m), 3.85 (1H, m), 5.29–5.42(2H, m), 6.17(1H, d, J=6.9 Hz), 7.07(1H, dd, J=1.2 and 5.1 Hz), 7.15(2H, d J=8.7 Hz), 7.43(1H, dd, J=3.0 and 5.1 Hz), 7.51(1H, dd, J=1.2 and 3.0 Hz), 7.62(2H, d, J=8.7 Hz). IR(CHCl3): 3510, 3447, 3110, 2666, 1708, 1651, 1596, 1515, 1482 cm−1. [α]D27+85.9±1.3°(c=1.007, MeOH) Anal. (C25H29NO3S2) Calcd.(%): C, 65.90; H, 6.42; N, 3.07; S, 14.07. Found(%): C, 65.60; H, 6.36; N, 3.36; S, 13.86.
Compound Number I-29
mp.123–125° C.; 1H-NMR (CDCl3) δ: 1.12(1H, m), 1.18–1.34(2H, m), 1.42–1.50(2H, m), 1.56–1.78(4H, m), 2.02–2.21(5H, m), 2.35(2H, t, J=7.2 Hz), 2.55(1H, m), 3.88(1H, m), 5.31–5.45(2H, m), 6.42(1H, d, J=6.0 Hz), 7.31 (1H, d, J=5.1 Hz), 7.40(1H, dd, J=3.0 and 5.1 Hz), 7.87 and 7.96(each 2H, each d, each J=8.7 Hz), 8.11(1H, d, J=3.0 Hz). IR(Nujol): 3286, 3108, 2671, 1701, 1641, 1546, 1327, 1156 cm−1. [α]D27+75.3±1.2°(c=1.004, MeOH) Anal. (C25H29NO5S2) Calcd.(%): C, 61.58; H, 5.99; N, 2.87; S, 13.15. Found(%): C, 61.39; H, 5.94; N, 3.02; S, 12.99.
Compound Number I-30
1H-NMR(CDCl3) δ: 1.12(1H, m), 1.23–1.34(2H, m), 1.43–1.52(2H, m), 1.58–1.79(4H, m), 2.02–2.24(5H, m), 2.36(2H, t, J=7.2 Hz), 2.53(1H, m), 3.87 (1H, m), 5.32–5.45(2H, m), 6.11(1H, d, J=3.6 Hz), 6.28(1H, d, J=7.5 Hz), 6.35 and 7.09(each 2H, each t, each J=2.1 Hz), 7.16(1H, d, J=3.6 Hz). IR (CHCl3): 3512, 3438, 3142, 1741, 1709, 1653, 1623, 1564, 1508 cm−1. [α]D25+102.4±1.4°(c=1.006, MeOH) Anal. (C23H28N2O4.0.2H2O) Calcd.(%): C, 69.05; H, 7.15; N, 7.00. Found(%): C, 69.12; H, 7.10; N, 6.95.
Compound Number I-31
1H-NMR(CDCl3) δ: 1.04(1H, m), 1.08–1.28(2H, m), 1.41–1.46(2H, m), 1.55–1.78(4H, m), 1.99–2.16(5H, m), 2.34(2H, t, J=7.2 Hz), 2.51(1H, m), 3.81(1H, m), 4.13(2H, s), 5.29–5.42(2H, m), 5.96(1H, d, J=8.1 Hz), 6.77(1H, ddd, J=0.9, 0.9 and 3.9 Hz), 7.20–7.35(5H, m), 7.37(1H, d, J=3.9 Hz). IR (CHCl3): 3511, 3445, 2670, 1708, 1642, 1544, 1507, 1455 cm−1. [α]D26+67.1±1.1°(c=1.015, MeOH) Anal. (C26H31NO3S) Calcd.(%): C, 71.36; H, 7.14; N, 3.20; S, 7.33. Found(%): C, 71.19; H, 7.16; N, 3.34; S, 7.26.
Compound Number I-32
1H-NMR(CDCl3) δ: 1.22–1.85(9H, m), 1.95–2.53(7H, m), 2.66(1H, m), 3.84(1H, m), 5.37–5.60(2H, m), 6.79(1H, d, J=6.0 Hz), 7.01–7.17(5H, m), 7.83 (1H, dd J=1.5 and 8.7 Hz), 7.53(1H, d, J=8.7 Hz), 7.89(1H, s), 8.35 (1H, s), 8.83(1H, d, J=1.5 Hz). IR(CHCl3): 3509, 3437, 3364, 3209, 1710, 1634, 1495, 1344, 1158 cm−1. [α]D26+36.6±0.8°(c=1.005, MeOH) Anal. (C29H32N2O5S2.0.2H2O) Calcd.(%): C, 62.61; H, 5.87; N, 5.04; S, 11.53. Found(%): C, 62.53; H, 5.87; N, 5.21; S, 11.42.
Compound Number I-33
1H-NMR(CDCl3) δ: 1.13(1H, m), 1.20–1.37(2H, m), 1.46–1.56(2H, m), 1.60–1.80 (4H, m), 2.02–2.28(5H, m), 2.38(2H, t, J=7.2 Hz), 2.64(1H, m), 3.94 (1H, m), 5.35–5.50(2H, m), 6.21(1H, d, J=7.2 Hz), 6.28 and 7.21(each 2H, each t, each J=2.4 Hz), 7.81(1H, dd, J=1.8 and 8.7 Hz), 7.91(1H, d, J=8.7 Hz), 7.99(1H, s), 8.97(1H, d, J=1.8 Hz). IR(CHCl3): 3513, 3438, 3144, 3096, 1708, 1656, 1518, 1374 cm−1. [α]D26+40.1±0.8°(c=1.010, MeOH) Anal. (C27H30N2O5S2.0.2H2O) Calcd.(%): C, 61.16; H, 5.78; N, 5.28; S, 12.09. Found(%): C, 61.16; H, 5.76; N, 5.43; S, 12.05.
Compound Number I-34
1H-NMR(CDCl3) δ: 1.18–1.35(3H, m), 1.40–1.48(2H, m), 1.57–1.79(4H, m), 1.99–2.21(5H, m), 2.37(2H, t, J=7.2 Hz), 2.50(1H, m), 3.80(1H, m), 5.32–5.47(2H, m), 6.38(2H, t, J=2.4 Hz), 6.54(1H, d, J=7.5 Hz), 7.12 and 7.13(each 1H, each d, each J=3.6 Hz), 7.20(2H, t, J=2.4 Hz). IR(CHCl3): 3512, 3433, 3144, 2686, 1708, 1669, 1591, 1528, 1475, 1457, 1394 cm−1. [α]D26+74.3±1.1°(c=1.007, MeOH) Anal. (C23H28N2O5S) Calcd.(%): C, 59.98; H, 6.13; N, 6.08; S, 6.96. Found(%): C, 59.71; H, 6.22; N, 6.10; S, 7.02.
Compound Number I-35
mp.102–103° C.; 1H-NMR(CDCl3) δ: 1.05(1H, m), 1.18–1.30(2H, m), 1.38–1.48(2H, m), 1.55–1.78(4H, m), 1.99–2.19(5H, m), 2.35(2H, t, J=7.2 Hz), 2.52(1H, m), 3.81(1H, m), 5.20(2H, d, J=0.9 Hz), 5.30–5.42(2H, m), 5.99 (1H, d, J=7.2 Hz), 6.20 and 6.71 (each 2H, each t, each J=2.1 Hz), 6.86(1H, td, J=0.9 and 3.9 Hz), 7.37(1H, d, J=3.9 Hz). IR(Nujol): 3393, 3093, 6064, 2669, 1704, 1616, 1523, 1522 cm−1. [α]D26+71.1±1.1°(c=1.005, MeOH) Anal. (C24H30N2O3S) Calcd.(%): C, 67.58; H, 7.09; N, 6.57; S, 7.52. Found(%): C, 67.45; H, 7.09; N, 6.58; S, 7.67.
Compound Number I-36
1H-NMR(CDCl3) δ: 1.07(1H, m), 1.18–1.31(2H, m), 1.40–1.48(2H, m), 1.56–1.78(4H, m), 2.00–2.20(5H, m), 2.35(2H, t, J=7.2 Hz), 2.53(1H, m), 3.82 (1H, m), 5.31–5.43(2H, m), 6.02(1H, d, J=7.2 Hz), 7.15 and 7.44 (each 1H, each d, each J=3.9 Hz), 7.20–7.33(5H, m). IR(CHCl3): 3511, 3444, 3426, 3031, 2665, 1708, 1646, 1530, 1499, 1477, 1421, 1318 cm−1. [α]D26+74.8±1.1°(c=1.004, MeOH) Anal. (C25H29NO3S2) Calcd.(%): C, 65.90; H, 6.42; N, 3.07; S, 14.07. Found(%): C, 65.61; H, 6.40; N, 3.19; S, 14.18.
Compound Number I-37
1H-NMR(CDCl3) δ: 1.09(1H, m), 1.17–1.31(2H, m), 1.38–1.47(2H, m), 1.54–1.74(4H, m), 2.00–2.17(5H, m), 2.34(2H, t, J=7.2 Hz), 2.52(1H, m), 3.80 (1H, m), 5.30–5.43(2H, m), 6.27(1H, d, J=7.2 Hz), 7.41(1H, d, J=4.2 Hz), 7.51–7.64(4H, m), 7.98(2H, m). IR(CHCl3): 3515, 3442, 3366, 1708, 1656, 1530, 1504, 1327, 1156 cm−1. [α]D26+73.1±1.1°(c=1.004, MeOH) Anal. (C25H29NO5S2.0.2H2O) Calcd.(%): C, 61.13; H, 6.03; N, 2.85; S, 13.05. Found(%): C, 60.94; H, 6.02; N, 2.86; S, 3.12.
Compound Number I-38
mp.163–165° C. 1H-NMR(CDCl3) δ: 1.24–1.43(3H, m), 1.52–1.87 (8H, m), 2.10(1H, d, J=3.0 Hz), 2.30–2.55(4H, m), 2.71(1H, m), 3.66(1H, m), 5.38 and 5.63(each 1H, each m), 7.13(1H, d, J=1.5 Hz), 7.34(1H, d, J=5.4 Hz), 7.49–7.60(3H, m), 7.86–7.89(2H, m), 8.49(1H, s), 8.69(1H, d, J=1.5 Hz). IR(KBr): 3367, 3261, 3090, 1726, 1645, 1618, 1589, 1577, 1535, 1513, 1426, 1396, 1289, 1197 cm−1. [α]D23+84.5±1.2°(c=1.006, MeOH) Anal. (C26H30N2O4S) Calcd.(%): C, 66.93; H, 6.48; N, 6.00; S, 6.87. Found(%): C, 66.97; H, 6.36; N, 6.01; S, 6.89.
Compound Number I-39
1H-NMR(CDCl3) δ: 1.25–1.80(9H, m), 1.87–2.05(3H, m), 2.14–2.29(2H, m), 2.37(2H, t, J=6.9 Hz), 2.57(1H, m), 3.73(1H, m), 5.35 and 5.49(each 1H, each m), 6.71(1H, d, J=6.6 Hz), 6.87(1H, d, J=1.5 Hz), 7.43–7.48(2H, m), 7.56 (1H, m), 7.63(1H s), 7.64((1H, d, J=1.5 Hz), 7.73–7.76(2H, m). IR (CHCl3): 3510, 3379, 3247, 3108, 1709, 1637, 1556, 1516, 1448, 1365, 1319, 1161 cm−1. [α]D23+61.1±1.0°(c=1.004, MeOH) Anal. (C25H30N2O5S2.0.2H2O) Calcd.(%): C, 59.31; H, 6.05; N, 5.53; S, 12.67. Found(%): C, 59.38; H, 6.11; N, 5.75; S, 12.41.
Compound Number I-40
1H-NMR(CDCl3) δ: 1.11(1H, m), 1.24–1.31(2H, m), 1.44–1.52(2H, m), 1.60–1.79 (4H, m), 2.00–2.21(5H, m), 2.37(2H, t, J=7.2 Hz), 2.56(1H, m), 3.86 (1H, m), 5.32–5.46(2H, m), 6.11(1H, d, J=7.8 Hz), 7.25 and 7.49(each 1H, each d, each J=4.2 Hz), 7.30–7.43(3H, m), 7.60–7.63(2H, m). IR(CHCl3): 3510, 3445, 3428, 1739, 1708, 1643, 1540, 1510, 1491, 1454 cm−1. [α]D35+88.0±1.3°(c=1.012, MeOH) Anal. (C25H29NO3S.0.2H2O) Calcd.(%): C, 70.29; H, 6.94; N, 3.28; S, 7.51. Found(%): C, 70.35; H, 7.01; N, 3.59; S, 7.46.
Compound Number I-41
1H-NMR(CDCl3) δ: 1.13(1H, m), 1.22–1.32(2H, m), 1.46–1.51(2H, m), 1.60–1.76(4H, m), 2.04–2.17(5H, m), 2.36(2H, t, J=7.2 Hz), 2.57(1H, m), 3.86(1H, m), 5.32–5.46(2H, m), 6.30(1H, d, J=8.4 Hz), 7.48–7.65(5H, m), 7.84–7.88(2H, m). IR(CHCl3): 3511, 3443, 3425, 1708, 1643, 1529, 1506, 1448 cm−1. [α]D25+92.4±1.3°(c=1.000, MeOH) Anal. (C26H29NO4S2.0.2H2O) Calcd.(%): C, 68.61; H, 6.51; N, 3.08; S, 7.04. Found(%): C, 68.55; H, 6.52; N, 3.13; S, 7.03.
Compound Number I-42
1H-NMR(CDCl3) δ: 1.10(1H, m), 1.27–1.31(2H, m), 1.49(2H, brs), 1.59–1.80 (4H, m), 2.00–2.20(5H, m), 2.36(2H, t, J=7.2 Hz), 2.55(1H, m), 3.85 (1H, m), 5.31–5.45(2H, m), 6.14(1H, d, J=7.2 Hz), 7.13(1H, d, J=3.9 Hz), 7.30 (1H, dd, J=1.2 and 5.1 Hz), 7.36(1H, dd, J=3.0 and 5.1 Hz), 7.45–7.46 (2H, m). IR(CHCl3): 3511, 3445, 3428, 3109, 1708, 1642, 1523, 1499, 1456 cm−1. [α]D25+82.9±1.20(c=1.006, MeOH) Anal. (C23H27NO3S2.0.1H2O) Calcd.(%): C, 64.04; H, 6.36; N, 3.25; S, 14.86. Found(%): C, 63.99; H, 6.52; N, 3.23; S, 14.85.
Compound Number I-43
1H-NMR(CDCl3) δ: 1.10(1H, m), 1.22–1.31(2H, m), 1.46–1.51(2H, m), 1.60–1.80(4H, m), 2.03–2.22(5H, m), 2.37(2H, t, J=7.2 Hz), 2.55(1H, m), 3.85 (1H, m), 5.32–5.45(2H, m), 6.07(1H, d, J=7.5 Hz), 7.04(1H, dd, J=3.6 and 5.4 Hz), 7.11(1H, d, J=3.9 Hz), 7.24(1H, dd, J=1.2 and 3.6 Hz), 7.28(1H, dd, J=1.2 and 5.4 Hz), 7.42(1H, d J=3.9 Hz). IR(CHCl3): 3511, 3445, 3428, 3113, 3073, 2667, 1708, 1643, 1521, 1498, 1455 cm−1. [α]D25+89.5±1.30°(c=1.005, MeOH) Anal. (C23H27NO3S2.0.1H2O) Calcd.(%): C, 64.04; H, 6.36; N, 3.25; S, 14.86. Found(%): C, 63.93; H, 6.39; N, 3.46; S, 14.61.
Compound Number I-44
mp.146–147° C.; 1H-NMR(CDCl3) δ: 1.10(1H, m), 1.24–1.31(2H, m), 1.46–1.51(2H, m), 1.61–1.82(4H, m), 2.00–2.24(5H, m), 2.37(2H, t, J=7.2 Hz), 2.37(3H, s), 2.56(1H, m), 3.85(1H, m), 5.31–5.45(2H, m), 6.06(1H, d, J=6.9 Hz), 7.20 and 7.51(each 2H, each d, each J=9.0 Hz), 7.21 and 7.48(each 1H, each d, each J=3.9 Hz). IR(CHCl3): 3517, 3445, 3428, 1740, 1708, 1642, 1542, 1518, 1498, 1451 cm−1. [α]D26+89.3±1.3°(c=1.009, MeOH) Anal. (C26H31NO3S) Calcd.(%): C, 71.36; H, 7.14; N, 3.20; S, 7.33. Found(%): C, 71.51; H, 7.10; N, 3.20; S, 7.33.
Compound Number I-45
mp.110–116° C. 1H-NMR(CDCl3) δ: 1.10(1H, m), 1.24–1.31(2H, m), 1.46–1.51(2H, m), 1.61–1..83(4H, m), 2.00–2.25(5H, m), 2.37(2H, t, J=7.2 Hz), 2.56(1H, m), 3.84(3H, s), 3.85(1H, m), 5.31–5.45(2H, m), 6.04(1H, d, J=7.5 Hz), 6.93 and 7.55(each 2H, each d, each J=8.7 Hz), 7.15 and 7.46 (each 2H, each d, each J=4.2 Hz). IR(CHCl3): 3515, 3445, 3428, 1740, 1708, 1640, 1608, 1541, 1499, 1453, 1178 cm−1. [α]D26+88.0±1.3°(c=1.010, MeOH) Anal. (C26H31NO4S) Calcd.(%): C, 68.85; H, 6.89; N, 3.09; S, 7.07. Found(%): C, 68.87; H, 6.82; N, 3.11; S, 7.19.
Compound Number I-46
mp.124–125° C.,; 1H-NMR(CDCl3) δ: 1.10(1H, m), 1.24–1.32(2H, m), 1.46–1.51(2H, m), 1.61–1.82(4H, m), 2.00–2.24(5H, m), 2.37(2H, t, J=7.2 Hz), 2.56 (1H, m), 3.85(1H, m), 5.32–5.45(2H, m), 6.06(1H, d, J=7.2 Hz), 7.10 (2H, t, J=8.7 Hz), 6.19 and 7.47(each 1H, each d, each J=3.6 Hz), 7.56–5.60 (2H, m). IR(CHCl3): 3516, 3445, 3428, 2672, 1740, 1708, 1643, 1542, 1519, 1498, 1452 cm−1. [α]D26+83.3±1.2°(c=1.005, MeOH) Anal. (C25H28FNO3S) Calcd.(%): C, 68.00; H, 6.39; N, 3.17; F, 4.30; S, 7.26. Found(%): C, 67.90; H, 6.34; N, 3.25; F, 4.31; S, 7.20.
Compound Number I-47
1H-NMR(CDCl3) δ: 1.10(1H, m), 1.18–1.32(2H, m), 1.38–1.48(2H, m), 1.56–1.76(4H, m), 2.00–2.18(5H, m), 2.35(2H, t, J=7.2 Hz), 2.53(1H, m), 3.81 (1H, m), 5.31–5.43(2H, m), 6.32(1H, d, J=7.5 Hz), 7.11(1H, dd, J=3.9 and 5.1 Hz), 7.4 and 7.62(each 1H, each d, each J=3.9 Hz), 7.70(1H, dd, J=1.5 and 5.1 Hz), 7.74(1H, dd, J=1.5 and 3.9 Hz). IR(CHCl3): 3516, 3442, 3378, 1708, 1655, 1530, 1504, 1336, 1153 cm−1. [α]D25+74.3±1.1°(c=1.000, MeOH) Anal. (C23H27NO5S3.0.1H2O) Calcd.(%): C, 55.76; H, 5.53; N, 2.83; S, 19.41. Found(%): C, 55.49; H, 5.64; N, 3.09; S, 19.32.
Compound Number I-48
mp.112–115° C. 1H-NMR(CDCl3) δ: 1.13–1.30(3H, m), 1.34–1.45 (2H, m), 1.50–1.82(4H, m), 1.94–2.27(5H, m), 2.34(2H, t, J=7.2 Hz), 2.56 (1H, m), 3.74(1H, m), 5.22(2H, s), 5.31–5.50(2H, m), 6.64(1H, d, J=6.6 Hz), 6.84 (1H, (1, J=3.9 Hz), 6.93 and 7.05(each 1H, each s), 7.47(1H, d, J=3.9 Hz), 7.66(1H, s). IR(Nujol): 3339, 3102, 2464, 1691, 1635, 1622, 1551, 1288 cm−1. [α]D25+71.2±1.1°(c=1.005, MeOH) Anal. (C23H29N3O3S) Calcd.(%): C, 64.61; H, 6.84; N, 9.83; S, 7.50. Found(%): C, 64.54; H, 6.85; N, 9.78; S, 7.42.
Compound Number I-49
1H-NMR(CDCl3) δ: 1.08(1H, m), 1.16–1.30(2H, m), 1.38–1.47(2H, m), 1.54–1.77(4H, m), 1.98–2.20(5H, m), 2.34(2H, t, J=7.2 Hz), 2.52(1H, m), 3.79 (1H, m), 5.30–5.42(2H, m), 5.47(2H, s), 6.16(1H, d, J=6.9 Hz), 6.30(1H, t, J=2.1 Hz) 6.94 and 7.41(each 1H, each d, each J=3.6 Hz), 7.47 and 7.57 (each 1H, each d, each J=2.1 Hz). IR(CHCl3): 3510, 3444, 3426, 1709, 1646, 1546, 1512 cm−1. [α]D25+68.6±1.1°(c=1.011, MeOH) Anal. (C23H29N3O3S.0.1H2O) Calcd.(%): C, 64.34; H, 6.85; N, 9.79; S, 7.47. Found(%): C, 64.10; H, 6.93; N, 9.90; S, 7.52.
Compound Number I-50
mp.126–128° C.; 1H-NMR(CDCl3) δ: 1.12(1H, m), 1.18–1.33(2H, m), 1.40–1.50(2H, m), 1.55–1.78(4H, m), 2.00–2.21(5H, m), 2.54(1H, m), 3.87(1H, m), 5.30–5.44(2H, m), 6.43(1H, d, J=6.6 Hz), 7.48–7.62(3H, m), 7.83–7.95(5H, m). IR(Nujol): 3284, 3058, 2669, 1701, 1641, 1546, 1326, 1294, 1160 cm−1. [α]hd D25+77.2±1.2°(c=1.007, MeOH) Anal. (C27H31NO5S) Calcd.(%): C, 67.34; H, 6.49; N, 2.91; S, 6.66. Found(%): C, 67.20; H, 6.38; N, 2.88; S, 6.58.
Compound Number I-51
mp.103–107° C. 1H-NMR(CDCl3) δ: 1.14(1H, m), 1.18–1.33(2H, m), 1.40–1.50(2H, m), 1.54–1.77(4H, m), 2.00–2.20(5H, m), 2.34(2H, t, J=7.2 Hz), 2.54(1H, m), 3.85(3H, s), 3.86(1H, m), 5.30–5.45(2H, m), 6.48(1H, d, J=6.9 Hz), 6.96(2H, m), 7.81–7.91(6H, m). IR(Nujol): 3273, 3067, 2669, 1702, 1639, 1560, 1548, 1323, 1301, 1274, 1156 cm−1. [α]D25+75.4±1.2°(c=1.002, MeOH) Anal. (C28H33NO6S) Calcd.(%): C, 65.73; H, 6.50; N, 2.74; S, 6.27. Found(%): C, 65.50; H, 6.46; N, 2.82; S, 6.25.
Compound Number I-52
1H-NMR(CDCl3) δ: 1.17(1H, m), 1.26–1.34(2H, m), 1.47–1.53(2H, m), 1.60–1.76(4H, m), 2.04–2.21(5H, m), 2.36(2H, t, J=7.2 Hz), 2.60(1H, m), 3.91(1H, m), 5.32–5.47(2H, m), 6.46(1H, d, J=8.4 Hz), 7.17(1H, dd, J=3.9 and 5.1 Hz), 7.61(1H, dd, J=1.2 and 3.9 Hz), 7.76(1H, dd, J=1.2 and 5.1 Hz), 7.87(4H, s-like). IR(CHCl3): 3518, 3444, 2663, 1708, 1638, 1517, 1494, 1414 cm−1. [α]D25+86.6±1.3°(c=1.008, MeOH) Anal. (C26H29NO4S) Calcd.(%): C, 69.15; H, 6.47; N, 3.10; S, 7.10. Found(%): C, 68.86; H, 6.70; N, 3.15; S, 6.95.
Compound Number I-53
mp.144–145° C.; 1H-NMR(CDCl3) δ: 1.20–2.54(16H, m), 2.62(1H, m), 3.69 (3H, s), 5.35–5.56(2H, m), 6.36 and 7.17(each 2H, each t, each J=2.4 Hz), 6.66(1H, d, J=6.3 Hz), 8.05 and 8.07(each 1H, each d, each J=1.5 Hz). IR(Nujol): 3509, 3406, 3146, 3110, 1728, 1708, 1653, 1535, 1375, 1189, 1166 cm−1. [α]D25+67.9±1.1°(c=1.007, MeOH) Anal. (C23H28N2O5S2) Calcd.(%): C, 57.96; H, 5.92; N, 5.88; S, 13.45. Found(%): C, 58.19; H, 5.95; N, 5.75; S, 13.09.
Compound Number I-54
1H-NMR(CDCl3) δ: 1.22–2.57(16H, m), 2.68(1H, m), 3.66(3H, s), 5.37–5.63 (2H, m), 6.20, 6.35, 6.74 and 6.87(each 2H, each t, each J=2.4 Hz), 6.92 (1H, d, J=5.4 Hz), 8.27(1H, s). IR(CHCl3): 3402, 3143, 3108, 1725, 1710, 1650, 1516, 1375 cm−1. [α]D26+70.0±1.1°(c=1.006, MeOH) Anal. (C27H31N3O5S2.0.3H2O) Calcd.(%): C, 59.28; H, 5.82; N, 7.68; S, 11.72. Found(%): C, 59.28; H, 5.77; N, 5.58; S, 11.68.
Compound Number I-55
1H-NMR(CDCl3) δ: 1.10(1H, m), 1.18–1.31(2H, m), 1.40–1.45(2H, m), 1.57–1.74(4H, m), 2.00–2.10(5H, m), 2.35(2H, t, J=7.2 Hz), 2.38(3H, s), 2.52 (1H, m), 3.80(1H, m), 5.31–5.43(2H, m), 5.99(1H, m), 6.20(1H, t, J=3.3 Hz), 6.30(1H, d, J=6.91 Hz), 7.18(1H, dd, J=1.8 and 3.3 Hz), 7.40 and 7.53(each 1H, each d, each J=3.9 Hz). IR(CHCl3): 3513, 3442, 3149, 3100, 1708, 1657, 1530, 1504, 1375, 1183, 1161 cm−1. [α]D27+70.3±1.5°(c=0.730, MeOH) Anal. (C24H30N2O5S2.0.4H2O) Calcd.(%): C, 57.90; H, 6.24; N, 5.63; S, 12.88. Found(%): C, 58.08; H, 6.28; N, 5.77; S, 12.54.
Compound Number I-56
1H-NMR((d6-DMSO) δ: 1.06–1.59(9H, m), 1.93–2.07(5H, m), 2.21(2H, t, J=7.2 Hz), 2.35(1H, m), 3.65(1H, m), 5.30–5.41(2H, m), 6.90 and 7.69 (each 1H, each d, each J=4.2 Hz), 7.55–7.64(3H, m), 7.99–8.04(3H, m), 11.73 (1H, s), 12.01(1H, brs). IR (KBr): 3562, 1708, 1616, 1564, 1523, 1454, 1295 cm−1. [α]D27+71.2±1.1°(c=1.000, MeOH) Anal. (C26H30N2O4S.0.2H2O) Calcd.(%): C, 66.42; H, 6.52; N, 5.96; S, 6.82. Found(%): C, 66.43; H, 6.32; N, 6.17; S, 6.75.
Compound Number I-57
1H-NMR(d6-DMSO) δ: 1.05–1.56(9H, m), 1.91–2.05(5H, m), 2.19(2H, t, J=7.2 Hz), 2.29(1H, m), 3.56(1H, m), 5.28–5.38(2H, m), 6.54 and 7.56(each 1H, each d, each J=4.2 Hz), 7.59–7.62(3H, m), 7.76–7.79(2H, m), 8.06(1H, d, J=6.9 Hz), 11.10(1H, s), 11.99(1H, brs). IR(KBr): 3384, 3084, 1707, 1616, 1553, 1523, 1459, 1350, 1322, 1161 cm−1. [α]D27+62.4±1.0°(c=1.005, MeOH) Anal. (C25H30N2O5S2.0.2H2O) Calcd.(%): C, 59.31; H, 6.05; N, 5.53; S, 12.66. Found(%): C, 59.36; H, 5.75; N, 5.55; S, 12.38.
Compound Number I-58
1H-NMR(CDCl3) δ: 1.07(1H, m), 1.17–1.33(2H, m), 1.36–1.50(2H, m), 1.54–1.75(4H, m), 2.00–2.20(5H, m), 2.35(2H, t, J=7.2 Hz), 2.45(3H, s), 2.52 (1H, m), 3.80(1H, m), 5.31–5.43(2H, m), 6.12(1H, d, J=7.5 Hz), 6.32 and 7.18(each 2H, each t, each J=2.4 Hz), 7.22(1H, s). IR(CHCl3): 3316, 3442, 3145, 2668, 1708, 1657, 1545, 1509, 1455, 1375, 1190, 1165, 1057 cm−1. [α]D26+75.8±1.2°(c=1.002, MeOH) Anal. (C24H30N2O5S2.0.1H2O) Calcd.(%): C, 58.54; H, 6.18; N, 5.69; S, 13.02. Found(%): C, 58.35; H, 6.29; N, 5.74; S, 12.92.
Compound Number I-59
1H-NMR(CDCl3) δ: 1.05(1H, m), 1.16–1.30(2H, m), 1.38–1.48(2H, m), 1.53–1.79(4H, m), 1.98–2.17(5H, m), 2.34(2H, t, J=7.2 Hz), 2.50(1H, m), 3.79(1H, m), 5.30–5.42(2H, m), 6.00(1H, d, J=7.5 Hz), 7.01(1H, dd, J=3.6 and 5.4 Hz), 7.03(1H, d, J=3.9 Hz), 7.29(1H, dd, J=1.2 and 3.6 Hz), 7.33(1H, d, J=3.9) 7.43(1H, dd, J=1.2 and 5.4 Hz). IR(CHCl3): 3517, 3444, 3426, 2670, 1708, 1645, 1530, 1499, 1421, 1318 cm−1. [α]D26+70.8±1.1°(c=1.018, MeOH) Anal. (C23H27NO3S3) Calcd.(%): C, 59.84; H, 5.89; N, 3.03; S, 20.84. Found(%): C, 59.73; H, 5.99; N, 3.15; S, 20.70.
Compound Number I-60
1H-NMR(CDCl3) δ: 1.07(1H, m), 1.17–1.32(2H, m), 1.40–1.50(2H, m), 1.56–1.80(4H, m), 1.99–2.21(5H, m), 2.34(2H, t, J=7.2 Hz), 2.54(1H, m), 3.85 (1H, m), 5.29–5.42(2H, m), 6.20(1H, d, J=6.9 Hz), 7.23–7.45(7H, m), 7.55 (2H, d, J=8.1 Hz). IR(CHCl3): 3516, 3447, 2667, 1708, 1651, 1596, 1514, 1481 cm−1. [α]D26+89.1±1.3°(c=1.006, MeOH) Anal. (C27H31NO3S.0.2H2O) Calcd.(%): C, 71.56; H, 6.98; N, 3.09; S, 7.07. Found(%): C, 71.39; H, 6.97; N, 3.16; S, 6.94.
Compound Number I-61
1H-NMR(CDCl3) δ: 1.06(1H, m), 1.18–1.31(2H, m), 1.41–1.50(2H, m), 1.55–1.80(4H, m), 1.99–2.20(5H, m), 2.35(2H, t, J=7.2 Hz), 2.52(1H, m), 3.82(1H, m), 5.31–5.43(2H, m), 5.97(1H, d, J=6.6 Hz), 6.45(1H, d, J=4.2 Hz), 7.11–7.20(3H, m), 7.28(1H, d, J=4.2 Hz), 7.33–7.40(2H, m). IR(CHCl3): 3515, 3445, 3427, 2667, 1740, 1708, 1640, 1506, 1475 cm−1. [α]D27+71.3±1.1°(c=1.002, MeOH) Anal. (C25H29NO4S) Calcd.(%): C, 68.31; H, 6.65; N, 3.19; S, 7.29. Found(%): C, 68.41; H, 6.87; N, 3.22; S, 7.35.
Compound Number I-62
1H-NMR(CDCl3) δ: 1.14(1H, m), 1.20–1.35(2H, m), 1.42–1.54(2H, m), 1.57–1.77(4H, m), 2.00–2.23(5H, m), 2.35(2H, t, J=7.2 Hz), 2.58(1H, m), 3.88(1H, m), 5.32–5.46(2H, m), 6.31 and 7.19(each 2H, each t, each J=2.4 Hz), 6.33(1H, d, J=7.5 Hz), 7.77(1H, dd, J=1.8 and 8.4 Hz), 7.77(1H, s), 7.87(1H, d, J=8.4 Hz), 8.38(1H, d, J=1.8 Hz). IR(CHCl3): 3514, 3442, 3422, 3144, 2670, 1708, 1654, 1525, 1375, 1193, 1171 cm−1. [α]D26+89.8±1.3°(c=1.000, MeOH) Anal. (C27H3N2O5S2) Calcd.(%): C, 61.58; H, 5.74; N, 5.32; S, 12.17. Found(%): C, 61.42; H, 5.86; N, 5.57; S, 11.98.
Compound Number I-63
mp.180–181° C.; 1H-NMR(CDCl3) δ: 1.04(1H, m), 1.22–1.30(2H, m), 1.41–1.46 (2H, m), 1.59–1.82(4H, m), 1.94–2.16(3H, m), 2.25–2.37(2H, m), 2.42 (2H, t, J=6.9 Hz), 2.52(1H, m), 2.52(3H, s), 3.79(1H, m), 5.41–5.59(2H, m), 5.73(1H, d, J=6.6 Hz), 7.48–7.53(2H, m), 7.60(1H, m), 8.07–8.10(2H, m). IR(Nujol): 3372, 3173, 3053, 2544, 1690, 1672, 1632, 1559, 1496, 1362, 1317 cm−1. [α]D28+77.7±1.2°(c=1.007, MeOH) Anal. (C26H31N3O4S) Calcd.(%): C, 64.84; H, 6.49; N, 8.72; S, 6.66. Found(%): C, 64.66; H, 6.31; N, 8.73; S, 6.65.
Compound Number I-64
1H-NMR(d6-DMSO) δ: 1.07(1H, m), 1.28–1.58(8H, m), 1.91–2.08(5H, m), 2.20(2H, t, J=7.2 Hz), 2.31(3H, s), 2.32(1H, s), 3.96(1H, m), 5.28–5.40(2H, m), 7.52–7.62(3H, m), 7.80–7.83(2H, m), 7.94(1H, d, J=6.9 Hz). IR(Nujol): 3316, 3161, 3106, 2677, 1709, 1629, 1531, 1284, 1142 cm−1. [α]D27+76.2±1.2°(c=1.002, MeOH) Anal. (C25H31N3O5S2.0.1H2O) Calcd.(%): C, 57.80; H, 6.05; N, 8.09; S, 12.34. Found(%): C, 57.59; H, 6.15; N, 8.10; S, 12.57.
Compound Number I-65
1H-NMR(CDCl3) δ: 1.28–1.31(2H, m), 1.47(2H, brs), 1.56–1.84(4H, m), 1.94–2.30(5H, m), 2.39(2H, t, J=6.9 Hz), 2.62(1H, s), 2.63(3H, s), 3.77(1H, m), 5.35–5.67(2H, m), 6.42(1H, d, J=6.3 Hz), 7.29–7.43(3H, m), 7.46(1H, s), 7.72(2H, d, J=7.2 Hz). IR(CHCl3): 3517, 3421, 3350, 3150, 2538, 1708, 1651, 1590, 1512, 1474, 1442, 1164 cm−1. [α]D28+100.8±1.4°(c=1.002, MeOH) Anal. (C27H31N3O3S.0.5H2O) Calcd.(%): C, 66.64; H, 6.63; N, 8.63; S, 6.59. Found(%): C, 66.55; H, 6.59; N, 8.68; S, 6.76.
Compound Number I-66
1H-NMR(CDCl3) δ: 1.08(1H, m), 1.19–1.33(2H, m), 1.42–1.50(2H, m), 1.58–1.79(4H, m), 2.01–2.22(5H, m), 2.35(2H, t, J=7.2 Hz), 2.55(1H, m), 3.86(1H, m), 4.37(2H, s), 5.30–5.43(2H, m), 6.19(1H, d, J=7.5 Hz), 6.90(1H, dd, J=3.6 and 5.1 Hz), 6.93(1H, m), 7.17(1H, dd, J=1.2 and 5.1 Hz), 7.33 and 7.65(each 2H, each d, J=8.4 Hz). IR(CHCl3): 3518, 3447, 2665, 1708, 1651, 1596, 1515, 1484 cm−1. [α]D26+82.4±1.4°(c=0.900, MeOH) Anal. (C26H31NO3S2.0.1H2O) Calcd.(%): C, 66.24; H, 6.67; N, 2.97; S, 13.60. Found(%): C, 66.14; H, 6.72; N, 2.96; S, 13.53.
Compound Number I-67
1H-NMR(CDCl3) δ: 1.16(1H, m), 1.21–1.34(2H, m), 1.43–1.52(2H, m), 1.57–1.76(4H, m), 2.04–2.22(5H, m), 2.35(2H, t, J=7.2 Hz), 2.56(1H, m), 3.89 (1H, m), 4.53(2H, s), 5.33–5.48(2H, m), 6.58(1H, d, J=6.9 Hz), 6.83(1H, dd, J=1.2 and 3.9 Hz), 6.93(1H, dd, J=3.9 and 5.1 Hz), 7.28(1H, dd, J=1.2 and 5.1 Hz), 7.65 and 7.81(each 2H, each d, J=8.4 Hz). IR(CHCl3): 3518, 3442, 3373, 2666, 1708, 1658, 1516, 1483, 1323, 1153 m−1. [α]D26+69.6±1.1°(c=1.003, MeOH) Anal. (C26H31NO5S2.0.5H2O) Calcd.(%): C, 61.15; H, 6.32; N, 2.74; S, 12.56. Found(%): C, 66.16; H, 6.25; N, 2.90; S, 12.57.
Compound Number I-68
1H-NMR(CDCl3) δ: 1.13(1H, m), 1.20–1.32(2H, m), 1.38–1.50(2H, m), 1.54–1.77(4H, m), 1.98–2.20(5H, m), 2.35(2H, t, J=7.2 Hz), 2.53(1H, m), 3.80 (1H, m), 5.31–5.46(2H, m), 6.47(1H, d, J=7.5 Hz), 6.87(1H, dd, J=1.5 and 3.6 Hz), 3.84(1H, dd, J=3.6 and 5.4 Hz), 7.03(1H, dd, J=1.5 and 5.4 Hz), 7.33 and 7.38(each 1H, each d, each J=3.9 Hz), 7.90(1H, br). IR(CHCl3): 3510, 3440, 3358, 3109, 1708, 1647, 1533, 1505, 1364, 1331, 1161 cm−1. [α]43629+151.3±1.9°(c=1.010, MeOH) Anal. (C23H28N2O5S3.0.1H2O) Calcd.(%): C, 54.12; H, 5.57; N, 5.49; S, 18.84. Found(%): C, 53.84; H, 5.46; N, 5.38; S, 18.62.
Compound Number I-69
1H-NMR(CDCl3) δ: 1.20(1H, m), 1.26–1.38(2H, m), 1.42–1.52(2H, m), 1.57–1.76(4H, m), 2.00–2.24(5H, m), 2.34(2H, t, J=7.2 Hz), 2.53(1H, m), 3.88 (1H, m), 5.31–5.49(2H, m), 6.63(1H, dd, J=1.2 and 3.9 Hz), 6.69(1H, d, J=7.5 Hz), 6.77(1H, dd, J=3.9 and 5.4 Hz), 6.98(1H, dd, J=1.2 and 5.4 Hz), 7.66 and 7.76(each 2H, each d, each J=8.4 Hz). IR(CHCl3): 3509, 3439, 3363, 3111, 1707, 1651, 1520, 1328, 1167 cm−1. [α]43629+155.7±2.0°(c=1.003, MeOH) Anal. (C25H30N2O5S3.0.3H2O) Calcd.(%): C, 59.10; H, 6.07; N, 5.51; S, 12.62. Found(%): C, 59.00; H, 5.95; N, 5.51; S, 12.46.
Compound Number I-70
mp.187–188° C.; 1H-NMR(d6-DMSO) δ: 1.16–1.62(9H, m), 1.90–2.14(5H, m), 2.21(2H, t, J=7.2 Hz), 2.38(1H, m), 3.66(1H, m), 5.27–5.41(2H, m), 7.10–7.15 (1H, m), 7.34–7.39(2H, m), 7.42–7.75(2H, m), 7.91 and 7.99(each 1H, each d, each J=3.9 Hz), 8.04(1H, d, J=6.6 Hz), 10.32(1H, s), 12.02(1H, s). IR(Nujol): 3316, 3075, 2678, 1704, 1635, 1614, 1544, 1323 cm−1. [α]D28+83.3±1.2°(c=1.003, MeOH) Anal. (C26H30N2O4S) Calcd.(%): C, 66.93; H, 6.48; N, 6.00; S, 6.87. Found(%): C, 67.04; H, 6.45; N, 5.98; S, 6.96.
Compound Number I-71
mp.192–194° C.; 1H-NMR(d6-DMSO) δ: 1.16–1.62(9H, m), 1.90–2.14(5H, m), 2.21(2H, t, J=7.2 Hz), 2.37(1H, m), 3.65(1H, m), 5.29–5.41(2H, m), 7.18–7.24 (2H, m), 7.33–7.78(2H, m), 7.91 and 7.97(each 1H, each d, each J=3.9 Hz), 8.04(1H, d, J=6.9 Hz), 10.38(1H, s), 12.01(1H, s). IR(Nujol): 3322, 3278, 3150, 3098, 3077, 2678, 1704, 1635, 1615, 1546, 1521, 1508, 1322 cm−1. [α]D2+83.3±1.2°(c=1.000, MeOH) Anal. (C26H29FN2O4S) Calcd.(%): C, 64.44; H, 6.03; N, 5.78; F, 3.92; S, 6.62. Found(%): C, 64.36; H, 6.00; N, 5.81; F, 3.94; S, 6.46.
Compound Number I-72
mp.192–193° C.; 1H-NMR(d6-DMSO) δ: 1.16–1.62(9H, m), 1.92–2.14 (5H, m), 2.21(2H, t, J=7.2 Hz), 2.37(1H, m), 3.66(1H, m), 3.75(3H, s), 5.30–5.41(2H, m), 6.94 and 7.63(each 2H, each d-like), 7.89 and 7.94(each 1H, each d, each J=3.9 Hz), 8.38(1H, d, J=6.9 Hz), 10.21(1H, s), 12.01(1H, s). IR(Nujol): 3316, 3075, 2678, 1704, 1635, 1614, 1544, 1323 cm−1. [α]D27+81.6±1.2°(c=1.000, MeOH) Anal. (C27H132N2O5S) Calcd.(%): C, 65.30; H, 6.49; N, 5.64; S, 6.46. Found(%): C, 65.19; H, 6.49; N, 5.45; S, 6.31.
Compound Number I-73
1H-NMR(CDCl3) δ: 1.14(1H, m), 1.18–1.32(2H, m), 1.40–1.78(6H, m), 1.94–2.20 (5H, m), 2.35(2H, t, J=7.2 Hz), 2.51(1H, m), 3.80(1H, m), 3.81(6H, s), 3.82(3H, s), 5.30–5.44(2H, m), 6.56(1H, d, J=7.2 Hz), 6.97(2H, s), 7.47 and 7.58(each 1H, each d, each J=3.9 Hz), 8.43(1H, s). IR(CHCl3): 3515, 3438, 3317, 1708, 1650, 1607, 1537, 1508, 1454, 1412, 1131 cm−1. [α]D27+75.8±1.2°(c=1.009, MeOH) Anal. (C29H36N2O7S.0.4H2O) Calcd.(%): C, 61.77; H, 6.58; N, 4.97; S, 5.69. Found(%): C, 61.74; H, 6.64; N, 4.89; S, 5.89.
Compound Number I-74
1H-NMR(CDCl3) δ: 1.10(1H, m), 1.20–1.33(2H, m), 1.43–1.52(2H, m), 1.57–1.78(4H, m), 2.00–2.21(5H, m), 2.36(2H, t, J=7.2 Hz), 2.55(1H, m), 3.85(1H, m), 5.32–5.45(2H, m), 6.09(1H, d, J=6.9 Hz), 6.32 and 7.00(each 2H, each t, each J=2.1 Hz), 6.81 and 7.34(each 1H, each d, each J=3.9 Hz). IR(CHCl3): 3515, 3445, 3109, 2678, 1740, 1708, 1642, 1507, 1489 cm−1. [α]D26+83.5±1.2°(c=1.007, MeOH) Anal. (C23H28N2O3S) Calcd.(%): C, 66.96; H, 6.84; N, 6.79; S, 7.77. Found(%): C, 66.66; H, 6.74; N, 6.74; S, 7.61.
Compound Number I-75
1H-NMR(CDCl3) δ: 1.09(1H, m), 1.20–1.32(2H, m), 1.39–1.49(2H, m), 1.57–1.66(4H, m), 2.01–2.22(5H, m), 2.35(2H, t, J=7.2 Hz), 2.56(1H, m), 3.88(1H, m), 3.95(2H, s), 5.30–5.44(2H, m), 6.27(1H, d, J=7.5 Hz), 6.89–6.91(2H, m), 7.32(1H, dd, J=2.4 and 3.9 Hz), 7.19 and 7.66(each 2H, each d, J=8.4 Hz). IR(CHCl3): 3516, 3447, 2670, 1708, 1651, 1523, 1496 m−1. [α]D26+71.8±1.1°(c=1.016, MeOH) Anal. (C26H3NO3S2.0.1H2O) Calcd.(%): C, 66.24; H, 6.67; N, 2.97; S, 13.60. Found(%): C, 66.36; H, 6.67; N, 3.27; S, 13.62.
Compound Number I-76
mp.135–136° C.; 1H-NMR(CDCl3) δ: 1.12(1H, m), 1.22–1.33(2H, m), 1.43–1.51(2H, m), 1.59–1.78(4H, m), 2.03–2.22(5H, m), 2.35(2H, t, J=7.2 Hz), 2.56 (1H, m), 3.87(1H, m), 4.44(2H, s), 5.31–5.45(2H, m), 6.30(1H, d, J=7.2 Hz), 7.08(1H, dd, J=3.9 and 5.1 Hz), 7.23(2H, d, J=8.4 Hz), 7.40(1H, dd, J=1.5 and 3.9 Hz), 7.69–7.71(3H, m). IR(CHCl3): 3516, 3445, 3096, 2665, 1708, 1655, 1523, 1496, 1403, 1327, 1152, 1127 m−1. [α]D26+65.0±1.1°(c=1.000, MeOH) Anal. (C26H31NO5S2.0.2H2O) Calcd.(%): C, 61.81; H, 6.26; N, 2.77; S, 12.69. Found(%): C, 61.76; H, 6.20; N, 2.90; S, 12.57.
Compound Number I-77
mp.215–217° C. 1H-NMR(d6-DMSO) δ: 1.16–1.62(9H, m), 1.90–2.14 (5H, m), 2.21(2H, t, J=7.2 Hz), 2.38(1H, m), 3.66(1H, m), 5.29–5.41 (2H, m), 6.91–6.94(2H, m), 7.05(1H, dd, J=2.4 and 4.2 Hz), 7.93 and 7.96 (each 1H, each d, each J=4.2 Hz), 8.43(1H, d, J=6.6 Hz), 10.67(1H, br), 12.01 (1H, br). IR(Nujol): 3315, 3222, 3097, 3049, 2672, 1705, 1621, 1548, 1504, 1311 cm−1. [α]D27+88.2±1.3°(c=1.009, MeOH) Anal. (C24H28N2O4S2) Calcd.(%): C, 60.99; H, 5.97; N, 5.93; S, 13.57. Found(%): C, 60.94; H, 5.74; N, 5.91; S, 13.61.
Compound Number I-78
1H-NMR(CDCl3) δ: 1.09(1H, m), 1.18–1.31(2H, m), 1.40–1.47(2H, m), 1.57–1.73(4H, m), 2.00–2.12(5H, m), 2.31(2H, t, J=7.2 Hz), 2.56(1H, m), 3.79 (1H, m), 4.70(2H, s), 5.30–5.45(2H, m), 6.26–6.30(2H, m), 6.34(1H, d, J=6.9 Hz), 7.22(1H, dd, J=1.8 and 3.3 Hz), 7.41 and 7.62(each 1H, each d, each J=4.2 Hz). IR(CHCl3): 3589, 3516, 3441, 3355, 3100, 1708, 1656, 1530, 1504, 1377, 1180, 1147 cm−1. [α]D26.5+70.8±1.1°(c=1.009, MeOH) Anal. (C24H30N2O6S2.0.2H2O) Calcd.(%): C, 56.50; H, 6.01; N, 5.49; S, 12.57. Found(%): C, 56.43; H, 6.02; N, 5.61; S, 12.47.
Compound Number I-79
1H-NMR(CDCl3) δ: 1.06(1H, m), 1.16–1.30(2H, m), 1.38–1.50(2H, m), 1.54–1.77(4H, m), 1.98–2.18(5H, m), 2.35(2H, t, J=7.2 Hz), 2.51(1H, m), 3.80(1H, m), 5.30–5.42(2H, m), 6.03(1H, d, J=7.2 Hz), 7.04–7.06(2H, m), 7.32–7.35(2H, m), 7.37(1H, d, J=3.6 Hz). IR(CHCl3): 3509, 3444, 3426, 3110, 2667, 1708, 1645, 1530, 1499, 1421 cm−1. [α]D26.5+69.5±1.1°(c=1.001, MeOH) Anal. (C23H27NO3S3.0.1H2O) Calcd.(%): C, 59.61; H, 5.92; N, 3.02; S, 20.76. Found(%): C, 59.66; H, 5.90; N, 3.15; S, 20.52.
Compound Number I-80
1H-NMR(CDCl3) δ: 1.10(1H, m), 1.17–1.32(2H, m), 1.38–1.48(2H, m), 1.54–1.77(4H, m), 2.00–2.20(5H, m), 2.35(2H, t, J=7.2 Hz), 2.53(1H, m), 3.81(1H, m), 5.31–5.43(2H, m), 6.31(1H, d, J=7.2 Hz), 7.37–7.44(3H, m), 7.61(1H, d, J=3.9 Hz), 8.15(1H, dd, J=1.2 and 3.0 Hz). IR(CHCl3): 3517, 3441, 3371, 3114, 1708, 1655, 1530, 1504, 1331, 1152 cm−1. [α]D26.5+73.9±1.1°(c=1.001, MeOH) Anal. (C23H27NO5S3.0.3H2O) Calcd.(%): C, 55.35; H, 5.57; N, 2.81; S, 19.28 Found(%): C, 55.47; H, 5.50; N, 2.80; S, 19.09.
Compound Number I-81
1H-NMR(CDCl3) δ: 1.05(1H, m), 1.16–1.30(2H, m), 1.38–1.48(2H, m), 1.54–1.77 (4H, m), 1.98–2.17(5H, m), 2.34(2H, t, J=7.2 Hz), 2.46(3H, d, J=0.9 Hz), 2.50(1H, m), 3.79(1H, m), 5.29–5.41(2H, m), 5.99(1H, d, J=7.2 Hz), 6.67(1H, m), 6.99, 7.10 and 7.32(each 1H, each d, each J=3.9 Hz). IR(CHCl3): 3517, 3445, 3426, 2668, 1708, 1644, 1530, 1499, 1420, cm−1. [α]D26.5+66.1±1.1°(c=1.002, MeOH) Anal. (C24H29NO3S3.0.1H2O) Calcd.(%): C, 60.37; H, 6.16; N, 2.93; S, 20.15. Found(%): C, 60.21; H, 6.10; N, 2.90; S, 20.45.
Compound Number I-82
1H-NMR(CDCl3) δ: 1.11(1H, m), 1.18–1.32(2H, m), 1.38–1.50(2H, m), 1.54–1.74. (4H, m), 2.00–2.20(5H, m), 2.35(2H, t, J=7.2 Hz), 2.53(4H, d and m, J=0.6 Hz), 3.80(1H, m), 5.31–5.43(2H, m), 6.34(1H, d, J=6.6 Hz), 6.77 (1H, m), 7.41, 7.55 and 7.58(each 1H, each d, each J=3.9 Hz). IR(CHCl3): 3511, 3442, 3373, 3096, 1708, 1655, 1530, 1504, 1436, 1335, 1152 cm−1. [α]D26.5+73.0±1.1°(c=1.002, MeOH) Anal. (C24H29NO5S3.0.3H2O) Calcd.(%): C, 56.18; H, 5.81; N, 2.73; S, 18.75. Found(%): C, 56.26; H, 5.74; N, 2.65; S, 18.50.
Compound Number I-83
1H-NMR(CDCl3) δ: 1.17(1H, m), 1.24–1.36(2H, m), 1.37–1.82(6H, m), 2.01–2.23 (5H, m), 2.36(2H, t, J=7.2 Hz), 2.51(1H, m), 3.83(1H, m), 5.31–5.45 (2H, m, 7.17(1H, dd, J=3.9 and 5.4 Hz), 7.36(1H, d, J=7.8 Hz), 7.47 (1H, dd, J=1.5 and 3.9 Hz), 7.66(1H, dd, J=1.5 and 5.4 Hz). IR(CHCl3): 3514, 3404, 3121, 1709, 1657, 1544, 1488, 1425 cm−1. [α]D25+73.2±2.2°(c=0.518, MeOH) Anal. (C22H26N2O3S3.0.2H2O) Calcd.(%): C, 56.67; H, 5.71; N, 6.01; S, 20.63. Found(%): C, 56.55; H, 5.71; N, 6.03; S, 20.93.
Compound Number I-84
1H-NMR(CDCl3) δ: 1.07(1H, m), 1.20–1.32(2H, m), 1.43–1.48(2H, m), 1.57–1.82(4H, m), 2.02(1H, d, J=3.3 Hz), 2.00–2.20(5H, m), 2.35(2H, t, J=7.2 Hz), 2.55(1H, m), 3.86(1H, m), 4.01(2H, s), 5.29–5.43(2H, m), 6.17(1H, d, J=7.2 Hz), 7.15–7.31(7H, m), 7.67(2H, d, J=8.1 Hz). IR(CHCl3): 3517, 3447, 2669, 1708, 1651, 1523, 1495 cm−1. [α]D25+77.9±1.2°(c=1.016, MeOH) Anal. (C28H33NO3) Calcd.(%): C, 77.93; H, 7.71; N, 3.25. Found(%): C, 77.65; H, 7.93; N, 3.32.
Compound Number I-85
1H-NMR(CDCl3) δ: 1.08(1H, m), 1.21–1.31(2H, m), 1.44–1.49(2H, m), 1.58–1.82(4H, m), 2.00–2.20(5H, m), 2.35(2H, t, J=7.2 Hz), 2.56(1H, m), 3.87(1H, m), 4.19(2H, s), 5.30–5.43(2H, m), 6.19(1H, d, J=7.2 Hz), 6.80(1H, m), 6.93(1H, dd, J=2.6 and 5.1 Hz), 7.16(1H, dd, J=1.5 and 5.1 Hz), 7.30 and 8.69(each 2H, each d, each J=8.1 Hz). IR(CHCl3): 3510, 3446, 2664, 1708, 1651, 1523, 1496 cm−1. [α]D25+73.2±1.1°(c=1.009, MeOH) Anal. (C26H31NO3S) Calcd.(%): C, 71.36; H, 7.14; N, 3.20; S, 7.33. Found(%): C, 71.48; H, 7.05; N, 3.29; S, 7.13.
Compound Number I-86
1H-NMR(CDCl3) δ: 1.07(1H, m), 1.19–1.31(2H, m), 1.43–1.48(2H, m), 1.58–1.81(4H, m), 2.00–2.17(5H, m), 2.34(2H, t, J=7.2 Hz), 2.55(1H, m), 3.87(1H, m), 3.98(2H, s), 5.30–5.43(2H, m), 6.19(1H, d, J=7.2 Hz), 6.93–7.00(2H, m), 7.09–7.13(2H, m), 7.22 and 7.70(each 2H, each d, each J=8.4 Hz). IR(CHCl3): 3516, 3447, 2664, 1709, 1651, 1612, 1522, 1509, 1496, cm−1. [α]D25+71.6±1.1°(c=1.019, MeOH) Anal. (C28H32FNO3) Calcd.(%): C, 74.81; H, 7.17; N, 3.12; F. 4.23. Found(%): C, 74.66; H, 7.19; N, 3.13; F, 4.10.
Compound Number I-87
1H-NMR(CDCl3) δ: 1.08(1H, m), 1.20–1.31(2H, m), 1.44–1.49(2H, m), 1.58–1.82(4H, m), 2.00–2.22(5H, m), 2.35(2H, t, J=7.2 Hz), 2.56(1H, m), 3.87 (1H, m), 4.02(2H, s), 5.30–5.43(2H, m), 6.18(1H, d, J=7.2 Hz), 6.88(1H, dd, J=1.5 and 4.8 Hz), 6.92(1H, m), 7.25–7.28(3H, m), 7.68(2H, d, J=8.1 Hz). IR(CHCl3): 3516, 3446, 2668, 1709, 1651, 1612, 1523, 1496 cm−1. [α]D25+72.7±1.1°(c=1.014, MeOH) Anal. (C26H31NO3S.0.1H2O) Calcd.(%): C, 71.07; H, 7.16; N, 3.18; S, 7.30. Found(%): C, 70.90; H, 7.08; N, 3.21; S, 7.46.
Compound Number I-88
mp.103–105° C.; 1H-NMR(CDCl3) δ: 1.05(1H, m), 1.19–1.29(2H, m), 1.42–1.47(2H, m), 1.58–1.81(4H, m), 2.00–2.15(5H, m), 2.35(2H, t, J=7.2 Hz), 2.52(1H, m), 3.82(1H, m), 4.16(2H, s), 5.30–5.43(2H, m), 5.97(1H, d, J=7.5 Hz), 6.79(1H, dt, J=0.9 and 3.9 Hz), 6.96(1H, dd, J=1.5 and 4.8 Hz), 7.05 (1H, m), 7.28(1H, dd, J=3.0 and 4.8 Hz), 7.37(1H, d, J=3.9 Hz). IR(CHCl3): 3516, 3445, 3427, 2670, 1708, 1642, 1544, 1507 cm−1. [α]D25+67.3±1.1°(c=1.002, MeOH) Anal. (C24H29NO3S2.0.3H2O) Calcd.(%): C, 64.20; H, 6.64; N, 3.12; S, 14.28. Found(%): C, 64.29; H, 6.49; N, 3.10; S, 14.11.
Compound Number I-89
1H-NMR(CDCl3) δ: 1.07(1H, m), 1.20–1.29(2H, m), 1.40–1.49(2H, m), 1.56–1.89(4H, m), 2.00–2.25(6H, m), 2.32–2.38(2H, m), 2.51(1H, m), 3.80 (1H, m), 5.04(2H, s), 5.27–5.41(2H, m), 5.90(1H, d, J=6.6 Hz), 6.38(1H, m), 6.63(1H, t, J=2.4 Hz), 7.14–7.17(2H, m), 7.29–7.35(4H, m). IR(CHCl3): 3510, 3448, 2663, 1736, 1709, 1636, 1555, 1497 cm−1. [α]D25+60.8±1.0°(c=1.003, MeOH) Anal. (C26H32N2O3.0.3H2O) Calcd.(%): C, 73.62; H, 7.70; N, 6.60. Found(%): C, 73.68; H, 7.62; N, 6.73.
Compound Number I-90
1H-NMR(CDCl3) δ: 1.06(1H, m), 1.20–1.29(2H, m), 1.40–1.48(2H, m), 1.56–1.87(4H, m), 2.00–2.24(5H, m), 2.32–2.38(2H, m), 2.50(1H, m), 3.80 (1H, m), 5.19(2H, s), 5.27–5.41(2H, m), 5.90(1H, d, J=7.5 Hz), 6.37(1H, dd, J=2.1 and 3.0 Hz), 6.67(1H, t, J=2.4 Hz), 6.95–6.98(2H, m), 7.27(1H, dd, J=1.8 and 4.5 Hz), 7.31(1H, dd, J=1.8 and 2.1 Hz). IR(CHCl3): 3513, 3448, 2661, 1709, 1637, 1555, 1497 cm−1. [α]D25+59.4±1.0°(c=1.011, MeOH) Anal. (C24H30N2O3S.0.2H2O) Calcd.(%): C, 67.01; H, 7.12; N, 6.51; S, 7.45. Found(%): C, 67.07; H, 7.03; N, 6.62; S, 7.55.
Compound Number I-91
1H-NMR(CDCl3) δ: 1.06(1H, m), 1.23–1.26(2H, m), 1.39–1.48(2H, m), 1.57–1.82(4H, m), 2.00–2.16(5H, m), 2.34(2H, t, J=7.2 Hz), 2.50(1H, m), 3.82(1H, m), 5.03(2H, s), 5.27–5.42(2H, m), 5.98(1H, brs), 6.40(1H, m), 6.91(1H, dd, J=1.2 and 4.8 Hz), 7.08(1H, brs), 7.28–7.31(2H, m). IR(CHCl3): 3516, 3448, 3108, 2663, 1736, 1709, 1636, 1555, 1497 cm−1. [α]D25+59.8±1.0°(C=1.008, MeOH) Anal. (C24H30N2O3S.0.2H2O) Calcd.(%): C, 67.01; H, 7.12; N, 6.51; S, 7.45. Found(%): C, 67.26; H, 7.06; N, 6.61; S, 7.55.
Compound Number I-92
1H-NMR(CDCl3) δ: 1.08(1H, m), 1.18–1.28(2H, m), 1.38–1.43(2H, m), 1.54–1.78(4H, m), 1.96–2.23(5H, m), 2.36(2H, dt, J=1.8 and 6.9 Hz), 2.52 (1H, m) 3.77(1H, m), 5.30–5.45(2H, m), 6.07(1H, d, J=6.9 Hz), 6.58(1H, dd, J=1.5 and 3.3 Hz), 7.14(1H, dd, J=2.1 and 3.3 Hz), 7.51–7.57(2H, m), 7.65 (1H, m), 7.77(1H, t, J=2.1 Hz), 7.88–7.92(2H, m). IR(CHCl3): 3510, 3444, 3144, 1732, 1708, 1651, 1570, 1509, 1382, 1176 cm−1. [α]D24+55.9±0.9°(c=1.013, MeOH) Anal. (C25H30N2O5S.0.3H2O) Calcd.(%): C, 63.08; H, 6.48; N, 5.88; S, 6.74. Found(%): C, 63.24; H, 6.27; N, 6.03; S, 6.74.
Compound Number I-93
1H-NMR(CDCl3) δ: 1.06(1H, m), 1.18–1.29(2H, m), 1.39–1.47(2H, m), 1.56–1.78 (4H, m), 1.98–2.18(5H, m), 2.35(2H, t, J=7.2 Hz), 2.52(1H, m), 3.81(1H, m), 4.33(2H, s), 5.29–5.42(2H, m), 6.03(1H, d, J=7.5 Hz), 6.84(1H, d, J=3.9 Hz), 6.90(1H, m), 6.95(1H, dd, J=3.6 and 5.1 Hz), 7.19(1H, dd, J=1.2 and 5.1 Hz), 7.38(1H, d, J=3.9 Hz). IR(CHCl3): 3510, 3554, 3427, 1708, 1643, 1544, 1507 m−1. [α]D27+70.1±1°(c=1.010, MeOH) Anal. (C24H29NO29NO3S2.0.1H2O) Calcd.(%): C, 64.72; H, 6.61; N, 3.14; S, 14.40. Found(%): C, 64.83; H, 6.60; N, 3.31; S, 14.46.
Compound Number I-94
1H-NMR(CDCl3) δ: 1.09(1H, m), 1.20–1.27(2H, m), 1.40–1.44(2H, m), 1.56–1.78(4H, m), 2.00–2.19(5H, m), 2.36(2H, d, J=7.2 Hz), 2.51(1H, m), 3.78 (1H, m), 5.30–5.44(2H, m), 6.13(1H, d, J=6.9 Hz), 6.59(1H, dd, J=1.5 and 3.3 Hz), 7.10(1H, dd, J=3.6 and 5.1 Hz), 7.16(1H, dd, J=2.1 and 3.3 Hz), 7.69–7.76(3H, m). IR(CHCl3): 3510, 3444, 3143, 1708, 1651, 1571, 1508, 1387, 1179 cm−1. [α]D24+56.0±1.0°(c=1.005, MeOH) Anal. (C23H28N2O5S2.0.2H2O) Calcd.(%): C, 57.53; H, 5.96; N, 5.83; S, 13.35. Found(%): C, 57.54; H, 6.07; N, 5.93; S, 12.91.
Compound Number I-95
1H-NMR(CDCl3) δ: 1.16(1H, m), 1.26–1.37(2H, m), 1.40–1.81(6H, m), 2.04–2.25(5H, m), 2.36(2H, t, J=7.2 Hz), 2.53(1H, m), 3.87(1H, m), 5.32–5.46 (2H, m), 6.37(2H, t, J=2.1 Hz), 7.31(1H, d, J=7.5 Hz), 7.33(2H, t, J=2.1 Hz), 7.82(1H, m). IR(CHCl3): 3512, 3408, 3127, 1708, 1658, 1540, 1525, 1493, 1341 m−1. [α]D25+88.2±1.3°(c=1.003, MeOH) Anal. (C22H27N3O3S.0.1H2O) Calcd.(%): C, 63.62; H, 6.60; N, 10.12; S, 7.72. Found(%): C, 63.72; H, 6.45; N, 9.99; S, 7.75.
Compound Number I-96
1H-NMR(CDCl3) δ: 1.07(1H, m), 1.18–1.30(2H, m), 1.39–1.48(2H, m), 1.57–1.78(4H, m), 2.01–2.22(5H, m), 2.35(2H, t, J=7.2 Hz), 2.52(1H, m), 3.80(1H, m), 5.30–5.43(2H, m), 6.11(1H, m), 6.98(1H, dd, J=3.6 and 5.4 Hz), 7.24(1H, dd, J=1.2 and 3.6 Hz), 7.38(1H, dd, J=1.2 and 5.4 Hz), 7.43 (1H, d, J=1.5 Hz), 7.85(1H, d, J=1.5 Hz). IR(CHCl3): 3510, 3445, 3108, 1708, 1650, 1535, 1498 m−1. [α]D25+70.7±1.1°(c=1.004, MeOH) Anal. (C23H27NO3S3.0.3H2O) Calcd.(%): C, 59.15; H, 5.96; N, 3.00; S, 20.60. Found(%): C, 59.06; H, 5.66; N, 3.07; S, 20.87.
Compound Number I-97
1H-NMR(CDCl3) δ: 1.20–2.52(16H, m), 2.61(1H, m), 3.72(1H, m), 5.34–5.55 (2H, m), 6.66(1H, d, J=6.3 Hz), 71.2(1H, m), 7.71(1H, m), 7.75(1H, m), 8.29(1H, m), 8.37(1H, brs). IR(CHCl3): 3512, 3405, 3096, 1726, 1710, 1653, 1542, 1505, 1402, 1329, 1152 m−1. [α]D25+65.4±1.1°(c=1.005, MeOH) Anal. (C23H27NO5S3.0.2H2O) Calcd.(%): C, 55.55; H, 5.55; N, 2.82; S, 19.35. Found(%): C, 55.47; H, 5.54; N, 3.09; S, 19.21.
Compound Number I-98
mp.103–104° C.; 1H-NMR(CDCl3) δ: 1.09(1H, m), 1.23–1.31(2H, m), 1.45–1.50(2H, m), 1.60–1.80(4H, m), 2.00–2.23(5H, m), 2.37(2H, t, J=7.2 Hz), 2.55 (1H, m), 3.85(1H, m), 5.31–5.45(2H, m), 6.05(1H, d, J=7.5 Hz), 6.98 and 7.04(each 1H, each d, each J=16.2 Hz), 6.97(1H, d, J=3.9 Hz), 7.25–7.33 (3H, m), 7.41(1H, d, J=3.9 Hz). IR(CHCl3): 3511, 3445, 3428, 2665, 1708, 1641, 1538, 1519, 1499 cm−1. [α]D24+77.8±1.2°(c=1.007, MeOH) Anal. (C25H29NO3S2.0.25AcOEt) Calcd.(%): C, 65.38; H, 6.54; N, 2.93; S, 13.43. Found(%): C, 65.64; H, 6.62; N, 2.95; S, 13.26.
Compound Number I-99
1H-NMR(CDCl3) δ: 1.05(1H, m), 1.20–1.30(2H, m), 1.41–1.46(2H, m), 1.59–1.80(4H, m), 2.00–2.20(5H, m), 2.35(2H, t, J=7.2 Hz), 2.52(1H, m), 3.80(1H, m), 5.30–5.43(2H, m), 5.94(1H, d, J=6.9 Hz), 6.57(2H, s), 6.94(1H, d, J=3.9 Hz), 7.03(1H, dd, J=1.5 and 4.5 Hz), 7.29(1H, s), 7.30(1H, m), 7.34 (1H, d, J=3.91 Hz). IR(CHCl3): 3511, 3445, 3427, 2670, 1708, 1642, 1536, 1518, 1500 cm−1. [α]D24+62.8±1.0°(c=1.003, MeOH) Anal. (C25H29NO3S2.0.2AcOEt) Calcd.(%): C, 65.48; H, 6.52; N, 2.96; S, 13.55. Found(%): C, 65.36; H, 6.47; N, 2.13; S, 13.58.
Compound Number I-100
1H-NMR(CDCl3) δ: 1.06(1H, m), 1.17–1.32(2H, m), 1.38–1.50(2H, m), 1.56–1.80 (4H, m), 1.98–2.20(5H, m), 2.35(2H, t, J=7.2 Hz), 2.44(3H, d, J=0.9 Hz), 2.52(1H, m), 3.80(1H, m), 5.30–5.43(2H, m), 5.99(1H, d, J=7.5 Hz), 5.99(1H, d, J=7.5. Hz), 6.70(1H, m), 7.03(1H, d, J=3.9 Hz), 7.10(1H, d, J=1.5 Hz), 7.36(1H, d, J=3.9 Hz). IR(CHCl3): 3510, 3445, 3426, 2671, 1708, 1644, 1530, 1499, 1420, 1318 cm−1. [α]D25+69.1±1.1°(c=1.018, MeOH) Anal. (C24H29NO3S3) Calcd.(%): C, 60.60; H, 6.14; N, 2.94; S, 20.22. Found(%): C, 60.49; H, 6.26; N, 2.98; S, 20.25.
Compound Number I-101
1H-NMR(CDCl3) δ: 1.10(1H, m), 1.18–1.32(2H, m), 1.38–1.50(2H, m), 1.54–1.77 (4H, m), 2.00–2.20(5H, m), 2.36(2H, t, J=7.2 Hz), 2.47(3H, d, J=0.9 Hz), 2.53(1H, m), 3.81(1H, m), 5.31–5.44(2H, m), 6.30(1H, d, J=7.2 Hz), 7.03(1H, m), 7.42 and 7.59(each 1H, each d, each J=3.9 Hz), 7.90(1H, d, J=1.5 Hz). IR(CHCl3): 3517, 3441, 3370, 3115, 2671, 1708, 1655, 1530, 1504, 1442, 1328, 1156, 1142 cm−1. [α]D24+71.6±1.1°(c=1.018, MeOH) Anal. (C24H29NO5S3.0.2H2O) Calcd.(%): C, 56.38; H, 5.80; N, 2.74; S, 18.81. Found(%): C, 56.28; H, 5.74; N, 2.79; S, 18.92.
Compound Number I-102
1H-NMR(CDCl3) δ: 1.09(1H, m), 1.21–1.28(2H, m), 1.42–1.47(2H, m), 1.57–1.74(4H, m), 2.00–2.18(5H, m), 2.35(2H, t, J=7.2 Hz), 2.53(1H, m), 3.82 (1H, m), 5.30–5.43(2H, m), 6.15(1H, d, J=7.5 Hz), 6.51 and 6.68(each 1H, each d, J=11.7 Hz), 6.98(1H, dd, J=3.6 and 5.1 Hz), 7.06(1H, dd, J=0.9 and 3.9 Hz), 7.13(1H, dt, J=0.9 and 3.6 Hz), 7.25(1H, dd, J=0.9 and 5.1 Hz), 7.41(1H, d, J=3.9 Hz). IR(CHCl3): 3510, 3445, 3427, 2665, 1708, 1643, 1535, 1501 cm−1. [α]D24+68.6±1.1°(c=1.006, MeOH) Anal. (C25H29NO3S2.0.2H2O) Calcd.(%): C, 65.45; H, 6.45; N, 3.05; S, 13.98. Found(%): C, 65.44; H, 6.37; N, 3.28; S, 13.82.
Compound Number I-103
mp.107–108° C.; 1H-NMR(CDCl3) δ: 1.09(1H, m), 1.26–1.32(2H, m), 1.45–1.50 (2H, m), 1.60–1.81(4H, m), 2.01–2.23(5H, m), 2.37(2H, t, J=7.2 Hz), 2.55 (1H, m, 3.84(1H, m), 5.31–5.45(2H, m), 6.03(1H, d, J=7.5 Hz), 6.97 and 7.14(each 1H, each d, J=15.9 Hz), 6.97(1H, d, J=3.9 Hz), 7.01(1H, dd, J=3.6 and 5.4 Hz), 7.08(1H, d, J=3.6 Hz), 7.23(1H, d, J=5.4 Hz), 7.40(1H, d, J=3.9 Hz). IR(CHCl3): 3517, 3445, 3428, 2670, 1708, 1641, 1536, 1518, 1500 cm−1. [α]D24+85.0±1.2°(c=1.009, MeOH) Anal. (C25H29NO3S2.0.15AcOEt) Calcd.(%): C, 65.58; H, 6.49; N, 2.99; S, 13.68. Found(%): C, 65.88; H, 6.74; N, 2.98; S, 13.35.
Compound Number I-104
1H-NMR(CDCl3) δ: 1.07(1H, m), 1.19–1.30(2H, m), 1.42–1.50(2H, m), 1.57–1.79(4H, m), 2.01–2.24(5H, m), 2.36(2H, t, J=7.2 Hz), 2.53(1H, m), 3.82 (1H, m), 4.10(sH, s), 5.31–5.44(2H, m), 6.03(1H, d, J=7.2 Hz), 6.70(1H, d, J=3.6 Hz), 6.95(1H, dd, J=3.6 and 5.4 Hz), 7.03(1H, dd, J=1.5 and 3.6 Hz), 7.30(1H, d, J=3.6 Hz), 7.36(1H, dd, J=1.5 and 5.4 Hz). IR(CHCl3): 3518, 3445, 3427, 1708, 1644, 1542, 1507 cm−1. [α]D24.5+65.0±1.0°(c=1.008, MeOH) Anal. (C24H29NO3S3.0.4H2O) Calcd.(%): C, 59.69; H, 6.22; N, 2.90; S, 19.92. Found(%): C, 59.40; H, 5.98; N, 2.95; S, 20.06.
Compound Number I-105
1H-NMR(CDCl3) δ: 1.11(1H, m), 1.21–1.31(2H, m), 1.42–1.49(2H, m), 1.58–1.76(4H, m), 2.01–2.21(5H, m), 2.36(2H, t, J=7.2 Hz), 2.53(1H, m), 3.81 (1H, m), 4.60(sH, s), 5.32–5.45(2H, m), 6.18(1H, d, J=7.2 Hz), 6.91(1H, d, J=3.9 Hz), 7.12(1H, dd, J=3.9 and 5.1 Hz), 7.40(1H, d, J=3.9 Hz), 7.52 (1H, dd, J=1.2 and 3.9 Hz), 7.72(1H, dd, J=1.2 and 5.1 Hz). IR(CHCl3): 3517, 3444, 3425, 3097, 1708, 1648, 1524, 1508, 1402, 1328, 1147 cm−1. [α]D24.5+61.5±1.0°(c=1.008, MeOH) Anal. (C24H29NO5S2.0.4H2O) Calcd.(%): C, 55.98; H, 5.83; N, 2.72; S, 18.68. Found(%): C, 55.77; H, 5.71; N, 2.84; S, 18.73.
Compound Number I-106
1H-NMR(CDCl3) δ: 1.07(1H, m), 1.19–1.31(2H, m), 1.41–1.49(2H, m), 1.57–1.78(4H, m), 2.00–2.21(5H, m), 2.36(2H, t, J=7.2 Hz), 2.53(1H, m), 3.81 (1H, m), 4.23(sH, s), 5.31–5.44(2H, m), 6.00(1H, d, J=7.2 Hz), 6.82(1H, m), 6.88(1H, dd, J=3.6 and 5.1 Hz), 6.92(1H, d, J=3.6 Hz), 7.21(1H, dd, J=1.2 and 5.1 Hz), 7.33(1H, d, J=3.6 Hz). IR(CHCl3): 3514, 3444, 3427, 2665, 1709, 1645, 1529, 1498, 1421, 1317 cm−1. [α]D24+67.1±1.1°(c=1.006, MeOH) Anal. (C24H29NO3S3.0.1H2O) Calcd.(%): C, 60.37; H, 6.16; N, 2.90; S, 20.15. Found(%): C, 60.46; H, 6.14; N, 2.96; S, 20.02.
Compound Number I-107
1H-NMR(CDCl3) δ: 1.09–1.32(3H, m), 1.38–1.48(2H, m), 1.53–1.79(4H, m), 1.96–2.20(5H, m), 2.34(2H, t, J=7.2 Hz), 2.54(4H, d and m, J=0.6 Hz), 3.79 (1H, m), 5.30–5.45(2H, m), 6.48 and 6.51(total 1H, each d, J=7.8 and 7.5 Hz), 7.12 (1H, dd, J=3.9 and 5.1 Hz), 7.42 and 7.43(total 1H, each d, each J=3.9 Hz), 7.52 and 7.53(total 1H, each d, each J=3.9 Hz), 7.58(1H, m), 7.69 (1H, dd, J=1.2 and 5.1 Hz). IR(CHCl3): 3509, 3443, 3425, 3092, 2666, 1708, 1650, 1532, 1503, 1403, 1322 cm−1. [α]D23+70.4±1.1°(c=1.007, MeOH) Anal. (C23H27NO4S3.0.4H2O) Calcd.(%): C, 56.97; H, 5.78; N, 2.89; S, 19.84. Found(%): C, 57.03; H, 5.67; N, 3.19; S, 19.73.
Compound Number I-108
1H-NMR(CDCl3) δ: 1.09–1.32(3H, m), 1.39–1.50(2H, m), 1.54–1.77(4H,m), 1.97–2.20(5H ,m), 2.35(2H, t, J=7.2 Hz), 2.52 and 2.53(total 3H, each s), 2.54(1H, m), 3.79(1H, m), 5.31–5.45(2H, m), 6.43 and 6.47(total 1H, each d, J=7.5 and 6.6 Hz), 6.76(1H, m), 7.39(1H, t-like), 7.40(1H, dd, J=2.1 and 3.6 Hz), 7.52(1H, dd, J=2.1 and 4.2 Hz). IR(CHCl3): 3510, 3443, 3425, 3092, 1708, 1650, 1531, 1503, 1437, 1237 cm−1. [α]D2368.6±1.1°(c=1.011, MeOH) Anal. (C24H29NO4S3.0.2H2O) Calcd.(%): C, 58.20; H, 5.98; N, 2.83; S, 19.42. Found(%): C, 58.18; H, 5.67; N, 2.90; S, 19.11.
Compound Number I-109
1H-NMR(CDCl3) δ: 1.13(1H, m), 1.21–1.34(2H, m), 1.45–1.52(2H, m), 1.59–1.78(4H, m), 2.03–2.23(5H, m), 2.37(2H, t, J=7.2 Hz), 2.58(1H, m), 3.86(1H, m), 5.32–5.46(2H, m), 6.28(1H, d, J=6.6 Hz), 7.20(1H, dd, J=3.9 and 5.1 Hz), 7.59(1H, d, J=3.9 Hz), 7.75(1H, dd, J=1.2 and 5.1 Hz), 7.81(1H, d, J=3.9 Hz), 7.92(1H, dd, J=1.2 and 3.9 Hz). IR(CHCl3): 3518, 3442, 3425, 3109, 1709, 1651, 1622, 1529, 1508, 1442, 1414, 1356, 1286, 1267 cm−1. [α]D23+89.2±1.3°(c=1.002, MeOH) Anal. (C24H27NO4S2.0.2H2O) Calcd.(%): C, 62.50; H, 5.99; N, 3.04; S, 13.90. Found(%): C, 62.63; H, 6.07; N, 2.97; S, 13.60.
Compound Number I-110
1H-NMR(CDCl3) δ: 1.12(1H, m), 1.22–1.33(2H, m), 1.44–1.52(2H, m), 1.59–1.79 (4H, m), 2.03–2.24(5H, m), 2.37(2H, t, J=7.2 Hz), 2.57(1H, m), 3.87(1H, m), 4.14(3H, s), 5.32–5.47(2H, m), 6.14(1H, d, J=7.5 Hz), 7.08(1H, dd, J=3.9 and 5.4 Hz), 7.27(1H, dd, J=1.2 and 3.9 Hz), 7.39(1H, dd, J=1.2 and 5.4 Hz), 7.41(1H, d, J=3.9 Hz), 7.49(1H, d, J=3.9 Hz). IR(CHCl3): 3516, 3444, 3425, 2665, 1709, 1649, 1529, 1498, 1049 cm−1. [α]D24+73.3±1.1°(c=1.003, MeOH) Anal. (C25H30N2O4S2.0.6H2O) Calcd.(%): C, 60.36; H, 6.32; N, 5.63; S, 12.89. Found(%): C, 60.30; H, 6.14; N, 5.84; S, 12.95.
Compound Number I-111
1H-NMR(CDCl3) δ: 1.08(1H, m), 1.19–1.30(2H, m), 1.40–1.50(2H, m), 1.55–1.82(4H, m), 1.98–2.21(5H ,m), 2.36(2H, t, J=7.2 Hz), 2.53(1H, m), 3.83(1H, m), 5.30–5.44(2H, m), 5.96(1H, d, J=7.5 Hz), 6.43(1H, br), 6.52 (1H, d, J=3.9 Hz), 6.90(1H, m), 7.08–7.11(2H, m), 7.26–7.32(3H, m). IR(CHCl3): 3514, 3444, 3419, 1739, 1709, 1633, 1601, 1500, 1456 cm−1. [α]D22+86.6±1.3°(c=1.005, MeOH) Anal. (C25H30N2O3S.0.1H2O) Calcd.(%): C, 68.18; H, 6.91; N, 6.36; S, 7.28. Found(%): C, 68.11; H, 6.95; N, 6.43; S, 7.31.
Compound Number I-112
1H-NMR(CDCl3) δ: 1.05(1H, m), 1.18–1.30(2H, m), 1.39–1.48(2H, m), 1.54–1.83(4H, m), 1.98–2.21(5H ,m), 2.35(2H, t, J=7.2 Hz), 2.51(1H, m), 3.38 (3H, s), 3.80(1H, m), 5.29–5.42(2H, m), 5.82(1H, d, J=6.0 Hz), 6.15(1H, d, J=4.2 Hz), 7.11–7.39(6H, m). IR(CHCl3): 3514, 3446, 3425, 1741, 1709, 1628, 1597, 1477, 1415 cm−1. [α]D22+83.2±1.2°(c=1.001, MeOH) Anal. (C26H32N2O3S) Calcd.(%): C, 69.00; H, 7.13; N, 6.19; S, 7.08. Found(%): C, 68.74; H, 7.08; N, 6.15; S, 7.01.
Compound Number I-113
1H-NMR(CDCl3) δ: 1.07(1H, m), 1.18–1.31(2H, m), 1.40–1.49(2H, m), 1.55–1.75(4H, m), 1.99–2.16(5H, m), 2.31(3H, s), 2.35(2H, t, J=7.2 Hz), 2.52 (1H, m), 3.82(1H, m), 5.31–5.43(2H, m), 6.06(1H, d, J=7.5 Hz), 7.03–7.20 (5H, m), 7.44(1H, d, J=3.9 Hz). IR(CHCl3): 3516, 3444, 3425, 2671, 1709, 1647, 1529, 1498, 1421, 1317 cm−1. [α]D23+70.2±1.1°(c=1.001, MeOH) Anal. (C26H31NO3S2) Calcd.(%): C, 66.49; H, 6.65; N, 2.98; S, 13.65. Found(%): C, 66.34; H, 6.74; N, 2.94; S, 13.78.
Compound Number I-114
mp.114–116° C.; 1H-NMR(CDCl3) δ: 1.09(1H, m), 1.18–1.32(2H, m), 1.37–1.47 (2H, m), 1.55–1.75(4H, m), 2.00–2.18(5H, m), 2.35(2H, t, J=7.2 Hz), 2.42 (3H, s), 2.52(1H, m), 3.80(1H, m), 5.30–5.43(2H, m), 6.23(1H, d, J=7.5 Hz), 7.41(3H, m), 7.59(1H, d, J=3.9 Hz), 7.78(2H, m). IR(CHCl3): 3514, 3442, 3371, 2669, 1707, 1655, 1529, 1504, 1329, 1151 cm−1. [α]D23+72.4±1.1°(c=1.004, MeOH) Anal. (C26H31NO5S2) Calcd.(%): C, 62.25; H, 6.23; N, 2.79; S, 12.78. Found(%): C, 61.83; H, 6.39; N, 2.73; S, 12.78.
Compound Number I-115
1H-NMR(CDCl3) δ: 1.07(1H, m), 1.18–1.31(2H, m), 1.40–1.50(2H, m), 1.56–1.78(4H, m), 1.99–2.20(5H, m), 2.35(2H, t, J=7.2 Hz), 2.53(1H, m), 3.77(3H, s), 3.82(1H, m), 5.31–5.43(2H, m), 6.06(1H, d, J=7.2 Hz), 6.74–6.89(3H, m), 7.16–7.23(2H, m), 7.45(1H, d, J=3.9 Hz). IR(CHCl3): 3516, 3444, 3425, 2665, 1709, 1647, 1591, 1529, 1498, 1477, 1423 cm−1. [α]D23+68.7±1.1°(c=1.014, MeOH) Anal. (C26H31NO4S2) Calcd.(%): C, 64.30; H, 6.43; N, 2.88; S, 13.20. Found(%): C, 64.04; H, 6.56; N, 2.87; S, 13.43.
Compound Number I-116
mp.67–70° C.; 1H-NMR(CDCl3) δ: 1.09(1H, m), 1.17–1.32(2H, m), 1.39–1.47 (2H, m), 1.55–1.75(4H, m), 2.00–2.20(5H, m), 2.35(2H, t, J=7.2 Hz), 2.52 (1H, m), 3.80(1H, m), 3.86(3H, s), 5.30–5.43(2H, m), 6.26(1H, d, J=7.2 Hz), 7.12 (1H, m), 7.40–7.47(2H, m), 7.55(1H, m), 7.59(1H, d, J=3.9 Hz). IR (CHCl3): 3514, 3442, 3373, 1707, 1655, 1599, 1529, 1504, 1481, 1327, 1151 cm−1. [α]D23+70.0±1.1°(c=1.008, MeOH) Anal. (C26H31NO6S2.0.7H2O) Calcd.(%): C, 58.89; H, 6.16; N, 2.64; S, 12.09. Found(%): C, 58.87; H, 6.15; N, 2.74; S, 12.10.
Compound Number I-117
1H-NMR(CDCl3) δ: 1.10–1.32(3H, m), 1.37–1.46(2H, m), 1.55–1.73(4H, m), 1.94–2.18(5H, m), 2.34(2H, t, J=7.2 Hz), 2.55(1H, m), 3.78(1H, m), 5.29–5.45(2H, m), 6.56(1H, d, J=6.6 Hz), 7.09(1H, m), 7.37(1H, t, J=8.1 Hz), 7.45 (1H, d, J=3.9 Hz), 7.47–7.53(2H, m), 7.55(1H, (d, J=3.9 Hz). IR(KBr): 3365, 3095, 1707, 1628, 1543, 1448, 1306, 1147 cm−1. [α]D23+70.8±1.1°(c=1.003, MeOH) Anal. (C25H29NO6S2.0.3H2O) Calcd.(%): C, 58.99; H, 5.86; N, 2.75; S, 12.60. Found(%): C, 58.85; H, 5.85; N, 2.67; S, 12.77.
Compound Number I-118
mp.133–134° C.; 1H-NMR(CDCl3) δ: 1.08(1H, m), 1.18–1.32(2H, m), 1.40–1.49 (2H, m), 1.55–1.78(4H, m), 1.96–2.24(5H, m), 2.34(2H, t, J=7.2 Hz), 2.52(1H, m), 3.81(1H, m), 5.31–5.46(2H, m), 6.14(1H, d, J=6.6 Hz), 6.71 (2H, m), 6.86(1H, m), 7.14(2H, m), 7.42(1H, d, J=3.9 Hz). IR(Nujol): 3336, 3091, 2656, 1703, 1603, 1581, 1545 cm−1. [α]D23+73.2±1.1°(c=1.007, MeOH) Anal. (C25H29NO4S2) Calcd.(%): C, 63.67; H, 6.20; N, 2.97; S, 13.60. Found(%): C, 63.78; H, 6.17; N, 3.10; S, 13.73.
Compound Number I-119
1H-NMR(CDCl3) δ: 1.05(1H, m), 1.17–1.30(2H, m), 1.38–1.48(2H, m), 1.54–1.80 (4H, m), 1.98–2.20(5H, m), 2.34(2H, t, J=7.2 Hz), 2.51(1H, m), 3.79 (3H, s), 3.81(1H, m), 4.10(2H, s), 5.29–5.42(2H, m), 5.97(1H, d, J=7.5 Hz), 6.77–6.84(4H, m), 7.23(2H, m), 7.37(1H, d, J=3.9 Hz). IR (CHCl3): 3514, 3446, 3427, 1741, 1709, 1641, 1543, 1506, 1456 cm−1. [α]D22+64.3±1.0°(c=1.005, MeOH) Anal. (C27H33NO4S.0.1H2O) Calcd.(%): C, 69.08; H, 7.13; N, 2.98; S, 6.83. Found(%): C, 69.03; H, 7.25; N, 3.06; S, 7.00.
Compound Number I-120
1H-NMR(CDCl3) δ: 1.07(1H, m), 1.16–1.28(2H, m), 1.36–1.46(2H, m), 1.52–1.78 (4H, m), 1.96–2.17(5H, m), 2.32(2H, t, J=7.2 Hz), 2.50(1H, m), 3.80(1H, m), 4.02(2H, s), 5.28–5.42(2H, m), 6.16(1H, d, J=7.5 Hz), 6.72–6.77(4H, m), 1H, m), 7.36(1H, d, J=3.9 Hz). IR(CHCl3): 3595, 3423, 3207, 1707, 1635, 1599, 1545, 1508, 1456 cm−1. [α]D23+66.8±1.1°(c=1.009, MeOH) Anal. (C26H31NO4S.0.4H2O) Calcd.(%): C, 67.77; H, 6.96; N, 3.04; S, 6.96. Found(%): C, 67.83; H, 6.92; N, 3.18; S, 7.14.
Compound Number I-121
1H-NMR(CDCl3) δ: 1.06(1H, m), 1.8–1.31(2H, m), 1.40–1.48(2H, m), 1.55–1.82(4H, m), 1.98–2.22(5H, m), 2.29(3H, s), 2.35(2H, t, J=7.2 Hz), 2.52 (1H, m), 3.80(1H, m), 4.14(2H, s), 5.29–5.43(2H, m), 5.97(1H, d, J=7.5 Hz), 6.78 (1H, m), 6.94–7.00(2H, m), 7.10(1H, m), 7.33(1H, m), 7.36(1H, d, J=3.9 Hz). IR(CHCl3): 3514, 3446, 3427, 2669, 1763, 1745, 1709, 1643, 1545, 1506, 1371 cm−1. [α]D23+61.3±1.0°(c=1.019, MeOH) Anal. (C28H33NO5S.0.1H2O) Calcd.(%): C, 67.61; H, 6.73; N, 2.82; S, 6.45. Found(%): C, 67.52; H, 6.77; N, 2.99; S, 6.48.
Compound Number I-122
1H-NMR(CDCl3) δ: 1.06(1H, m), 1.18–1.30(2H, m), 1.40–1.48(2H, m), 1.56–1.76(4H, m), 1.99–2.17(5H, m), 2.35(2H, t, J=7.2 Hz), 2.52(1H, m), 3.81(1H, m), 4.25(2H, s), 5.30–5.43(2H, m), 6.00(1H, d, J=7.5 Hz), 6.81(1H, d, J=3.9 Hz), 7.20–7.36(6H, m). IR(CHCl3): 3516, 3446, 3427, 2667, 1709, 1643, 1543, 1506 cm1. [α]D23+65.0±1.0°(c=1.008, MeOH) Anal. (C26H31NO3S2.0.1H2O) Calcd.(%): C, 66.24; H, 6.67; N, 2.97; S, 13.60. Found(%): C, 66.14; H, 6.63; N, 3.05; S, 13.49.
Compound Number I-123
1H-NMR(CDCl3) δ: 1.08(1H, m), 1.20–1.32(2H, m), 1.40–1.50 (2H, m), 1.56–1.80 (4H, m), 2.00–2.20(5H, m), 2.36(2H, t, J=7.2 Hz), 2.54 (1H, m), 3.84 (1H, m), 5.20(2H, s), 5.31–5.44(2H, m), 6.06(1H, d, J=7.5 Hz), 6.94–7.05 (4H, m), 7.27–7.33(2H, m), 7.42(1H, d, J=3.9 Hz). IR(CHCl3): 3516, 3444, 3427, 2669, 1709, 1645, 1599, 1545, 1508, 1497 cm−1. [α]D24+65.4±1.1°(c=1.003, MeOH) Anal. (C26H31NO4S.0.2H2O) Calcd.(%): C, 68.30; H, 6.92; N, 3.06; S, 7.01. Found(%): C, 68.32; H, 6.83; N, 3.08; S, 6.99.
Compound Number I-124
1H-NMR(CDCl3) δ: 1.06(1H, m), 1.18–1.32(2H, m), 1.40–1.50(2H, m), 1.55–1.80(4H, m), 2.00–2.20(5H, m), 2.35(2H, t, J=7.2 Hz), 2.52(1H, m), 3.81(1H, m), 4.51(2H, d, J=0.9 Hz), 5.30–5.43(2H, m), 6.01(1H, d, J=7.5 Hz), 6.65–6.97(3H, m), 6.96(1H, d, J=3.9 Hz), 7.16–7.21(1H, m), 7.41(1H, d, J=3.9 Hz). IR(CHCl3): 3516, 3444, 3427, 1709, 1643, 1603, 1545, 1504, 1309, 1260 cm−1. [α]D22+65.7±1.0°(c=1.014, MeOH) Anal. (C26H32N2O3S.0.2H2O) Calcd.(%): C, 68.45; H, 7.16; N, 6.14; S, 7.03. Found(%): C, 68.43; H, 7.18; N, 6.27; S, 6.94.
Compound Number I-125
1H-NMR(CDCl3) δ: 1.05(1H, m), 1.18–1.27(2H, m), 1.40–1.45(2H, m), 1.56–1.77(4H, m), 2.00–2.13(5H, m), 2.28(3H, s), 2.34(2H, t, J=7.5 Hz), 2.51(1H, m), 3.80(1H, m), 4.12(2H, s), 5.29–5.41(2H, m), 5.98(1H, d, J=7.2 Hz), 6.69(1H, d, J=3.6 Hz), 7.18(4H, s), 7.36(1H, d, J=3.6 Hz). IR (CHCl3): 3518, 3446, 3426, 1741, 1709, 1641, 1543, 1506, 1458 cm−1. [α]D22.5+66.8±1.1°(c=1.003, MeOH) Anal. (C27H33NO3S.H2O) Calcd.(%): C, 69.05; H, 7.51; N, 2.98; S, 6.83. Found(%): C, 69.07; H, 7.11; N, 3.23; S, 7.04.
Compound Number I-126
1H-NMR(CDCl3) δ: 1.04(1H, m), 1.17–1.28(2H, m), 1.41–1.46(2H, m), 1.55–1.77(4H, m), 2.00–2.20(5H, m), 2.34(2H, t, J=7.2 Hz), 2.51(1H, m), 3.80(1H, m), 4.12(2H, s), 5.29–5.41(2H, m), 5.91(1H, d, J=7.2 Hz), 6.77(1H, d, J=3.3 Hz), 6.86–6.90(2H, m), 7.15(1H, dd, J=1.8 and 7.5 Hz), 7.20–7.26 (1H, m), 7.34(1H, d, J=3.6 Hz). IR(CHCl3): 3519, 3446, 3427, 2669, 1741, 1709, 1641, 1543, 1504, 1458, 1248 cm−1. [α]D22.5+64.2±1.0°(c=1.005, MeOH) Anal. (C27H33NO4S.0.1H2O) Calcd.(%): C, 69.08; H, 7.13; N, 2.98; S, 6.83. Found(%): C, 68.97; H, 6.90; N, 3.09; S, 6.77.
Compound Number I-127
1H-NMR(CDCl3) δ: 1.04(1H, m), 1.18 (3H, t, J=7.7 Hz), 1.15–1.29 (2H, m), 1.41–1.46 (2H, m), 1.56–1.80 (4H, m), 2.00–2.15 (5H, m), 2.35 (2H, t, J=7.2 Hz), 2.51 (1H, s), 2.64 (2H, q, J=7.7 Hz), 3.80 (1H, m), 4.16 (2H, s), 5.29–5.41 (2H, m), 5.91 (1H, d, J=7.5 Hz), 6.69 (1H, d, J=3.6 Hz), 7.16–7.25 (4H, m), 7.35 (1H, d, J=3.6 Hz). IR (CHCl3): 3516, 3447, 3427, 2669, 1709, 1641, 1543, 1506, 1456 cm−1. [α]D21+65.8±1.1°(c=1.011, MeOH). Anal. (C28H35NO3S.0.2H2O) Calcd.(%): C, 71.67; H, 7.60; N, 2.98; S, 6.83. Found(%): C, 71.83; H, 7.49; N, 3.12; S, 6.89.
Compound Number I-128
1H-NMR(CDCl3) δ: 1.04 (1H, m), 1.18–1.29 (2H, m), 1.41–1.46 (2H, m), 1.56–1.80 (4H, m), 2.00–2.20 (5H, m), 2.24 and 2.31 (each 3H, each s), 2.35 (2H, t, J=7.4 Hz), 2.51 (1H, s), 3.80 (1H, m), 4.19 (2H, s), 5.29–5.41 (2H, m), 5.91 (1H, d, J=7.2 Hz), 6.70 (1H, d, J=3.6 Hz), 6.99 (1H, d, J=7.5 Hz), 7.00 (1H, s), 7.07 (1H, d, J=7.5 Hz), 7.35 (1H, d, J=3.6 Hz). IR (CHCl3): 3514, 3446, 3426, 1741, 1709, 1641, 1543, 1506, 1456 cm−1. [α]D21+65.2±1.0°(c=1.014, MeOH) Anal. (C28H35NO3S.0.2H2O) Calcd.(%): C, 71.67; H, 7.60; N, 2.98; S, 6.83. Found(%): C, 71.53; H, 7.49; N, 3.31; S, 6.90.
Compound Number I-129
1H-NMR(CDCl3) δ: 1.05(1H, m), 1.18–1.29(2H, m), 1.42–1.47(2H, m), 1.56–1.78(4H, m), 2.00–2.20(5H, m), 2.35(2H, t, J=7.5 Hz), 2.43(3H, s), 2.52 (1H, s),3.81(1H, m), 4.24(2H, s), 5.30–5.42(2H, m), 5.97(1H, d, J=7.5 Hz), 6.57(1H, m), 6.67(1H, d, J=3.3 Hz), 6.83(1H, d, J=3.9 Hz), 7.37 (1H, d, J=3.9 Hz). IR(CHCl3): 3514, 3446, 3427, 1709, 1643, 1545, 1506, 1456 cm−1. [α]D22+67.1±1.1°(c=1.002, MeOH) Anal. (C25H31NO3S2) Calcd.(%): C, 65.61; H, 6.83; N, 3.06; S, 14.01. Found(%): C, 65.42; H, 6.76; N, 3.20; S, 13.73.
Compound Number I-130
1H-NMR(CDCl3) δ: 1.04(1H, m), 1.18–1.28(2H, m), 1.41–1.45(2H, m), 1.55–1.78 (4H, m), 1.99–2.16(5H, m), 2.34(2H, t, J=7.2 Hz), 2.38(3H, s), 2.51 (1H, m), 3.80(1H, m), 4.09(2H, s), 5.29–5.41(2H, m), 5.96(1H, d, J=6.9 Hz), 6.76(1H, d, J=3.6 Hz), 7.12(4H, s), 7.37(1H, d, J=3.6 Hz). IR (CHCl3): 3510, 3446, 3427, 1741, 1709, 1641, 1543, 1508, 1458 cm−1. [α]D22+67.0±1.1°(c=1.014, MeOH) Anal. (C27H33NO3S) Calcd.(%): C, 71.81; H, 7.36; N, 3.10; S, 7.10. Found(%): C, 71.53; H, 7.24; N, 3.21; S, 7.36.
Compound Number I-131
1H-NMR(CDCl3) δ: 1.04(1H, m), 1.18–1.28(2H, m), 1.41–1.46(2H, m), 1.56–1.78(4H, m), 1.99–2.19(5H, m), 2.33(3H, s), 2.34(2H, t, J=7.5 Hz), 2.51 (1H, m), 3.81(1H, m), 4.09(2H, s), 5.29–5.42(2H, m), 5.96(1H, d, J=7.2 Hz), 6.77 (1H, d, J=3.6 Hz), 7.02–7.07(3H, m), 7.21(1H, m), 7.37(1H, d, J=3.6 Hz). IR (CHCl3): 3516, 3446, 3427, 1741, 1709, 1641, 1543, 1506, 1458 cm−1. [α]D23+66.1±1.1°(c=1.006, MeOH) Anal. (C27H33NO3S.0.2H2O) Calcd.(%): C, 71.24; H, 7.40; N, 3.08; S, 7.04. Found(%): C, 71.26; H, 7.20; N, 3.19; S, 7.12.
Compound Number I-132
1H-NMR(CDCl3) δ: 1.06(1H, m), 1.19–1.30(2H, m), 1.41–1.49(2H, m), 1.57–1.78(4H, m), 2.00–2.21(5H, m), 2.30(3H, s), 2.35(2H, t, J=7.2 Hz), 2.52(1H, m), 3.81(1H, m), 4.25(2H, s), 5.30–5.43(2H, m), 6.01(1H, d, J=6.9 Hz), 6.82(1H, d, J=3.9 Hz), 7.02(1H, m), 7.10–7.19(3H, m), 7.31(1H, d, J=3.9 Hz). IR(CHCl3): 3516, 3446, 3427, 2671, 1739, 1709, 1643, 1543, 1506, 1475, 1456 cm−1. [α]D23+63.2±1.0°(c=1.007, MeOH) Anal. (C27H33NO3S2.0.2H2O) Calcd.(%): C, 66,55; H, 6.91; N, 2.87; S, 13.16. Found(%): C, 66.44; H, 6.87; N, 2.99; S, 13.11.
Compound Number I-133
1H-NMR(CDCl3) δ: 1.07(1H, m), 1.20–1.30(2H, m), 1.45–1.51(2H, m), 1.56–1.82(4H, m), 2.00–2.20(5H, m), 2.35(2H, t, J=7.2 Hz), 2.52(1H, m), 3.82 (1H, m), 4.16(2H, s), 5.30–5.43(2H, m), 5.98(1H, d, J=7.2 Hz), 6.13 (1H, dd, J=3.3 and 0.9 Hz), 6.32(1H, dd, J=3.3 and 1.8 Hz), 6.84(1H, d, J=3.6 Hz), 7.35(1H, dd, J=1.8 and 0.9 Hz), 7.37(1H, d, J=3.6 Hz). IR (CHCl3): 3512, 3446, 3427, 2669, 1709, 1.643, 1545, 1506 cm−1. [α]D22+69.6±1.1°(c=1.015, MeOH) Anal. (C24H29NO4S.0.2H2O) Calcd.(%): C, 66.86; H, 6.87; N, 3.25; S, 7.44. Found(%): C, 66.75; H, 6.63; N, 3.32; S, 7.50.
Compound Number I-134
1H-NMR(CDCl3) δ: 1.07(1H, m), 1.19–1.29(2H, m), 1.45–1.60(2H, m), 1.61–1.80(4H, m), 2.00–2.21(5H, m), 2.36(2H, t, J=7.2 Hz), 2.52(1H, m), 3.81(1H, m), 3.96(2H, s), 5.29–5.42(2H, m), 5.96(1H, d, J=6.9 Hz), 6.30 (1H, m), 6.80(1H, m), 7.32(1H, m), 7.35–7.39(2H, m). IR(CHCl3): 3516, 3446, 3427, 2663, 1709, 1643, 1545, 1506 cm−1. [α]D21+70.2±1.1°(c=1.007, MeOH) Anal. (C24H29NO4S) Calcd.(%): C, 67.42; H, 6.84; N, 3.28; S, 7.50. Found(%): C, 67.13; H, 6.57; N, 3.40; S, 7.40.
Compound Number I-135
1H-NMR(CDCl3) δ: 1.06(1H, m), 1.20–1.29(2H, m), 1.42–1.47(2H, m), 1.58–1.82(4H, m), 2.00–2.15(5H, m), 2.35(2H, t, J=7.2 Hz), 2.52(1H, m), 3.81 (1H, m), 4.41(2H, s), 5.29–5.41(2H, m), 5.96(1H, d, J=7.2 Hz), 6.91 (1H, d, J=3.6 Hz), 7.11(1H, s), 7.25–7.35(3H, m), 7.39(1H, d, J=3.6 Hz), 7.76 (1H, d, J=7.8 Hz). IR(CHCl3): 3510, 3444, 3427, 2667, 1709, 1643, 1543, 1508 cm−1. [α]D24+66.5±1.1°(c=1.012, MeOH) Anal. (C28H31NO3S2.0.5H2O) Calcd.(%): C, 66.90; H, 6.42; N, 2.79; S, 12.76. Found(%): C, 66.99; H, 6.12; N, 2.81; S, 12.48.
Compound Number I-136
1H-NMR(CDCl3) δ: 1.07(1H, m), 1.20–1.42(2H, m), 1.44–1.49(2H, m), 1.55–1.80(4H, m), 2.00–2.20(5H, m), 2.35(2H, t, J=7.2 Hz), 2.52(1H, m), 3.81 (1H, m), 4.30(2H, s), 5.29–5.41(2H, m), 5.98(1H, d, J=7.8 Hz), 6.51 (1H, d, J=0.6 Hz), 6.92(1H, d, J=3.9 Hz), 7.17–7.25(2H, m), 7.38–7.51 (3H, m). IR (CHCl3): 3514, 3444, 3427, 2669, 1709, 1643, 1545, 1508, 1454 cm−1. [α]D23+63.8±1.0°(c=1.004, MeOH) Anal. (C28H31NO4S.0.3H2O) Calcd.(%): C, 69.62; H, 6.59; N, 2.90; S, 6.64. Found(%): C, 69.51; H, 6.52; N, 2.92; S, 6.63.
Compound Number I-137
1H-NMR(CDCl3) δ: 1.05(1H, m), 1.18–1.29(2H, m), 1.40–1.48(2H, m), 1.55–1.78(4H, m), 1.98–2.18(5H, m), 2.34(2H, t, J=7.2 Hz), 2.51(1H, m), 3.81(1H, m), 4.17(2H, s), 5.29–5.42(2H, m), 5.98(1H, d, J=7.5 Hz), 6.81 (1H, d, J=3.6 Hz), 7.29–7.46(6H, m), 7.52–7.60(41H, m). IR(CHCl3): 3510, 3446, 3427, 1741, 1709, 1643, 1543, 1506, 1489 cm−1. [α]D23+59.4±1.0°(c=1.007, MeOH) Anal. (C32H35NO3S.0.2H2O) Calcd.(%): C, 74.30; H, 6.90; N, 2.71; S, 6.20. Found(%): C, 74.24; H, 6.78; N, 2.97; S, 6.16.
Compound Number I-138
1H-NMR(CDCl3) δ: 1.04(1H, m), 1.17–1.29(2H, m), 1.39–1.47(2H, m), 1.54–1.76(4H, m), 1.97–2.38(5H, m), 2.33(2H, t, J=7.5 Hz), 2.51(1H, m), 3.80 (1H, m), 4.19(2H, s), 5.28–5.41(2H, m), 5.98(1H, d, J=7.5 Hz), 6.79 (1H, d, J=3.6 Hz), 7.21(1H, d, J=7.8 Hz), 7.31–7.49(7H, m), 7.56(2H, m). IR (CHCl3): 3512, 3446, 3427, 2669, 1741, 1709, 1643, 1543, 1506, 1479, 1456 cm−1. [α]D24+59.2±1.0°(c=1.006 MeOH) Anal. (C32H35NO3S.0.2H2) Calcd.(%): C, 74.30; H, 6.90; N, 2.71; S, 6.20. Found(%): C, 74.26; H, 6.92; N, 3.00; S, 6.20.
Compound Number I-139
1H-NMR(CDCl3) δ: 1.05(1H, m), 1.17–1.32(2H, m), 1.43–1.48(2H, m), 1.58–1.80(4H, m), 2.02–2.24(5H, m), 2.34(2H, t, J=7.2 Hz), 2.58(1H, s), 3.91(1H, m),4.11(2H, s), 5.30–5.44(2H, m), 6.11(1H, d, J=7.2 Hz), 7.18–7.30(6H, m), 7.75(1H, d, J=8.4 Hz), 7.86(1H, s), 8.16(1H, s). IR(CHCl3): 3516, 3430, 2665, 1741, 1709, 1651, 1513, 1494, 1454, 1435 cm−1. [α]D24+45.6±0.9°(c=1.004, MeOH) Anal. (CO30H33NO3S.0.1H2O) Calcd.(%): C, 73.62; H, 6.84; N, 2.86; S, 6.55. Found(%): C, 73.57; H, 6.71; N, 3.07; S, 6.30.
Compound Number I-140
1H-NMR(CDCl3) δ: 1.09(1H, m), 1.20–1.32(2H, m), 1.46–1.51(2H, m), 1.58–1.78(4H, m), 2.02–2.24(5H, m), 2.35(2H, t, J=7.41 Hz), 2.60(1H, s), 3.92(1H, m),4.10(2H, s), 5.32–5.46(2H, m), 6.14(1H, d, J=7.2 Hz), 7.19–7.32(6H, m), 7.64(1H, s), 7.81(1H, s), 8.20(1H, d, J=8.4 Hz). IR(CHCl3): 3516, 3438, 2669, 1709, 1651, 1516, 1494, 1406 cm−1. [α]D24+53.0±0.9°(c=1.002, MeOH) Anal. (C30H33NO3S) Calcd.(%): C, 73.89; H, 6.82; N, 2.87; S, 6.58. Found(%): C, 73.57; H, 7.05; N, 3.08; S, 6.63.
Compound Number I-141
mp.54–56° C.; 1-NMR(CDCl3) δ: 0.97(1H, m), 1.10–1.43(4H, m), 1.53–1.72 (4H, m), 1.97–2.15(5H, m), 2.31(2H, t, J=7.4 Hz), 2.45(1H, s), 3.83(1H, m), 4.39 and 4.52(each 1H, each d, J=16.5 Hz), 5.25–5.40(2H, m), 5.98 (1H, d, J=7.5 Hz), 7.00–7.31(7H, m), 7.57(1H, s), 7.73(1H, d, J=7.5 Hz). IR (CHCl3): 3514, 3433, 2671, 1709, 1655, 1512, 1454 cm−1. [α]D25+76.7±1.2°(c=1.005, MeOH) Anal. (C30H33NO3S.0.1H2O) Calcd.(%): C, 73.62; H, 6.84; N, 2.86; S, 6.55. Found(%): C, 73.45; H, 6.91; N, 3.21; S, 6.34.
Compound Number I-142
mp.118–119° C.; 1H-NMR(CDCl3) δ: 1.07(1H, m), 1.20–1.27(2H, m), 1.42–1.46(2H, m), 1.55–1.73(4H, m), 1.99–2.12(5H, m), 2.33(2H, t, J=7.5 Hz), 2.52(1H, s), 3.82(1H, m),3.93(2H, s), 5.29–5.42(2H, m), 6.10 (1H, d, J=7.2 Hz), 7.05(1H, d, J=0.9 Hz), 7.16–7.32(6H, m). IR(CHCl3): 3516, 3444, 3429, 2669, 1739, 1709, 1665, 1549, 1508, 1454 cm−1. [α]D24+72.7±0.1.1°(c=1.001, MeOH) Anal. (C26H31NO3S) Calcd.(%): C, 71.36; H, 7.14; N, 3.20; S, 7.33. Found(%): C, 71.31; H, 7.27; N, 3.36; S, 7.31.
Compound Number I-143
1H-NMR(CDCl3) δ: 1.09(1H, m), 1.19–1.32(2H, m), 1.46–1.51(2H, m), 1.58–1.78(4H, m), 2.02–2.24(5H, m), 2.35(2H, t, J=7.2 Hz), 2.60(1H, s), 3.92(1H, m),4.24(2H, s), 5.32–5.47(2H, m), 6.14(1H, d, J=7.5 Hz), 7.18–7.30(6H, m), 7.43(1H, t, J=7.8 Hz), 7.83(1H, s), 8.17(1H, d, J=7.8 Hz). IR(CHCl3): 3516, 3438, 2671, 1709, 1651, 1518, 1495, 1454 cm−1. [α]D25+62.8±1.0°(c=1.011, MeOH) Anal. (C30H33NO3S.0.1H2O) Calcd.(%): C, 73.62; H, 6.84; N, 2.86; S, 6.55. Found(%): C, 73.52; H, 6.87; N, 3.13; S, 6.47.
Compound Number I-144
1H-NMR(CDCl3) δ: 1.05(1H, m), 1.23–1.29(2H, m), 1.41–1.49(2H, m), 1.58–1.77(4H, m), 2.00–2.21(5H, m), 2.35(2H, t, J=7.2 Hz), 2.52(1H, m), 3.81 (1H, m), 4.05(2H, s), 5.12(2H, s), 5.29–5.42(2H, m), 5.94(1H, d, J=7.8 Hz), 6.76(1H, d, J=3.9 Hz), 6.90–6.98(31H, m), 7.32–7.45 (6H, m). IR (CHCl3): 3516, 3446, 3427, 1741, 1709, 1643, 1543, 1510, 1456, 1273 cm−1. [α]D23+53.7±0.9°(c=1.006, MeOH) Anal. (C33H36FNO4S.0.2H2O) Calcd.(%): C, 70.11; H, 6.49; N, 2.48; S, 5.67; F, 3.36. Found(%): C, 70.00; H, 6.44; N, 2.50; S, 5.75; F, 3.32.
Compound Number I-145
mp.136–137° C.; 1H-NMR(CDCl3) δ: 1.06(1H, m), 1.23–1.29(2H, m), 1.41–1.49(2H, m), 1.58–1.77(4H, m), 2.00–2.21(5H, m), 2.35(2H, t, J=7.2 Hz), 2.52(1H, m), 3.78(1H, m), 4.05(2H, s), 5.29–5.42(2H, m), 5.93 (1H, d, J=10.8 Hz), 6.77(1H, d, J=3.6 Hz), 6.88–6.98(3H, m), 7.36 (1H, d, J=3.6 Hz). IR (Nujol): 3377, 3101, 2752, 1703, 1618, 1601, 1550, 1518 cm−1. [α]D23+64.2±1.0°(c=1.009, MeOH) Anal. (C26H30FNO4S) Calcd.(%): C, 66.23; H, 6.41; N, 2.97; S, 6.80; F, 4.03. Found(%): C, 66.15; H, 6.38; N, 2.94; S, 6.76; F, 3.94.
Compound Number I-146
1H-NMR(CDCl3) δ: 1.06(1H, m), 1.20–1.29(2H, m), 1.41–1.46(2H, m), 1.61–1.81(4H, m), 2.00–2.16(5H, m), 2.35(2H, t, J=7.2 Hz), 2.51(1H, m), 3.79 (1H, m), 4.03(2H, s), 5.08(2H, s), 5.29–5.40(2H, m), 5.63(1H, brs), 5.93 (1H, d, J=7.5 Hz), 6.70(1H, dd, J=2.1 and 8.4 Hz), 6.77 (1H, d, J=3.9 Hz), 6.83 (1H, d, J=5.7 Hz). 6.86(1H, d, J=8.4 Hz), 7.36–7.41(6H, m). IR(CHCl3): 3539, 3446, 3425, 1741, 1709, 1641, 1543, 1508, 1475, 1273 cm−1. [α]D23+53.8±0.9°(c=1.003, MeOH) Anal. (C33H37NO5S.0.5H2O) Calcd.(%): C, 69.69; H, 6.73; N, 2.46; S, 5.64. Found(%): C, 69.68; H, 6.85; N, 2.68; S, 5.76.
Compound Number I-147
mp.150–151° C.; 1H-NMR(CDCl3) δ: 1.06(1H, m), 1.20–1.29(2H, m), 1.41–1.46(2H, m), 1.58–1.79(4H, m), 2.00–2.16(5H, m), 2.35(2H, t, J=7.2 Hz), 2.51(1H, m), 3.79(1H, m), 3.86(3H, s), 4.06(2H, s), 5.29–5.41 (2H, m), 5.56 (1H, brs), 5.93(1H, d, J=8.4 Hz), 6.72–6.77(3H, m), 6.87 (1H, d, J=8.1 Hz), 7.37(1H, d, J=3.6 Hz). IR(Nujol): 3452, 3361, 3130, 1.743, 1707, 1620, 1599, 1550, 1522, 1286 cm−1. [α]D23+62.6±1.0°(c=1.002, MeOH) Anal. (C27H33NO5S) Calcd.(%): C, 67.05; H, 6.88; N, 2.90; S, 6.63. Found(%): C, 67.20; H, 7.04; N, 2.98; S, 6.58.
Compound Number I-148
1H-NMR(CDCl3) δ: 1.07(1H, m), 1.19–1.31(2H, m), 1.41–1.50(2H, m), 1.56–1.81 (4H, m), 1.99–2.21(5H, m), 2.35(2H, t, J=7.2 Hz), 2.53(1H, m), 2.95–3.00 (2H, m), 3.10–3.15(2H, m),3.83(1H, m), 5.31–5.44(2H, m), 6.02 (1H, d, J=7.2 Hz), 6.70(1H, d, J=3.9 Hz), 7.15–7.32(5H, m), 7.33(1H, d, J=3.9 Hz). IR(CHCl3): 3510, 3446, 3429, 2671, 1741, 1709, 1641, 1543, 1506, 1456 cm−1. [α]D23+68.4±1.1°(c=1.004, MeOH) Anal. (C27H33NO3S.0.1H2O) Calcd.(%): C, 71.52; H, 7.38; N, 3.09; S, 7.07. Found(%): C, 71.35; H, 7.37; N, 3.19; S, 7.19.
Compound Number I-149
1H-NMR(CDCl3) δ: 1.07(1H, m), 1.19–1.32(2H, m), 1.41–1.50(2H, m), 1.56–1.81 (4H, m), 1.99–2.23(5H, m), 2.36(2H, t, J=7.2 Hz), 2.43(3H, s), 2.53 (1H, m), 3.05–3.19(4H, m), 3.83(1H, m), 5.31–5.44(2H, m), 6.00(1H, d, J=6.9 Hz), 6.23–6.56(2H, m), 6.75 and 7.34(each 1H, each d, each J=3.6 Hz). IR (CHCl3): 3510, 3446, 3429, 2669, 1709, 1641, 1543, 1506, 1458 cm−1. [α]D23+64.6±1.0°(c=1.014, MeOH) Anal. (C26H33NO3S2.0.1H2O) Calcd.(%): C, 65.96; H, 7.07; N, 2.96; S, 13.54. Found(%): C, 65.87; H, 7.03; N, 3.02; S, 13.50.
Compound Number I-150
1H-NMR(CDCl3) δ: 1.07(1H, m), 1.19–1.31(2H, m), 1.41–1.50(2H, m), 1.56–1.80(4H, m), 1.99–2.20(5H, m), 2.35(2H, t, J=7.5 Hz), 2.53(1H, m), 3.18(3H, s), 3.83(1H, m), 5.31–5.44(2H, m), 6.05(1H, d, J=7.2 Hz), 6.74 (1H, d, J=3.6 Hz), 6.79(1H, m), 6.91(1H, dd, J=3.6 and 5.4 Hz), 7.13(1H, dd, J=1.2 and 5.4 Hz), 7.34(1H, d, J=3.6 Hz). IR(CHCl3): 3516, 34446, 3429, 2669, 1709, 1641, 1543, 1506 cm−1. [α]D2430 66.1±1.0°(c=1.019, MeOH) Anal. (C25H31NO3S2) Calcd.(%): C, 65.61; H, 6.83; N, 3.06; S, 14.01. Found(%): C, 65.47; H, 6.89; N, 3.12; S, 13.82.
Compound Number I-151
1H-NMR(CDCl3) δ: 1.09(1H, m), 1.20–1.32(2H, m), 1.42–1.51(2H, m), 1.57–1.81(4H, m), 2.00–2.22(5H, m), 2.33(2H, t, J=7.5 Hz), 2.56(1H, m), 2.99–3.05(2H, m), 3.11–3.17(2H, m), 3.88(1H, m), 5.30–5.44(2H, m), 6.22 (1H, d, J=7.2 Hz), 6.74(1H, m), 6.89(1H, dd, J=3.3 and 5.1 Hz), 7.11(1H, dd, J=1.2 and 5.1 Hz), 7.23 and 7.67(each 2H, each d, each J=8.1 Hz). IR (CHCl3): 3516, 3448, 2665, 1709, 1651, 1523, 1496 cm−1. [α]D24+71.8±1.1°(c=1.009, MeOH) Anal. (C27H33NO3S) Calcd.(%): C, 71.81; H, 7.37; N, 3.10; S, 7.10. Found(%): C, 71.68; H, 7.40; N, 3.18; S, 6.96.
Compound Number I-152
1H-NMR(CDCl3) δ: 1.07(1H, m), 1.19–1.31(2H, m), 1.42–1.50(2H, m), 1.56–1.81(4H, m), 2.00–2.21(5H, m), 2.36(2H, t, J=7.2 Hz), 2.53(1H, m), 2.92–2.97(2H, m), 3.07–3.12(2H, m), 3.83(1H, m), 5.31–5.44(2H, m), 5.99 (1H, d, J=7.2 Hz), 6.68(1H, d, J=3.6 Hz), 6.92–7.00(2H, m), 7.08–7.15(2H, m), 7.32(1H, d, J=3.6 Hz). IR(CHCl3): 3516, 3446, 3429, 1741, 1709, 1641, 1543, 1510, 1458 cm−1. [α]D23+64.1±1.0°(c=1.012, MeOH) Anal. (C27H32FNO3S) Calcd.(%): C, 69.06; H, 6.87; N, 2.98; S, 6.83; F, 4.05. Found(%): C, 68.92; H, 6.90; N, 3.03; S, 6.81; F, 4.02.
Compound Number I-153
1H-NMR(CDCl3) δ: 1.05(1H, m), 1.19–1.29(2H, m), 1.41–1.46(2H, m), 1.56–1.78(4H, m), 2.00–2.19(5H, m), 2.29(6H, s), 2.34(2H, t, J=7.5 Hz), 2.51(1H, m), 3.81(1H, m), 4.05(2H, s), 5.29–5.42(2H, m), 5.96(1H, d, J=7.5 Hz), 6.77(1H, td, J=0.9 and 3.6 Hz), 6.85(2H, s), 6.88(1H, s), 7.37 (1H, d, J=3.6 Hz). IR(CHCl3): 3516, 3446, 3427, 1739, 1709, 1641, 1606, 1543, 1506, 1458 cm−1. [α]D23+64.6±1.0°(c=1.004, MeOH) Anal. (C28H35NO3S.0.1H2O) Calcd.(%): C, 71.94; H, 7.59; N, 3.00; S, 6.86. Found(%): C, 71.87; H, 7.52; N, 3.31; S, 6.94.
Compound Number I-154
1H-NMR(CDCl3) δ: 1.05(1H, m), 1.18–1.29(2H, m), 1.41–1.46(2H, m), 1.56–1.78 (4H, m), 2.00–2.19(5H, m), 2.34(2H, t, J=7.5 Hz), 2.51(1H, m), 3.81(1H, m), 4.10(2H, s), 5.29–5.42(2H, m), 5.98(1H, d, J=7.2 Hz), 6.75 (1H, td, J=0.9 and 3.9 Hz), 6.97–7.03(2H, m), 7.17–7.22(2H, m), 7.36(1H, d, J=3.9 Hz). IR(CHCl3): 3512, 3446, 3427, 1741, 1709, 1643, 1543, 1508 cm−1. [α]D24+66.1±1.1°(c=1.008, MeOH) Anal. (C26H30FNO3S) Calcd.(%): C, 68.54; H, 6.64; N, 3.07; S, 7.04; F, 4.17. Found(%): C, 68.41; H, 6.70; N, 3.19; S, 6.90; F,3.98.
Compound Number I-155
1H-NMR(CDCl3) δ: 1.05(1H, m), 1.19–1.29(2H, m), 1.42–1.46(2H, m), 1.58–1.78(4H, m), 2.00–2.17(5H, m), 2.35(2H, t, J=7.5 Hz), 2.52(1H, m), 3.81 (1H, m), 4.19(2H, s), 5.29–5.42(2H, m), 5.97(1H, d, J=7.8 Hz), 6.75 (1H, td, J=0.9 and 3.6 Hz), 7.34–7.37(3H, m), 7.56–7.59(2H, m). IR (CHCl3): 3512, 3444, 3427, 1741, 1709, 1643, 1543, 1506, 1325, 1167, 1130, 1066 cm−1. [α]D24+60.3±1.0°(c=1.001, MeOH) Anal. (C27H30F3NO3S) Calcd.(%): C, 64.14; H, 5.98; N, 2.77; S, 6.34; F, 11.27. Found(%): C, 64.16; H, 6.04; N, 3.02; S, 6.19; F, 11.17.
Compound Number I-156
mp.66–70° C.; 1H-NMR(CDCl3) δ: 1.11(1H, m), 1.22–1.30(2H, m), 1.43–1.50(2H, m), 1.60–1.78(4H, m), 2.03–2.22(5H, m), 2.36(2H, t, J=7.5 Hz), 2.54(1H, m), 3.87(1H, m), 4.08(2H, s), 5.31–5.45(2H, m), 6.21 (1H, d, J=7.2 Hz), 7.18–7.32(6H, m), 7.60(1H, d, J=0.9 Hz), 7.70(1H, d, J=0.6 Hz), 7,74 (1H, d, J=8.1 Hz). IR(KBr): 3338, 1707, 1616, 1556, 1537 cm−1. [α]D23+97.2±1.4°(c=1.016, MeOH) Anal. (C30H33NO3S.0.3H2O) Calcd.(%): C, 73.08; H, 6.87; N, 2.84; S, 6.50. Found(%): C, 73.19; H, 7.11; N, 2.98; S, 6.32.
Compound Number I-157
1H-NMR(CDCl3) δ: 1.03(1H, m), 1.17–1.29(2H, m), 1.38–1.47(2H, m), 1.55–1.76(4H, m), 1.97–2.18(5H, m), 2.33(2H, t, J=7.5 Hz), 2.50(1H, m), 3.80 (1H, m), 4.29(2H, s), 5.28–5.40(2H, m), 5.94(1H, d, J=7.5 Hz), 6.81 (1H, d, J=3.9 Hz), 7.32–7.39(2H, m), 7.42–7.50(2H, m), 7.69(1H, s), 7.77–7.83 (3H, m). IR(CHCl3): 3516, 3446, 3427, 2665, 1739, 1709, 1643, 1543, 1506, 1458 cm−1. [α]D23+62.8±1.0°(c=1.005, MeOH) Anal. (C30H12NO3S.0.2H2O) Calcd.(%): C, 73.35; H, 6.85; N, 2.85; S, 6.53. Found(%): C, 73.36; H, 6.84; N, 3.19; S, 6.55.
Compound Number I-158
1H-NMR(CDCl3) δ: 1.07(1H, m), 1.20–1.32(2H, m), 1.42–1.50(2H, m), 1.57–1.84 (4H, m), 2.00–2.23(5H, m), 2.36(2H, t, J=7.5 Hz), 2.53(1H, m), 2.95–3.00(2H, m), 3.06–3.12(2H, m), 3.82(1H, m),3.83(3H, s), 5.30–5.43 (2H, m), 5.95(1H, d, J=6.9 Hz), 6.73(1H, d, J=3.6 Hz), 6.84–6.89(2H, m), 7.09 (1H, dd, J=1.5 and 7.5 Hz), 7.20(1H, dt, J=1.5 and 7.5 Hz), 7.34(1H, d, J=3.6 Hz). IR(Nujol): 3367, 3221, 3186, 3091, 3055, 2654, 1711, 1631, 1566, 1541, 1321 cm−1. [α]D25+61.3±1.020 (c=1.003, MeOH) Anal. (C28H35NO4S) Calcd.(%): C, 69.82; H, 7.32; N, 2.91; S, 6.66. Found(%): C, 69.93; H, 7.48; N, 3.09; S, 6.54.
Compound Number I-159
1H-NMR(CDCl3) δ: 1.07(1H, m), 1.18–1.30(2H, m), 1.40–1.50(2H, m), 1.54–1.78(4H, m), 1.98–2.21(5H, m), 2.33(2H, t, J=7.2 Hz), 2.53(1H, m), 2.94–3.03 (2H, m), 3.06–3.15(2H, m), 3.83(1H, m), 5.29–5.43(2H, m), 6.12 (1H, d, J=7.5 Hz), 6.72(1H, d, J=3.6 Hz), 6.77–6.83(2H, m), 7.04–7.08(2H, m), 7.36(1H, d, J=3.6 Hz). IR(CHCl3): 3599, 3444, 3425, 3195, 1709, 1635, 1543, 1508, 1456 cm−1. [α]D25+64.8±1.0°(c=1.006, MeOH) Anal. (C27H33NO4S.0.2H2O) Calcd.(%): C, 68.82; H, 7.14; N, 2.97; S, 6.80. Found(%): C, 68.81; H, 7.10; N, 3.03; S, 6.88.
Compound Number I-160
mp.139–141° C.; 1H-NMR(CDCl3) δ: 1.12(1H, m), 1.25–1.31(2H, m), 1.45–1.51(2H, m), 1.60–1.78(4H, m), 2.02–2.22(5H, m), 2.35(2H, t, J=7.5 Hz), 2.57 (1H, m), 3.87(1H, m), 4.09(2H, s), 5.31–5.45(2H, m), 6.22 (1H, d, J=7.2 Hz), 7.19–7.33(6H, m), 7.63(1H, m), 7.71(1H, d, J=8.7 Hz), 7,73(1H, s). IR (KBr): 3338, 1705, 1616, 1560, 1537 cm−1. [α]D25+92.1±1.3°(c=1.006, MeOH) Anal. (C30H33NO3S) Calcd.(%): C, 73.89; H, 6.82; N, 2.87; S, 6.58. Found(%): C, 73.69; H, 6.75; N, 2.91; S, 6.58.
Compound Number I-161
1H-NMR(CDCl3) δ: 1.12(1H, m), 1.25–1.31(2H, m), 1.47–1.51(2H, m), 1.60–1.76(4H, m), 2.03–2.20(5H, m), 2.36(2H, t, J=7.2 Hz), 2.57(1H, m), 3.87 (1H, m), 4.08(2H, s), 5.31–5.45(2H, m), 6.22(1H, d, J=7.5 Hz), 6.90 (1H, dd, J=1.2 and 4.8 Hz), 6.93(1H, m), 7.25–7.29(2H, m), 7.61 and 7.71 (each 1H, each s), 7.75(1H, d, J=8.4 Hz). IR(CHCl3): 3512, 3444, 3423, 2671, 1709, 1649, 1531, 1502 cm−1. [α]D25+96.1±1.4°(c=1.005, MeOH) Anal. (C28H31NO3S2) Calcd.(%): C, 68.12; H, 6.33; N, 2.84; S, 12.99. Found(%): C, 67.89; H, 6.32; N, 2.88; S, 12.88.
Compound Number I-162
1H-NMR(CDCl3) δ: 1.12(1H, m), 1.24–1.31(2H, m), 1.45–1.51(2H, m), 1.60–1.78(4H, m), 2.03–2.22(5H, m), 2.36(2H, t, J=7.2 Hz), 2.57(1H, m), 3.87(1H, m), 4.25(2H, s), 5.31–5.45(2H, m), 6.25(1H, d, J=7.2 Hz), 6.81 (1H, m), 6.93(1H, dd, J=3.3 and 5.4 Hz), 7.15(1H, dd, J=1.5 and 5.4 Hz), 7.31 (1H, dd, J=1.5 and 8.1 Hz), 7.65 and 7.71(each 1H, each s), 7.76(1H, d, J=8.1 Hz). IR(CHCl3): 3516, 3444, 3423, 1741, 1709, 1649, 1531, 1502 cm−1. [α]D25+98.5±1.4°(c=1.007, MeOH) Anal. (C28H31NO3S2.0.1H2O) Calcd.(%): C, 67.87; H, 6.35; N, 2.83; S, 12.94. Found(%): C, 67.83; H, 6.29; N, 3.00; S, 12.99.
Compound Number I-163
mp.114–115° C.; 1NMR(CDCl3) δ: 1.09(1H, m), 1.20–1.30(2H, m), 1.40–1.49 (2H, m), 1.55–1.77(4H, m), 1.99–2.19(5H, m), 2.34(2H, t, J=7.2 Hz), 2.53(1H, m, 3.83(1H, m), 4.12(2H, s), 5.30–5.43(2H, m), 6.14 (1H, d, J=7.5 Hz), 6.81 and 6.93(each 1H, each m), 7.14–7.17(2H, m), 7.37(1H, d, J=1.8 Hz). IR (CHCl3): 3516, 3444, 3428, 2671, 1709, 1645, 1550, 1508, 1435 cm−1. [α]D25+71.6±1.1°(c=1.002, MeOH) Anal. (C24H29NO3S2.0.1H2O) Calcd.(%): C, 64.72; H, 6.61; N, 3.14; S, 14.40. Found(%): C, 64.50; H, 6.54; N, 3.24; S, 14.45.
Compound Number I-164
1H-NMR(CDCl3) δ: 1.08(1H, m), 1.20–1.31(2H, m), 1.41–1.49(2H, m), 1.56–1.77(4H, m), 1.99–2.19(5H, m), 2.34(2H, t, J=7.211 Hz), 2.53(1H, m), 3.83(1H, 3.94(2H, s), 5.30–5.43(2H, m), 6.08(1H, d, J=6.9 Hz), 6.91 and 6.95 (each 1H, each m), 7.08(1H, d, J=1.5 Hz), 7.27(1H, m), 7.34(1H, d, J=1.5 Hz). IR(CHCl3): 3512. 3444, 3429, 1739, 1709, 1644, 1550, 1508 cm−1. [α]D25+69.7±1.1°(c=1.000, MeOH) Anal. (C24H29NO3S2.0.2H2O) Calcd.(%): C, 64.45; H, 6.63; N, 3.13; S, 14.34. Found(%): C, 64.37; H, 6.49; N, 3.16; S, 14.41.
Compound Number I-165
1H-NMR(CDCl3) δ: 1.08(1H, m), 1.19–1.31(2H, m), 1.41–1.51(2H, m), 1.55–1.74(4H, m), 1.99–2.16(5H, m), 2.34(2H, t, J=7.2 Hz), 2.53(1H, m), 3.73(2H, s), 3.83(1H, m), 5.30–5.42(2H, m), 6.15(1H, d, J=6.6 Hz), 6.25, 7.10 and 7.24(each 1H, each s), 7.35–7.38(2H, m). IR(CHCl3): 3510, 3444, 3429, 2669, 1709, 1645, 1550, 1508 cm−1. [α]D25+71.635 1.1°(c=1.008, MeOH) Anal. (C24H29NO4S.0.2H2O) Calcd.(%): C, 66.85; H, 6.78; N, 3.25; S, 7.44. Found(%): C, 66.94; H, 6.81; N, 3.26; S, 7.38.
Compound Number I-166
1H-NMR(CDCl3) δ: 1.02(1H, m), 1.15–1.27(2H, m), 1.36–1.45(2H, m), 1.53–1.76(4H, m), 1.96–2.14(5H, m), 2.32(2H, t, J=7.2 Hz), 2.49(1H, m), 3.78 (1H, m), 4.58(2H, s), 5.27–5.39(2H, m), 5.92(1H, d, J=7.2 Hz), 6.73 and 7.32(each 1H, each d, each J=3.9 Hz), 7.37–7.51(4H, m), 7.80(1H, d, J=7.5 Hz), 7.87 and 7.97(each 1H, each m). IR(CHCl3): 3516, 3446, 3427, 2669, 1739, 1709, 1641, 1543, 1508, 1458 cm−1. [α]D25.5+62.8±1.0°(c=1.012, MeOH) Anal. (C30H33NO3S.0.1H2O) Calcd.(%): C, 73.62; H, 6.84; N, 2.86; S, 6.55. Found(%): C, 73.35; H, 6.54; N, 3.06; S, 6.51.
Compound Number I-167
mp.129–130° C.; 1H-NMR(CDCl3) δ: 1.04(1H, m), 1.16–1.28(2H, m), 1.38–1.46(2H, m), 1.54–1.73(4H, m), 1.97–2.15(5H, m), 2.31(2H, t, J=7.2 Hz), 2.51(1H, m), 3.81(1H, m), 4.37(2H, s), 5.28–5.41(2H, m), 6.04 (1H, d, J=7.5 Hz), 6.97(1H, s), 7.30–7.50(5H, m), 7.77(1H, d, J=8.1 Hz), 7.86 and 7.94(each 1H, each m). IR(CHCl3): 3514, 3444, 3427, 1739, 1709, 1645, 1549, 1508 cm−1. [α]D24+59.4±1.0°(c=1.011, MeOH) Anal. (C30H33NO3S) Calcd.(%): C, 73.89; H, 6.82; N, 2.87; S, 6.58. Found(%): C, 73.85; H, 6.90; N, 2.85; S, 6.81.
Compound Number I-168
1H-NMR(CDCl3) δ: 1.10(1H, m), 1.21–1.33(2H, m), 1.47–1.52(2H, m), 1.59–1.80 (4H, m), 2.04–2.27(5H, m), 2.36(2H, t, J=7.5 Hz), 2.61(1H, m), 3.93(1H, m), 4.42(2H, s), 5.33–5.47(2H, m), 6.13(1H, d, J=7.5 Hz), 6.88 (1H, m), 6.92(1H, m), 7.15(1H, dd, J=1.2 and 5.1 Hz), 7.28(1H, d, J=7.5 Hz), 7.43 (1H, d, J=8.1 Hz), 7.84(1H, s), 8.20(1H, d, J=8.1 Hz). IR(CHCl3): 3512, 3438, 1709, 1651, 1518, 1495 cm−1. [α]D25+61.6±1.0°(c=1.003, MeOH) Anal. (C28H31NO3S2) Calcd.(%): C, 68.12; H, 6.33; N, 2.84; S, 12.99. Found(%): C, 67.83; H, 6.28; N, 2.96; S, 12.76.
Compound Number I-169
1H-NMR(CDCl3) δ: 1.10(1H, m), 1.22–1.32(2H, m), 1.46–1.51(2H, m), 1.58–1.76(4H, m), 2.02–2.24(5H, m), 2.35(2H, t, J=7.2 Hz), 2.60(1H, m), 3.92 (1H, m), 4.23(2H, s), 5.32–5.47(2H, m), 6.18(1H, d, J=8.1 Hz), 6.92 (1H, dd, J=1.2 and 4.8 Hz), 7.01(1H, m), 7.20–7.25(2H, m), 7.41(1H, t, J=8.1 Hz), 7.84(1H, s), 8.18(1H, d, J=7.5 Hz). IR (CHCl3): 3510, 3438, 2667, 1709, 1651, 1518, 1495 cm−1. [α]D25+61.3±1.0°(c=1.006, MeOH) Anal. (C28H31NO3S2) Calcd.(%): C, 68.12; H, 6.33; N, 2.84; S, 12.99. Found(%): C, 67.94; H, 6.30; N, 2.97; S, 12.87.
Compound Number I-170
1H-NMR(CDCl3) δ: 1.10(1H, m), 1.21–1.33(2H, m), 1.47–1.52(2H, m), 1.59–1.79(4H, m), 2.03–2.27(5H, m), 2.36(2H, t, J=7.5 Hz), 2.61(1H, m), 3.93 (1H, m), 4.03(2H, s), 5.33–5.48(2H, m), 6.15(1H, d, J=7.2 Hz), 7.23 (1H, d, J=7.2 Hz), 7.29(1H, m), 7.35(1H, t, J=1.5 Hz), 7.42(1H, t, J=7.8 Hz), 7.85 (1H, s), 8.18(1H, (c, J=7.8 Hz). IR (CHCl3): 3518, 3438, 2663, 1739, 1709, 1651, 1518, 1496 cm−1. [α]D25+60.3±1.0®(c=1.002, MeOH) Anal. (C28H31NO4S.0.1H2O) Calcd.(%): C, 70.15; H, 6.56; N, 2.92; S, 6.69. Found(%): C, 70.03; H, 6.49; N, 2.92; S, 6.69.
Compound Number I-171
1H-NMR(CDCl3) δ: 1.05(1H, m), 1.18–1.28(2H, m), 1.41–1.46(2H, m), 1.56–1.79(4H, m), 2.00–2.15(5H, m), 2.34(2H, t, J=7.2 Hz), 2.45(3H, s), 2.50(1H, m), 3.80(1H, m), 4.25(2H, s), 5.29–5.42(2H, m), 5,95(1H, d, J=7.5 Hz), 6.78(1H, d, J=3.6 Hz), 7.11–7.27(4H, m), 7.36(1H, d, J=3.6 Hz). IR(CHCl3): 3512, 3446, 3427, 2669, 1739, 1709, 1643, 1543, 1506 cm−1. [α]D23.5+62.8±1.0°(c=1.005, MeOH) Anal. (C27H33NO3S2) Calcd.(%): C, 67.05; H, 6.88; N, 2.90; S, 13.26. Found(%): C, 66.94; H, 7.05; N, 3.00; S, 13.14.
Compound Number I-172
1H-NMR(CDCl3) δ: 1.07(1H, m), 1.19–1.29(2H, m), 1.41–1.46(2H, m), 1.57–1.78(4H, m), 2.01–2.19(5H, m), 2.34(2H, t, J=7.5 Hz), 2.51(1H, m), 2.90(3H, s), 3.80(1H, m), 4.68(2H, s), 5.29–5.43(2H, m), 6.02(1H, d, J=7.5 Hz), 6.84(1H, td, J=0.9 and 3.9 Hz), 7.37(1H,d, J=3.9 Hz), 7.42–7.51 (2H, m), 7.62(1H, dt, J=1.5 and 7.5 Hz), 8.08(1H, dd, J=1,5 and 7.5 Hz). IR(CHCl3): 3518, 3444, 3427, 1709, 1643, 1543, 1508, 1311, 1153 cm−1. [α]D23.5+59.3±1.0°(c=1.007, MeOH) Anal. (C27H33NO5S2.0.2H2O) Calcd.(%): C, 62.45; H, 6.48; N, 2.70; S, 12.35. Found(%): C, 62.47; H, 6.60; N, 2.73; S, 12.36.
Compound Number I-173
1H-NMR(CDCl3) δ: 1.13(1H, m), 1.23–1.36(2H, m), 1.43–1.80(6H, m), 2.03–2.24(5H, m), 2.36(2H, t, J=7.2 Hz), 2.60(1H, m), 3.91(1H, m), 3.93 (2H, s), 5.31–5.46(2H, m), 6.31(1H, d, J=7.2 Hz), 7.32–7.42(2H, m), 7.57 (1H, d, J=6.9 Hz), 7.73–7.82(3H, m), 7.94(1H, s). IR(CHCl3): 3516, 3446, 2665, 1709, 1649, 1616, 1514, 1481, 1468 cm−1. [α]D24+100.7±1.4°(c=1.008, MeOH) Anal. (C28H31NO3.0.2H2O) Calcd.(%): C, 77.64; H, 7.31; N, 3.23. Found(%): C, 77.64; H, 7.57; N, 3.29.
Compound Number I-174
1H-NMR(CDCl3) δ: 1.06(1H, m), 1.19–1.28(2H, m), 1.40–1.47(2H, m), 1.57–1.78(4H, m), 1.99–2.18(5H, m), 2.35(2H, t, J=7.4 Hz), 2.51(1H, s), 3.21(2H, t, J=8.7 Hz), 3.81(1H, m), 4.01(2H, s), 4.58(2H, t, J=8.7 Hz), 5.29–5.42 (2H, m), 6.02(1H, d, J=7.5 Hz), 6.80(1H, d, J=3.9 Hz), 7.06(1H, d, J=1.8 Hz), 7.18(1H, d, J=1.8 Hz), 7.36(1H, d, J=3.9 Hz). IR (CHCl3): 3512, 3446, 3427, 2669, 1709, 1641, 1543, 1506, 1477, 1460, 1173 cm−1. [α]D25+53.8±0.9°(c=1.007, MeOH) Anal. (C28H32BrNO4S.0.1H2O) Calcd.(%): C, 60.02; H, 5.79; Br, 14.26; N, 2.50; S, 5.72. Found(%): C, 59.87; H, 5.68; Br, 14.13; N, 2.59; S, 5.71.
Compound Number I-175
1H-NMR(CDCl3) δ: 1.12(1H, m), 1.23–1.31(2H, m), 1.44–1.51(2H, m), 1.60–1.78(4H, m), 2.03–2.28(5H, m), 2.36(2H, t, J=7.4 Hz), 2.56(1H, s), 3.87(1H, m),4.21(2H, s), 5.31–5.45(2H, m), 6.21(1H, d, J=7.2 Hz), 7.18–7.37(7H, m), 7.70(1H, d, J=7.2 Hz), 7.80(1H, s). IR(CHCl3): 3514, 3444, 3423, 2667, 1709, 1649, 1537, 1502, 1454 cm−1. [α]D25+78.2±1.2°(c=1.002, MeOH) Anal. (C30H33BrNO3S.0.1H2O) Calcd.(%): C, 73.62; H, 6.84; N, 2.86; S, 6.55. Found(%): C, 73.49; H, 6.88; N, 2.89; S, 6.57.
Compound Number I-176
1H-NMR(CDCl3) δ: 1.12(1H, m), 1.23–1.32(2H, m), 1.44–1.51(2H, m), 1.61–1.78(4H, m), 2.03–2.28(5H, m), 2.36(2H, t, J=7.4 Hz), 2.57(1H, s), 3.88 (1H, m),4.21(2H, s), 5.31–5.45(2H, m), 6.22(1H, d, J=7.2 Hz), 6.94 (1H, dd, J=1.5 and 4.8 Hz), 7.04(1H, m), 7.21–7.25(2H, m), 7.35(1H, dd, J=7.2 and 7.8 Hz), 7.71(1H, d, J=7.2 Hz), 7.80(1H, s). IR(CHCl3): 3512, 3444, 3423, 2669, 1709, 1647, 1539, 1504 cm−1. [α]D25+77.1±1.2°(c=1.002, MeOH) Anal. (C28H31NO3S2.0.2H2O) Calcd.(%): C, 67.63; H, 6.36; N, 2.82; S, 12.90. Found(%): C, 67.57; H, 6.34; N, 2.97; S, 12.98.
Compound Number I-177
1H-NMR(CDCl3) δ: 1.12(1H, m), 1.25–1.32(2H, m), 1.44–1.51(2H, m), 1.60–1.78(4H, m), 2.03–2.28(5H, m), 2.31(3H, s), 2.36(2H, t, J=7.2 Hz), 2.56 (1H, s),3.87(1H, m),4.17(2H, s), 5.31–5.45(2H, m), 6.22(1H, d, J=7.2 Hz), 7.09 and 7.15(each 2H, each d, J=8.1 Hz), 7.19(1H, d, J=7.2 Hz), 7.34(1H, dd, J=7.2 and 7.8 Hz), 7.69(1H, d, J=7.8 Hz), 7.79(1H, s). IR (CHCl3): 3510, 3444, 3423, 2669, 1709, 1647, 1537, 1504 cm−1. [α]D25+75.9±1.2°(c=1.004, MeOH) Anal. (C31H35NO3S) Calcd.(%): C, 74.22; H, 7.03; N, 2.79; S, 6.39. Found(%): C, 73.93; H, 7.13; N, 2.91; S, 6.38.
Compound Number I-178
1H-NMR(CDCl3) δ: 1.13(1H, m), 1.24–1.31(2H, m), 1.44–1.51(2H, m), 1.60–1.77(4H, m), 2.03–2.22(5H, m), 2.36(2H, t, J=7.2 Hz), 2.56(1H, s), 3.88(1H, m),4.39(2H, s), 5.31–5.45(2H, m), 6.26(1H, d, J=7.2 Hz), 6.90–6.94(2H, m), 7.15(1H, dd, J=1.5 and 5.1 Hz), 7.27(1H, d, J=7.5 Hz), 7.36 (1H, t, J=7.5 Hz), 7.71(1H, d, J=7.5 Hz), 7.80(1H, s). IR(CHCl3): 3510, 3444, 3423, 2667, 1709, 1649, 1537, 1504 cm−1. [α]D25+76.6±1.2°(c=1.003, MeOH) Anal. (C23H31NO3S2) Calcd.(%): C, 68.12; H, 6.33; N, 2.84; S, 12.99. Found(%): C, 67.83; H, 6.45; N, 3.04; S, 13.03.
Compound Number I-179
1H-NMR(CDCl3) δ: 1.04(1H, m), 1.18–1.28(2H, m), 1.39–1.47(2H, m), 1.56–1.78(4H, m), 1.98–2.18(5H, m), 2.34(2H, t, J=7.2 Hz), 2.50(1H, m), 3.8(1H, m), 4.08(2H, s), 5.29–5.41(2H, m), 5.95(1H, d, J=7.2 Hz), 6.53 (1H, d, J=3.6 Hz), 7.23–7.41(10H, m). IR(CHCl3): 3516, 3446, 3427, 1741, 1709, 1641, 1543, 1506, 1479, 1456 cm−1. [α]D24.5+57.6±1.0°(c=1.007, MeOH) Anal. (C32H35NO3S.0.2H2O) Calcd.(%): C, 74.30; H, 6.90; N, 2.71; S, 6.20. Found(%): C, 74.24; H, 6.89; N, 2.88; S, 6.47.
Compound Number I-180
1H-NMR(CDCl3) δ: 1.17(1H, m), 1.24–1.35(2H, m), 1.48–1.55(2H, m), 1.61–1.79(4H, m), 2.06–2.26(5H, m), 2.37(2H, t, J=7.2 Hz), 2.61(1H, m), 3.90 (1H, m), 5.33–5.48(2H, m), 6.44(1H, d, J=7.2 Hz), 7.31(1H, m), 7.47–7.65 (5H, m), 7.90(1H, s). IR(CHCl3): 3516, 3440, 1714, 1655, 1604, 1514, 1473, 1446 cm−1. [α]D25+92.1±1.3°(c=1.001, MeOH) Anal. (C28H29NO4.0.3H2O) Calcd.(%): C, 74.91; H, 6.65; N, 3.12. Found(%): C, 74.81; H, 6.51; N, 3.29.
Compound Number I-181
1H-NMR(CDCl3) δ: 1.04(1H, m), 1.18–1.28(2H, m), 1.41–1.46(2H, m), 1.55–1.77(4H, m), 1.99–2.16(5H, m), 2.34(2H, t, J=7.4 Hz), 2.51(1H, s), 3.79(3H, s),3.80(1H, m), 4.08(2H, s), 5.29–5.42(2H, m), 5.97(1H, d, J=7.2 Hz), 6.75(1H, d, J=3.9 Hz), 6.85 and 7.15(each 2H, each d, J=8.4 Hz), 7.37(1H, d, J=3.9 Hz). IR(CHCl3): 3518, 3446, 3427, 1741, 1709, 1641, 1612, 1543, 1510, 1458 cm−1. [α]D25+63.6±1.0°(c=1.000, MeOH) Anal. (C27H33NO4S.0.2H2O) Calcd.(%): C, 68.88; H, 7.14; N, 2.97; S, 6.80. Found(%): C, 68.92; H, 7.02; N, 3.12; S, 6.96.
Compound Number I-182
1H-NMR(CDCl3) δ: 1.04(1H, m), 1.18–1.27(2H, m), 1.40–1.45(2H, m), 1.59–1.78(4H, m), 1.99–2.14(5H, m), 2.34(2H, t, J=7.4 Hz), 2.51(1H, s), 3.80 (1H, m),4.37(2H, s), 5.29–5.41(2H, m), 5.97(1H, d, J=7.2 Hz), 6.82 (1H, d, J=3.6 Hz), 7.20(1H, s), 7.34–7.37(3H, m), 7.69(1H, m), 7.86(1H, m). IR (CHCl3): 3512, 3444 3427, 2669, 1709, 1643, 1543, 1508, 1458, 1431 cm−1. [α]D25+60.7±1.0°(c=1.008, MeOH) Anal. (C28H31NO3S2.0.3H2O) Calcd.(%): C, 67.39; H, 6.38; N, 2.81; S, 12.85. Found(%): C, 67.44; H, 6.30; N, 3.15; S, 12.81.
Compound Number I-183
1H-NMR(CDCl3) δ: 1.04(1H, m), 1.18–1.26(2H, m), 1.39–44(2H, m), 1.54–1.75(4H, m), 1.99–2.15(5H, m), 2.32(2H, t, J=7.4 Hz), 2.50(1H, s), 3.80 (1H, m),4.12(2H, s), 5.28–5.42(2H, m), 6.05(1H, d, J=7.5 Hz), 6.78 (1H, d, J=3.9 Hz), 6.82–6.87(2H, m), 7.07–7.14(2H, m), 7.35(1H, d, J=3.9 Hz). IR (CHCl3): 3508, 3444, 3197, 1707, 1635, 1543, 1508, 1456 cm−1. [α]D25+64.7±1.0°((c=1.004, MeOH) Anal. (C26H31NO4S.0.2H2O) Calcd.(%): C, 68.30; H, 6.92; N, 3.06; S, 7.01. Found(%): C, 68.21; H, 6.96; N, 3.09; S, 6.93.
Compound Number I-184
1H-NMR(CDCl3) δ: 1.15(1H, m), 1.26–1.35(2H, m), 1.47–1.56(2H, m), 1.62–1.82(4H, m), 2.05–2.26(5H, m), 2.37(2H, t, J=7.2 Hz), 2.61(1H, m), 3.92(1H, m), 3.93(2H, s), 5.32–5.47(2H, m), 6.34(1H, d, J=6.9 Hz), 7.31–7.43 (2H, m), 7.53–7.59(2H, m), 7.67(1H, m), 7.5(1H, d, J=6.9 Hz), 8.17 (1H, s). IR(CHCl3): 3514, 3444, 2667, 1709, 1651, 1572, 1516, 1481, 1452 cm−1. [α]D24+81.2±1.2°(c=1.002, MeOH) Anal. (C28H31NO3.0.2H2O) Calcd.(%): C, 77.64; H, 7.31; N, 3.23. Found(%): C, 77.59; H, 7.15; N, 3.44.
Compound Number I-185
1H-NMR(CDCl3) δ: 1.06(1H, m), 1.21–1.28(2H, m), 1.41–1.46(2H, m), 1.58–1.78(4H, m), 2.00–2.16(5H, m), 2.35(2H, t, J=7.2 Hz), 2.51(1H, m), 3.79 (1H, m), 4.16(2H, s), 5.31–5.40(2H, m), 5.93(1H, d, J=7.8 Hz), 6.80 (1H, d, J=3.6 Hz), 7.03–7.12(2H, m), 7.20–7.28(2H, m), 7.35(1H, d, J=3.6 Hz). IR (CHCl3): 3518, 3444, 3427, 1741, 1709, 1643, 1543, 1506, 1456 cm−1. [α]D24+56.2±0.9°(c=1.03, CHCl3) Anal. (C26H30FNO3S.0.4H2O) Calcd.(%): C, 67.48; H, 6.71; N, 3.03; S, 6.93; F, 4.11. Found(%): C, 67.49; H, 6.72; N, 3.09; S, 6.93; F, 4.11.
Compound Number I-186
1H-NMR(CDCl3) δ: 1.04(1H, m), 1.19–1.29(2H, m), 1.41–1.46(2H, m), 1.58–1.82(4H, m), 2.00–2.16(5H, m), 2.34(2H, t, J=7.4 Hz), 2.51(1H, s), 3.80(1H, m),4.17(2H, s), 5.08(2H, s), 5.28–5.41(2H, m), 5.90(1H, d, J=7.5 Hz), 6.76(1H, d, J=3.9 Hz), 6.90–6.95(2H, m), 7.18–7.25(2H, m), 7.31–7.38 (6H, m). IR(CHCl3): 3516, 3446, 3427, 1741, 1709, 1641, 1601, 1543, 1502, 1454 cm−1. [α]D24+53.9±0.9°(c=1.005, MeOH) Anal. (C33H37NO4S) Calcd.(%): C, 72.90; H, 6.86; N, 2.58; S, 5.90. Found(%): C, 72.64; H, 6.92; N, 2.52; S, 5.74.
Compound Number I-187
1H-NMR(CDCl3) δ: 1.04(1H, m), 1.18–1.28(2H, m), 1.41–1.46(2H, m), 1.57–1.78(4H, m), 1.99–2.15(5H, m), 2.34(2H, t, J=7.4 Hz), 2.51(1H, s), 3.80 (1H, m),4.16(2H, s), 4.54–4.57(2H, m), 5.24–5.41(4H, m), 5.94(1H, d, J=7.5 Hz), 6.04(1H, m), 6.79(1H, d, J=3.9 Hz), 6.85–6.93(2H, m), 7.15–7.24 (2H, m), 7.34(1H, d, J=3.9 Hz). IR(CHCl3): 3516, 3446, 3427, 1739, 1709, 1641, 1543, 1506, 1477 cm−1. [α]D24+59.0±1.0°(c=1.007, MeOH) Anal. (C29H35NO4S.0.2H2O) Calcd.(%): C, 70.05; H, 7.18; N, 2.82; S, 6.45. Found(%): C, 69.97; H, 7.16; N, 2.80; S, 6.52.
Compound Number I-188
mp.84–85° C.; 1-NMR(CDCl3) δ: 1.04(1H, m), 1.18–1.29(2H, m), 1.41–1.46 (2H, m), 1.56–1.81(4H, m), 2.00–2.17(5H, m), 2.35(2H, t, J=7.2 Hz), 2.51 (1H, s), 3.80(1H, m),4.07(2H, s), 5.05(2H, s), 5.29–5.42(2H, m), 5.93 (1H, d, J=7.5 Hz), 6.75(1H, d, J=3.9 Hz), 6.92 and 7.15(each 2H, each d, J=8.7 Hz), 7.31–7.44(6H, m). IR(CHCl3): 3521, 3446, 3427, 1741, 1709, 1643, 1612, 1543, 1510, 1456 cm−1. [α]D24+56.1±1.0°(c=1.002, MeOH) Anal. (C33H37NO4S) Calcd.(%): C, 72.90; H, 6.86; N, 2.58; S, 5.90. Found(%): C, 72.78; H, 6.88; N, 2.74; S, 5.84.
Compound Number I-189
1H-NMR(CDCl3) δ: 1.04(1H, m), 1.19–1.29(2H, m), 1.41–1.46(2H, m), 1.56–1.79(4H, m), 2.00–2.15(5H, m), 2.35(2H, t, J=7.2 Hz), 2.51(1H, s), 3.80 (1H, m),4.07(2H, s), 4.51–4.53(2H, m), 5.26–5.44(4H, m), 5.94(1H, d, J=7.5 Hz), 6.05(1H, m), 6.76(1H, d, J=3.9 Hz), 6.87 and 7.14(each 2H, each d, J=8.7 Hz), 7.36(1H, d, J=3.9 Hz). IR(CHCl3): 3512, 3446, 3427, 1741, 1709, 1643, 1612, 1543, 1508, 1458 cm−1. [α]D24+61.6±1.0°(c=1.004, MeOH) Anal. (C29H35NO4S.0.4H2O) Calcd.(%): C, 69.54; H, 7.20; N, 2.78; S, 6.40. Found(%): C, 69.47; H, 7.22; N, 2.84; S, 6.51.
Compound Number I-190
1H-NMR(CDCl3) δ: 1.05(1H, m), 1.18–1.32(2H, m), 1.39–1.48(2H, m), 1.54–1.80(4H, m), 1.98–2.20(5H, m), 2.34(2H, t, J=7.2 Hz), 2.51(1H, m), 3.81(1H, m), 4.04(2H, s), 5.29–5.42(2H, m), 5.93(1H, d, J=7.5 Hz), 6.68–6.78(2H, m), 7.36(1H, d, J=3.6 Hz). IR(CHCl3): 3517, 3446, 3427, 1741, 1709, 1643, 1543, 1504, 1489, 1444, 1250, 1041 cm−1. [α]D24+59.4±1.0°(c=1.0111, MeOH) Anal. (C27H31NO5S) Calcd.(%): C, 67.34; H, 6.49; N, 2.91; S, 6.66. Found(%): C, 67.27; H, 6.45; N, 3.04; S, 6.63.
Compound Number I-191
1H-NMR(CDCl3) δ: 1.06(1H, m), 1.18–1.32(2H, m), 1.39–1.48(2H, m), 1.54–1.80(4H, m), 1.98–2.20(5H, m), 2.34(2H, t, J=7.5 Hz), 2.51(1H, m), 3.81 (1H, m), 4.12(2H, s), 5.30–5.42(2H, m), 6.04(1H, d, J=7.2 Hz), 6.77 (1H, d, J=3.6 Hz), 6.89–7.04(3H, m), 7.28(1H, m), 7.38(1H, d, J=3.6 Hz). IR(CHCl3): 3518, 3446, 3427, 1739, 1709, 1643, 1545, 1506 cm−1. [α]D25+62.6±1.0°(c=1.009, MeOH) Anal. (C26H30FNO3S) Calcd.(%): C, 68.54; H, 6.64; N, 3.07; S, 7.04; F, 4.17. Found(%): C, 68.25; H, 6.37; N, 3.19; S, 7.12; F, 4.12.
Compound Number I-192
1H-NMR(CDCl3), : 1.06(1H, m), 1.18–1.32(2H, m), 1.40–1.48(2H, m), 1.54–1.80(4H, m), 1.98–2.20(5H, m), 2.35(2H, t, J=7.5 Hz), 2.52(1H, m), 3.81(1H, m), 4.19(2H, s), 5.30–5.42(2H, m), 5.99(1H, d, J=7.2 Hz), 6.78 and 7.37(each 1H, each d, each J=3.6 Hz), 7.40–7.54(4H, m). IR(CHCl3): 3516, 3446, 3427, 1740, 1709, 1643, 1545, 1506, 1450, 1330, 1167, 1130, 1074 cm−1. [α]D25+55.4±0.9°(c=1.029, MeOH) Anal. (C27H30F3NO3S) Calcd.(%): C, 64.14; H, 5.98; N, 2.77; S, 6.34; F, 11.27. Found(%): C, 63.95; H, 5.99; N, 2.90; S, 6.36; F, 10.98.
Compound Number I-193
1H-NMR(CDCl3) δ: 1.05(1H, m), 1.24–1.28(2H, m), 1.42–1.46(2H, m), 1.58–1.79(4H, m), 2.01–2.21(5H, m), 2.35(2H, t, J=7.2 Hz), 2.51(1H, m), 3.80 (1H, m), 4.26(2H, s), 5.33–5.38(2H, m), 5.94(1H, (c, J=7.2 Hz), 6.79 (1H, d, J=3.9 Hz), 7.21–7.28(3H, m), 7.35–7.40(2H, m). IR(CHCl3): 3518, 3446, 3427, 1743, 1709, 1643, 1543, 1506 cm−1. [α]D25+55.5±0.9°(c=1.06, CHCl3) Anal. (C26H30ClNO3S.0.3H2O) Calcd.(%): C, 65.41; H, 6.46; N, 2.93; S, 6.72; Cl, 7.43. Found(%): C, 65.41; H, 6.40; N, 3.08; S, 6.75; Cl, 7.31.
Compound Number I-194
1H-NMR(CDCl3) δ: 1.04(1H, m), 1.18–1.28(2H, m), 1.39–1.46(2H, m), 1.56–1.78 (4H, m), 1.98–2.16(5H, m), 2.30(6H, s), 2.34(2H, t, J=7.2 Hz), 2.50 (1H, m), 3.80(1H, m), 4.16(2H, s), 5.28–5.41(2H, m), 5.93(1H, d, J=6.9 Hz), 6.78(1H, d, J=3.9 Hz), 7.03–7.14(3H, m), 7.77(1H, d, J=3.9 Hz). IR (CHCl3): 3516, 3446, 3427, 2669, 1709, 1641, 1543, 1506, 1456 cm−1. [α]D24+66.6±1.0°(c=1.009, MeOH) Anal. (C28H35NO3S.0.2H2O) Calcd.(%): C, 71.67; H, 7.60; N, 2.98; S, 6.83. Found(%): C, 71.71; H, 7.54; N, 3.15; S, 6.81.
Compound Number I-195
1H-NMR(CDCl3) δ: 1.05(1H, m), 1.22–1.28(2H, m), 1.42–1.47(2H, m), 1.59–1.78(4H, m), 2.01–2.17(5H, m), 2.35(2H, t, J=7.2 Hz), 2.50(1H, m), 3.82(1H, m), 4.32(2H, s), 5.35–5.37(2H, m), 5.94(1H, d, J=6.9 Hz), 6.76 (1H, d, J=3.9 Hz), 7.33–7.39(3H, m), 7.50 (1H, m), 7.69(1H, d, J=3.9 Hz). IR (CHCl3): 3316, 3446, 3427, 1743, 1709, 1643, 1543, 1506, 1456, 1163, 1126 cm−1. [α]D25+54.5±1.0°(c=1.00, CHCl3) Anal. (C27H30F3NO3S.0.2H2O) Calcd.(%): C, 63.93; H, 6.02; N, 2.75; S, 6.30. Found(%): C, 63.92; H, 5.85; N, 2.94; S, 6.38.
Compound Number I-196
1H-NMR(CDCl3) δ: 1.05(1H, m), 1.22–1.28(2H, m), 1.42–1.46.(2H, m), 1.58–1.80 (4H, m), 2.01–2.21(5H, m), 2.35(2H, t, J=7.2 Hz), 2.52(1H, m), 3.81 (1H, m), 3.88(3H, s), 4.06(2H, s), 5.33–5.38(2H, m), 5.94(1H, d, J=10.2 Hz), 6.70(1H, d, J=3.6 Hz), 6.87–6.97(3H, m), 7.36(1, d, J=3.6 Hz). IR (CHCl3): 3517, 3446, 3427, 2673, 1741, 1709, 1643, 1543, 1516, 1274 1030 cm−1. [α]D25+54.2±0.9°(c=1.00, CHCl3) Anal. (C27H32FNO4S.0.3H2O) Calcd.(%): C, 66.04; H, 6.69; N, 2.85; S, 6.53; F, 3.87. Found(%): C, 66.16; H, 6.61; N, 2.82; S, 6.34; F, 3.66.
Compound Number I-197
1H-NMR(CDCl3) δ: 1.05(1H, m), 1.18–1.27(2H, m), 1.41–1.45(2H, m), 1.56–1.77(4H, m), 1.98–2.13(5H, m), 2.34(2H, t, J=7.5 Hz), 2.50(1H, s), 3.21 (2H, t, J=8.7 Hz), 3.80(1H, m), 4.07(2H, s), 4.57(2H, t, J=8.7 Hz), 5.29–5.41 (2H, m), 6.00(1H, d, J=7.5 Hz), 6.79(1H, d, J=3.6 Hz), 6.79(1H, dd, J=7.2 and 7.5 Hz), 6.95(1H, d, J=7.5 Hz), 7.09(1H, d, J=7.2 Hz), 7.36(1H, d, J=3.6 Hz). IR(CHCl3): 3514, 3446, 3427, 2669,.1739, 1709, 1641, 1543, 1506, 1477, 1456, 1441 cm−1. [α]D25+61.1±1.0°(c=1.004, MeOH) Anal. (C28H33NO4S.0.2H2O) Calcd.(%): C, 69.60; H, 6.97; N, 2.90; S, 6.63. Found(%): C, 69.68; H, 6.89; N, 3.19; S, 6.65.
Compound Number I-198
1H-NMR(CDCl3) δ: 1.04(1H, m), 1.18–1.27(2H, m), 1.40–1.46(2H, m), 1.56–1.76(4H, m), 1.98–2.13(5H, m), 2.33(2H, t, J=7.5 Hz), 2.50(1H, s), 3.21(2H, t, J=8.7 Hz), 3.80(1H, m), 4.24(2H, s), 5.28–5.40(2H, m), 5.97(1H, d, J=7.2 Hz), 6.79(1H, d, J=3.6 Hz), 7.22(1H, dd, J=1.2 and 8.1 Hz), 7.29 (1H, d, J=5.4 Hz), 7.38(1H, d,J=3.6 Hz), 7.44(1H, d, J=5.4 Hz), 7.68(1H, d, J=1.2 Hz), 7.81(1H, d, J=8.1 Hz). IR(CHCl3): 3516, 3446, 3427, 1741, 1709, 1643, 1543, 1506, 1547 cm−1. [α]D25+62.0±1.0°(c=1.000, MeOH) Anal. (C28H31NO3S2.0.2H2O) Calcd.(%): C, 67.63; H, 6.36; N, 2.82; S, 12.90. Found(%): C, 67.55; H, 6.28; N, 2.97; S, 12.90.
Compound Number I-199
1H-NMR(CDCl3) δ: 1.04(1H, m), 1.17–1.27(2H, m), 1.40–1.45(2H, m), 1.54–1.77(4H, m), 1.98–2.15(5H, m), 2.34(2H, t, J=7.2 Hz), 2.51(1H, s), 3.80 (1H, m),4.25(2H, s), 5.28–5.41(2H, m), 5.97(1H, d, J=7.2 Hz), 6.79(1H, d, J=3.9 Hz), 7.24(1H, dd, J=1.5 and 8.1 Hz), 7.30(1H, d, J=5.4 Hz), 7.38(1H, d, J=3.6 Hz), 7.41(1H, d, J=5.4 Hz), 7.73(1H, m), 7.76(1H, d, J=8.1 Hz). IR(CHCl3): 3516, 3447, 3427, 1741, 1709, 1643, 1543, 1506, 1458 cm−1. [α]D25+62.1±1.0°(c=1.008, MeOH) Anal. (C28H31NO3S2.0.3H2O) Calcd.(%): C, 67.39; H, 6.38; N, 2.81; S, 12.85. Found(%): C, 67.42; H, 6.29; N, 2.99; S, 12.94.
Compound Number I-200
1H-NMR(CDCl3) δ: 1.03(1H, m), 1.16–1.22(2H, m), 1.39–1.44(2H, m), 1.53–1.76 (4H, m), 1.97–2.14(5H, m), 2.33(2H, t, J=7.5 Hz), 2.49(1H, s), 3.79 (1H, m),4.39(2H, s), 5.28–5.40(2H, m), 5.98(1H, d, J=7.5 Hz), 6.86(1H, d, J=3.9 Hz), 7.21(1H, d, J=6.9 Hz), 7.35(1H, dd, J=6.9 and 8.1 Hz), 7.36(1H, d, J=5.4 Hz), 7.36(1H, d, J=3.9 Hz), 7.42(1H, d, J=5.4 Hz), 7.74(1H, d, J=8.1 H). IR(CHCl3): 3516, 3446, 3427, 1739, 1709, 1643, 1543, 1506, 1458 cm−1. [α]D25+58.4±1.0°(c=1.003, MeOH) Anal. (C28H31NO3S2.0.2H2O) Calcd.(%): C, 67.63; H, 6.36; N, 2.82; S, 12.90. Found(%): C, 67.62; H, 6.27; N, 3.09; S, 12.92.
Compound Number I-201
1H-NMR(CDCl3+CD3OD) δ: 1.08(1H, m), 1.22–1.28(2H, m), 1.41–1.46(2H, m), 1.55–1.71(4H, m), 2.01–2.10(5H, m), 2.29(2H, t, J=7.4 Hz), 2.51(1H, s), 3.77(1H, m), 4.29(2H, s), 5.34–5.40(2H, m), 6.80(1H, d, J=3.9 Hz), 6.93(1H, dd, J=1.8 and 8.7 Hz), 7.10(1H, d, J=1.8 Hz), 7.22(1H, s), 7.36(1H, d, J=3.9 Hz), 7.65(1H, d, J=8.7 Hz). IR(CHCl3): 3508, 3423, 3236, 1709, 1633, 1601, 1545, 1510, 1441 cm−1. [α]D25+57.5±1.0°(c=1.006, MeOH) Anal. (C28H31NO4S2.0.2H2O) Calcd.(%): C, 64.84; H, 6.21; N, 2.70; S, 12.36. Found(%): C, 67.57; H, 6.20; N, 2.93; S, 12.38.
Compound Number I-202
1H-NMR(CDCl3) δ: 1.05(1H, m), 1.24–1.28(2H, m), 1.41–1.48(2H, m), 1.58–1.79(4H, m), 2.02–2.22(5H, m), 2.33(2H, t, J=7.5 Hz), 2.51(1H, m), 3.78 (1H, m), 4.25(2H, s), 4.70(2H, s), 5.31–5.42(2H, m), 6.00(1H, d, J=7.2 Hz), 6.74(1H, d, J=3.6 Hz), 7.24–7.42(5H, m). IR(CHCl3): 3518, 3444, 3427, 1709, 1643, 1543, 1506, 1456 cm−1. [α]D26+51.9±0.9°(c=1.04, CHCl3) Anal. (C27H33FNO4S.0.7H2O) Calcd.(%): C, 67.53; H, 7.22; N, 2.92; S, 6.02. Found(%): C, 67.92; H, 7.13; N, 2.88; S, 6.11.
Compound Number I-203
1H-NMR(CDCl3) δ: 1.02(1H, m), 1.22–1.28(2H, m), 1.40–1.42(2H, m), 1.57–1.72(4H, m), 1.82–1.85(4H, m), 2.01–2.13(5H, m), 2.27(2H, t, J=7.5 Hz), 2.49(1H, m), 2.71–2.73(4H, m), 3.67(1H, d, J=13.2 Hz), 3.76 (1H,m), 3.83(1H, d, J=13.2 Hz), 4.26(1H, d, J=16.5 Hz), 4.34(1H, d, J=16.5 Hz), 5.33–5.45(2H, m), 6.04(1H, d, J=7.2 Hz), 6.70(1H, d, J=3.6 Hz), 7.16–7.33 (4H, m), 7.43((1H, d, J=3.6 Hz). IR(CHCl3): 3518, 3446, 3424, 2472, 1707, 1643, 1545, 1506, 1456 cm−1. [α]D26+41.9.±0.8°(c=1.03, CHCl3) Anal. (C31H40N2O3S.0.6H2O) Calcd.(%): C, 70.05; H, 7.81; N, 5.27; S, 6.03. Found(%): C, 70.01; H, 7.81; N, 5.18; S, 5.86.
Compound Number I-204
1H-NMR(CDCl3) δ: 1.06(1H, m), 1.22–1.29(2H, m), 1.41–1.46(2H, m), 1.58–1.72(4H, m), 2.03–2.17(5H, m), 2.31(2H, t, J=7.2 Hz), 2.51(1H, m), 2.60 (6H, s), 3.79(1H, m), 3.94(1H, d, J=13.2 Hz), 3.99(1H, d, J=13.2 Hz), 4.39 (2H,s), 5.30–5.44(2H, m), 6.01(1H, d, J=7.2 Hz), 6.72(1H, d, J=3.9 Hz), 7.26–7.40(4H, m), 7.56(1H, d, J=7.2 Hz). IR(CHCl3): 3519, 3444, 3425, 2455, 1753, 1712, 1643, 1545, 1508, 1458 cm−1. [α]D26+41.2±0.8°(c=1.02, CHCl3) Anal. (C29H38N2O3S.1.7H20.2CHCl3) Calcd.(%): C, 63.86; H, 7.63; N, 5.10; S, 5.84; Cl, 3.87. Found(%): C, 63.88; H, 7.51; N, 4.94; S, 5.63; Cl, 4.22.
Compound Number I-205
1H-NMR(CDCl3) δ: 1.14(1H, m), 1.24–1.36(2H, m), 1.45–1.54(2H, m), 1.60–1.79(4H, m), 2.03–2.26(5H, m), 2.36(2H, t, J=7.5 Hz), 2.58(1H, m), 3.19–3.26(4H, m), 3.89(1H, m), 5.32–5.45(2H, m), 6.33(1H, d, J=6.3 Hz), 7.24(1H, d, J=7.2 Hz), 7.34 and 7.46(each 1H, each m), 7.61(1H, dd, J=1.5 and 8.4 Hz), 7.68(1H, d, J=1.5 Hz), 7.98–8.04(2H, m). IR(CHCl3): 3518, 3444, 2667, 1709, 1649, 1597, 1514, 1483, 1450, 1294 cm−1. [α]D25+78.7±1.2°(c=1.003, MeOH) Anal. (C30H33NO4) Calcd.(%): C, 75.54; H, 7.10; N, 2.94. Found(%): C, 75.62; H, 7.05; N, 2.94.
Compound Number I-206
1H-NMR(CDCl33) δ: 1.10(1H, m), 1.22–1.36(2H, m), 1.40–1.52(2H, m), 1.56–1.81(4H, m), 2.00–2.24(5H, m), 2.35(2H, t, J=7.2 Hz), 2.50(1H, m), 3.84 (1H, m), 3.99(2H, s), 5.30–5.43(2H, m), 6.05(1H, d, J=3.3 Hz), 6.29(1H, d, J=7.8 Hz), 6.99–7.05(3H, m), 7.17–7.22(2H, m). IR(CHCl3): 3512, 3435, 1739, 1709, 1653, 1606, 1549, 1510 cm−1. [α]D26+71.0±1.1°(c=1.005, MeOH) Anal. (C26H30FNO4O) Calcd.(%): C, 71.05; H, 6.88; N, 3.19; F, 4.32. Found(%): C, 70.78; H, 6.97; N, 3.30; F, 4.27.
Compound Number I-207
1H-NMR(CDCl3) δ: 1.10(1H, m), 1.22–1.34(2H, m), 1.40–1.50(2H, m), 1.56–1.81(4H, m), 2.00–2.24(5H, m), 2.35(2H, t, J=7.2 Hz), 2.50(1H, m), 3.84 (1H, m), 4.02(2H, s), 5.30–5.43(2H, m), 6.07(1H, d, J=3.3 Hz), 6.30(1H, d, J=7.5 Hz), 7.02(1H, d, J=3.3 Hz), 7.22–7.36(5H, m). IR(CHCl3): 3516, 3435, 2669, 1709, 1651, 1606, 1547, 1498 cm−1. [α]D24+76.5±1.2°(c=1.005, MeOH) Anal. (C26H31FNO4.0.1H2O) Calcd.(%): C, 73.77; H, 7.43; N, 3.31. Found(%): C, 73.63; H, 7.27; N, 3.42.
Compound Number I-208
1H-NMR(CDCl3) δ: 1.04(1H, m), 1.16–1.26(2H, m), 1.39–1.44(2H, m), 1.55–1.76(4H, m), 1.98–2.18(5H, m), 2.33(2H, t, J=7.2 Hz), 2.50(1H, s), 3.79 (1H, m),4.42(2H, s), 5.28–5.40(2H, m), 5.98(1H, d, J=6.9 Hz), 6.78(1H, d, J=2.1 Hz), 6.84(1H, d, J=3.6 Hz), 7.12–7.21(2H, m), 7.36(1H, d, J=3.6 Hz), 7.50(1H, dd, J=1.5 and 7.5 Hz), 7.63(1H, d, J=2.1 Hz). IR(CHCl3): 3516, 3446, 3427, 2665, 1741, 1709, 1643, 1523, 1506, 1458, 1427 cm−1. [α]D25+63.4±1.0°(c=1.006, MeOH) Anal. (C28H31NO4S.0.2H2O) Calcd.(%): C, 69.89; H, 6.58; N, 2.91; S, 6.66. Found(%): C, 69.68; H, 6.48; N, 3.10; S, 6.62.
Compound Number I-209
1H-NMR(CDCl3) δ: 1.07(1H, m), 1.22–1.29(2H, m), 1.42–1.47(2H, m), 1.59–1.82(4H, m), 2.01–2.20(5H, m), 2.35(2H, t, J=7.2 Hz), 2.52(1H, m), 2.94 (3H,s), 3.81(1H, m), 4.19(2H, s), 4.44(2H, s), 5.31–5.38(2H, m), 5.35 (1H,d, J=7.2 Hz), 6.63–6.72(4H, m), 7.16–7.25(6H, m), 7.36(1H, d, J=3.6 Hz). IR (CHCl3): 3514, 3444, 3427, 1741, 1709, 1643, 1599, 1543, 1506, 1456 cm−1. [α]D26+50.8±0.9°(c=1.04, CHCl3) Anal. (C34H40N2O3S.0.7H2O) Calcd.(%): C, 71.72; H, 7.33; N, 4.92; S, 5.63. Found(%): C, 71.81; H, 7.29; N, 4.81; S, 5.54.
Compound Number I-210
1H-NMR (CHCl3) δ: 1.14–1.68(11H, m), 1.91–2.16(9H, m), 2.21(2H, t, J=7.2 Hz), 2.57(1H, m), 2.98(1H, m), 3.71(1H, m), 3.89(2H, s), 4.28(1H, d, J=16.5 Hz), 4.30(1H, d, J=16.5 Hz), 5.28–5.50(3H, m), 6.56(1H, m), 6.75(1H, m), 7.20–7.33 (2H, m), 7.49–7.55(2H, m). IR(CHCl3): 3518, 3425, 1753, 1711, 1641, 1545, 1508, 1456 cm−1. [α]D26+35.6±0.7°(c=1.03, CHCl3)
Compound Number I-211
1H-NMR(CDCl3) δ: 1.04(1H, m), 1.17–1.28(2H, m), 1.39–1.46(2H, m), 1.54–1.78(4H, m), 1.98–2.19(5H, m), 2.33(2H, t, J=7.2 Hz), 2.51(1H, m), 3.80(1H, m), 4.29(2H, s), 5.28–5.40(2H, m), 5.95(1H, d, J=7.2 Hz), 6.82(1H, d, J=3.6 Hz), 7.23(1H, dd, J=1.5 and 8.1 Hz), 7.30–7.47(4H, m), 7.55(1H, d, J=8.1 Hz), 7.89(1H, d, J=7.8 Hz), 7.93(1H, dd, J=1.5 and 7.8 Hz). IR (CHCl3): 3510, 3446, 3427, 2671, 1739, 1709, 1641, 1545, 1506, 1458, 1427 cm−1. [α]D24+60.2±1.0°(c=1.006, MeOH) Anal. (C32H33NO4S.0.2H2O) Calcd.(%): C, 72.34; H, 6.34; N, 2.64; S, 6.04. Found(%): C, 72.28; H, 6.25; N, 2.72; S, 5.93.
Compound Number I-212
1H-NMR(CDCl3) δ: 1.05(1H, m), 1.18–1.30(2H, m), 1.38–1.47(2H, m), 1.54–1.80(4H, m), 1.98–2.20(5H, m), 2.34(2H, t, J=7.5 Hz), 2.51(1H, m), 3.78 (3H, s), 3.80(1H, m), 3.86(3H, s), 4.15(2H, s), 5.29–5.42(2H, m), 5.93(1H, d, J=7.5 Hz), 6.78–6.85(3H, m), 7.01(1H, t, J=8.1 Hz), 7.36(1H, d, J=3.9 Hz). IR(CHCl3): 3516, 3446, 3425, 2667, 1739, 1709, 1641, 1543, 1506, 1481, 1273, 1076 cm−1. [α]D25+60.8±1.0°(c=1.002, MeOH) Anal. (C28H35NO5S.0.1H2O) Calcd.(%): C, 67.33; H, 7.10; N, 2.80; S, 6.42. Found(%): C, 67.21; H, 7.08; N, 2.92; S, 6.45.
Compound Number I-213
1H-NMR(CDCl3) δ: 1.08(1H, m), 1.19–1.30(2H, m), 1.42–1.47(2H, m), 1.58–1.78(4H, m), 2.01–2.16(5H, m), 2.38(2H, t, J=7.2 Hz), 2.39(3H, s), 2.53 (1H, s),3.82(1H, m), 4.15(2H, s), 5.31–5.44(2H, m), 5.87(1H, s), 6.05(1H, d, J=7.2 Hz), 6.86(1H, d, J=3.9 Hz), 7.38(1H, d, J=3.9 Hz). IR(CHCl3): 3516, 3444, 3427, 2669, 1709, 1643, 1608, 1545, 1508, 1456 cm−1. [α]D25+64.3±1.0°(c=1.012, MeOH) Anal. (C24H30N2O4S.0.2H2O) Calcd.(%): C, 64.61; H, 6.87; N, 6.28; S, 7.19. Found(%): C, 64.70; H, 6.84; N, 6.34; S, 7.27.
Compound Number I-214
1H-NMR(CDCl3) δ: 1.06(1H, m), 1.19–1.28(2H, m), 1.41–1.46(2H, m), 1.58–1.79(4H, m), 2.00–2.15(5H, m), 2.33–2.37(5H, m), 2.51(1H, s), 3.81–3.82 (4H,m), 4.08(2H, s), 5.29–5.42(2H, m), 5.93(1H, d, J=6.9 Hz), 6.70(1H, s), 6.72(1H, d, J=7.8 Hz), 6.77(1H, d, J=3.6 Hz), 7.04(1H, d, J=7.8 Hz), 7.34 (1H, d, J=3.6 Hz). IR(CHCl3): 3516, 3446, 3427, 2669, 1741, 1709, 1641, 1614, 1583, 1506, 1458 cm−1. [α]D25+58.9±1.0°(c=1.012, MeOH) Anal. (C28H35N4S.0.2H2O) Calcd.(%): C, 69.31; H, 7.35; N, 2.89; S, 6.61. Found(%): C, 69.21; H, 7.35; N, 3.03; S, 6.65.
Compound Number I-215
mp.128–129° C.; 1H-NMR(CDCl3) δ: 1.05 (1H, m), 1.19–1.28 (2H, m), 1.41–1.46 (2H, m), 1.56–1.79(4H, m), 2.00–2.15(5H, m), 2.34(2H, t, J=7.2 Hz), 2.51(1H, s), 3.80(1H, m), 3.84(3H, s), 4.33(2H, s), 5.29–5.42 (2H, m), 5.94(1H, d, J=6.9 Hz), 6.83(1H, d, J=3.6 Hz), 7.01(1H, dd, J=2.7 and 9.0 Hz), 7.11(1H, d, J=2.7 Hz), 7.21(1H, s), 7.36(1H, d, J=3.6 Hz), 7.72 (1H, d, J=9.0 Hz). IR(CHCl3): 3516, 3446, 3427, 1739, 1709, 1643, 1601, 1543, 1506, 1458, 1427 cm−1. [α]D25+55.7±1.0°(c=1.008, MeOH) Anal. (C29H33NO4S2) Calcd.(%): C, 66.51; H, 6.35; N, 2.67; S, 12.25. Found(%): C, 66.41; H, 6.30; N, 2.96; S, 12.15.
Compound Number I-216
1H-NMR(CDCl3) δ: 1.04(1H, m), 1.16–1.29(2H, m), 1.39–1.46(2H, m), 1.55–1.79 (4H, m), 1.98–2.19(5H, m), 2.34(2H, t, J=7.2 Hz), 2.51(1H, m), 3.80 (1H, m), 3.87 and 4.20(each 2H, each s), 5.28–5.40(2H, m), 5.93(1H, d, J=8.1 Hz), 6.81(1H, d, J=3.9 Hz), 7.24–7.39(5H, m), 7.53(1H, d, J=7.2 Hz), 7.71–7.77(2H, m). IR(CHCl3): 3516, 3446, 3427, 1739, 1709, 1643, 1543, 1506, 1456 cm−1. [α]D25+56.7±1.0°(c=1.000, MeOH) Anal. (C33H35NO3S.0.1H2O) Calcd.(%): C, 75.14; H, 6.73; N, 2.66; S, 6.08. Found(%): C, 75.14; H, 6.80; N, 2.74; S, 5.83.
Compound Number I-217
1H-NMR(CDCl3) δ: 1.07(1H, m), 1.19–1.32(2H, m), 1.40–1.48(2H, m), 1.56–1.78 (4H, m), 2.00–2.21(5H, m), 2.34(2H, t, J=7.5 Hz), 2.54(1H, m), 3.13–3.24 (4H, m), 3.85(1H, m), 4.13(2H, s), 5.28–5.42(2H, m), 6.17(1H, d, J=7.2 Hz), 7.06–7.17(4H, m), 7.22(1H, d, J=7.8 Hz), 7.44(1H, dd, J=1.8 and 7.8 Hz), 7.53(1H, d, J=1.8 Hz). IR(CHCl3): 3518, 3446, 1739, 1709, 1651, 1570, 1518, 1491, 1456 cm−1. [α]D25+73.3±1.1°(c=1.000, MeOH) Anal. (C30H35NO3.0.2H2O) Calcd.(%): C, 78.13; H, 7.44; N, 3.04. Found(%): C, 78.25; H, 7.76; N, 3.29.
Compound Number I-218
1H-NMR(CDCl3) δ: 1.05(1H, m), 1.18–1.30(2H, m), 1.39–1.48(2H, m), 1.54–1.81(4H, m), 1.98–2.20(5H, m), 2.34(2H, t, J=7.2 Hz), 2.51(1H, m), 3.80(1H, m), 3.82, 3.85 and 3.87(each 3H, each s), 4.07(2H, s), 5.29–5.42 (2H, m), 5.94(1H, d, J=7.5 Hz), 6.62(1H, d, J=8.7 Hz), 6.76(1H, d, J=3.6 Hz), 6.85(11H, d, J=8.7 Hz), 7.35(1H, d, J=3.6 Hz). IR(CHCl3): 3514, 3446, 3427, 1739, 1709, 1641, 1603, 1543, 1495, 1468, 1277, 1259, 1097 cm−1. [α]D26+54.8±1.0°(c=1.013, MeOH) Anal. (C29H37NO6S.0.2H2O) Calcd.(%): C, 65.56; H, 7.10; N, 2.64; S, 6.04. Found(%): C, 65.54; H, 6.96; N, 2.74; S, 5.98.
Compound Number I-219
1H-NMR(CDCl3) δ: 1.05(1H, m), 1.18–1.30(2H, m), 1.39–1.48(2H, m), 1.54–1.81(4H, m), 1.98–2.20(5H, m), 2.34(2H, t, J=7.2 Hz), 2.51(1H, m), 3.80 (1H, m), 3.82, 3.85 and 3.87(each 3H, each s), 4.07(2H, s), 5.29–5.42 (2H, m), 5.94(1H, d, J=7.5 Hz), 6.62(1H, d, J=8.7 Hz), 6.76(1H, d, J=3.6 Hz), 6.85(1H, d, J=8.7 Hz), 7.35(1H, d, J=3.6 Hz). IR(CHCl3): 3514, 3446, 3427, 1739, 1709, 1641, 1603, 1543, 1495, 1468, 1277, 1259, 1097 cm−1. [α]D26+54.8±1.0°(c=1.013, MeOH) Anal. (C29H37NO6S.0.2H2O) Calcd.(%): C, 65.56; H, 7.10; N, 2.64; S, 6.04. Found(%): C, 65.54; H, 6.96; N, 2.74; S, 5.98.
Compound Number I-220
mp.131–133° C.; 1H-NMR(CDCl3) δ: 1.06(1H, m), 1.18–1.31(2H, m), 1.40–1.48 (2H, m), 1.56–1.82(4H, m), 2.00–2.21(5H, m), 2.35(2H, t, J=7.5 Hz), 2.52 (1H, m), 3.82(1H, m), 3.83(3H, s), 3.84(6H, s), 4.07(2H, s), 5.30–5.42 (2H, m), 5.95(1H, d, J=7.5 Hz), 6.45(2H, s), 6.79(1H, d, J=3.6 Hz), 7.36(1H, d, J=3.6 Hz). IR(CHCl3): 3516, 3446, 3427, 1739, 1709, 1643, 1593, 1543, 1506, 1462, 1421, 1331, 1240, 1130 cm−1. [α]D24+57.5±1.0°(c=1.007, MeOH) Anal. (C29H37NO6S) Calcd.(%): C, 66.01; H, 7.07; N, 2.65; S, 6.08. Found(%): C, 65.84; H, 6.93; N, 2.71; S, 6.06.
Compound Number I-221
1H-NMR(CDCl3) δ: 1.05(1H, m), 1.17–1.30(2H, m), 1.39–1.48(2H, m), 1.54–1.80(4H, m), 1.98–2.20(5H, m), 2.34(2H, t, J=7.5 Hz), 2.51(1H, m), 3.81 (1H, m), 4.08(2H, s), 5.29–5.42(2H, m), 5.95(2H, s), 5.98(1H, d, J=7.5 Hz), 6.68–6.80(4H, m), 7.35(1H, d, J=3.9 Hz). IR(CHCl3): 3516, 3446, 3427, 1741, 1709, 1641, 1543, 1504, 1460, 1252, 1063 cm−1. [α]D24+62.7±1.0°(c=1.006, MeOH) Anal. (C27H31NO5S) Calcd.(%): C, 67.34; H, 6.49; N, 2.91; S, 6.66. Found(%): C, 67.12; H, 6.37; N, 2.98; S, 6.55.
Compound Number I-222
1H-NMR(CDCl3) δ: 1.08(1H, m), 1.24–1.28(2H, m), 1.41–1.45(2H, m), 1.56–1.78(4H, m), 1.97–2.20(5H, m), 2.14(3H, s), 2.33(2H, t, J=7.2 Hz), 2.51 (1H, m), 3.77(1H, m), 4.06(2H, s), 5.28–5.42(2H, m), 6.16(1H, d, J=7.2 Hz), 6.74 (1H, d, J=3.6 Hz), 6.96(1H, d, J=7.5 Hz), 7.24(1H, t, J=8.7 Hz), 7.35–7.38 (3H, m), 7.74(1H, br s). IR(KBr): 3309, 1707, 1672, 1614, 1547, 1523, 1489, 1441, 1371, 1319 cm−1. [α]D26+57.7±1.0°(c=1.012, MeOH) Anal. (C28H34N2O4S.0.4H2O) Calcd.(%): C, 67.01; H, 6.99; N, 5.58; S, 6.39. Found(%): C, 66.98; H, 6.72, N, 5.47; S, 6.27.
Compound Number I-223
1H-NMR(CDCl3) δ: 1.05(1H, m), 1.22–1.28(2H, m), 1.42–1.46(2H, m), 1.55–1.75(4H, m), 2.02–2.22(5H, m), 2.34(2H, t, J=7.5 Hz), 2.51(1H, m), 2.99 (3H, s), 3.81(1H, m), 4.11(2H, s), 5.29–5.45(2H, m), 6.04(1H, d, J=7.2 Hz), 6.78 (1H, d, J=3.6 Hz), 7.04–7.06(2H, m), 7.16(1H, m), 7.25(1H, br s), 7.29(1H, t, J=7.8 Hz), 7.36 (1H, d, J=3.6 Hz). IR (CHCl3): 3512, 3444, 3427, 3371, 1709, 1639, 1608, 1545, 1508, 1475, 1458, 1389, 1335, 1151 cm−1. [α]D24+55.0±1.0°(c=1.003, MeOH) Anal. (C27H34N2O5S2.0.2H2O) Calcd.(%): C, 60.69; H, 6.49; N, 5.24; S, 12.00. Found(%): C, 60.70; H, 6.44; N, 5.15; S, 11.56.
Compound Number I-224
1H-NMR(CDCl3) δ: 1.07(1H, m), 1.22–1.28(2H, m), 1.42–1.53(2H, m), 1.57–1.74(4H, m), 2.00–2.24(5H, m), 2.35(2H, t, J=7.2 Hz), 2.52(1H, m), 3.81 (1H, m), 4.33(2H, s), 5.29–5.42(2H, m), 5.98(1H, d, J=7.8 Hz), 6.86, 6.88 and 7.14 (each 1H, each d, each J=3.6 Hz), 7.22–7.37(4H, m), 7.53–7.56(2H, m).
Compound Number I-225
1H-NMR (CDCl3) δ: 1.05(1H, m), 1.17–1.30(2H, m), 1.39–1.48(2H, m), 1.54–1.81(4H, m), 1.98–2.20(5H, m), 2.35(2H, t, J=7.5 Hz), 2.51(1H, m), 3.81 (1H, m), 4.08(2H, s), 4.23–4.30(4H, m), 5.29–5.42(2H, m), 5.95(1H, d, J=7.2 Hz), 6.71–6.80(4H, m), 7.34(1H, d, J=3.6 Hz). IR(CHCl3): 3514, 3446, 3427, 1739, 1709, 1641, 1603, 1543, 1506, 1475, 1456, 1284, 1090 cm−1. [α]D24.5+58.9±1.0°(c=1.013, MeOH) Anal. (C28H33NO5S) Calcd.(%): C, 67.85; H, 6.71; N, 2.83; S, 6.47. Found(%): C, 68.01; H, 6.72; N, 2.97; S, 6.50.
Compound Number I-226
1H-NMR(CDCl3) δ: 1.05(1H, m), 1.18–1.30(2H, m), 1.38–1.47(2H, m), 1.54–1.81 (4H, m), 1.98–2.20(5H, m), 2.31(3H, s), 2.34(2H, t, J=7.5 Hz), 2.51(1H, m), 3.70(3H, s), 3.80(1H, m), 4.16(2H, s), 5.29–5.42(2H, m), 5.95 (1H, d, J=7.2 Hz), 6.78(1H, d, J=3.6 Hz), 6.96–7.11(3H, m), 7.37(1H, d, J=3.6 Hz). IR(CHCl3): 3514, 3446, 3427, 2669, 1709, 1641, 1543, 1506, 1473, 1458, 1259, 1011 cm−1. [α]D24+62.7±1.0°(c=1.009, MeOH) Anal. (C28H35NO4S) Calcd.(%): C, 69.82; H, 7.32; N, 2.91; S, 6.66. Found(%): C, 69.55; H, 7.27; N, 3.09; S, 6.55.
Compound Number I-227
1H-NMR(CDCl3) δ: 1.07(1H, m), 1.24–1.28(2H, m), 1.41–1.46(2H, m), 1.56–1.79(4H, m), 2.00–2.17(5H, m), 2.16(3H, s), 2.33(2H, t, J=7.5 Hz), 2.51 (1H, m), 3.79(1H, m), 4.08(2H, s), 5.28–5.42(2H, m), 6.05(1H, d, J=7.5 Hz), 6.75 (1H, d, J=3.6 Hz), 7.16(2H, d, J=8.1 Hz), 7.37(1H, d, J=3.6 Hz), 7.43 (2H, d, J=8.1 Hz), 7.53(1H, br s). IR(CHCl3): 3512, 3437, 1707, 1639, 1543, 1516, 1410 cm−1. [α]D24.5+60.7±1.0°(c=1.012, MeOH) Anal. (C28H34N2O4S.0.5H2O) Calcd.(%): C, 67.77; H, 7.00; N, 5.56; S, 6.37. Found(%): C, 66.84; H, 6.91; N, 5.56; S, 6.26.
Compound Number I-228
1H-NMR(CDCl3) δ: 1.06(1H, m), 1.22–1.29(2H, m), 1.41–1.46(2H, m), 1.58–1.76 (4H, m), 2.01–2.17(5H, m), 2.34(2H, t, J=7.5 Hz), 2.51(1H, m), 2.99 (3H, s), 3.80(1H, m), 4.11(2H, s), 5.29–5.43(2H, m), 6.01(1H, d, J=7.5 Hz), 6.78(1H, d, J=3.6 Hz), 6.86(1H, br s), 7.17–7.23(4H, m), 7.36(1H, d, J=3.6 Hz). IR(CHCl3): 3510, 3444, 3427, 3371, 1709, 1639, 1543, 1510, 1456, 1389, 1338, 1155 cm−1. [α]D24.5+56.5±1.0°(c=0.953, MeOH) Anal. (C27H34N2O5S2.0.1H2O) Calcd.(%): C, 60.90; H, 6.47; N, 5.26; S, 12.04. Found(%): C, 61.06; H, 6.45; N, 5.29; S, 11.52.
Compound Number I-229
mp.103–105° C.; 1H-NMR(CDCl3) δ: 1.02 (1H, m), 1.15–1.27 (2H, m), 1.37–1.45(2H, m), 1.53–1.77(4H, m), 1.96–2.18(5H, m), 2.33 (2H, t, J=7.5 Hz), 2.49(1H, m), 3.79(1H, m), 4.40(2H, s), 5.27–5.39 (2H, m), 5.94(1H, d, J=7.8 Hz), 6.89(1H, d, J=3.9 Hz), 7.32–7.37(2H, m), 7.43–7.48 (3H, m), 7.84(1H, m), 8.08(1H, d, J=6.9 Hz), 8.15(1H, m). IR(CHCl3): 3514, 3444, 3427, 2667, 1739, 1709, 1643, 1543, 1506, 1458, 1444 cm−1. [α]D24.5+58.9±1.0°(c=1.006, MeOH) Anal. (C32H33NO3S2) Calcd.(%): C, 70.68; H, 6.12; N, 2.58; S, 11.79. Found(%): C, 70.52; H, 6.11; N, 2.67; S, 11.72.
Compound Number I-230
mp.86–87° C.; 1H-NMR(CDCl3) δ: 1.02(1H, m), 1.16–1.28(2H, m), 1.37–1.45 (2H, m), 1.54–1.77(4H, m), 1.97–2.17(5H, m), 2.32(2H, t, J=7.5 Hz), 2.49 (1H, m), 3.78(1H, m), 3.79 and 4.26(each 2H, each s), 5.27–5.39(2H, m), 5.93 (1H, d, J=7.2 Hz), 6.78(1H, d, J=3.9 Hz), 7.18(1H, d, J=7.2 Hz), 7.29 (1H, m), 7.34–7.40(3H, m), 7.52(1H, d, J=7.2 Hz), 7.72(1H, d, J=7.5 Hz), 7.78(1H, d, J=7.2 Hz). IR(CHCl3): 3514, 3446, 3427, 2669, 1709, 1641, 1543, 1506, 1456 cm−1. [α]D24.5+59.2±1.0°(c=1.006, MeOH) Anal. (C33H35NO3S) Calcd.(%): C, 75.40; H, 6.71; N, 2.66; S, 6.10. Found(%): C, 75.33; H, 6.73; N, 2.75; S, 6.06.
Compound Number I-231
1H-NMR (CHCl3) δ: 1.04(1H, m), 1.16–1.30(2H, m), 1.38–1.46(2H, m), 1.54–1.81(4H, m), 1.98–2.16(5H, m), 2.21 and 2.50(each 3H, each s), 2.34 (2H, t, J=7.2 Hz), 2.51(1H, m), 3.66(3H, s), 3.80(1H, m), 4.13(2H, s), 5.29–5.42 (2H, m), 5.93(1H, d, J=6.9 Hz), 6.78(1H, d, J=3.6 Hz), 6.89 and 6.96 (each 1H, each d, each J=7.5 Hz), 7.36(1H, d, J=3.6 Hz). IR(CHCl3): 3516, 3446, 3425, 2669, 1709, 1641, 1545, 1506, 1458, 1263, 1084, 1009 cm−1. [α]D24+61.8±1.0°(c=1.006, MeOH) Anal. (C29H37NO4S.0.2H2O) Calcd.(%): C, 69.76; H, 7.55; N, 2.81; S, 6.42. Found(%): C, 69.80; H, 7.59; N, 2.97; S, 6.34.
Compound Number I-232
1H-NMR(CDCl3) δ: 1.02(1H, m), 1.16–1.27(2H, m), 1.37–1.45(2H, m), 1.53–1.77(4H, m), 1.96–2.15(5H, m), 2.33(2H, t, J=7.5 Hz), 2.50(1H, m), 3.79 (1H, m), 4.50(2H, s), 5.27–5.40(2H, m), 5.94(1H, d, J=7.5 Hz), 6.88(1H, d, J=3.9 Hz), 7.29–7.38(4H, m), 7.47(1H, m), 7.58(1H, d, J=8.4 Hz), 7.86(1H, m), 7.95(1H, d, J=7.8 Hz). IR(CHCl3): 3512, 3444, 3427, 2669, 1739, 1708, 1641, 1543, 1506, 1475, 1452, 1423 cm−1. [α]D24+58.5±1.0°(c=1.006, MeOH) Anal. (C32H33NO4S.0.2H2O) Calcd.(%): C, 72.34; H, 6.34; N, 2.64; S, 6.04. Found(%): C, 72.36; H, 6.16; N, 2.72; S, 5.94.
Compound Number I-233
mp.125–126° C.; 1H-NMR(CDCl3) δ: 1.05(1H, m), 1.18–1.28(2H, m), 1.41–1.45 (2H, m), 1.57–1.78(4H, m), 2.00–2.20 (5H, m), 2.33(2H, t, J=7.4 Hz), 2.51 (1H, s), 3.80(1H, m),4.05 (2H, s), 5.28–5.42 (2H, m), 5.98(1H, d, J=6.6 Hz), 6.76 (1H, d, J=3.6 Hz), 6.80 and 7.09(each 2H, each d, J=8.4 Hz), 7.37(1H, d, J=3.6 Hz). IR(KBr): 3354, 3132, 2688, 1703, 1616, 1599, 1549, 1514, 1458, 1250 cm−1. [α]D25+67.7±1.1°(c=1.001, MeOH) Anal. (C26H31NO4S) Calcd.(%): C, 68.85; H, 6.89; N, 3.09; S, 7.07. Found(%): C, 69.12; H, 6.95; N, 3.10; S, 7.12.
Compound Number II-1
1H-NMR(CDCl3) δ: 0.93(1H, d, J=10.2 Hz), 1.08 and 1.21(each 3H, each s), 1.50–2.41(14H, m), 4.20(1H, m), 5.35–5.47(2H, m), 6.16(1H, d, J=8.7 Hz), 6.33 and 7.16(each 2H, each t, each J=2.4 Hz), 7.30 and 7.56 (each 1H, each d, each J=3.9 Hz). IR(CHCl3): 3515, 3446, 3144, 3100, 1708, 1658, 1529, 1504, 1456, 1385, 1167 cm−1. [α]D 26.5+54.1±0.9°(c=1.004, MeOH) Anal. (C25H32N2O5S2.0.2H2O) Calcd.(%): C, 59.08; H, 6.43; N, 5.51; S, 12.62. Found(%): C, 59.12; H, 6.36; N, 5.57; S, 12.59.
Compound Number II-6
1H-NMR(CDCl3) δ: 0.98(1H, d, J=10.2 Hz), 1.14 and 1.24(each 3H, each s), 1.54–2.48(14H, m), 4.30(1H, m), 5.35–5.52(2H, m), 6.26 (1H, d, J=8.7 Hz), 6.38 and 7.13 (each 2H, each t, J=2.1 Hz), 7.44 and 7.79 (each 2H, each d, each J=8.4 Hz). IR(CHCl3): 3453, 2662, 1739, 1708, 1652, 1609, 1500, 1333 cm−1. [α]D22+65.2±1.1°(c=1.006, MeOH) Anal. (C27H34N2O3.0.3H2O) Calcd.(%): C, 73.71; H, 7.93; N, 6.37. Found(%): C, 73.85; H, 7.88; N, 6.37.
Compound Number II-7
1H-NMR(CDCl3) δ: 0.95(1H, d, J=10.2 Hz), 1.10 and 1.22 (each 3H, each s), 1.52–2.42(14H, m), 4.25(1H, m), 5.34–5.51(2H, m), 6.35(1H, d, J=8.7 Hz), 7.07–7.15(3H, m), 7.21–7.26(2H, m), 7.73 and 7.77(each 2H, each d, each J=8.7 Hz). IR(CHCl3): 3518, 3446, 3365, 3249, 2673, 1709, 1655, 1516, 1348, 1167 cm−1. [α]D21.5+56.1±0.9°(c=1.000, MeOH) Anal. (C29H36N2O5S.0.6H2O) Calcd.(%): C, 65.05; H, 7.00; N, 5.23; S, 5.99. Found(%): C, 65.07; H, 6.94; N, 5.37; S, 6.03.
Compound Number II-8
1H-NMR(CDCl3) δ: 0.89(1H, d, J=10.2 Hz), 1.05 and 1.19(each 3H, each s), 1.50–2.44(14H, m), 4.15(1H, m), 5.31–5.50(2H, m), 6.31 (1H, d, J=8.1 Hz), 7.00(1H, d, J=1.8 Hz), 7.42–7.47(2H, m), 7.54 (1H, d, J=1.8 Hz), 7.56(1H, m), 7.76–7.79(2H, m), 8.29(1H, s). IR (CHCl3): 3509, 3446, 3360, 3108, 1708, 1639, 1515, 1448, 1330, 1164 cm−1. [α]D20+39.0±0.8°(c=1.006, MeOH) Anal. (C27H34N2O5S2.0.2H2O) Calcd.(%): C, 60.09; H, 6.54; N, 5.19; S, 11.88. Found(%): C, 60.07; H, 6.48; N, 5.31; S, 11.92.
Compound Number II-9
1H-NMR(CDCl3) δ: 0.73(1H, d, J=10.2 Hz), 1.06 and 1.16(each 3H, each s), 1.43–2.36(14H, m), 4.07(1H, m), 5.28–5.49(2H, m), 6.37 (1H, d, J=8.7 Hz), 7.28 and 7.33(each 1H, each d, each J=1.8 Hz), 7.38–7.43 (2H, m), 7.50(1H, m), 7.96–7.99(2H, m). IR(CHCl3): 3440, 3254, 3096, 3062, 1708, 1643, 1560, 1530, 1298 cm−1. [α]D20+49.0±0.9°(c=1.008, MeOH) Anal. (C28H34N2O4S.0.4H2O) Calcd.(%): C, 67.01; H, 6.99; N, 5.58; S, 6.39. Found(%): C, 66.96; H, 7.04; N, 5.67; S, 6.32.
Compound Number II-10
1H-NMR(CDCl3) δ: 0.96(1H, d, J=10.5 Hz), 1.09 and 1.22(each 3H, each s), 1.52–2.44(14H, m), 4.26(1H, m), 5.33–5.49(2H, m), 6.26(1H, d, J=8.4 Hz), 6.31 and 7.15(each 2H, each t, each J=2.1 Hz), 7.81 and 7.89 (each 2H, each d, each J=8.4 Hz). IR(CHCl3): 3514, 3446, 3144, 1708, 1663, 1514, 1377, 1173 cm−1. [α]D22+64.1±0.9°(c=1.000, MeOH) Anal. (C27H34N2O5S.0.2H2O) Calcd.(%): C, 64.57; H, 6.90; N, 5.58; S, 6.38. Found(%): C, 64.50; H, 6.97; N, 5.71; S, 6.28.
Compound Number II-11
1H-NMR(CDCl3) δ: 0.94(1H, d, J=10.2 Hz), 1.08 and 1.21(each 3H, each s), 1.50–2.43(14H, m), 4.12(2H, s), 4.22(1H, m), 5.33–5.49(2H, m), 6.06(1H, d, J=8.7 Hz), 7.04(1H, d, J=1.2 Hz), 7.22–7.34(2H, m), 7.63 (1H, d, J=1.2 Hz). IR(CHCl3): 3517, 3451, 3087, 3065, 2670, 1708, 1708, 1647, 1549, 1508 cm−1. [α]D21.5+41.9±0.8°(c=1.015, MeOH) Anal. (C28H35NO3S) Calcd.(%): C, 72.22; H, 7.58; N, 3.01; S, 6.89. Found(%): C, 72.07; H, 7.57; N, 3.21; S, 6.77.
Compound Number II-12
1H-NMR(CDCl3) δ: 0.94(1H, d, J=10.5 Hz), 1.09 and 1.21(each 3H, each s), 1.50–2.44 (14H, m), 4.24(1H, m), 5.32–5.48(2H, m), 6.24(1H, d, J=8.7 Hz), 7.17 and 7.60(each 2H, each d, each J=8.7 Hz), 7.41–7.46 (2H, m), 7.54(1H, m), 7.80–7.84(2H, m). IR(CHCl3): 3510, 3451, 3371, 3139, 1709, 1647, 1609, 1496, 1163 cm−1. [α]D22.5+47.1±0.9°(c=1.006, MeOH) Anal. (C29H36N2O5S.0.4H2O) Calcd.(%): C, 65.49; H, 6.97; N, 5.27; S, 6.03. Found(%): C, 65.51; H, 6.87; N, 5.39; S, 5.89.
Compound Number II-14
1H-NMR(CHCl3) δ: 0.92(1H, d, J=10.2 Hz), 1.09 and 1.21(each 3H, each s), 1.53–2.47(14H, m), 4.17(1H, m), 5.35–5.55(2H, m), 6.35 and 7.17 (each 2H, each t, each J=2.1 Hz), 6.38(1H, d, J=8.7 Hz), 8.09 and 8.17 (each 1H, each d, each J=1.5 Hz). IR(CHCl3): 3510, 3409, 3144, 3107, 1727, 1.709, 1657, 1538, 1503, 1456, 1387, 1166 cm−1. [α]D25+46.1±0.9°(c=1.005, MeOH) Anal. (C25H32N2O5S2.0.2H2O) Calcd.(%): C, 59.08; H, 6.43; N, 5.51; S, 12.62. Found(%): C, 59.10; H, 6.45; N, 5.69; S, 12.58.
Compound Number II-15
mp.119–121° C. 1H-NMR(CDCl3) δ: 0.97(1H, d, J=10.2 Hz), 1.11 and 1.24(each 3H, each s), 1.53–2.49(14H, m), 4.29(1H, m), 5.39–5.57 (2H, m), 6.37 and 7.22(each 2H, each t, each J=2.1 Hz), 7.13 (1H, d, J=8.4 Hz), 7.50 and 7.93(each 1H, each d, each J=3.9 Hz). IR(Nujol): 3365, 3145, 3100, 1739, 1621, 1548, 1405, 1367, 1187 cm−1. [α]D26.5+45.5±0.8°(c=1.012, MeOH) Anal. (C25H32N2O5S2) Calcd.(%): C, 59.74; H, 6.02; N, 5.57; S, 12.76. Found(%): C, 59.56; H, 6.33; N, 5.64; S, 12.76.
Compound Number II-17
1H-NMR(CDCl3) δ: 0.96 (1H, d, J=10.5 Hz), 1.11 and 1.23(each 3H, each s), 1.54–2.49(14H, m), 4.25(1H, m), 5.35–5.56(2H, m), 6.33 (2H, t, J=2.4 Hz), 6.56(1H, d, J=7.8 Hz), 7.17(2H, t, J=2.4 Hz), 7.58(1H, t, J=7.8 Hz), 7.93(1H, m), 8.04(1H, d, J=7.8 Hz), 8.24(1H, m). IR (CHCl3): 3513, 3389, 3144, 2669, 1726, 1709, 1659, 1515, 1470, 1455, 1375 cm−1. [α]D25+54.0±0.9°(c=1.008, MeOH) Anal. (C27H34N2O5S.0.2H2O) Calcd.(%): C, 64.46; H, 6.90; N, 5.53; S, 6.38. Found(%): C, 64.45; H, 6.89; N, 5.75; S, 6.42.
Compound Number II-18
1H-NMR(CDCl3) δ: 0.96(1H, d, J=10.2 Hz), 1.10 and 1.23(each 3H, each s), 1.52–2.42(14H, m), 2.29(3H, t), 4.26(1H, m), 5.35–5.49(2H, m), 5.96(1H, brs), 6.19(1H, t, J=3.2 Hz), 6.26(1H, d, J=8.1 Hz), 7.25 (1H, m), 7.81(4H, s). IR(CHCl3): 3511, 3446, 3152, 1708, 1662, 1514, 1485, 1368, 1164 cm−1. [α]D27+59.4±1.0°(c=1.006, MeOH) Anal. (C28H36N2O5S) Calcd.(%): C, 65.60; H, 7.08; N, 5.46; S, 6.25. Found(%): C, 65.41; H, 7.00; N, 5.67; S, 6.24.
Compound Number II-19
1H-NMR(CDCl3) δ: 0.97(1H, d, J=10.5 Hz), 1.03 and 1.22(each 3H, each s), 1.452–2.46 (14H, m), 4.26(1H, m), 5.33–5.50(2H, m), 6.20 (2H, t, J=2.1 Hz), 6.22(1H, d, J=8.1 Hz), 6.68(2H, t, J=2.1 Hz), 7.15 and 7.67 (each 2H, each d, each J=8.1 Hz). IR(CHCl3): 3511, 3452, 3103, 2666, 1709, 1652, 1523, 1496 cm−1. [α]D23+57.7±1.0°(c=1.010, MeOH) Anal. (C28H36N2O3.0.1H2O) Calcd.(%): C, 74.67; H, 8.10; N, 6.22. Found(%): C, 74.69; H, 8.21; N, 6.38.
Compound Number II-20
1H-NMR(CDCl3) δ: 0.94(1H, d, J=10.2 Hz), 1.06 and 1.20(each 3H, each s), 1.49–2.40(14H, m), 4.21(1H, m), 5.31–5.45(2H, m), 6.19(1H, d, J=8.4 Hz), 6.88(1H, d, J=3.6 Hz), 7.22–7.35(2H, m), 7.52–7.55(2H, m), 7.74 and 7.91(each 2H, each d, each J=8.4 Hz), 7.98(1H, d, J=8.4 Hz). IR(CHCl3): 3481, 3440, 3145, 3116, 2661, 1709, 1660, 1516, 1485, 1446, 1377, 1261, 1178, 1130 cm−1. [α]D26+56.6±1.0°(c=1.000, MeOH) Anal. (C31H36N2O5S.0.1H2O) Calcd.(%): C, 67.64; H, 6.63; N, 5.09; S, 5.82. Found(%): C, 67.68; H, 6.72; N, 5.35; S, 5.73.
Compound Number II-21
1H-NMR(CDCl3) δ: 0.95(1H, d, J=10.2 Hz), 1.09 and 1.22 (each 3H, each s), 1.52–2.45(14H, m), 4.24(1H, m), 4.63(2H, s), 5.34–5.50(2H, m), 6.25–6.27(2H, m), 6.40(1H, d, J=8.4 Hz), 7.25(1H, dd, J=1.8 and 3.0 Hz), 7.80 and 7.85(each 2H, each d, each J=8.7 Hz). IR(CHCl3): 3581, 3518, 3445, 3149, 2666, 1709, 1661, 1515, 1472, 1371, 1182, 1150 cm−1. [α]D27+58.1±1.0°(c=1.007, MeOH) Anal. (C28H36N2O6S) Calcd.(%): C, 63.61; H, 6.86; N, 5.30; S, 6.07. Found(%): C, 63.50; H, 6.84; N, 5.44; S, 5.89.
Compound Number II-31
mp.98–100° C. 1H-NMR(CDCl3) δ: 0.94(1H, d, J=10.2 Hz), 1.08 and 1.21(each 3H, each s), 1.50–2.43(14H, m), 4.13(2H, s), 4.20 (1H, m), 5.33–5.49(2H, m), 5.97(1H, d, J=8.4 Hz), 6.77(1H, m), 7.21–7.35(6H, m). IR(KBr): 3407, 2674, 1703, 1630, 1511 cm−1. [α]D24+46.8±0.9°(c=1.006, MeOH) Anal. (C28H35NO3S) Calcd.(%): C, 72.22; H, 7.58; N, 3.01; S, 6.89. Found(%): C, 72.04; H, 7.36; N, 3.27; S, 6.91.
Compound Number II-37
1H-NMR(CDCl3) δ: 0.93(1H, d, J=10.5 Hz), 1.08 and 1.21(each 3H, each s), 1.50–2.41(14H, m), 4.20(1H, m), 5.39–5.47(2H, m), 6.19(1H, d, J=8.4 Hz), 7.35(1H, d, J=3.9 Hz), 7.51–7.64(4H, m), 7.98(2H, m). IR(CHCl3): 3516, 3446, 2667, 1709, 1657, 1529, 1504, 1327, 1157 cm−1. [α]D20+55.6°±1.0°(c=1.004, MeOH) Anal. (C27H3NO5S.0.2H2O) Calcd.(%) C, 62.45; H, 6.48; N, 2.70; S, 12.35. Found(%): C, 62.46; H, 6.40; N, 2.75; S, 12.19.
Compound Number II-47
1H-NMR(CDCl3) δ: 0.93(1H, d, J=10.2 Hz), 1.08 and 1.21(each 3H, each s), 1.50–2.41(14H, m), 4.21(1H, m), 5.34–5.48(2H, m), 6.21(1H, d, J=8.4 Hz), 7.36 and 7.63(each 1H, each d, each J=3.9 Hz), 7.70(1H, dd, J=1.5 and 5.1 Hz), 7.75(1H, dd, J=1.5 and 3.9 Hz). IR(CHCl3): 3516, 3446, 3097, 1708, 1656, 1529, 1504, 1337, 1153 cm−1. [α]D25+54.1±0.9°(c=1.000, MeOH) Anal. (C25H31NO5S3) Calcd.(%): C, 57.56; H, 5.99; N, 2.68; S, 18.44. Found(%): C, 57.33; H, 5.95; N, 2.68; S, 18.38.
Compound Number II-55
1H-NMR(CDCl3) δ: 0.93(1H, d, J=10.5 Hz), 1.08 and 1.22(each 3H, each s), 1.50–2.41(14H, m), 2.39(3H, d, J=0.6 Hz), 4.21(1H, m), 5.35–5.48(2H, m), 5.99(1H, m), 6.15(1H, d, J=8.7 Hz), 6.20(1H, t, J=3.3 Hz), 7.18(1H, dd, J=1.8 and 3.3 Hz), 7.31 and 7.54(each 1H, each d, each J=3.9 Hz). IR(CHCl3): 3511, 3446, 3150, 3101, 1708, 1658, 1529, 1504, 1375, 1183, 1160 cm−1. [α]D23+50.3±0.9°(c=1.007, MeOH) Anal. (C26H34N2O5S2.0.2H2O) Calcd.(%): C, 59.79; H, 6.64; N, 5.36; S, 12.28. Found(%): C, 59.72; H, 6.61; N, 5.51; S, 12.37.
Compound Number II-59
1H-NMR(CDCl3) δ: 0.93(1H, d, J=10.2 Hz), 1.07 and 1.21(each 3H, each s), 1.49–2.41(14H, m), 4.19(1H, m), 5.33–5.47(2H, m), 5.99(1H, d, J=8.7 Hz), 7.01(1H, dd, J=3.6 and 5.4 Hz), 7.04 and 7.28(each 1H, each d, each J=3.6 Hz), 7.29(1H, dd, J=1.2 and 3.6 Hz), 7.43(1H, dd, J=1.2 and 5.4 Hz). IR(CHCl3): 3518, 3449, 3430, 2672, 1708, 1646, 1530, 1500, 1421 cm−1. [α]D25.5+45.9±0.9°(c=1.010, MeOH) Anal. (C25H31NO3S3) Calcd.(%): C, 61.32; H, 6.38; N, 2.86; S, 19.64. Found(%): C, 61.17; H, 6.42; N, 3.00; S, 19.80.
Compound Number II-60
1H-NMR (CHCl3) δ: 0.96 (1H,d,J=10.2 Hz),1.10 and 1.22 (each 3H, each s), 1.51–1.79 (3H, m), 1.83–2.44 (11H, m), 4.26 (1H, m), 5.33–5.49 (2H, m), 6.21 (1H, d, J=8.7 Hz), 7.25 (2H, d, J=9.0 Hz), 7.34–7.47 (5H,m), 7.60 (2H, d, J=9.0 Hz) IR (CHCl3): 3453, 3062, 3029, 3014, 2925, 2870, 1739, 1708, 1651, 1595, 1583, 1557, 1515, 1481 cm−1. [α]D22+61.0°(c=1.01,CH3OH) Anal. (C29H35NO3S.0.1H2O) Calcd.(%): C, 72.65; H, 7.48; N, 2.92; S, 6.69. Found (%): C, 72.50; H, 7.45; N, 3.19; S, 6.69.
Compound Number II-81
1H-NMR(CDCl3) δ: 0.93(1H, d, J=10.2 Hz), 1.07 and 1.21(each 3H, each s), 1.49–2.41(14H, m), 2.46(3H, d, J=1.2 Hz), 4.18(1H, m), 5.33–5.47(2H, m), 5.99(1H, d, J=8.4 Hz), 6.66(1H, m), 6.99(1H, d, J=3.9 Hz), 7.10(1H, d, J=3.3 Hz), 7.26(1H, d, J=3.9 Hz). IR(CHCl3): 3509, 3449, 2671, 1708, 1645, 1530, 1500, 1420 cm−1. [α]D25.5+43.5±0.8°(c=1.002, MeOH) Anal. (C26H33NO3S3) Calcd.(%): C, 61.99; H, 6.60; N, 2.78; S, 19.10. Found(%): C, 61.77; H, 6.68; N, 2.83; S, 18.91.
Compound Number II-82
mp.118–120° C. 1H-NMR(CDCl3) δ: 0.94(1H, d, J=10.2 Hz), 1.09 and 1.22(each 3H, each s), 1.51–2.42(14H, m), 2.53(3H, d, J=0.9 Hz), 4.20 (1H, m), 5.35–5.48(2H, m), 6.17(1H, d, J=8.7 Hz), 6.77(1H, m), 7.34 (1H, d, J=3.9 Hz), 7.57(1H, d, J=3.6 Hz), 7.60(1H, d, J=3.9 Hz). IR (Nujol): 3399, 3082, 1733, 1613, 1543, 1328, 1318, 1151 cm−1. [α]D25.5+54.0±0.9°(c=1.012, MeOH) Anal. (C26H33NO5S3) Calcd.(%): C, 58.29; H, 6.21; N, 2.61; S, 17.95. Found(%): C, 58.08; H, 6.18; N, 2.73; S, 17.66.
Compound Number II-88
mp.91–92° C. 1H-NMR(CDCl3) δ: 0.95(1H, d, J=10.5 Hz), 1.09 and 1.22(each 3H, each s),1.51–2.44(14H, m), 4.16(2H, s), 4.20 (1H, m), 5.34–5.49(2H, m), 5.99(1H, d, J=8.7 Hz), 6.79(1H, d, J=3.9 Hz), 6.96 (1H, dd, J=1.2 and 4.8 Hz), 7.05(1H, m), 7.28(1H, dd, J=3.0 and 4.8 Hz), 7.32(1H, d, J=3.9 Hz). IR(Nujol): 3408, 2677, 1703, 1626, 1541, 1514, 1246 cm−1. [α]D26+43.8±0.8°(c=1.005, MeOH) Anal. (C26H33NO3S2) Calcd.(%): C, 66.21; H, 7.05; N, 2.97; S, 13.60. Found(%): C, 66.00; H, 7.81; N, 3.11; S, 13.69.
Compound Number II-92
mp.165–166° C. 1H-NMR(CDCl3) δ: 0.93(1H, d, J=10.2 Hz), 1.08 and 1.20(each 3H, each s), 1.50–2.45(14H, m), 4.17(1H, m), 5.33–5.51(2H, m), 6.04(1H, d, J=8.4 Hz), 6.51(1H, dd, J=1.5 and 3.3 Hz), 7.15(1H, dd, J=2.4 and 3.3 Hz), 7.52–7.57(2H, m), 7.65(1H, m), 7.74(1H, dd, J=1.8 and 2.1 Hz), 7.89–7.93(1H, m). IR(CHCl3): 3510, 3449, 3144, 1733, 1708, 1650, 1570, 1507, 1384, 1185, 1176 cm−1. [α]D24+33.8±0.7°(c=1.011, MeOH) Anal. (C27H34N2O5S) Calcd.(%): C, 65.04; H, 6.87; N, 5.62; S, 6.43. Found(%): C, 64.95; H, 6.68; N, 5.69; S, 6.40.
Compound Number II-93
1H-NMR(CDCl3) δ: 0.93(1H, d, J=10.2 Hz), 1.08 and 1.21(each 3H, each s), 150–2.46(14H, m), 4.19(1H, m), 5.33–5.50(2H, m), 6.03(1H, d, J=8.7 Hz), 6.52(1H, dd, J=1.5 and 3.3 Hz), 7.11(1H, dd, J=3.9 and 4.8 Hz), 7.17(1H, dd, J=2.1 and 3.3 Hz), 7.70–7.72(2H, m), 7.74(1H, dd, J=1.2 and 3.9 Hz). IR(CHCl3): 3510, 3448, 3143, 2666, 1733, 1708, 1650, 1572, 1507, 1387, 1179 cm−1. [α]D24+39.1°±0.8° (c=1.003, MeOH) Anal. (C25H32N2O5S2) Calcd.(%): C, 59.50; H, 6.39; N, 5.55; S, 12.71. Found(%): C, 59.49; H, 6.46; N, 5.47; S, 12.70.
Compound Number II-94
mp.132–133° C. 300 MHz 1H-NMR(CDCl3) δ: 0.93(1H, d, J=10.2 Hz), 1.08 and 1.21(each 3H, each s), 1.54–2.44(14H, m), 4.19(1H, m), 5.33–5.50 (2H, m), 6.03(1H, d, J=8.7 Hz), 6.52(1H, dd, J=1.5 and 3.3 Hz), 7.11(1H, dd, J=3.9 and 4.8 Hz), 7.17(1H, dd, J=2.1 and 3.3 Hz), 7.70–7.72(2H, m), 7.74(1H, dd, J=1.5 and 3.9 Hz). IR(CHCl3): 3510, 3448, 3143, 3099, 1733, 1708, 1650, 1572, 1507, 1473, 1387, 1179 cm−1. [α]D24+39.1±0.8°(c=1.003, MeOH) Anal. (C25H32N2O5S2) Calcd.(%): C, 59.50; H, 6.39; N, 5.55; S, 12.71. Found(%): C, 59.49; H, 6.46; N, 5.47; S, 12.70.
Compound Number II-98
mp.138–139° C. 1H-NMR(CDCl3) δ: 0.97(1H, d, J=10.2 Hz), 1.13 and 1.24(each 3H, each s), 1.50–2.47(14H, m), 4.24(1H, m), 5.36–5.52 (2H, m), 6.06(1H, d, J=8.4 Hz), 6.98(1H, d, J=3.9 Hz), 6.99 and 7.05 (each 1H, each d, each J=16.2 Hz), 7.28–7.34(3H, m), 7.37 (1H, d, J=3.9 Hz). IR(CHCl3): 3518, 3449, 3431, 2665, 1708, 1642, 1538, 1519, 1500 cm−1. [α]D24+49.1±0.9°(c=1.014, MeOH) Anal. (C27H33NO3S2) Calcd.(%): C, 67.05; H, 6.88; N, 2.90; S, 13.26. Found(%): C, 67.94; H, 6.86; N, 2.99; S, 13.23.
Compound Number II-99
1H-NMR(CDCl3) δ: 0.94(1H, d, J=9.9 Hz), 1.07 and 1.22 (each 3H, each s), 1.50–2.44(14H, m), 4.20(1H, m), 5.30–5.51(2H, m), 5.97(1H, d, J=9.0 Hz), 6.58(2H, s), 6.95(1H, d, J=3.9 Hz), 7.02(1H, dd, J=1.5 and 4.8 Hz), 7.25–7.31(2H, m), 7.31(1H, d, J=3.9 Hz). IR(CHCl3): 3517, 3449, 3430, 2664, 1708, 1642, 1536, 1519, 1501 cm−1. [α]D24+38.6±0.8°(c=1.006, MeOH) Anal. (C27H33NO3S2.0.2H2O) Calcd.(%): C, 66.55; H, 6.91; N, 2.87; S, 13.16. Found(%): C, 66.52; H, 6.81; N, 3.11; S, 12.93.
Compound Number II-100
1H-NMR(CDCl3) δ: 0.94(1H, d, J=10.2 Hz), 1.09 and 1.22(each 3H, each s), 1.50–2.39(14H, m), 2.44(3H, d, J=0.9 Hz), 4.20(1H, m), 5.34–5.49(2H, m), 5.98(1H, d, J=8.7 Hz), 6.70(1H, m), 7.06(1H, d, J=3.9 Hz), 7.10(1H, d, J=1.8 Hz), 7.30(1H, d, J=3.9 Hz). IR(CHCl3): 3518, 3450, 3430, 3110, 2669, 1740, 1708, 1645, 1530, 1499, 1420 cm−1. [α]D24+46.0±0.9°(c=0.968, MeOH) Anal. (C26H33NO3S3) Calcd.(%): C, 61.99; H, 6.60; N, 2.78; S, 19.10. Found(%): C, 61.99; H, 6.61; N, 2.87; S, 19.18.
Compound Number II-101
1H-NMR(CDCl3) δ: 0.94(1H, d, J=10.5 Hz), 1.09 and 1.22(each 3H, each s), 1.51–2.42(14H, m), 2.47(3H, d, J=0.9 Hz), 4.21(1H, m), 5.35–5.49(2H, m), 6.18(1H, d, J=8.7 Hz), 7.04(1H, m), 7.36 and 7.60(each 1H, each d, each J=3.9 Hz), 7.91(1H, d, J=1.5 Hz). IR(CHCl3): 3510, 3447, 3115, 2670, 1708, 1656, 1529, 1504, 1443, 1329, 1156, 1143 cm−1. [α]D24+53.8±0.9°(c=1.008, MeOH) Anal. (C26H33NO5S3) Calcd.(%): C, 58.29; H, 6.21; N, 2.61; S, 17.96. Found(%): C, 58.07; H, 6.05; N, 2.69; S, 17.94.
Compound Number II-102
1H-NMR(CDCl3) δ: 0.94(1H, d, J=10.2 Hz), 1.09 and 1.22(each 3H, each s), 1.50–2.45(14H, m), 4.22(1H, m), 5.35–5.49(2H, m), 6.04(1H, d, J=8.7 Hz), 6.52 and 6.69(each 1H, each d, each J=12.0 Hz), 6.99 (1H, dd, J=3.6 and 5.1 Hz), 7.07(1H, d, J=3.9 Hz), 7.13(1H, d, J=3.9 Hz), 7.27(1H, dd, J=0.9 and 5.1 Hz) 7.36(1H, d, J=3.9 Hz). IR (CHCl3): 3510, 3449, 3430, 2664, 1708, 1643, 1536, 1501 cm−1. [α]D24+40.3±0.8°(c=1.011, MeOH) Anal. (C27H33NO3S2.0.3H2O) Calcd.(%): C, 66.31; H, 6.92; N, 2.86; S, 13.11. Found(%): C, 66.29; H, 6.81; N, 3.07; S, 13.13.
Compound Number II-103
mp.117–118° C. 1H-NMR(CDCl3) δ: 0.97(1H, d, J=10.2 Hz), 1.13 and 1.24(each 3H, each s), 1.50–2.47(14H, m), 4.24(1H, m), 5.36–5.52(2H, m), 6.06(1H, d, J=8.7 Hz), 6.97 and 7.15(each 1H, each d, each J=15.9 Hz), 6.98(1H, d, J=3.9 Hz), 7.01(1H, dd, J=3.3 and 4.8 Hz), 7.09 (1H, d, J=3.3 Hz), 7.23(1H, d, J=4.8 Hz), 7.36(1H, d, J=3.9 Hz). IR(CHCl3): 3517, 3450, 2670, 1738, 1708, 1641, 1537, 1518, 1500 cm−1. [α]D24+55.7±1.0°(c=1.001, MeOH) Anal. (C27H33NO3S2) Calcd.(%): C, 67.05; H, 6.88; N, 2.90; S, 13.26. Found(%): C, 66.91; H, 6.83; N, 2.97; S, 13.13.
Compound Number II-107
1H-NMR(CDCl3) δ: 0.93(1H, d, J=10.2 Hz), 1.09 and 1.22(each 3H, each s), 1.51–2.44(14H, m), 4.20(1H, m), 5.34–5.50(2H, m), 6.22 and 6.23(total 1H, each d, J=8.1 and 8.7 Hz), 7.12(1H, dd, J=3.9 and 5.1 Hz), 7.44(2H, m), 7.60(1H, m), 7.69(1H, m). IR(CHCl3): 3509, 3447, 3092, 1708, 1653, 1530, 1503 cm−1. [α]D23+49.3±0.9°(c=1.002, MeOH) Anal. (C25H31NO4S3.0.4H2O) Calcd.(%): C, 58.54; H, 6.25; N, 2.73; S, 18.75. Found(%): C, 58.62; H, 6.16; N, 2.88; S, 18.72.
Compound Number II-108
1H-NMR(CDCl3) δ: 0.94(1H, d, J=10.2 Hz), 1.09 and 1.10(total 3H, each s), 1.22 and 1.23(total 3H, each s), 1.51–2.44(14H, m), 2.52 and 2.53(total 3H, each d, J=0.6 Hz), 4.20(1H, m), 5.35–5.50(2H, m), 6.23 and 6.24(total 1H, each d, J=8.7 and 8.4 Hz), 6.77(1H, m), 7.39–7.46 (3H, m). IR (CHCl3): 3510, 3447, 3429, 3093, 2665, 1708, 1652, 1530, 1502, 1437 cm−1. [α]D23+47.4±0.9°(c=1.008, MeOH) Anal. (C26H33NO4S3.0.3H2O) Calcd.(%): C, 59.47; H, 6.45; N, 2.67; S, 18.32. Found(%): C, 59.59; H, 6.16; N, 2.76; S, 18.11.
Compound Number II-112
1H-NMR(CDCl3) δ: 0.94(1H, d, J=10.2 Hz), 1.09 and 1.21(each 3H, each s), 1.51–2.43(14H, m), 3.38(3H, s), 4.18(1H, m), 5.33–5.50(2H, m), 5.83(1H, d, J=8.7 Hz), 6.16(1H, d, J=3.9 Hz), 7.14(1H, m), 7.21–7.27 (4H, m), 7.33–7.39(2H, m). IR(CHCl3): 3514, 3450, 2661, 1739, 1709, 1628, 1597, 1495, 1479, 1415, 1132 cm−1. [α]D23.5+50.8°±0.9° (c=1.005, MeOH) Anal. (C28H36N2O3S.0.2H2O) Calcd.(%): C, 69.45; H, 7.58; N, 5.78; S, 6.62. Found(%): C, 69.45; H, 7.39; N, 5.99; S, 6.65.
Compound Number II-113
1H-NMR(CDCl3) δ: 0.95(1H, d, J=10.5 Hz), 1.09 and 1.22(each 3H, each s), 1.50–2.44(14H, m), 2.31(3H, s), 4.22(1H, m), 5.35–5.49(2H, m), 6.01(1H, d, J=8.7 Hz), 7.03–7.21(4H, m), 7.38(1H, d, J=3.9 Hz). IR(CHCl3): 3516, 3448, 3429, 1739, 1709, 1647, 1529, 1500, 1473, 1421 cm−1. [α]D20+46.2°±1.0°(c=1.003, MeOH) Anal. (C28H35NO3S2.0.2H2O) Calcd.(%): C, 67.08; H, 7.12; N, 2.79; S, 12.79. Found(%): C, 67.12; H, 7.04; N, 2.94; S, 12.88.
Compound Number II-114
mp.112–115° C. 1H-NMR(CDCl3) δ: 0.93(1H, d, J=10.2 Hz), 1.08 and 1.21(each 3H, each s), 1.50–2.39(14H, m), 2.42(3H, s), 4.20(1H, m), 5.34–5.47(2H, m), 6.17(1H, d, J=8.7 Hz), 7.34(1H, d, J=3.9 Hz), 7.41 (2H, m), 7.59(1H, d, J=3.9 Hz), 7.78(2H, m). IR(CHCl3): 3516, 3446, 1739, 1707, 1655, 1529, 1504, 1331, 1151 cm−1. [α]D20+53.0°±0.9°(c=1.002, MeOH) Anal. (C28H35NO5S2.0.2H2O) Calcd.(%): C, 63.06; H, 6.69; N, 2.63; S, 12.02. Found(%): C, 63.07; H, 6.62; N, 2.73; S, 12.04.
Compound Number II-115
1H-NMR(CDCl3) δ: 0.95(1H, d, J=10.2 Hz), 1.09 and 1.22(each 3H, each s), 1.50–2.44(14H, m), 3.77(3H, s), 4.22(1H, m), 5.35–5.49(2H, m), 6.04(1H, d, J=8.7 Hz), 6.74–6.89(3H, m), 7.17–7.23(2H, m), 7.40 (1H, d, J=3.9 Hz). IR(CHCl3): 3514, 3448, 3431, 1739, 1707, 1649, 1529, 1500, 1477 cm−1. [α]D20+45.8°±0.9°(c=1.011, MeOH) Anal. (C28H35NO4S2.0.3H2O) Calcd.(%): C, 64.78; H, 6.91; N, 2.70; S, 12.35. Found(%): C, 64.62; H, 6.83; N, 2.85; S, 12.65.
Compound Number II-116
1H-NMR(CDCl3) δ: 0.93(1H, d, J=10.5 Hz), 1.08 and 1.21(each 3H, each s), 1.50–2.41(14H, m), 3.86(3H, s), 4.20(1H, m), 5.34–5.47 (2H, m), 6.17(1H, d, J=8.7 Hz), 7.12(1H, m), 7.35(1H, d, J=3.9 Hz), 7.40–7.48(2H, m), 7.56(1H, m), 7.60(1H, d, J=3.9 Hz). IR(CHCl3): 3514, 3446, 2667, 1707, 1657, 1599, 1529, 1504, 1481, 1329, 1252, 1151 cm−1. [α]D20+52.6°±0.9°(c=1.011, MeOH) Anal. (C28H35NO6S2.0.2H2O) Calcd.(%): C, 61.22; H, 6.50; N, 2.55; S, 11.67. Found(%): C, 61.10; H, 6.36; N, 2.65; S, 11.73.
Compound Number II-117
1H-NMR(CDCl3) δ: 0.92(1H, d, J=10.5 Hz), 1.07 and 1.20(each 3H, each s), 1.52–2.43(14H, m), 4.18(1H, m), 5.33–5.50(2H, m), 6.42(1H, d, J=8.4 Hz), 7.07(1H, m), 7.33–7.39(2H, m), 7.46–7.51(2H, m), 7.56 (1H, d, J=3.9 Hz). IR(CHCl3): 3587, 3442, 3280, 1707, 1643, 1531, 1329, 1308, 1149 cm−1. [α]D20+53.2°±0.9°(c=1.010, MeOH) Anal. (C27H33NO6S2.0.4H2O) Calcd.(%): C, 60.18; H, 6.32; N, 2.60; S, 11.90. Found(%): C, 60.19; H, 6.06; N, 2.63; S, 11.99.
Compound Number II-118
1H-NMR(CDCl3) δ: 0.91(1H, d, J=10.2 Hz), 1.08 and 1.21(each 3H, each s), 1.50–2.45(14H, m), 4.20(1H, m), 5.33–5.50(2H, m), 6.17(1H, d, J=8.7 Hz), 6.72(2H, m), 6.79(1H, m), 7.11(2H, m), 7.38(1H, d, J=3.9 Hz). IR(CHCl3): 3342, 2669, 1707, 1622, 1583, 1535 cm−1. [α]D23+45.6°±0.9°(c=1.007, MeOH) Anal. (C27H33NO4S2.0.2H2O) Calcd.(%): C, 64.44; H, 6.69; N, 2.78; S, 12.74. Found(%): C, 64.33; H, 6.59; N, 2.83; S, 13.07.
Compound Number II-119
1H-NMR(CDCl3) δ: 0.94(1H, d, J=10.5 Hz), 1.08 and 1.21(each 3H, each s), 1.50–2.43(14H, m), 3.79(3H, s), 4.10(2H, s), 4.20(1H, m), 5.33–5.49(2H, m), 5.98(1H, d, J=8.7 Hz), 6.76–6.85(4H, m), 7.24(1H, m), 7.32(1H, d, J=3.9 Hz). IR(CHCl3): 3516, 3450, 3431, 2669, 1738, 1709, 1641, 1600, 1437, 1261 cm−1. [α]D23.5+42.8°±0.8°(c=1.005, MeOH.) Anal. (C29H37NO4S) Calcd.(%): C, 70.27; H, 7.52; N, 2.83; S, 6.47. Found(%): C, 70.05; H, 7.55; N, 2.84; S, 6.45.
Compound Number II-125
1H-NMR(CDCl3) δ: 0.93(1H, d, J=9.9 Hz), 1.08 and 1.21(each 3H, each s), 1.50–2.42(14H, m), 2.28(3H, s), 4.12(2H, s), 4.20(1H, m), 5.33–5.48 (2H, m), 5.98(1H, d, J=9.0 Hz), 6.71(1H, d, J=3.6 Hz), 7.17 (4H, s), 7.30(1H, d, J=3.6 Hz). IR(CHCl3): 3518, 3450, 3430, 1739, 1709, 1641, 1543, 1506, 1471, 1458 cm−1. [α]D22.5+42.9°±0.8°(c=1.000, MeOH) Anal. (C29H37NO3S) Calcd.(%): C, 72.61; H, 7.77; N, 2.92; S, 6.68. Found(%): C, 72.43; H, 7.78; N, 3.09; S, 6.62.
Compound Number II-126
1H-NMR(CDCl3) δ: 0.93(1H, d, J=10.5 Hz), 1.08 and 1.21(each 3H, each s), 1.50–2.42(14H, m), 3.84(3H, s), 4.12(2H, s), 4.19(1H, m), 5.33–5.48 (2H, m), 5.98(1H, d, J=9.0 Hz), 6.77(1H, dt, J=0.9 and 3.9 Hz), 6.88(1H, d, J=8.1 Hz), 9.90(1H, m), 7.15(1H, m), 7.23(1H, m), 7.28(1H, d, J=3.9 Hz). IR(CHCl3): 3509, 3450, 3431, 2664, 1739, 1708, 1639, 1544, 1506, 1464 cm−1. [α]D24+40.4°±0.8°(c=1.003, MeOH) Anal. (C29H37NO4S.0.1H2O) Calcd.(%): C, 70.02; H, 7.53; N, 2.81; S, 6.45. Found(%): C, 69.92; H, 7.53; N, 2.96; S, 6.46.
Compound Number II-127
1H-NMR(CDCl3) δ: 0.94(1H, d, J=10.5 Hz), 1.08 and 1.21(each 3H, each s),1.18(3H, t, J=7.8 Hz), 1.50–2.42(14H, m), 2.64(2H, q, J=7.8 Hz), 4.15(2H, s), 4.19(1H, m), 5.33–5.48(2H, m), 5.96(1H, d, J=9.3 Hz), 6.68 (1H, d, J=3.6 Hz), 7.16–7.25(4H, m), 7.29(1H, d, J=3.6 Hz). IR (CHCl3): 3516, 3450, 3431, 2667, 1739, 1709, 1641, 1543, 1506, 1471, 1456 cm−1. [α]D21+41.9±0.8°(c=1.013, MeOH) Anal. (C30H39NO3S.0.1H2O) Calcd.(%): C, 72.72; H, 7.97; N, 2.83; S, 6.47. Found(%): C, 72.55; H, 7.88; N, 3.19; S, 6.62.
Compound Number II-129
1H-NMR(CDCl3) δ: 0.94(1H, d, J=9.9 Hz), 1.09 and 1.22(each 3H, each s),1.50–2.42(14H, m), 2.43(3H, s), 4.20(1H, m), 4.24(2H, s), 5.34–5.49 (2H, m), 5.99(1H, d, J=8.7 Hz), 6.58(1H, m), 6.67(1H, d, J=3.3 Hz), 6.83(1H, d, J=3.9 Hz), 7.32(1H, d, J=3.9 Hz). IR (CHCl3): 3516, 3450, 3431, 2667, 1709, 1643, 1545, 1508, 1471, 1458 cm−1. [α]D22+42.8±0.8°(c=1.006, MeOH) Anal. (C27H35NO3S2) Calcd.(%): C, 66.77; H, 7.26; N, 2.88; S, 13.20. Found(%): C, 66.60; H, 7.23; N, 2.93; S, 13.19.
Compound Number II-132
1H-NMR(CDCl3) δ: 0.94(1H, d, J=10.5 Hz), 1.09 and 1.22(each 3H, each s), 1.50–2.44(14H, m), 2.31(3H, s), 4.21(1H, m), 4.25(2H, s), 5.34–5.49 (2H, m), 6.01(1H, d, J=8.7 Hz), 6.83(1H, d, J=3.9 Hz), 7.03 (1H, m), 7.11–7.20(3H, m), 7.27(1H, d, J=3.9 Hz). IR(CHCl3): 3516, 3450, 3431, 2665, 1739, 1709, 1643, 1543, 1508, 1473 cm1. [α]D22+42.6±1.0°(c=0.861, MeOH) Anal. (C29H37NO3S2H2O) Calcd.(%): C, 67.59; H, 7.31; N, 2.72; S, 12.44. Found(%): C, 67.49; H, 7.27; N, 2.82; S, 12.35.
Compound Number II-133
1H-NMR(CDCl3) δ: 0.95(1H, d, J=10.5 Hz), 1.09 and 1.21(each 3H, each s), 1.50–2.44(14H, m), 4.15(2H, s), 4.20(1H, m), 5.33–5.49(2H, m), 6.0(1H, d, J=9.3 Hz), 6.13(1H, dd, J=0.6 and 3.0 Hz), 6.32(1H, dd, J=1.8 and 3.0 Hz), 6.84 and 7.22(each 1H, each d, each J=3.6 Hz), 7.47(1H, dd, J=0.6 and 1.8 Hz). IR(CHCl3): 3518, 3450, 3431, 2669, 1739, 1709, 1643, 1545, 1506 cm−1. [α]D23+45.8±0.9°(c=1.003, MeOH) Anal. (C26H33NO4S.0.6H2O) Calcd.(%): C, 66.95; H, 7.39; N, 3.00; S, 6.87. Found(%): C, 67.04; H, 7.17; N, 3.11; S, 7.03.
Compound Number II-134
1H-NMR(CDCl3) δ: 0.95(1H, d, J=10.5 Hz), 1.10 and 1.22(each 3H, each s), 1.52–2.45(14H, m), 3.96(2H, s), 4.20(1H, m), 5.33–5.49(2H, m), 6.00(1H, d, J=8.7 Hz), 6.30(1H, dd, J=0.9 and 1.8 Hz), 6.81(1H, d, J=3.6 Hz), 7.31–7.33(2H, m), 7.38(1H, t, J=1.8 Hz). IR(CHCl3): 3516, 3450, 3431, 2663, 1739, 1709, 1643, 1545, 1506 cm−1. [α]D21+46.5±0.9°(c=1.002, MeOH) Anal. (C26H33NO4S.0.1H2O) Calcd.(%): C, 68.27; H, 7.32; N, 3.06; S, 7.01. Found(%): C, 68.08; H, 7.14; N, 3.21; S, 7.19.
Compound Number II-135
1H-NMR(CDCl3) δ: 0.94(1H, d, J=10.2 Hz), 1.09 and 1.21(each 3H, each s), 1.50–2.42(14H, m), 4.20(1H, m), 4.41(2H, s), 5.33–5.49(2H, m), 6.01(1H, d, J=8.7 Hz), 6.91(1H, d, J=3.6 Hz), 7.11(1H, s), 7.27–7.35(3H, m), 7.68–7.77(2H, m). IR(CHCl3): 3512, 3446, 3431, 1709, 1645, 1543, 1508 cm−1. [α]D24+44.9±0.9°(c=1.002, MeOH) Anal. (C30H35NO3S2.0.3H2O) Calcd.(%): C, 68.35; H, 6.81; N, 2.66; S, 12.17. Found(%): C, 68.17; H, 6.52; N, 2.68; S, 12.04.
Compound Number II-136
1H-NMR(CDCl3) δ: 0.94(1H, d, J=10.5 Hz), 1.09 and 1.21(each 3H, each s), 1.50–2.41(14H, m), 4.19(1H, m), 4.29(2H, s), 5.33–5.48(2H, m), 6.02(1H, d, J=8.4 Hz), 6.51(1H, s), 6.91(1H, d, J=3.6 Hz), 7.16–7.25 (2H, m), 7.34(1H, d, J=3.6 Hz), 7.42(1H, d, J=8.4 Hz), 7.50(1H, m). IR(CHCl3): 3516, 3450, 3431, 1739, 1709, 1643, 1545, 1508, 1454 cm−1. [α]D23+42.3±0.8°(c=1.001, MeOH) Anal. (C30H35NO4S.0.3H2O) Calcd.(%): C, 70.50; H, 7.02; N, 2.74; S, 6.27. Found(%): C, 70.36; H, 6.94; N, 2.70; S, 6.17.
Compound Number II-138
1H-NMR(CDCl3) δ: 0.94(1H, d, J=10.2 Hz), 1.08 and 1.20(each 3H, each s), 1.49–2.42(14H, m), 4.20(1H, m), 4.19(2H, s), 5.33–5.48(2H, m), 5.99(1H, d, J=9.0 Hz), 6.80(1H, d, J=3.6 Hz), 7.22 (1H, d, J=7.5 Hz), 7.31–7.50(7H, m), 7.57(2H, m). IR(CHCl3): 3518, 3450, 3431, 2671, 1739, 1709, 1643, 1543, 1506, 1471, 1456 cm−1. [α]D24+38.7±0.8°(c=1.014, MeOH) Anal. (C34H39NO3S.0.2H2O) Calcd.(%): C, 74.88; H, 7.28; N, 2.57; S, 5.88. Found(%): C, 74.92; H, 7.30; N, 2.75; S, 5.99.
Compound Number II-139
1H-NMR(CDCl3) δ: 0.97(1H, d, J=10.2 Hz), 1.06 and 1.22(each 3H, each s),1.52–2.48(14H, m), 4.11(2H, s), 4.31(1H, m), 5.34–5.51(2H, m), 6.15(1H, d, J=9.0 Hz), 7.19–7.30(6H, m), 7.76(1H, d, J=8.1 Hz), 7.83(1H, s), 8.15(1H, s) IR(CHCl3): 3516, 3442, 2667, 1739, 1709, 1651, 1514, 1495, 1471, 1454, 1435 cm−1. [α]D24+42.8±0.8°(c=1.011, MeOH) Anal. (C32H37NO3S) Calcd.(%): C, 74.53; H, 7.23; N, 2.72; S, 6.22. Found(%): C, 74.25; H, 7.20; N, 2.97; S, 6.05.
Compound Number II-140
1H-NMR(CDCl3) δ: 0.98(1H, d, J=10.2 Hz), 1.10 and 1.23(each 3H, each s),1.52–2.49(14H, m), 4.10(2H, s), 4.32(1H, m), 5.35–5.53(2H, m), 6.17(1H, d, J=8.7 Hz), 7.19–7.32(6H, m), 7.64(1H, d, J=0.9 Hz), 7.76(1H, s), 8.21(1H, d, J=8.4 Hz). IR(CHCl3): 3518, 3442, 2671, 1739, 1707, 1651, 1514, 1493, 1469, 1454, 1404 cm−1. [α]D24+47.1±0.9°(c=1.001, MeOH) Anal. (C32H37NO3S.0.2H2O) Calcd.(%): C, 74.01; H, 7.26; N, 2.70; S, 6.17. Found(%): C, 73.89; H, 7.44; N, 2.93; S, 6.04.
Compound Number II-141
mp.134–135° C. 300 MHz 1H-NMR(CDCl3) δ: 0.93(1H, d, J=10.5 Hz), 0.98 and 1.15(each 3H, each s),1.48–2.43(14H, m), 4.20(1H, m), 4.40 and 4.54(each 1H, each d, J=16.5 Hz), 5.33–5.50(2H, m), 6.04(1H, d, J=8.4 Hz), 6.99–7.30(6H, m), 7.55(1H, s), 7.73(1H, d, J=8.4 Hz). IR(CHCl3): 3518, 3437, 2669, 1741, 1709, 1653, 1510, 1471, 1454 cm−1. [α]D25+54.2±0.9°(c=1.003, MeOH) Anal. (C32H37NO3S.0.1H2O) Calcd.(%): C, 74.27; H, 7.25; N, 2.71; S, 6.20. Found(%): C, 74.11; H, 7.16; N, 3.15; S, 6.25.
Compound Number II-142
1H-NMR(CDCl3) δ: 0.94(1H, d, J=10.5 Hz), 1.08 and 1.21(each 3H, each s),1.49–2.43(14H, m), 3.94(2H, s), 4.22(1H, m), 5.33–5.49(2H, m), 6.03(1H, d, J=8.7 Hz), 7.04(1H, s), 7.17–7.33(6H, m). IR(CHCl3): 3516, 3448, 3433, 2669, 1739, 1709, 1645, 1549, 1508, 1471, 1454 cm−1. [α]D25+40.5±0.8°(c=1.003, MeOH) Anal. (C28H35NO3S.0.1H2O) Calcd.(%): C, 71.95; H, 7.59; N, 3.00; S, 6.86. Found(%): C, 71.82; H, 7.49; N, 3.37; S, 6.83.
Compound Number II-143
1H-NMR(CDCl3) δ: 0.98(1H, d, J=10.5 Hz), 1.10 and 1.23(each 3H, each s),1.53–2.50(14H, m), 4.24(2H, s), 4.33(1H, m), 5.35–5.54(2H, m), 6.18(1H, d, J=8.4 Hz), 7.19–7.30(6H, m), 7.42(1H, t, J=7.8 Hz), 7.78(1H, s), 8.18(1H, d, J=7.8 Hz). IR(CHCl3): 3514, 3442, 2671, 1709, 1651, 1516, 1495, 1471, 1454, cm−1. [α]D25+53.6±0.9°(c=1.003, MeOH), Anal. (C32H37NO3S.0.1H2O) Calcd.(%): C, 74.27; H, 7.25; N, 2.71; S, 6.20. Found(%): C, 74.18; H, 7.24; N, 2.90; S, 6.14.
Compound Number II-147
mp.117–118° C. 300 MHz 1H-NMR(CDCl3) δ: 0.94(1H, d, J=9.9 Hz), 1.09 and 1.21(each 3H, each s), 1.55–2.42(14H, m), 3.87(3H, s), 4.06 (2H, s), 4.18(1H, m), 5.35–5.49(2H, m), 5,56(1H, brs), 5.89(1H, d, J=8.7 Hz), 6.72–6.77(3H, m), 6.87(1H, d, J=8.1 Hz), 7.31(1H, d, J=3.6 Hz). IR(Nujol): 3373, 3184, 2667, 1705, 1622, 1599, 1547, 1520, 1286 cm−1. [α]D23+42.0±0.8°(c=1.008, MeOH) Anal. (C29H37NO5S) Calcd.(%): C, 68.07; H, 7.29; N, 2.74; S, 6.27. Found(%): C, 67.84; H, 7.43; N, 2.71; S, 6.18.
Compound Number II-148
1H-NMR(CDCl3) δ: 0.95(1H, d, J=9.9 Hz), 1.10 and 1.23(each 3H, each s), 1.53–2.45(14H, m), 3.87(3H, s), 2.96–3.01(2H, m), 3.10–3.16(2H, m), 4.22(1H, m), 5.34–5.50(2H, m), 6.01(1H, d, J=8.4 Hz), 6.71(1H, d, J=3.9 Hz), 7.16–7.32(6H, m). IR(CHCl3): 3518, 3450, 3431, 2671, 1739, 1709, 1641, 1545, 1508 cm−1. [α]D22+44.3±0.8°(c=1.006, MeOH) Anal. (C29H37NO3S.0.1H2O) Calcd.(%): C, 72.34; H, 7.79; N, 2.91; S, 6.66. Found(%): C, 72.24; H, 7.68; N, 3.11; S, 6.73.
Compound Number II-149
1H-NMR(CDCl3) δ: 0.95(1H, d, J=10.2 Hz), 1.10 and 1.23(each 3H, each s), 1.52–2.45(14H, m), 2.43(3H, d, J=0.9 Hz), 3.07–3.18(4H, m), 4.21(1H, m), 5.35–5.50(2H, m), 6.02(1H, d, J=8.4 Hz), 6.53–6.57(2H, m), 6.76 and 7.30(each 1H, each d, each J=3.9 Hz). IR(CHCl3): 3516, 3450, 3431, 2667, 1709, 1641, 1543, 1508 cm−1. [α]D22+43.1±0.8°(c=1.005, MeOH) Anal. (C28H37NO3S2.0.3H2O) Calcd.(%): C, 66.58; H, 7.50; N, 2.77; S, 12.70. Found(%): C, 66.47; H, 7.46; N, 2.99; S, 12.62.
Compound Number II-150
1H-NMR(CDCl3) δ: 0.95(1H, d, J=10.2 Hz), 1.10 and 1.23(each 3H, each s), 1.52–2.45(14H, m), 3.19(4H, s), 4.21(1H, m), 5.34–5.50(2H, m), 6.01(1H, d, J=8.4 Hz), 6.75(1H, d, J=3.9 Hz), 6.79(1H, m), 6.91 (1H, dd, J=3.6 and 5.1 Hz), 7.13(1H, dd, J=0.9 and 5.1 Hz), 7.29(1H, d, J=3.9 Hz). IR(CHCl3): 3514, 3450, 3433, 2667,n 1739, 1709, 1641, 1545, 1508 cm−1. [α]D24+33.5±0.8°(c=1.009, MeOH) Anal. (C27H35NO3S2) Calcd.(%): C, 66.77; H, 7.26; N, 2.88; S, 13.20. Found(%): C, 66.48; H, 7.31; N, 2.97; S, 13.22.
Compound Number II-151
1H-NMR(CDCl3) δ: 0.97(1H, d, J=9.9 Hz), 1.12 and 1.23(each 3H, each s), 1.53–2.47(14H, m), 3.00–3.06(2H, m), 3.12–3.17(2H, m), 4.27 (1H, m), 5.34–5.51(2H, m), 6.24(1H, d, J=9.0 Hz), 6.75(1H, m), 6.90(1H, dd, J=3.6 and 5.4 Hz), 7.12(1H, dd, J=1.2 and 5.4 Hz), 7.25 and 7.64(each 2H, each d-like). IR(CHCl3): 3516, 3452, 2665, 1738, 1709, 1649, 1523, 1495 cm−1. [α]D24+54.5±0.9°(c=1.016, MeOH) Anal. (C29H37NO3S) Calcd.(%): C, 72.61; H, 7.77; N, 2.92; S, 6.68. Found(%): C, 72.51; H, 7.69; N, 2.98; S, 6.62.
Compound Number II-152
1H-NMR(CDCl3) δ: 0.95(1H, d, J=10.2 Hz), 1.10 and 1.23(each 3H, each s), 1.51–2.45(14H, m), 2.92–2.97(2H, m), 3.08–3.13(2H, m), 4.22 (1H, m), 5.34–5.50(2H, m), 6.00(1H, d, J=8.7 Hz), 6.69(1H, d, J=3.6 Hz), 6.92–7.00 (2H, m), 7.09–7.15(2H, m), 7.28(1H, d, J=3.6 Hz). IR(CHCl3): 3516, 3450, 3431, 1741, 1709, 1641, 1543, 1510, 1471 cm−1. [α]D23+42.6±0.8°(c=1.014, MeOH) Anal. (C29H36FNO3S) Calcd.(%): C, 69.99; H, 7.29; N, 2.81; S, 6.44; F, 3.82. Found(%): C, 69.87; H, 7.29; N, 2.88; S, 6.50; F, 3.85.
Compound Number II-156
mp.93–95° C. 1H-NMR(CDCl3) δ: 0.96(1H, d, J=10.2 Hz), 1.13 and 1.23(each 3H, each s), 1.52–2.47(14H, m), 4.08(2H, s), 4.27(1H, m), 5.34–5.51(2H, m), 6.21(1H, d, J=8.7 Hz), 7.18–7.32(6H, m), 7.61 and 7.66(each 1H, each s), 7.74(1H, d, J=8.4 Hz). IR(KBr): 3367, 1705, 1618, 1556, 1533, 1508 cm−1. [α]D23+60.4±0.8°(c=1.012, MeOH) Anal. (C32H37NO3S) Calcd.(%): C, 74.53; H, 7.23; N, 2.72; S, 6.22. Found(%): C, 74.31; H, 7.37; N, 2.99; S, 6.10.
Compound Number II-157
1H-NMR(CDCl3) δ: 0.92(1H, d, J=10.2 Hz), 1.06 and 1.19(each 3H, each s), 1.47–2.42(14H, m), 4.20(1H, m), 4.28(2H, s), 5.32–5.47(2H, m), 5.98(1H, d, J=8.7 Hz), 6.80(1H, d, J=3.3 Hz), 7.32–7.36(2H, m), 7.41–7.50(2H, m), 7.68(1H, s), 7.77–7.83(3H, m). IR(CHCl3): 3518, 3450, 3431, 1739, 1709, 1641, 1545, 1508, 1471 cm−1. [α]D23+42.7±0.8°(c=1.003, MeOH) Anal. (C32H37NO3S.0.2H2O) Calcd.(%): C, 74.01; H, 7.26; N, 2.70; S, 6.17. Found(%): C, 73.94; H, 7.30; N, 2.89; S, 6.15.
Compound Number II-158
1H-NMR(CDCl3) δ: 0.95(1H, d, J=10.5 Hz), 1.11 and 1.22(each 3H, each s), 1.51–2.45(14H, m), 2.94–3.00(2H, m), 3.06–3.12(2H, m), 3.83 (3H, s), 4.22(1H, m), 5.34–5.50(2H, m), 6.00(1H, d, J=8.7 Hz), 6.73 (1H, d, J=3.6 Hz), 6.84–6.89(2H, m), 7.09(1H, dd, J=1.5 and 7.8 Hz), 7.20 (1H, dt, J=1.5 and 7.8 Hz), 7.30(1H, d, J=3.6 Hz). IR(CHCl3): 3518, 3450, 3431, 1741, 1709, 1639, 1545, 1506, 1496, 1466 cm−1. [α]D25+41.3±0.8°(c=1.007, MeOH) Anal. (C30H39FNO4S) Calcd.(%): C, 70.69; H, 7.71; N, 2.75; S, 6.29. Found(%): C, 70.42; H, 7.64; N, 2.78; S, 6.37.
Compound Number II-159
1H-NMR(CDCl3) δ: 0.94(1H, d, J=10.2 Hz), 1.10 and 1.22(each 3H, each s), 1.53–2.48(14H, m), 2.96–3.04(2H, m), 3.07–3.16(2H, m), 4.22 (1H, m), 5.34–5.52(2H, m), 6.04(1H, d, J=8.7 Hz), 6.74(1H, d, J=3.6 Hz), 6.77–6.85 (2H, m), 7.05–7.11 (2H, m), 7.31(1H, d, J=3.6 Hz). IR(CHCl3): 359, 3510, 3429, 3190, 1709, 1636, 1545, 1508, 1456 cm−1. [α]D25+42.7±0.8°(c=1.009, MeOH) Anal. (C29H37NO4S.0.3H2O) Calcd.(%): C, 69.51; H, 7.56; N, 2.80; S, 6.40. Found(%): C, 69.25; H, 7.43; N, 2.89; S, 6.43.
Compound Number II-160
mp.125–126° C. 300 MHz 1H-NMR(CDCl3) δ: 0.96(1H, d, J=10.2 Hz), 1.13 and 1.23(each 3H, each s), 1.52–2.47(14H, m), 4.10(2H, s), 4.27 (1H, m), 5.34–5.51(2H, m), 6.20(1H, d, J=9.0 Hz), 7.19–7.33(6H, m), 7.62 and 7.69(each 1H, each s), 7.73(1H, d, J=8.4 Hz). IR(KBr): 3415, 3199, 1736, 1703, 1633, 1523 cm−1. [α]D25+53.3±0.8°(c=1.002, MeOH) Anal. (C32H37NO3S.0.1H2O) Calcd.(%): C, 74.27; H, 7.25; N, 2.71; S, 6.23. Found(%): C, 74.19; H, 7.16; N, 2.81; S, 6.23.
Compound Number II-161
mp.98–101° C. 1H-NMR(CDCl3) δ: 0.97(1H, d, J=10.5 Hz), 1.14 and 1.24(each 3H, each s), 1.53–2.47(14H, m), 4.08(2H, s), 4.27 (1H, m), 5.35–5.51(2H, m), 6.21(1H, d, J=8.7 Hz), 6.90(1H, dd, J=1.2 and 5.1 Hz), 6.93(1H, m), 7.24–7.29(2H, m), 7.63(1H, s), 7.75(1H, d, J=8.1 Hz). IR(KBr): 3394, 3097, 1707, 1643, 1533, 1500 cm−1. [α]D25+58.7±1.0°(c=1.006, MeOH) Anal. (C30H35NO3S2.0.3H2O) Calcd.(%): C, 68.35; H, 6.81; N, 2.66; S, 12.17. Found(%): C, 68.27; H, 6.76; N, 2.94; S, 12.17.
Compound Number II-162
mp.106–109° C. 1H-NMR(CDCl3) δ: 0.97(1H, d, J=10.2 Hz), 1.14 and 1.24(each 3H, each s), 1.53–2.47(14H, m), 4.26(2H, s), 4.27(1H, m), 5.35–5.51(2H, m), 6.22(1H, d, J=8.7 Hz), 6.82(1H, m), 6.93(1H, dd, J=3.6 and 5.1 Hz), 7.16(1H, dd, J=1.2 and 5.1 Hz), 7.32(1H, dd, J=8.1 and 1.8 Hz), 7.68(2H, m), 7.76(1H, d, J=8.1 Hz). IR(KBr): 3396, 3070, 1707, 1645, 1535, 1500 cm−1. [α]D25+59.9±1.0°(c=1.005, MeOH) Anal. (C30H35NO3S2.0.2H2O) Calcd.(%): C, 68.59; H, 6.79; N, 2.67; S, 12.21. Found(%): C, 68.57; H, 6.62; N, 2.76; S, 12.17.
Compound Number II-163
1H-NMR(CDCl3) δ: 0.94(1H, d, J=10.2 Hz), 1.09 and 1.22(each 3H, each s), 1.49–2.44(14H, m), 4.12(2H, s), 4.23(1H, m), 5.34–5.49(2H, m), 6.09(1H, d, J=8.7 Hz), 6.82 and 6.93(each 1H, each m), 7.13–7.17 (2H, m), 7.34(1H, d, J=1.5 Hz). IR(CHCl13): 3512, 3448, 3431, 1739, 1709, 1645, 1550, 1508, 1471, 1456 cm−1. [α]D25+43.3±0.8°(c=1.007, MeOH) Anal. (C26H33NO3S2.0.1H2O) Calcd.(%): C, 65.95; H, 7.07; N, 2.96; S, 13.54. Found(%): C, 66.12; H, 7.06; N, 3.04; S, 13.66.
Compound Number II-164
1H-NMR(CDCl3) δ: 0.94(1H, d, J=10.5 Hz), 1.09 and 1.22 (each 3H, each s), 1.49–2.44(14H, m), 3.95(2H, s), 4.22(1H, m), 5.34–5.49 (2H, m), 6.06(1H, d, J=8.7 Hz), 6.92 and 6.96(each 1H, each m), 7.07(1H, d, J=1.5 Hz), 7.28(1H, m), 7.30(1H, d, J=1.5 Hz). IR(CHCl3): 3510, 3431, 1739, 1709, 1645, 1550, 1508, 1471 cm−1. [α]D25+41.1±0.8°(c=1.009, MeOH) Anal. (C26H33NO3S2.0.2H2O) Calcd.(%): C, 65.70; H, 7.08; N, 2.95; S, 13.49. Found(%): C, 65.57; H, 6.97; N, 3.08; S, 13.63.
Compound Number II-165
1H-NMR(CDCl3) δ: 0.95(1H, d, J=10.2 Hz), 1.10 and 1.22(each 3H, each s), 1.50–2.44(14H, m), 3.74(2H, s), 4.23(1H, m), 5.34–5.50(2H, m), 6.07(1H, d, J=8.0 Hz), 6.23(1H, s), 7.08(1H, d, J=1.5 Hz), 7.24(1H, s), 7.31(1H, d, J=1.5 Hz), 7.36(1H, m). IR(CHCl3): 3510, 3448, 3431, 2663, 1709, 1645, 1550, 1508, 1471 cm−1. [α]D25+44.2±0.8°(c=1.001, MeOH) Anal. (C26H33NO4S.0.2H2O) Calcd.(%): C, 68.00; H, 7.33; N, 3.05; S, 6.98. Found(%): C, 68.00; H, 7.30; N, 3.15; S, 7.12.
Compound Number II-166
1H-NMR(CDCl3) δ: 0.92(1H, d, J=10.2 Hz), 1.05 and 1.19(each 3H, each s), 1.48–2.40(14H, m), 4.17(1H, m), 4.58(2H, s), 5.31–5.46(2H, m), 5.96(1H, d, J=8.7 Hz), 6.72 and 7.26(each 1H, each d, each J=3.9 Hz), 7.37–7.51(4H, m), 7.79(1H, d, J=8.1 Hz), 7.87 and 7.97 (each 1H, each m). IR(CHCl3): 3516, 3450, 3431, 2667, 1739, 1709, 1641, 1543, 1508, 1471 cm−1. [α]D25.5+41.9±0.8°(c=1.011, MeOH) Anal. (C32H37NO3S.0.2H2O) Calcd.(%): C, 74.01; H, 7.26; N, 2.70; S, 6.17. Found(%): C, 74.10; H, 7.13; N, 2.99; S, 6.15.
Compound Number II-167
1H-NMR(CDCl3) δ: 0.93(1H, d, J=10.2 Hz), 1.05 and 1.20(each 3H, each s), 1.48–2.42(14H, m), 4.20(1H, m), 4.39(2H, m), 5.31–5.46(2H, m), 6.00(1H, d, J=9.0 Hz), 6.96(1H, s), 7.30–7.33(2H, m), 7.40–7.50 (3H, m), 7.78(1H, d, J=8.1 Hz), 7.87 and 7.95(each 1H, each m). IR(CHCl3): 3518, 3448, 3431, 2665, 1738, 1709, 1645, 1549, 1508, 1471 cm−1. [α]D24+37.9±0.8°(c=1.004, MeOH) Anal. (C32H37NO3S.0.1H2O) Calcd.(%): C, 74.27; H, 7.25; N, 2.71; S, 6.20. Found(%): C, 74.13; H, 7.18; N, 2.87; S, 6.26.
Compound Number II-169
1H-NMR(CDCl3) δ: 0.98(1H, d, J=10.5 Hz), 1.10 and 1.23(each 3H, each s),1.53–2.50(14H, m), 4.23(2H, s), 4.33(1H, m), 5.35–5.54(2H, m), 6.18(1H, d, J=8.7 Hz), 6.92(1H, dd, J=1.2 and 4.8 Hz), 7.01(1H, m), 7.22(1H, d, J=7.8 Hz), 7.24(1H, dd, J=3.0 and 4.8 Hz), 7.42(1H, d, J=7.8 and 8.1 Hz), 7.79(1H, s), 8.18(1H, d, J=8.1 Hz). IR(CHCl3): 3516, 3442, 2667, 1709, 1651, 1516, 1495, 1471 cm−1. [α]D26+50.9±0.9°(c=1.009, MeOH), Anal. (C30H35NO3S2.0.2H2O) Calcd.(%): C, 68.59; H, 6.79; N, 2.67; S, 12.21. Found(%): C, 68.51; H, 6.69; N, 2.73; S, 12.39.
Compound Number II-170
1H-NMR(CDCl3) δ: 0.99(1H, d, J=10.2 Hz), 1.11 and 1.24(each 3H, each s), 1.53–2.50(14H, m), 4.03(2H, s), 4.34(1H, m), 5.36–5.54 (2H, m), 6.20(1H, d, J=8.4 Hz), 7.24(1H, d, J=8.4 Hz), 7.24(1H, d, J=7.2 Hz), 7.30(1H, m), 7.35(1H, t, J=1.8 Hz), 7.42(1H, dd, J=7.2 and 8.1 Hz), 7.81(1H, s), 8.19(1H, d, J=7.2 Hz). IR(CHCl3): 3518, 3442, 1739, 1709, 1651, 1516, 1496, 1471 cm−1. [α]D25+54.3±1.0°(c=1.002, MeOH) Anal. (C30H35NO4S.0.1H2O) Calcd.(%): C, 71.00; H, 6.99; N, 2.76; S, 6.32. Found(%): C, 70.95; H, 6.82; N, 2.74; S, 6.35.
Compound Number II-173
1H-NMR(CDCl3) δ: 0.99(1H, d, J=10.5 Hz), 1.16 and 1.24(each 3H, each s), 1.53–2.48(14H, m), 3.93(2H, s), 4.32(1H, m), 5.34–5.52(2H, m), 6.35(1H, d, J=8.7 Hz), 7.31–7.42(2H, m), 7.56(1H, d, J=6.9 Hz), 7.71(1H, dd, J=1.5 and 8.1 Hz), 7.78–7.83(2H, m), 7.92(1H, s). IR (CHCl3): 3516, 3452, 3026, 2667, 1738, 1709, 1649, 1641, 1514, 1481, 1469, 1454 cm−1. [α]D24+67.5±1.1°(c=1.005, MeOH) Anal. (C30H35NO3.0.1H2O) Calcd.(%): C, 78.43; H, 7.72; N, 3.05. Found(%): C, 78.36; H, 7.99; N, 3.24.
Compound Number II-174
1H-NMR(CDCl3) δ: 0.93(1H, d, J=10.2 Hz), 1.09 and 1.21(each 3H, each s),1.50–2.42(14H, m), 3.21(2H, t, J=8.7 Hz), 4.02(2H, s), 4.20 (1H, m), 4.59(2H, t, J=8.7 Hz), 5.34–5.49(2H, m), 6.01(1H, d, J=8.7 Hz), 6.80 (1H, d, J=3.6 Hz), 7.06(1H, d, J=1.8 Hz), 7.19(1H, m), 7.30 (1H, d, J=3.6 Hz). IR(CHCl3): 3512, 3450, 3431, 2667, 1739, 1709, 1641, 1543, 1508, 1460 cm−1. [α]D25+35.7±0.8°(c=1.002, MeOH), Anal. (C30H36BrNO4S) Calcd.(%): C, 61.43; H, 6.19; Br, 13.62; N, 2.39; S, 5.47. Found(%): C, 61.26; H, 6.11; Br, 13.54; N, 2.46; S, 5.47.
Compound Number II-175
1H-NMR(CDCl3) δ: 0.96(1H, d, J=10.2 Hz), 1.14 and 1.23(each 3H, each s),1.52–2.46(14H, m), 4.21((2H, s), 4.28(1H, m), 5.34–5.51(2H, m), 6.23(1H, d, J=9.0 Hz), 6.94(1H, dd, J=1.2 and 4.8 Hz), 7.05(1H, m), 7.21–7.26(2H, m), 7.35(1H, dd, J=7.5 and 8.1 Hz), 7.71(1H, d, J=7.5 Hz), 7.75(1H, s). IR(CHCl3): 3510, 3448, 3427, 2665, 1709, 1649, 1539, 1504, 1469, 1454 cm−1. [α]D25+47.4±0.9°(c=1.005, MeOH), Anal. (C32H37NO3S.0.1H2O) Calcd.(%): C, 74.27; H, 7.25; N, 2.71; S, 6.20. Found(%): C, 74.15; H, 7.14; N, 2.89; S, 6.26.
Compound Number II-176
1H-NMR(CDCl3) δ: 0.97(1H, d, J=10.2 Hz), 1.14 and 1.24(each 3H, each s), 1.53–2.47(14H, m), 4.22((2H, s), 4.27(1H, m), 5.35–5.51(2H, m), 6.22(1H, d, J=8.7 Hz), 6.94(1H, dd, J=1.2 and 4.8 Hz), 7.05(1H, m), 7.21–7.26(2H, m), 7.35(1H, dd, J=7.5 and 8.1 Hz), 7.71(1H, d, J=7.5 Hz), 7.75(1H, s). IR(CHCl3): 3512, 3448, 3427, 2665, 1709, 1649, 1539, 1504, 1469 cm−1. [α]D25+46.1±0.9°(c=1.011, MeOH), Anal. (C30H35NO3S2) Calcd.(%): C, 69.06; H, 6.76; N, 2.68; S, 12.29. Found(%): C, 68.77; H, 6.84; N, 2.78; S, 12.30.
Compound Number II-177
1H-NMR(CDCl3) δ: 0.96(1H, d, J=10.2 Hz), 1.14 and 1.24(each 3H, each s),1.53–2.46(14H, m), 2.31(3H, s), 4.17((2H, s), 4.28(1H, m), 5.34–5.51 (2H, m), 6.22(1H, d, J=9.0 Hz), 7.09 and 7.15(each 2H, each d, J=7.8 Hz), 7.19(1H, d, J=7.2 Hz), 7.34(1H, dd, J=7.2 and 7.8 Hz), 7.70 (1H, d, J=7.8 Hz), 7.75(1H, s). IR(CHCl3): 3510, 3448, 3427, 2669, 1709, 1649, 1537, 1504, 1469 cm−1. [α]D25+45.6±0.9°(c=1.005, MeOH), Anal. (C33H39NO3S.0.1H2O) Calcd.(%): C, 74.57; H, 7.43; N, 2.64; S, 6.03. Found(%): C, 74.46; H, 7.48; N, 2.78; S, 6.15.
Compound Number II-178
1H-NMR(CDCl3) δ: 0.97(1H, d, J=10.2 Hz), 1.14 and 1.24(each 3H, each s),1.53–2.47(14H, m), 2.31(3H, s), 4.28(1H, m), 4.40((2H, s), 5.35–5.51 (2H, m), 6.23(1H, d, J=8.7 Hz), 6.92–6.94(2H, m), 7.16(1H, dd, J=1.5 and 5.1 Hz), 7.28(1H, d, J=7.5 Hz), 7.36(1H, t, J=7.5 Hz), 7.72 (1H, d, J=7.5 Hz), 7.75(1H, s). IR(CHCl3): 3508, 3448, 3427, 2663, 1709, 1649, 1539, 1504, 1469 cm−1. [α]D25+46.2±0.9°(c=1.005, MeOH), Anal. (C30H35NO3S2) Calcd.(%): C, 69.06; H, 6.76; N, 2.68; S, 12.29. Found(%): C, 68.84; H, 6.86; N, 2.79; S, 12.28.
Compound Number II-179
1H-NMR(CDCl3) δ: 0.94(1H, d, J=10.5 Hz), 1.08 and 1.21(each 3H, each s), 1.51–2.42(14H, m), 4.09(2H, s), 4.18(1H, m), 5.33–5.48(2H, m), 5.96(1H, d, J=9.3 Hz), 6.54(1H, d, J=3.6 Hz), 7.24–7.42(10H, m). IR(CHCl3): 3510, 3450, 3431, 1739, 1709, 1641, 1543, 1506, 1479, 1458 cm−1. [α]D24.5+39.4±0.8°(c=1.007, MeOH) Anal. (C34H39NO3S.0.1H2O) Calcd.(%): C, 75.13; H, 7.27; N, 2.58; S, 5.90. Found(%): C, 75.05; H, 7.32; N, 2.69; S, 6.17.
Compound Number II-180
1H-NMR(CDCl3) δ: 1.00(1H, d, J=10.2 Hz), 1.15 and 1.26(each 3H, each s), 1.55–2.49(14H, m), 4.30(1H, m), 5.37–5.53(2H, m), 6.38(1H, d, J=8.1 Hz), 7.32(1H, m), 7.49–7.58(3H, m), 7.64–7.67(2H, m), 7.92 (1H, s). IR(CHCl3): 3514, 3446, 1714, 1655, 1618, 1514, 1469, 1446 cm−1. [α]D25+66.7±1.1°(c=1.005, MeOH) Anal. (C30H33NO4.0.2H2O) Calcd.(%): C, 75.83; H, 7.08; N, 2.95. Found(%): C, 75.69; H, 7.05; N, 3.08.
Compound Number II-181
mp.103–104° C. 300 MHz 1H-NMR(CDCl3) δ: 0.93(1H, d, J=10.2 Hz), 1.08 and 1.21(each 3H, each s),1.49–2.42(14H, m), 3.79(3H, s), 4.07 ((2H, s), 4.20(1H, m), 5.33–5.48(2H, m), 5.98(1H, d, J=8.7 Hz), 6.75 (1H, d, J=3.6 Hz), 6.85 and 7.15(each 2H, each d, J=8.4 Hz), 7.31 (1H, d, J=3.6 Hz). IR(CHCl3): 3519, 3450, 3431, 1741, 1709, 1641, 1612, 1543, 1510, 1464 cm−1. [α]D25+43.8±0.8°(c=1.009, MeOH) Anal. (C29H37NO4S) Calcd.(%): C, 70.27; H, 7.52; N, 2.83; S, 6.47. Found(%): C, 70.33; H, 7.55; N, 3.05; S, 6.46.
Compound Number II-182
1H-NMR(CDCl3) δ: 0.93(1H, d, J=10.5 Hz), 1.07 and 1.21(each 3H, each s),1.49–2.42(14H, m), 4.20(1H, m), 4.37(2H, s), 5.33–5.48(2H, m), 5.99(1H, d, J=8.4 Hz), 6.82(1H, d, J=3.6 Hz), 7.21(1H, s), 7.30 (1H, d, J=3.6 Hz), 7.34–7.37(2H, m), 7.69(1H, m), 7.86(1H, m). IR (CHCl3): 3512, 3450, 3431, 2671, 1739, 1709, 1643, 1543, 1508, 1471, 1460 cm−1. [α]D25+40.2±0.8°(c=1.005, MeOH), Anal. (C30H35NO3S2.0.4H2O) Calcd.(%): C, 68.12; H, 6.82; N, 2.64; S, 12.12. Found(%): C, 68.05; H, 6.70; N, 2.87; S, 12.00.
Compound Number II-183
1H-NMR(CDCl3) δ: 0.93(1H, d, J=10.2 Hz), 1.08 and 1.21(each 3H, each s), 1.50–2.47(14H, m), 4.13(2H, s), 4.20(1H, m), 5.33–5.50(2H, m), 6.01(1H, d, J=9.0 Hz), 6.80(1H, m), 6.82(1H, m), 6.86(1H, m), 7.12 (1H, m), 7.15(1H, m), 7.31(1H, d, J=3.9 Hz). IR(CHCl3): 3597, 3510, 3448, 3427, 3190, 1709, 1633, 1545, 1508, 1456 cm−1. [α]D24+41.8°±0.8°(c=1.004, MeOH) Anal. (C28H35NO4S.0.3H2O) Calcd.(%): C, 69.11; H, 7.37; N, 2.88; S, 6.59. Found(%): C, 68.94; H, 7.42; N, 2.96; S, 6.73.
Compound Number II-184
1H-NMR(CDCl3) δ: 1.00(1H, d, J=10.5 Hz), 1.17 and 1.25(each 3H, each s), 1.55–2.50(14H, m), 3.93 (2H, s), 4.32(1H, m), 5.35–5.49(2H, m), 6.37(1H, d, J=8.7 Hz), 7.31–7.43(2H, m), 7.54–7.63(3H, m), 7.84 (1H, d, J=7.2 Hz), 8.16(1H, s). IR (CDCl3): 3514, 3450, 2667, 1709, 1651, 1572, 1514, 1481, 1452 cm−1. [α]D24+58.3±1.0°(c=1.003, MeOH) Anal. (C30H35NO3.0.1H2O) Calcd.(%): C, 78.43; H, 7.72; N, 3.05. Found(%): C, 78.26; H, 7.73; N, 3.28.
Compound Number II-185
1H-NMR(CDCl3) δ: 0.94(1H, d, J=10.2 Hz), 1.09 and 1.21(each 3H, each s), 1.52–2.42(14H, m), 4.16(2H, s), 4.19(1H, m), 5.33–5.47(2H, m), 5.99(1H, d, J=9.3 Hz), 6.78(1H, d, J=3.6 Hz), 7.00–7.12(2H, m), 7.20–7.27 (2H, m), 7.30(1H, d, J=3.6 Hz). IR(CHCl3): 3510, 3450, 3431, 1741, 1709, 1643, 1543, 1508, 1456 cm−1. [α]D24+38.0±0.8°(c=1.03, CHCl3) Anal. (C28H34FNO3S.0.5H2O) Calcd.(%): C, 68.26; H, 7.16; N, 2.86; S, 6.51; F, 3.86. Found(%): C, 68.24; H, 7.08; N, 2.93; S, 6.50; F, 3.80.
Compound Number II-188
mp.53–55° C. 300 MHz 1H-NMR(CDCl3) δ: 0.94(1H, d, J=10.2 Hz), 1.08 and 1.21(each 3H, each s),1.51–2.42(14H, m), 4.07(2H, s), 4.19 (1H, m), 5.05(2H, s), 5.33–5.48(2H, m), 5.98(1H, d, J=9.0 Hz), 6.76 (1H, d, J=3.6 Hz), 6.92 and 7.15(each 2H, each d, J=8.7 Hz), 7.31(1H, d, J=3.6 Hz), 7.32.–7.43 (5H, m) IR(CHCl3): 3518, 3450, 3431, 1741, 1709, 1641, 1612, 1545, 1510, 1469, 1456 cm−1. [α]D24+36.0±0.8°(c=1.005, MeOH), Anal. (C35H41NO4S.0.4H2O) Calcd.(%): C, 72.61; H, 7.28; N, 2.42; S, 5.54. Found(%): C, 72.58; H, 7.33; N, 2.65; S, 5.53.
Compound Number II-189
300 MHz 1H-NMR(CDCl3) δ: 0.94(1H, d, J=10.5 Hz), 1.08 and 1.21 (each 3H, each s),1.51–2.42(14H, m), 4.07(2H, s), 4.19(1H, m), 4.51–4.53 (2H, m), 5.26–5.46(4H, m), 5.98(1H, d, J=8.7 Hz), 6.05(1H, m), 6.76 (1H, d, J=3.6 Hz), 6.87 and 7.14(each 2H, each d, J=8.7 Hz), 7.31 (1H, d, J=3.6 Hz). IR(CHCl3): 3511, 3450, 3431, 1741, 1709, 1641, 1612, 1543, 1508, 1471, 1458 cm−1. [α]D24+39.7±0.8°(c=1.008, MeOH), Anal. (C31H39NO4S.0.2H2O) Calcd.(%): C, 70.88; H, 7.56; N, 2.67; S, 6.10. Found(%): C, 70.86; H, 7.60; N, 2.68; S, 6.17.
Compound Number II-190
1H-NMR(CDCl3) δ: 0.94(1H, d, J=10.2 Hz), 1.09 and 1.21(each 3H, each s),1.50–2.43(14H, m), 4.04(2H, s), 4.20(1H, m), 5.33–5.49(2H, m), 5.94(2H, s), 5.98(1H, d, J=8.7 Hz), 6.68–6.78(4H, m), 7.31(1H, d, J=3.9 Hz). IR(CHCl3): 3518, 3450, 3431, 1739, 1709, 1641, 1543, 1504, 1489, 1444, 1250, 1041 cm−1. [α]D24+42.2±0.8°(c=1.010, MeOH), Anal. (C29H35NO5S) Calcd.(%): C, 68.34; H, 6.92; N, 2.75; S, 6.29. Found(%): C, 68.19; H, 6.88; N, 2.86; S, 6.20.
Compound Number II-191
mp.76–80° C. 1H-NMR(CDCl3) δ: 0.94(1H, d, J=9.9 Hz), 1.09 and 1.21 (each 3H, each s),1.51–2.43(14H, m), 4.13(2H, s), 4.20(1H, m), 5.34–5.49(2H, m), 6.00(1H, d, J=8.4 Hz), 6.78(1H, d, J=3.9 Hz), 6.90–7.04 (3H, m), 7.27(1H, m), 7.32(1H, d, J=3.9 Hz). IR(Nujol): 3408, 1703, 1631, 1514, 1250 cm−1. [α]D25+51.0±0.9°(c=1.001, MeOH), Anal. (C28H34FNO3S) Calcd.(%): C, 69.54; H, 7.09; N, 2.90; S, 6.63; F, 3.93. Found(%): C, 69.77; H, 7.23; N, 2.95; S, 6.55; F, 3.93.
Compound Number II-192
1H-NMR(CDCl3) δ: 0.94(1H, d, J=10.2 Hz), 1.09 and 1.22(each 3H, each s),1.51–2.44(14H, m), 4.19(2H, s), 4.20(1H, m), 5.34–5.49(2H, m), 6.00(1H, d, J=8.4 Hz), 6.78 and 7.32(each 1H, each d, each J=3.6 Hz), 7.40–7.54(4H, m). IR(CHCl3): 3516, 3450, 3431, 1739, 1709, 1643, 1543, 1508, 1331, 1167, 1130 cm−1. [α]D25+39.5±0.8°(c=1.012, MeOH), Anal. (C29H34F3NO3S) Calcd.(%): C, 65.27; H, 6.42; N, 2.62; S, 6.01; F, 10.68. Found(%): C, 65.05; H, 6.46; N, 2.74; S, 6.02; F, 10.63.
Compound Number II-193
1H-NMR(CDCl3) δ: 0.94(1H, d, J=10.2 Hz), 1.09 and 1.21(each 3H, each s), 1.51–2.26(14H, m), 4.19(1H, m), 4.26(2H, s), 5.33–5.49(2H, m), 6.00(1H, d, J=8.4 Hz), 6.79(1H, d, J=3.9 Hz), 7.20–7.25(3H, m), 7.30(1H, d, J=3.9 Hz), 7.37–7.40(1H, m). IR(CHCl3): 3516, 3450, 3431, 1741, 1709, 1643, 1543, 1508, 1471 cm−1. [α]D25+38.5±0.8°(c=1.00, CHCl3) Anal. (C28H34FNO3S.0.5H2O) Calcd.(%): C, 66.06; H, 6.93; N, 2.75; S, 6.30; Cl, 6.96. Found(%): C, 66.21; H, 6.87; N, 2.97; S, 6.24; Cl, 6.75.
Compound Number II-194
1H-NMR(CDCl3) δ: 0.93(1H, d, J=10.5 Hz), 1.07 and 1.20(each 3H, each s), 1.49–2.42(14H, m), 2.30(6H, s), 4.15(2H, s), 4.19(1H, m), 5.33–5.48 (2H, m), 5.97(1H, d, J=8.7 Hz), 6.56(1H, d, J=3.9 Hz), 7.03–7.13 (3H, m), 7.26(1H, d, J=3.9 Hz). IR(CHCl3): 3518, 3450, 3431, 2671, 1739, 1709, 1641, 1543, 1506, 1471 cm−1. [α]D24+43.7±0.8°(c=1.004, MeOH) Anal. (C30H39FNO3S.0.1H2O) Calcd.(%): C, 72.72; H, 7.97; N, 2.83; S, 6.47. Found(%): C, 72.68; H, 7.95; N, 2.96; S, 6.48.
Compound Number II-195
1H-NMR(CDCl3) δ: 0.94(1H, d, J=9.9 Hz), 1.09 and 1.21(each 3H, each s), 1.53–2.50(14H, m), 4.19(1H, m), 4.32(2H, s), 5.34–5.47(2H, m), 6.00(1H, d, J=8.7 Hz), 6.76(1H, d, J=3.6 Hz), 7.28–7.39(3H, m), 7.50 (1H, m), 7.66(1H, d, J=3.6 Hz). IR(CHCl3): 3516, 3450, 3431, 2669, 1741, 1709, 1643, 1543, 1508, 1456, 1315, 1163, 1126, 1059, 1038 cm−1. [α]D25+36.4±0.7°(c=1.03, CHCl3) Anal. (C29H34F3NO3S) Calcd.(%): C, 65.27; H, 6.42; N, 2.62; S, 6.01. Found(%): C, 65.34; H, 6.30; N, 2.82; S, 6.00.
Compound Number II-197
1H-NMR(CDCl3) δ: 0.93(1H, d, J=10.5 Hz), 1.08 and 1.20(each 3H, each s),1.49–2.42(14H, m), 3.22(2H, t, J=8.7 Hz), 4.07(2H, s), 4.20 (1H, m), 4.57(2H, t, J=8.7 Hz), 5.33–5.48(2H, m), 5.99(1H, d, J=9.0 Hz), 6.79 (1H, t, 7.5 Hz), 6.80(1H, d, J=3.6 Hz), 6.95(1H, d, J=7.5 Hz), 7.09(1H, d, J=7.5 Hz), 7.30(1H, d, J=3.6 Hz). IR(CDCl3): 3514, 3450, 3431, 2667, 1739, 1709, 1641, 1545, 1506, 1458 cm−1. [α]D25+42.0±0.8°(c=1.004, MeOH), Anal. (C30H37NO4S.0.1H2O) Calcd.(%): C, 70.72; H, 7.36; N, 2.75; S, 6.29. Found(%): C, 70.59; H, 7.39; N, 2.95; S, 6.31.
Compound Number II-198
1H-NMR(CDCl3) δ: 0.92 (1H, d, J=10.5 Hz), 1.07 and 1.19 (each 3H, each s),1.47–2.41(14H, m), 4.20(1H, m), 4.24(2H, s), 5.32–5.47(2H, m), 6.00(1H, d, J=8.7 Hz), 6.78(1H, d, J=3.9 Hz), 7.21(1H, dd, J=1.8 and 8.4 Hz), 7.26(1H, d, J=5.7 Hz), 7.33(1H, d, J=3.9 Hz), 7.43(1H, d, J=5.7 Hz), 7.67(1H, d, J=1.8 Hz), 7.81(1H, d, J=8.4 Hz). IR(CHCl3): 3516, 3450, 3431, 1739, 1709, 1641, 1545, 1458 cm−1. [α]D25+40.9±0.8°(c=1.002, MeOH), Anal. (C30H35NO3S2.0.3H2O) Calcd.(%): C, 68.36; H, 6.81; N, 2.66; S, 12.17. Found(%): C, 68.30; H, 6.68; N, 2.94; S, 12.25.
Compound Number II-199
1H-NMR(CDCl3) δ: 0.93(1H, d, J=10.5 Hz), 1.07 and 1.20(each 3H, each s),1.49–2.42(14H, m), 4.20(1H, m), 4.27(2H, s), 5.32–5.48(2H, m), 5.99(1H, d, J=8.7 Hz), 6.80(1H, d, J=3.6 Hz), 7.24(1H, dd, J=1.5 and 8.1 Hz), 7.31(1H, dd, J=0.6 and 5.4 Hz), 7.33(1H, d, J=3.6 Hz), 7.40 (1H, d, J=5.4 Hz), 7.73(1H, m), 7.77(1H, d, J=8.1 Hz). IR (CHCl3): 3516, 3450, 3431, 1741, 1709, 1641, 1543, 1508, 1469 cm−1. [α]D25+41.5±0.8°(c=1.002, MeOH), Anal. (C30H35NO3S2.0.3H2O) Calcd.(%): C, 68.36; H, 6.81; N, 2.66; S, 12.17. Found(%): C, 68.37; H, 6.73; N, 2.86; S, 12.21.
Compound Number II-200
1H-NMR(CDCl3) δ: 0.93(1H, d, J=10.2 Hz), 1.06 and 1.19(each 3H, each s),1.48–2.41(14H, m), 4.19(1H, m), 4.39(2H, s), 5.32–5.47(2H, m), 5.99(1H, d, J=8.7 Hz), 6.86(1H, d, J=3.6 Hz), 7.21(1H, d, J=7.2 Hz), 7.30(1H, d, J=3.6 Hz), 7.35(1H, t, J=7.2 Hz), 7.36(1H, d, J=5.4 Hz), 7.42(1H, d, J=5.4 Hz), 7.74(1H, d, J=7.2 Hlz). IR(CHCl3): 3516, 3450, 3431, 1739, 1709, 1641, 1543, 1508, 1471, 1460 cm−1. [α]D25+42.0±0.8°(c=1.001, MeOH), Anal. (C30H35NO3S2.0.3H2O) Calcd.(%): C, 68.36; H, 6.81; N, 2.66; S, 12.17. Found(%): C, 68.63; H, 6.78; N, 2.84; S, 12.26.
Compound Number II-201
1H-NMR(CDCl3) δ: 0.92(1H, d, J=10.2 Hz), 1.07 and 1.20(each 3H, each s),1.52–2.47(14H, m), 4.20(1H, m), 4.23(2H, s), 5.32–5.51(2H, m), 6.08(1H, d, J=8.7 Hz), 6.75(1H, d, J=3.6 Hz), 6.95(1H, dd, J=2.4 and 9.0 Hz), 7.10(1H, d, J=2.4 Hz), 7.19(1H, s), 7.27(1H, d, J=3.6 Hz), 7.66(1H, d, J=9.0 Hz). IR(CHCl3): 3427, 3249, 1707, 1633, 1601, 1545, 1510, 1442 cm−1. [α]D25+40.1±0.8°(c=1.007, MeOH), Anal. (C30H35NO4S2.0.3H2O) Calcd.(%): C, 66.34; H, 6.61; N, 2.58; S, 11.81. Found(%): C, 66.21; H, 6.70; N, 2.70; S, 11.75.
Compound Number II-202
1H-NMR(CDCl) δ: 0.93(1H, d, J=10.2 Hz), 1.08 and 1.21(each 3H, each s), 1.53–2.45(14H, m), 4.17(1H, m), 4.24(2H, m), 4.69(2H, m), 5.35–5.47(2H, m), 6.02(1H, d, J=9.3 Hz), 6.72(1H, d, J=3.9 Hz), 7.23–7.31(4H, m), 7.40(1H, m). IR(CHCl3): 3516, 3450, 3431, 1709, 1641, 1527, 1508, 1456 cm−1. [α]D26+32.7±0.7°(c=1.00, CHCl3)
Compound Number II-203
1H-NMR(CDCl3) δ: 0.92(1H, d, J=10.2 Hz), 1.08 and 1.21(each 31H, each s), 1.54–2.48(18H, m), 3.20 (4H, m), 4.11–4.22(3H, m), 4.43(2H, s), 5.33–5.55(2H, m), 5.99(1H, d, J=8.4 Hz), 6.67(1H, d, J=4.2 Hz), 7.30–7.43 (4H, m), 7.64(1H, d, J=4.2 Hz). IR(CHCl3): 3514, 3448, 3420, 2555, 2459, 1711, 1643, 1543, 1508, 1456 cm−1. [α]D26+20.4±0.6°(c=1.05, CHCl3) Anal. (C33H44N2O3S.1.1H2O) Calcd.(%): C, 69.71; H, 8.19; N, 4.93; S, 5.64. Found(%): C, 69.69; H, 8.08; N, 4.92; S, 5.54.
Compound Number II-204
1H-NMR(CDCl3) δ: 0.93(1H, d, J=10.5 Hz), 1.07 and 1.21(each 3H, each s), 1.53–2.46(14H, m), 2.49(6H,s), 3.79(1H, d, J=10.8 Hz), 3.84 (1H, d, J=10.8 Hz), 4.19(1H, m), 4.35(1H, d, J=20.1 Hz), 4.37(1H, d, J=20.1 Hz), 5.36–5.54 (2H, m), 5.94(1H, d, J=9.0 Hz), 6.71(1H, d, J=3.6 Hz), 7.25–7.43(5H, m). IR(CHCl3): 3516, 3448, 3429, 2553, 2459, 1711, 1643, 1545, 1506, 1471 cm−1. [α]D26+20.9±0.6°(c=1.03, CHCl3) Anal. (C31H42N2O3S.3.1H2O) Calcd.(%): C, 64.35; H, 8.40; N, 4.84; S, 5.54. Found(%): C, 64.36; H, 7.87; N, 4.63; S, 5.17.
Compound Number II-205
1H-NMR(CDCl3) δ: 0.98(1H, d, J=10.5 Hz), 1.13 and 1.24(each 3H, each s), 1.53–2.47(14H, m), 3.20–3.27(4H, m), 4.28(1H, m), 5.35–5.51 (2H, m), 6.32(1H, d, J=8.4 Hz), 7.24(1H, d, J=7.5 Hz), 7.34 and 7.46 (each 1H, each m), 7.55(1H, dd, J=1.8 and 8.4 Hz), 7.67(1H, d, J=1.8 Hz), 8.00–8.04(2H, m). IR(CHCl3): 3518, 3448, 1709, 1649, 1597, 1514, 1294 cm−1. [α]D25+58.8±1.0°(c=1.001, MeOH) Anal. (C32H37NO4.0.2H2O) Calcd.(%): C, 76.37; H, 7.49; N, 2.78. Found(%): C, 76.33; H, 7.50; N, 2.88.
Compound Number II-206
1H-NMR(CDCl3) δ: 0.95(1H, d, J=10.2 Hz), 1.07 and 1.22(each 3H, each s), 1.51–2.43(14H, m), 3.97(2H, s), 4.21(1H, m), 5.34–5.49(2H, m), 6.07(1H, d, J=3.3 Hz), 6.38(1H, d, J=9.3 Hz), 6.98–7.04(3H, m), 7.13–7.22(2H, m). IR (CHCl3): 3518, 3438, 1739, 1709, 1651, 1606, 1549, 1508 cm−1. [α]D26+57.2±1.0°(c=1.016, MeOH) Anal. (C28H34FNO4.0.1H2O) Calcd.(%): C, 71.65; H, 7.34; N, 2.98; F, 4.05. Found(%): C, 71.57; H, 7.44; N, 3.14; F, 4.01.
Compound Number II-207
1H-NMR(CDCl3) δ: 0.96(1H, d, J=10.5 Hz), 1.07 and 1.21(each 3H, each s), 1.52–2.43(14H, m), 4.00(2H, s), 4.21(1H, m), 5.34–5.49(2H, m), 6.09(1H, d, J=3.3 Hz), 6.40(1H, d, J=9.6 Hz), 7.01(1H, d, J=3.3 Hz), 7.22–7.36(5H, m). IR (CHCl3): 3516, 3439, 2667, 1738, 1709, 1651, 1606, 1547, 1498 cm−1. [α]D24+62.2±1.0°(c=1.007, MeOH) Anal. (C28H35NO4.0.2H2O) Calcd.(%): C, 74.21; H, 7.87; N, 3.09. Found(%): C, 74.14; H, 7.81; N, 3.25.
Compound Number II-208
1H-NMR(CDCl3) δ: 0.92(1H, d, J=10.2 Hz), 1.07 and 1.20(each 3H, each s),1.48–2.42(14H, m), 4.19(1H, m), 4.42(2H, s), 5.32–5.47(2H, m), 5.98(1H, d, J=8.7 Hz), 6.78(1H, d, J=2.1 Hz), 6.84(1H, d, J=3.9 Hz), 7.13(1H, dd, J=1.5 and 7.5 Hz), 7.19(1H, t, J=7.5 Hz), 7.30(1H, d, J=3.9 Hz), 7.50(1H, dd, J=1.5 and 7.5 Hz), 7.63(1H, d, 2.1 Hz). IR(CHCl3): 3516, 3450, 3431, 1741, 1709, 1641, 1543, 1508, 1471, 1458, 1427 cm−1. [α]D25+43.5±0.8°(c=1.010, MeOH), Anal. (C30H35NO4S.0.2H2O) Calcd.(%): C, 70.75; H, 7.01; N, 2.75; S, 6.30. Found(%): C, 70.80; H, 7.02; N, 2.96; S, 6.26.
Compound Number II-209
1H-NMR(CDCl3) δ: 0.94(1H, d, J=10.2 Hz), 1.09 and 1.22(each 3H, each s), 1.55–2.41(14H, m), 2.95(3H, s), 4.18–4.21(3H, m), 4.45(2H, s), 5.39–5.43(2H, m), 6.00(1H, d, J=8.7 Hz), 6.63–6.71(4H, m), 7.16–7.26(6H, m), 7.32(1H, m). IR(CHCl3): 3516, 3450, 3431, 1739, 1709, 1643, 1599, 1543, 1505, 1454 cm−1. [α]D26+32.2±0.7°(c=1.00, CHCl3) Anal. (C36H44N2O3S.0.6H2O) Calcd.(%): C, 72.59; H, 7.65; N, 4.70; S, 5.38. Found(%): C, 72.68; H, 7.47; N, 4.74; S, 5.29.
Compound Number II-211
1H-NMR(CDCl3) δ: 0.93(1H, d, J=9.9 Hz), 1.07 and 1.20(each 3H, each s), 1.49–2.41(14H, m), 4.19(1H, m), 4.30(2H, s), 5.32–5.48(2H, m), 5.99(1H, d, J=9.0 Hz), 6.82(1H, d, J=3.6 Hz), 7.24(1H, dd, J=1.5 and 8.1 Hz), 7.30–7.36(2H, m), 7.4–7.47(2H, m), 7.55(1H, d, J=8.1 Hz), 7.87–7.94(2H, m). IR(CHCl3): 3510, 3450, 3431, 2669, 1739, 1709, 1641, 1545, 1506, 1458, 1429 cm−1. [α]D24+39.4±0.8°(c=1.002, MeOH) Anal. (C34H37NO4S.0.1H2O) Calcd.(%): C, 73.25; H, 6.73; N, 2.51; S, 5.75. Found(%): C, 73.13; H, 6.53; N, 2.69; S, 5.79.
Compound Number II-212
1H-NMR(CDCl3) δ: 0.93(1H, d, J=10.2 Hz), 1.08 and 1.21(each 3H, each s), 1.50–2.43(14H, m), 3.79 and 3.86(each 3H, each s), 4.14(2H, s), 4.19(1H, m), 5.33–5.48(2H, m), 5.96(1H, d, J=8.4 Hz), 6.78–6.85 (3H, m), 7.00(1H, t, J=8.1 Hz), 7.30(1H, d, J=3.6 Hz). IR(CHCl3): 3516, 3450, 3431, 2667, 1739, 1709, 1641, 1543, 1506, 1481, 1273, 1076 cm−1. [α]D26+39.6±0.8°(c=1.007, MeOH) Anal. (C30H39NO5S.0.1H2O) Calcd.(%): C, 68.31; H, 7.49; N, 2.66; S, 6.08. Found(%): C, 68.17; H, 7.50; N, 2.76; S, 6.13.
Compound Number II-213
1H-NMR(CDCl3) δ: 0.94(1H, d, J=10.2 Hz), 1.09 and 1.22 (each 3H, each s),1.51–2.45(14H, m), 2.39(3H, s), 4.15(2H, s), 4.21(1H, m), 5.34–5.50 (2H, m), 5.87(1H, s), 6.04(1H, d, J=8.7 Hz), 6.86(1H, d, J=3.6 Hz), 7.32(1H, d, J=3.6 Hz). IR(CHCl3): 3514, 3450, 3431, 1709, 1645, 1608, 1545, 1508, 1471, 1456 cm−1. [α]D25+47.0±0.9°(c=1.017, MeOH), Anal. (C26H34N2O4S.0.3H2O) Calcd.(%): C, 65.60; H, 7.33; N, 5.88; S, 6.74. Found(%): C, 65.49; H, 7.31; N, 6.00; S, 6.86.
Compound Number II-214
1H-NMR(CDCl3) δ: 0.93(1H, d, J=10.2 Hz), 1.08 and 1.21(each 3H, each s),1.50–2.42(14H, m), 2.33(3H, s), 3.82(3H, s), 4.07(2H, s), 4.18 (1H, m), 5.33–5.48(2H, m), 5.96(1H, d, J=8.7 Hz), 6.69(1H, s), 6.74 (1H, d, J=7.8 Hz), 6.76(1H, d, J=3.6 Hz), 7.03(1H, d, J=7.8 Hz), 7.28 (1H, d, J=3.6 Hz). IR(CHCl3): 3516, 3450, 3431, 1741, 1709, 1639, 1614, 1543, 1506, 1464 cm−1. [α]D24+43.3±0.8°(c=1.012, MeOH), Anal. (C30H39NO4S.0.1H2O) Calcd.(%): C, 70.45; H, 7.73; N, 2.74; S, 6.27. Found(%): C, 70.35; H, 7.78; N, 2.96; S, 6.20.
Compound Number II-215
1H-NMR(CDCl3) δ: 0.93(1H, d, J=10.2 Hz), 1.07 and 1.21(each 3H, each s),1.49–2.43(14H, m), 3.84(3H, s), 4.20(1H, m), 4.32(2H, s), 5.33–5.48(2H, m), 5.99(1H, d, J=8.4 Hz), 6.83(1H, d, J=3.6 Hz), 7.01 (1:H, dd, J=2.4 and 8.7 Hz), 7.12(1H, d,J=2.4 Hz), 7.21(1H, s), 7.31 (1H, d, J=3.6 Hz), 7.71(1H, d, J=8.7 Hz). IR(CDCl3): 3516, 3450, 3431, 1739, 1709, 1643, 1601, 1543, 1508, 1458, 1427 cm−1. [α]D25+38.5±0.8°(c=1.004, MeOH), Anal. (C31H37NO4S2.0.1H2O) Calcd.(%): C, 67.26; H, 6.72; N, 2.53; S, 11.58. Found(%): C, 67.24; H, 6.73; N, 2.77; S, 11.51.
Compound Number II-216
1H-NMR(CDCl3) δ: 0.94(1H, d, J=10.5 Hz), 1.07 and 1.20(each 3H, each s), 1.50–2.42(14H, m), 3.87(2H, s), 4.18(1H, m), 4.20(2H, s), 5.32–5.48 (2H, m), 5.98(1H, d, J=7.2 Hz), 6.81(1H, d, J=3.6 Hz), 7.23–7.41 (5H, m), 7.53(1H, d, J=7.5 Hz), 7.71–7.77(2H, m). IR(CHCl3): 3514, 3450, 3431, 1739, 1709, 1641, 1545, 1506, 1469, 1456 cm−1. [α]D25+38.5±0.8°(c=1.007, MeOH) Anal. (C35H39NO3S.0.2H2O) Calcd.(%): C, 75.42; H, 7.13; N, 2.51; S, 5.75. Found(%): C, 75.36; H, 7.18; N, 2.79; S, 5.50.
Compound Number II-217
1H-NMR(CDCl3) δ: 0.96(1H, d, J=10.2 Hz), 1.10 and 1.21(each 3H, each s), 1.52–2.44(14H, m), 3.14–3.24(4H, m), 4.13(2H, s), 4.24(1H, m), 5.32–5.49(2H, m), 6.19(1H, d, J=9.0 Hz), 7.06–7.18(4H, m), 7.22 (1H, d, J=8.1 H), 7.39(1H, dd, J=1.8 and 8.1 Hz), 7.51(1H, d, J=1.8 Hz). IR(CHCl3): 3516, 3452, 1738, 1709, 1649, 1570, 1518, 1491, 1471 cm−1. [α]D25+54.4±0.9°(c=1.002, MeOH) Anal. (C32H39NO4.0.1H2O) Calcd.(%): C, 78.85; H, 8.11.; N, 2.87. Found(%): C, 78.74; H, 8.14; N, 3.17.
Compound Number II-218
1H-NMR(CDCl3) δ: 0.94(1H, d, J=10.2 Hz), 1.08 and 1.21(each 3H, each s), 1.50–2.43(14H, m), 3.83, 3.85 and 3.86(each 3H, each s), 4.07 (2H, s), 4.19(1H, m), 5.33–5.49(2H, m), 5.97(1H, d, J=9.0 Hz), 6.62 (1H, d, J=8.7 Hz), 6.76(1H, td, J=0.9 and 3.6 Hz), 6.87(1H, d, J=8.7 Hz), 7.30 (1H, d, (1, J=3.6 Hz). IR(CHCl3): 3516, 3450, 3431, 1739, 1709, 1641, 1603, 1543, 1495, 1469, 1277, 1259, 1097 cm−1. [α]D26+38.4±0.8°(c=1.013, MeOH) Anal. (C31H41NO6S.0.2H2O) Calcd.(%): C, 66.57; H, 7.46; N, 2.50; S, 5.73. Found(%): C, 66.54; H, 7.42; N, 2.61; S, 5.71.
Compound Number II-219
1H-NMR(CDCl3) δ: 0.94(1H, d, J=10.2 Hz), 1.08 and 1.21(each 3H, each s), 1.50–2.42(14H, m), 2.18 and 2.29(each 3H, each s), 4.14(2H, s), 4.19(1H, m), 5.33–5.49(2H, m), 5.96(1H, d, J=8.4 Hz), 6.67(1H, td, J=0.9 and 3.6 Hz), 7.02–7.12(3H, m), 7.29(1H, t, J=3.6 Hz). IR (CDCl3): 3516, 3450, 3431, 1741, 1709, 1641, 1543, 1506, 1471 cm−1. [α]D26+42.8±0.8°(c=1.007, MeOH) Anal. (C30H39NO3S) Calcd.(%): C, 72.98; H, 7.96; N, 2.84; S, 6.50. Found(%): C, 72.67; H, 7.98; N, 2.94; S, 6.38.
Compound Number II-220
1H-NMR(CDCl3) δ: 0.95(1H, d, J=10.2 Hz), 1.09 and 1.22(each 3H, each s), 1.51–2.44(14H, m), 3.83(3H, s), 3.84(6H, s), 4.07(2H, s), 4.20 (1H, m), 5.34–5.49(2H, m), 6.00(1H, d, J=8.7 Hz), 6.45(2H, s), 6.79 and 7.31 (each 1H, each d, each J=3.6 Hz). IR(CHCl3): 3516, 3450, 3431, 1741, 1709, 1641, 1593, 1543, 1506, 1464, 1421, 1331, 1240, 1130 cm−1. [α]D24+38.3±0.8°(c=1.004, MeOH) Anal. (C31H41NO6S.0.2H2O) Calcd.(%): C, 66.57; H, 7.46; N, 2.50; S, 5.73. Found(%): C, 66.48; H, 7.37; N, 2.59; S, 5.63.
Compound Number II-221
1H-NMR(CDCl3) δ: 0.94(1H, d, J=10.2 Hz), 1.08 and 1.21(each 3H, each s), 1.50–2.43(14H, m), 4.08(2H, s), 4.20(1H, m), 5.33–5.49(2H, m), 5.95(2H, s), 5.99(1H, d, J=8.7 Hz), 6.68–6.82(4H, m), 7.30(1H, d, J=3.6 Hz). IR(CHCl3): 3512, 3450, 3431, 1739, 1709, 1641, 1545, 1506, 1460, 1252, 1063 cm−1. [α]D24+41.8±0.8°(c=1.007, MeOH) Anal. (C29H35NO5S) Calcd.(%): C, 68.34; H, 6.92; N, 2.75; S, 6.29. Found(%): C, 68.04; H, 6.90; N, 2.79; S, 6.29.
Compound Number II-222
1H-NMR(CDCl3) δ: 0.92(1H, d, J=10.5 Hz), 1.09 and 1.21(each 3H, each s), 1.51–2.45(14H, m), 2.14(3H, s), 4.08(2H, s), 4.18(1H, m), 5.32–5.50 (2H, m), 6.08(1H, d, J=8.4 Hz), 6.76(1H, d, J=3.6 Hz), 6.97 (1H, d, J=7.8 Hz), 7.24(1H, t, J=8.4 Hz), 7.30(1H, d, J=3.6 Hz), 7.38–7.40 (2H, m), 7.74(1H, br s). IR(CHCl3): 3514, 3435, 3311, 1705, 1639, 1612, 1534, 1508, 1439 cm−1. [α]D25+40.1±0.8°(c=1.008, MeOH) Anal. (C30H38N2O4S.0.4H2O) Calcd.(%): C, 68.00; H, 7.38; N, 5.29; S, 6.05. Found(%): C, 68.11; H, 7.17; N, 5.22; S, 5.93.
Compound Number II-223
1H-NMR(CDCl3) δ: 0.94(1H, d, J=10.5 Hz), 1.09 and 1.22(each 3H, each s), 1.53–2.50(14H, m), 2.99(3H, s), 4.13(2H, s), 4.21(1H, m), 5.34–5.52 (2H, m), 6.02(1H, d, J=9.3 Hz), 6.80(1H, d, J=3.9 Hz), 7.04–7.07(2H, m), 7.16(1H, m), 7.25–7.32(3H, m). IR(CHCl3): 3510, 3440, 3431, 3371, 1709, 1639, 1608, 1543, 1508, 1471, 1386, 1335, 1151 cm−1. [α]D24+38.3±0.8°(c=1.006, MeOH) Anal. (C29H38N2O5S2.0.2H2O) Calcd.(%): C, 61.94; H, 6.88; N, 4.98; S, 11.40. Found(%): C, 61.99; H, 6.92; N, 4.95; S, 10.97.
Compound Number II-224
1H-NMR(CDCl3) δ: 0.94(1H, d, J=10.2 Hz), 1.09 and 1.21(each 3H, each s), 1.50–2.44(14H, m), 4.21(1H, m), 4.32(2H, s), 5.34–5.50(2H, m), 6.01(1H, d, J=9.0 Hz), 6.86, 6.88 and 7.14(each 1H, each d, each J=3.6 Hz), 7.23–7.37(4H, m), 7.53–7.56(2H, m).
Compound Number II-225
1H-NMR(CDCl3) δ: 0.94 (1H, d, J=10.2 Hz), 1.08 and 1.21(each 311, each s), 1.50–2.43(14H, m), 4.08(2H, s), 4.17–4.30(5H, m), 5.33–5.49 (2H, m), 5.98(1H, d, J=8.4 Hz), 6.71–6.80(4H, m), 7.28(1H, d, J=3.6 Hz). IR(CHCl3): 3516, 3450, 3431, 1739, 1709, 1639, 1602, 1543, 1506, 1475, 1456, 1284, 1090 cm−1. [α]D24.5+40.2±0.8°(c=1.011, MeOH) Anal. (C30H37NO5S.0.2H2O) Calcd.(%): C, 68.34; H, 7.15; N, 2.66; S, 6.08. Found(%): C, 68.35; H, 7.03; N, 2.71; S, 6.17.
Compound Number II-226
1H-NMR(CDCl3) δ: 0.94(1H, d, J=10.2 Hz), 1.08 and 1.21(each 3H, each s), 1.50–2.43(14H, m), 2.31 and 3.70(each 3H, each s), 4.15(2H, s), 4.19(1H, m), 5.33–5.49(2H, m), 5.98(1H, d, J=8.7 Hz), 6.77(1H, d, J=3.9 Hz), 6.96–7.11(3H, m), 7.31(1H, d, J=3.9 Hz). IR(CHCl3): 3516, 3450, 3431, 2669, 1738, 1709, 1641, 1545, 1506, 1471, 1259, 1011 cm−1. [α]D24+41.2±0.8°(c=1.003, MeOH) Anal. (C30H39NO4S) Calcd.(%): C, 70.69; H, 7.71; N, 2.75; S, 6.29. Found(%): C, 70.41; H, 7.76; N, 2.97; S, 6.04.
Compound Number II-227
1H-NMR(CDCl3) δ: 0.93(1H, d, J=10.2 Hz), 1.08 and 1.21(each 3H, each s), 1.51–2.42(14H, m), 2.16(3H, s), 4.09(2H, s), 4.18(1H, m), 5.32–5.50 (2H, m), 6.01(1H, d, J=8.7 Hz), 6.77(1H, d, J=3.6 Hz), 7.17 (2H, d, J=8.1 Hz), 7.32(1H, d, J=3.6 Hz), 7.43(1H, br s), 7.44(2H, d, J=8.1 Hz). IR(CHCl3): 3514, 3435, 3311, 1705, 1639, 1541, 1513, 1410 cm−1. [α]D24.5+40.8±0.8°(c=1.000, MeOH) Anal. (C30H38N2O4S.0.4H2O) Calcd.(%): C, 68.00; H, 7.38; N, 5.29; S, 6.05. Found(%): C, 68.06; H, 7.38; N, 5.28; S, 5.92.
Compound Number II-228
1H-NMR(CDCl3) δ: 0.94(1H, d, J=9.9 Hz), 1.09 and 1.21(each 3H, each s), 1.51–2.42(14H, m), 2.99(3H, s), 4.11(2H, s), 4.20(1H, m), 5.33–5.49(2H, m), 6.01(1H, d, J=9.3 Hz), 6.78(1H, d, J=3.6 Hz), 6.86 (1H, br s), 7.17–7.25(4H, m), 7.31(1H, d, J=3.6 Hz). IR(CHCl3): 3510, 3448, 3431, 3371, 1707, 1639, 1543, 1510, 1471, 1456, 1387, 1330, 1155 cm−1. [α]D24.5+37.6±0.8°(c=1.006, MeOH) Anal. (C29H38N2O5S2.0.3H2O) Calcd.(%): C, 61.74; H, 6.90; N, 4.97; S, 11.37. Found(%): C, 61.84; H, 6.93; N, 5.03; S, 11.14.
Compound Number II-229
mp.149–150° C. 1H-NMR(CDCl3) δ: 0.92(1H, d, J=10.5 Hz), 1.05 and 1.19(each 3H, each s), 1.47–2.40(14H, m), 4.18(1H, m), 4.40 (2H, s), 5.31–5.46(2H, m), 5.98(1H, d, J=8.4 Hz), 6.88(1H, d, J=3.9 Hz), 7.30–7.35(2H, m), 7.42–7.48(3H, m), 7.58(1H, m), 8.08(1H, d, J=6.6 Hz), 8.14(1H, m). IR(CHCl3): 3514, 3450, 3431, 2667, 1738, 1707, 1643, 1543, 1508, 1471, 1458, 1444 cm−1. [α]D24.5+39.7±0.8°(c=1.008, MeOH) Anal. (C34H37NO3S2) Calcd.(%): C, 71.42; H, 6.52; N, 2.45; S, 11.22. Found(%): C, 71.21; H, 6.53; N, 2.51; S, 10.97.
Compound Number II-230
1H-NMR(CDCl3) δ: 0.92(1H, d, J=10.5 Hz), 1.06 and 1.19(each 3H, each s), 1.48–2.40(14H, m), 3.79(2H, s), 4.18(1H, m), 4.26(2H, s), 5.21–5.47(2H, m), 5.96(1H, d, J=8.4 Hz), 6.78(1H, d, J=3.6 Hz), 7.18 (1H, d, J=7.2 Hz), 7.27–7.40(4H, m), 7.53(1H, d, J=7.2 Hz), 7.72(1H, d, J=7.8 Hz), 7.78(1H, d, J=6.9 Hz). IR(CHCl3): 3510, 3450, 3431, 2669, 1739, 1709, 1641, 1543, 1506, 1471, 1456 cm−1. [α]D24+36.6±0.8°(c=1.006, MeOH) Anal. (C35H39NO3S.0.2H2O) Calcd.(%): C, 75.42; H, 7.13; N, 2.51; S, 5.75. Found(%): C, 75.46; H, 7.15; N, 2.73; S, 5.55.
Compound Number II-231
1H-NMR(CDCl3) δ: 0.93(1H, d, J=9.9 Hz), 1.08 and 1.21(each 3H, each s), 1.50–2.43(14H, m), 2.20, 2.45 and 3.67(each 3H, each s), 4.13 (2H, s), 4.19(1H, m), 5.33–5.49(2H, m), 5.97(1H, d, J=8.4 Hz), 6.77 (1H, td, J=0.9 and 3.9 Hz), 6.89 and 6.95(each 1H, each d, each J=7.8 Hz), 7.31(1H, d, J=3.6 Hz). IR(CHCl3): 3516, 3450, 3431, 1738, 1709, 1641, 1545, 1506, 1458, 1263, 1084, 1009 cm−1. [α]D24+39.8±0.8°(c=1.006, MeOH) Anal. (C31H41NO4S) Calcd.(%): C, 71.09; H, 7.89; N, 2.67; S, 6.12. Found(%): C, 70.80; H, 8.02; N, 2.92; S, 6.06.
Compound Number II-232
1H-NMR(CDCl3) δ: 0.93(1H, d, J=10.2 Hz), 1.06 and 1.19(each 3H, each s), 1.49–2.41(14H, m), 4.18(1H, m), 4.50(2H, s), 5.32–5.47(2H, m), 5.98(1H, d, J=9.0 Hz), 6.89(1H, d, J=3.9 Hz), 7.29–7.38(4H, m), 7.47 (1H, m), 7.59(1H, d, J=8.4 Hz), 7.86(1H, m), 7.95(1H, d, J=7.8 Hz). IR(CHCl3): 3510, 3450, 3431, 2669, 1739, 1709, 1641, 1545, 1508, 1471, 1450, 1423 cm−1. [α]D24+40.3±0.8°(c=1.007, MeOH) Anal. (C34H37NO4S.0.2H2O) Calcd.(%): C, 73.01; H, 6.74; N, 2.50; S, 5.73. Found(%): C, 72.91; 11, 6.58; N, 2.59; S, 5.75.
Compound Number II-233
1H-NMR(CDCl3) δ: 0.92(1H, d, J=10.2 Hz), 1.08 and 1 .20(each 3H, each s),1.50–2.43(14H, m), 4.04(2H, s), 4.20(1H, m), 5.32–5.49(2H, m), 6.03(1H, d, J=9.0 Hz), 6.75(1H, d, J=3.6 Hz), 6.80 and 7.06(each 2H, each d, J=8.7 Hz), 7.32(1H, d, J=3.6 Hz). IR(CHCl3): 3446, 3510, 3182, 2673, 1709, 1635, 1614, 1545, 1512, 1471, 1458 cm−1. [α]D25+43.8±0.8°(c=1.000, MeOH), Anal. (C28H35NO4S) Calcd.(%): C, 69.82; H, 7.32; N, 2.91; S, 6.66. Found(%): C, 69.57; H, 7.43; N, 3.00; S, 6.61.
Compound Number II-295
mp.156–157° C. 1H-NMR(CDCl3) δ: 1.00(1H, d, J=10.2 Hz), 1.17 and 1.25 (each 3H, each s), 1.57–2.51(14H, m), 4.31(1H, m), 5.34–5.54(2H, m), 6.37(1H, d, J=9.3 Hz), 7.33–7.47(3H, m), 7.61(1H, s), 7.64(1H, m), 7.70–7.73 (2H, m), 7.87(1H, d, J=8.4 Hz), 8.15(1H, d, J=1.2 Hz). IR (CHCl3); 3518, 3452, 1741, 1709, 1649, 1510 cm−1. [α]D23+67.2±2.1°(c=0.503, MeOH) Anal. (C31H35NO3S.0.1H2O) Calcd.(%): C, 73.95; H, 7.05; N, 2.78; S, 6.37. Found(%): C, 73.94; H, 7.08; N, 3.04; S, 6.53.
Compound Number II-296
mp.126–127° C. 1H-NMR(CDCl3) δ: 0.93(1H, d, J=10.2 Hz), 1.08 and 1.20(each 3H, each s), 1.50–2.46(14H, m), 4.17(1H, m), 5.33–5.51(2H, m), 6.04(1H, d, J=8.4 Hz), 6.51(1H, dd, J=1.5 and 3.3 Hz), 7.13(1H, dd, J=2.7 and 3.3 Hz), 7.22(1H, dd, J=7.8 and 9.0 Hz), 7.73(1H, dd, J=1.5 and 2.1 Hz), 7.91–7.96(2H, m). IR(CHCl3): 3513, 3449, 3144, 1733, 1709, 1651, 1592, 1507, 1496, 1385, 1181 cm−1. [α]D24+36.2±0.8°(c=1.005, MeOH) Anal. (C27H33FN2O5S) Calcd.(%): C, 62.77; H, 6.44; N, 5.42; F, 3.68; S, 6.21. Found(%): C, 62.71; H, 6.49; N, 5.39; F, 3.69; S, 6.21.
Compound Number II-297
mp.145–146° C. 1H-NMR(CDCl3) δ: 0.93(1H, d, J=10.2 Hz), 1.08 and 1.20(each 3H, each s), 1.50–2.45(14H, m), 3.86(3H, s), 4.17(1H, m), 5.33–5.51 (2H, m), 6.04(1H, d, J=8.4 Hz), 6.48(1H, dd, J=1.5 and 3.3 Hz), 6.98 and 7.85(each 2H, each d, each J=9.0 Hz), 7.12(1H, dd, J=2.7 and 3.3 Hz), 7.71(1H, dd, J=1.8 and 2.1 Hz). IR(CHCl3): 3513, 3449, 3413, 3143, 1733, 1709, 1649, 1596, 1576, 1499, 1379, 1266, 1189, 1167 cm−1. [α]D24+34.5±0.7°(c=1.005, MeOH) Anal. (C28H36N2O6S) Calcd.(%): C, 63.61; H, 6.86; N, 5.30; S, 6.07. Found(%): C, 63.54; H, 6.93; N, 5.18; S, 6.08.
Compound Number II-298
1H-NMR(CDCl3) δ: 0.97(1H, d, J=10.5 Hz), 1.12 and 1.23(each 3H, each s), 1.50–2.50(14H, m), 4.23(1H, m), 5.39–5.51(2H, m), 6.09(1H, d, J=9.6 Hz), 6.35(1H, dd, J=2.4 and 3.9 Hz), 6.48(1H, dd, J=2.4 and 3.9 Hz), 7.02(1H, dd, J=3.6 and 4.8 Hz), 7.18(1H, dd, J=0.6 and 4.8 Hz), 7.41(1H, dd, J=0.6 and 3.6 Hz), 10.92(1H, brs). IR(CHCl3): 3506, 3447, 3220, 3164, 1704, 1617, 1537, 1508 cm−1. [α]D24+50.7±0.9°(c=1.009, MeOH) Anal. (C25H32N2O3S.0.2H2O) Calcd.(%): C, 67.59; H, 7.35; N, 6.31; S, 7.22. Found(%): C, 67.60; H, 7.23; N, 6.39; S, 7.34.
Compound Number II-299
1H-NMR(CDCl3) δ: 0.93(1H, d, J=10.2 Hz), 1.08 and 1.21(each 3H, each s), 1.50–2.44(14H, m), 2.27(3H, s), 4.05(2H, s), 4.20(1H, m), 5.33–5.49(2H, m), 6.01(1H, d, J=8.7 Hz), 6.71(1H, d, J=3.9 Hz), 7.09 (1H, dd, J=1.2 and 7.8 Hz), 7.17–7.32(3H, m), 7.28(1H, d, J=3.9 Hz). IR(CHCl3): 3516, 3450, 3431, 2669, 1747, 1709, 1641, 1543, 1506, 1456, 1369 cm−1. [α]D24+40.2°±0.8°(c=1.006, MeOH) Anal. (C30H37NO5S.0.2H2O) Calcd.(%): C, 68.34; H, 7.15; N, 2.66; S, 6.08. Found(%): C, 68.33; H, 6.94; N, 2.83; S, 6.31.
Compound Number II-300
1H-NMR(CDCl3) δ: 0.93(1H, d, J=9.9 Hz), 1.08 and 1.21(each 3H, each s), 1.50–2.41(14H, m), 2.60(3H, s), 4.20(1H, m), 5.34–5.48(2H, m), 6.18(1H, d, J=8.7 Hz), 7.28(1H, d-like), 7.36(1H, d, J=3.9 Hz), 7.40 (1H, t-like), 7.51(1H, dt, J=1.2 and 7.2 Hz), 7.61(1H, d, J=3.9 Hz), 8.15(1H, dd, J=1.2 and 8.1 Hz). IR(CHCl3): 3512, 3446, 1739, 1709, 1655, 1529, 1504, 1325, 1157 cm−1. [α]D24+51.1±0.9°(c=1.010, MeOH) Anal. (C28H35NO5S2) Calcd.(%): C, 63.49; H, 6.66; N, 2.64; S, 12.11. Found(%): C, 63.23; H, 6.53; N, 2.70; S, 12.17.
Compound Number II-301
1H-NMR(CDCl3) δ: 0.93(1H, d, J=10.2 Hz), 1.07 and 1.21(each 3H, each s), 1.50–2.40(14H, m), 2.42(3H, s), 4.20(1H, m), 5.34–5.47(2H, m), 6.17(1H, d, J=8.7 Hz), 7.32(1H, d-like), 7.34 and 7.57(each 1H, each d, each J=4.2 Hz), 7.86(2H, d-like). IR(CDCl3): 3512, 3446, 1741, 1707, 1655, 1529, 1504, 1331, 1153 cm−1. [α]D24+54.9±0.9°(c=1.008, MeOH) Anal. (C28H35NO5S2) Calcd.(%): C, 63.49; H, 6.66; N, 2.64; S, 12.11. Found(%): C, 63.16; H, 6.54; N, 2.70; S, 12.16.
Compound Number II-302
1H-NMR(CDCl3) δ: 0.96(1H, d, J=10.2 Hz), 1.14 and 1.25(each 3H, each s),1.53–2.47(14H, m), 4.25(1H, m), 5.37–5.52(2H, m), 6.23(1H, d, J=8.7 Hz), 7.16–7.22(2H, m), 7.36(1H, m), 7.46(1H, s), 7.45–7.49(1H, m). IR(CHCl3): 3516, 3446, 3429, 1734, 1703, 1652, 1606, 1521, 1496, 1457, 1419 cm−1. [α]D25+72.8°±1.1°(c=1.005, MeOH), Anal. (C28H31NO4S.0.3H2O) Calcd.(%): C, 69.63; H, 6.59; N, 2.90; S, 6.63. Found(%): C, 69.51; H, 6.72; N, 3.30; S, 6.56.
Compound Number III-1
1H-NMR(CDCl3) δ: 0.88(1H, d, J=10.2 Hz), 1.07 and 1.23(each 3H, each s), 1.56–2.51(13H, m), 2.67(1H, m), 4.41(1H, m), 5.29–5.41(2H, m), 6.07(1H, d, J=8.1 Hz), 6.34 and 7.16(each 2H, each t, each J=2.1 Hz), 7.35 and 7.52(each 1H, each d, each J=3.9 Hz). IR (CHCl3): 3511, 3431, 3144, 3101, 2668, 1708, 1656, 1530, 1505, 1455, 1384, 1167 cm−1. [α]D24+34.2±0.7°(c=1.007, MeOH) Anal. (C25H32N2O5S2.0.5H2O) Calcd.(%): C, 58.46; H, 6.48; N, 5.45; S, 12.48. Found(%): C, 58.77; H, 6.40; N, 5.65; S, 12.72.
Compound Number III-47
1H-NMR(CDCl3) δ: 0.94(1H, d, J=9.9 Hz), 1.07 and 1.23(each 3H, each s), 1.56–2.48(13H, m), 2.68(1H, m), 4.42(1H, m), 5.29–5.42(2H, m), 6.16(1H, d, J=8.4 Hz), 7.16(1H, dd, J=3.9 and 5.1 Hz), 7.42 and 7.63(each 1H, each d, each J=3.9 Hz), 7.70(1H, dd, J=1.5 and 5.1 Hz), 7.76(1H, dd, J=1.5 and 3.9 Hz). IR (CHCl3): 3516, 3431, 3365, 3097, 1708, 1654, 1530, 1505, 1402, 1336, 1153 cm−1. [α]D24+34.5±0.7°(c=1.010, MeOH) Anal. (C25H31NO5S3.0.1H2O) Calcd.(%): C, 57.36; H, 6.01; N, 2.68; S, 18.38. Found(%): C, 57.16; H, 5.88; N, 2.76; S, 18.36.
Compound Number III-55
1H-NMR (CDCl3) δ: 0.88(1H, d, J=9.9 Hz), 1.07 and 1.23(each 3H, each s), 1.58–2.34(12H, m), 2.39(3H, s), 2.44(1H, m), 2.68(1H, m), 4.41(1H, m), 5.29–5.42(2H, m), 5.99(1H, m), 6.08(1H, d, J=8.4 Hz), 6.20(1H, t, J=3.3 Hz), 7.19(1H, m), 7.38 and 7.55(each 1H, each d, each J=3.9 Hz). IR(CHCl3): 3510, 3431, 3150, 3100, 1708, 1656, 1530, 1505, 1375, 1161 cm−1. [α]D24+30.9±0.7°(c=1.000, MeOH) Anal. (C26H34N2O5S2.0.3H2O) Calcd.(%): C, 59.58; H, 6.65; N, 5.35; 12.24. Found(%): C, 59.57; H, 6.48; N, 5.51; S, 12.22.
Compound Number III-80
1H-NMR(CDCl3) δ: 0.90(1H, d, J=9.9 Hz), 1.06 and 1.23(each 3H, each s), 1.58–2.48(13H, m), 2.67(1H, m), 4.41(1H, m), 5.29–5.42(2H, m), 6.27(1H, d, J=8.1 Hz), 7.38–7.44(3H, m), 6.34(1H, d, J=3.9 Hz), 8.14(1H, dd, J=1.5 and 3.0 Hz). IR(CHCl3): 3517, 3431, 3361, 3114, 1708, 1654, 1530, 1504, 1332, 1151 cm−1. [α]D24+33.7±0.7°(c=1.003, MeOH) Anal. (C25H31NO5S3.0.2H2O) Calcd.(%): C, 57.16; H, 6.02; N, 2.67; S, 18.31. Found(%): C, 57.09; H, 5.88; N, 2.76; S, 18.15.
Compound Number IV-1
1H-NMR(CDCl3) δ: 0.84 and 1.22(each 3H, each s), 1.43(1H, d, J=10.5 Hz), 1.53–2.50(14H, m), 4.09(1H, m), 5.30–5.41(2H, m), 6.17 (1H, d, J=8.7 Hz) 6.33 and 7.16(each 2H, each t-like), 7.40 and 7.57 (each 1H, each d, each J=3.9 Hz). IR(CHCl3): 3514, 3432, 3144, 3102, 1708, 1657, 1531, 1506, 1456, 1384, 1167 cm−1. [α]D23−45.4±0.9°(c=1.010, MeOH) Anal. (C25H30N2O5S2.0.3H2O) Calcd.(%): C, 59.10; H, 6.07; N, 5.51; S, 12.62. Found(%): C, 59.12; H, 5.83; N, 5.53; S, 12.41.
Compound Number IV-47
1H-NMR(CDCl3) δ: 0.85 and 1.22(each 3H, each s), 1.44(1H, d, J=10.2 Hz), 1.54–2.51(14H, m), 4.10(1H, m), 5.31–5.41(2H, m), 6.21 (1H, d, J=8.4 Hz), 7.11(1H, dd, J=3.9 and 4.8 Hz), 7.44 and 7.63 (each 1H, each d, each J=3.9 Hz), 7.70(1H, dd, J=1.2 and 4.8 Hz), 7.75 (1H, dd, J=1.2 and 3.9 Hz). IR(CHCl3): 3517, 3423, 3366, 3097, 2665, 1708, 1655, 1530, 1505, 1335, 1153 cm−1. [α]D23−46.4±0.9°(c=1.010, MeOH) Anal. (C25H31NO5S3.0.3H2O) Calcd.(%): C, 56.97; H, 6.04; N, 2.66; S, 18.25. Found(%): C, 57.10; H, 5.96; N, 2.70; S, 18.02.
Compound Number V-88
mp.105–106° C.; 1H-NMR(CDCl3) δ: 1.06(1H, m), 1.19–1.29(2H, m), 1.42–1.47(2H, m), 1.58–1.78(4H, m), 2.00–2.19(5H, m), 2.35(2H, t, J=7.2 Hz), 2.52(1H, m), 3.82(1H, m), 4.16(2H, s), 5.30–5.42(2H, m), 5.99(1H, d, J=7.5 Hz), 6.79(1H, dt, J=0.9 and 3.9 Hz), 6.96(1H, dd, J=1.5 and 4.8 Hz), 7.05(1H, m), 7.28(1H, dd, J=3.0 and 4.8 Hz), 7.37(1H. d, J=3.9 Hz). IR(KBr): 3367, 2667, 1700, 1612, 1543, 1520, 1317, 1244 cm−1. [α]D24+70.2±1.1°(c=1.006, MeOH) Anal. (C24H29NO3S2) Calcd.(%): C, 64.98; H, 6.59; N, 3.16; S, 14.46. Found(%): C, 64.92; H, 6.52; N, 3.32; S, 14.48.
Compound Number VI-1
1H-NMR(CDCl3) δ: 1.24–2.13(13H, m), 2.22(1H, m), 2.32(2H, t, J=7.2 Hz), 3.41(1H, m), 3.44(1H, m), 5.18–5.36(2H, m), 6.19(1H, m), 6.33 and 7.15(each 2H, each t, each J=2.4 Hz), 7.28 and 7.55(each 2H, each t, each J=3.9 Hz). IR(CHCl3): 3512, 3439, 3144, 3100, 1708, 1658, 1535, 1508, 1446, 1167 cm−1. [α]D26+69.5±1.1°(c=1.012, MeOH) Anal. (C23H28N2O5S.0.5H2O) Calcd.(%): C, 56.89; H, 6.02; N, 5.77; S, 13.21. Found(%): C, 56.91; H, 5.96; N, 5.91; S, 13.37.
Compound Number VI-31
1H-NMR(CDCl3) δ: 1.18–2.10(13H, m), 2.11(1H, m), 2.21–2.35(2H, m), 3.35(1H, m), 3.46(1H, m), 4.12(2H, s), 5.17–5.34(2H, m), 5.88(1H, m), 6.74(1H, d, J=3.9 Hz), 7.21–7.38(6H, m). IR(CHCl3): 3511, 3432, 3065, 1708, 1642, 1547, 1515, 1455 cm−1. [α]D2330 69.1±1.1°(c=1.009, MeOH) Anal. (C26H31NO3S.0.1H2O) Calcd.(%): C, 71.07; H, 7.16; N, 3.19; S, 7.30. Found(%): C, 70.91; H, 7.18; N, 3.19; S, 7.34.
Compound Number VI-40
1H-NMR(CDCl3) δ: 1.18–2.15(14H, m), 2.24–2.34(2H, m), 3.36(1H, m), 3.58(1H, m), 5.19–5.40(2H, m), 6.07(1H, m), 7.28–7.42(3H, m), 7.51(1H, d, J=0.6 Hz), 7.56–7.59(2H, m), 7.72(1H, d, J=0.6 Hz). IR (CHCl3): 3514, 3446, 1709, 1649, 1550, 1520, 1491 cm−1. [α]D22+79.4±1.2°(c=1.004, MeOH) Anal. (C25H29NO3S.0.2H2O) Calcd.(%): C, 70.29; H, 6.94; N, 3.28; S, 7.51. Found(%): C, 70.26; H, 6.68; N, 3.48; S, 7.44.
Compound Number VI-47
1H-NMR(CDCl3) δ: 1.14–2.16(13H, m), 2.23(1H, m), 2.30–2.37(2H, m), 3.41(1H, m), 3.45(1H, m), 5.18–5.36(2H, m), 6.19(1H, m), 7.11 (1H, dd, J=3.9 and 5.1 Hz), 7.32 and 7.62(each 1H, each d, each J=3.9 Hz), 7.39(1H, dd, J=1.5 and 5.1 Hz), 7.75(1H, dd, J=1.5 and 3.9 Hz). IR(CHCl3): 3512, 3440, 3096, 1708, 1657, 1534, 1507, 1402, 1336, 1153 cm−1. [α]D25+69.2±1.1°(c=1.006, MeOH) Anal. (C23H27NO5S3.0.1H2O) Calcd.(%): C, 55.57; H, 5.51; N, 2.83; S, 19.42. Found(%): C, 55.55; H, 5.32; N, 2.85; S, 19.21.
Compound Number VI-55
1H-NMR(CDCl3) δ: 1.18–2.18(13H, m), 2.23(1H, m), 2.31–2.35 (2H, m), 2.38(3H, s), 3.43(2H, m), 5.18–5.36(2H, m), 5.98(1H, m), 6.14(1H, m), 6.19(1H, t, J=3.3 Hz), 7.17(1H, m), 7.29 and 7.53(each 1H, each d, each J=3.9 Hz). IR(CHCl3): 3512 3440, 3150, 3101, 1708, 1658, 1535, 1508, 1375, 1161 cm−1. [α]D24+30.9±0.7°(c=1.000, MeOH) Anal. (C26H34N2O5S2.0.3H2O) Calcd.(%): C, 59.58; H, 6.65; N, 5.35; S, 12.24. Found(%): C, 59.57; H, 6.48; N, 5.51; S, 12.22.
Compound Number VI-80
1H-NMR(CDCl3) δ: 1.16–2.14(13H, m), 2.23(1H, m), 2.28–2.36(2H, m), 3.54–3.46(2H, m), 5.17–5.37(2H, m), 6.14(1H, m), 7.32(1H, d, J=3.9 Hz), 7.38–7.44(2H, m), 7.61(1H, d, J=3.9 Hz), 8.15(1H, dd, J=1.2 and 3.0 Hz). IR(CHCl3): 3508, 3431, 3114, 1708, 1656, 1534, 1508, 1331, 1152, 1102 cm−1. [α]D24+66.5±1.1°(c=1.003, MeOH) Anal. (C23H27NO5S3.0.3H2O) Calcd.(%): C, 55.35; H, 5.57; N, 2.81; S, 19.28. Found(%): C, 55.29; H, 5.54; N, 2.85; S, 19.01.
Compound Number VI-104
1H-NMR(CDCl3) δ: 1.18–2.14(13H, m), 2.25(1H, m), 2.31–2.39(2H, m), 3.32(2H, m), 3.56(1H, m), 4.09(2H, d, J=0.3 Hz), 5.18–5.38(2H, m), 5.89(1H, m), 6.68(1H, d, J=3.6 Hz), 6.94(1H, dd, J=3.6 and 5.1 Hz), 7.02(1H, dd, J=1.5 and 3.6 Hz), 7.23(1H, d, J=3.6 Hz), 7.35(1H, dd, J=1.5 and 5.1 Hz). IR(CHCl3): 3514, 3433, 1709, 1645, 1545, 1516, 1458 cm−1. [α]D23+61.8±1.0°(c=1.008, MeOH) Anal. (C24H29NO3S3.0.2H2O) Calcd.(%): C, 60.14; H, 6.18; N, 2.92; S, 20.07. Found(%): C, 60.08; H, 6.11; N, 2.90; S, 20.05.
Compound Number VI-122
1H-NMR(CDCl3) δ: 1.06–2.15(13H, m), 2.27(1H, m), 2.28–2.38(2H, m), 3.31(1H, m), 3.54(1H, m), 4.24(2H, d, J=0.6 Hz), 5.17–5.36(2H, m), 5.87(1H, m), 6.78(1H, d, J=3.6 Hz), 7.21–7.42(6H, m). IR(CHCl3): 3514, 3433, 3062, 2669, 1709, 1643, 1545, 1514 cm−1. [α]D22+64.3±1.0°(c=1.000, MeOH) Anal. (C26H31NO3S2.0.5H2O) Calcd.(%): C, 65.24; H, 6.74; N, 2.93; S, 13.40. Found(%): C, 65.23; H, 6.55; N, 3.00; S, 13.46.
Compound Number VI-123
1H-NMR(CDCl3) δ: 1.06–2.15(13H, m), 2.23(1H, m), 2.28–2.38(2H, m), 3.35(1H, m), 3.54(1H, m), 5.20(2H, s), 5.19–5.37(2H, m), 5.95(1H, m), 6.94–7.04(4H, m), 7.27–7.35(3H, m). IR(CHCl3): 3514, 3433, 1709, 1647, 1599, 1547, 1518, 1495 cm−1. [α]D24+67.8±1.1°(c=1.008, MeOH) Anal. (C26H31NO4S.0.2H2O) Calcd.(%): C, 68.30; H, 6.92; N, 3.06; S, 7.01. Found(%): C, 68.31; H, 6.84; N, 3.16; S, 7.11.
Compound Number VI-124
1H-NMR(CDCl3) δ: 1.06–2.14(13H, m), 2.24(1H, m), 2.30–2.37(2H, m), 3.31(1H, m), 3.53(1H, m), 4.50(2H, d, J=0.9 Hz), 5.15–5.36(2H, m), 5.89(1H, m), 6.65–6.79(3H, m), 6.95(1H, d, J=3.9 Hz), 7.15–7.21 (2H, m), 7.33(1H, d, J=3.9 Hz). IR(CHCl3): 3512, 3440, 1707, 1643, 1603, 1547, 1506 cm−1. [α]D22+67.3±1.1°(c=1.009, MeOH) Anal. (C26H32N2O3S.0.3H2) Calcd.(%): C, 68.18; H, 7.17; N, 6.20; S, 7.00. Found(%): C, 68.04; H, 7.09; N, 6.25; S, 7.02.
Compound Number VI-133
1H-NMR(CDCl3) δ: 1.18–1.81(7H, m), 1.85–1.94(2H, m), 2.01–2.13 (2H, m), 2.22–2.33(3H, m), 3.41(1H, m), 3.33(1H, m), 3.49(2H, s), 3.54 (1H, m), 4.15(2H, s), 5.17–5.37(2H, m), 5.90(1H, m), 6.12(1H, dd, J=0.9 and 3.0 Hz), 6.31(1H, dd, J=1.8 and 3.0 Hz), 6.81 and 7.30 (each 1H, each d, each J=3.6 Hz), 7.34(1H, dd, J=0.9 and 1.8 Hz). IR(CHCl3): 3516, 3433, 1709, 1643, 1547, 1516 cm−1. [α]D23+71.3±1.1°(c=1.004, MeOH) Anal. (C24H29NO4S.0.3H2O) Calcd.(%): C, 66.58; H, 6.89; N, 3.24; S, 7.41. Found(%): C, 66.55; H, 6.63; N, 3.37; S, 7.51.
Compound Number VI-303
1H-NMR(CDCl3) δ: 1.18–2.14(13H, m), 2.26(1H, m), 2.31–2.36(2H, m), 3.30(1H, m), 3.64(1H, m), 3.82(3H, s), 5.19–5.39(2H, m), 6.06(1H, m), 6.89–7.0(6H, m), 7.66(2H, d, J=8.1 Hz). IR(CHCl3): 3514, 3446, 1709, 1649, 1550, 1520, 1491 cm−1. [α]D22+76.3±1.2°(c=1.009, MeOH) Anal. (C28H33NO5.0.2H2O) Calcd(%): C, 71.99; H, 7.21; N, 3.00. Found(%): C, 72.05; H, 7.35; N, 2.93.
The compounds prepared in Examples above were tested for determining the in vivo and in vitro activities according to the method as shown in Experimental examples below.
Experiment 1 Binding Activity to PGD2 Receptor
(1) Preparation of Human Platelet Membrane Fraction
Blood was collected using a plastic syringe containing 3.8% sodium citrate from the vein of healthy volunteers (adult male and female), then put into a plastic test tube and mixed by slow-reversion. The sample was then centrifuged at 1800 rpm, for 10 min at room temperature, and the supernatant containing PRP (platelet-rich plasma) was collected. The PRP was re-centrifuged at 2300 rpm, for 22 min at room temperature to obtain platelets. The platelets were homogenized using a homogenizer (Ultra-Turrax) followed by centrifugation 3 times at 20,000 rpm, 10 min at 4° C. to obtain a platelet membrane fraction. After protein determination, the membrane fraction was adjusted to 2 mg/ml and preserved in a refrigerator at −80° C. until using for the binding test.
(2) Binding to PGD2 Receptor
To a binding-reaction solution (50 mM Tris/HCl, pH 7.4, 5 mM MgCl2) (0.2 ml) were added the human platelet membrane fraction (0.1 mg) and 5 nM [3H]PGD2 (115 Ci/mmol), and the mixture was reacted at 4° C. for 90 min. After the reaction, the mixture was filtered through a glass fiber filter paper and washed several times with cooled physiological saline, then the radioactivity retained on the filter paper was measured. The specific-binding ratio was calculated by subtracting the non-specific binding ratio which is the radioactivity similarly measured in the presence of 10 μM PGD2 from the total binding. The inhibitory activity of each compound was expressed as the concentration required for 50% inhibition (IC50), which was determined by depicting a substitution curve by plotting the binding ratio (%) in the presence of each compound, where the binding ratio in the absence of a test compound is 100%.
Experiment 2 Binding Activity to TXA2 Receptor
(1) Preparation of Human Platelet Membrane Fraction
The human platelet membrane fraction was prepared in accordance with Experiment 1 (1).
(2) Binding to TXA2 Receptor
To a binding-reaction solution (50 mM Tris/HCl, pH 7.4, 10 mM MgCl2) (0.2 ml) were added the human platelet membrane fraction (0.05 mg) and 2 nM Sodium [3H](+)-(5Z)-7-[3-endo-[(phenylsulfonyl)amino]bicyclo[2.2.1]hept-2-exo-yl]heptenoate (Japanese Patent Publication (Kokoku) No.79060/1993, hereinafter referred to as (+)-S-145 sodium salt) (26.4 Ci/mmol), and the mixture was reacted at room temperature for 90 min. After the reaction, the resultant mixture was filtered through a glass fiber filter paper and washed several times with cooled physiological saline, then the radioactivity retained on the filter paper was measured. The specific-binding ratio was calculated by subtracting the non-specific binding ratio (the radio activity similarly determined in the presence of 10 μM (+)-S-145 sodium salt) from the total binding. The inhibitory activity of each compound was expressed as the concentration required for 50% inhibition (IC50), which was determined by depicting a substitution curve by plotting the binding ratio (%) in the presence of each compound, where the binding ratio in the absence of a test compound is 100%.
Experiment 3 Evaluation of Antagonistic Activity Against PGD2 Receptor
Receptor Using Human Platelet
Peripheral blood was collected from a healthy volunteer using a syringe in which 1/9 volume of a citric acid/dextrose solution was previously added. The sample was subjected to centrifugation at 1200 rpm for 10 min to obtain the supernatant (PRP: platelet rich plasma). The resultant PRP was washed 3 times with a washing buffer and the number of platelets was counted with a micro cell counter. A suspension adjusted to contain the platelets at a final concentration of 5×108/ml was warmed at 37° C., then subjected to the pre-treatment with 3-isobutyl-1-methylxanthine (0.5 mM) for 5 min. To the suspension was added a test compound diluted at various concentration, and 10 minutes later, 0.1 μM PGD2 was added to induce the reaction 2 minutes later, hydrochloric acid was added to terminate the reaction. The platelet was destroyed with an ultrasonic homogenizer. After centrifugation, the cAMP in the supernatant was determined by radioimmunoassay. PGD2 receptor antagonism of a drug was evaluated as follows: the inhibition rate regarding cAMP increased by the addition of PGD2 was determined at each concentration, and the concentration of the drug required for 50% inhibition (IC50) was calculated.
The results of Experiment 1–3 are shown below. The results of Experiment of compounds of Example are shown in Table 68 and Table 69 and the results of Experiment of compounds of Example of reference are shown in Table 70 and Table 71.










TABLE 68






Binding activity
Binding activity
Inhibitory



to PGD2 receptor
to TXA2 receptor
activity for the



in human platelet
in human platelet
increase of cAMP



membrane
membrane
caused by PGD2



fraction
fraction
in human platelet


Compd. No..
IC50(μM)
IC50(μM)
IC50(μM)







I-5A-59a

0.011
0.079


I-7A-1a
0.0076
0.0046
0.035


I-7A-31a

0.063
0.057


I-7A-47a
0.073
0.003
0.018


I-7A-59a

0.0098
0.012


I-7A-88a

0.034
0.036


I-7A-104a

0.024
0.082


I-7A-143a

0.084
0.036


I-7I-1a

0.0026
0.064


I-7I-31a

0.065
0.092


I-7I-47a

0.0012
0.085


I-7I-88a

0.033
0.025


I-71-126a

0.061
0.021


I-71-270a

0.0009
0.026


I-7I-307a

0.051
0.097


I-7M-1e

0.044
0.039


I-7M-59a

0.040
0.024


I-7M-143a

0.021
0.026


I-7M-270a

0.0014
0.012


I-7M-307a

0.100
0.024


I-7M-315a

0.039
0.028


I-7M-316a

0,062
0.11


I-7M-317a

0.074
0.018


I-7M-318a

0.068
0.028


I-7M-333a

0.013
0.094


I-7M-337a

0.037
0.019


I-7M-343a

0.029
0.033


I-7M-393a

0.019
0.11


I-7M-424a

0.0076
0.02


I-7M-446a

0.0063
0.027


I-7P-1a

0.034
0.036


I-7R-1a

0.01
0.018


I-7R-270a

0.012
0.027



















TABLE 69






Binding activity
Binding activity
Inhibitory



to PGD2 receptor
to TXA2 receptor
activity for the



in human platelet
in human platelet
increase of cAMP



membrane
membrane
caused by PGD2



fraction
fraction
in human platelet


Compd. No..
IC50(μM)
IC50(μM)
IC50(μM)







II-5A-1a
0.027
0.0012
0.066


II-5A-31a

0.013
0.045


II-5A-55a
0.0053
0.0006
0.017


II-5A-88a

0.022
0.019


II-5A-104a

0.013
0.047


II-5A-143a

0.047
0.024


II-5B-55a
0.0042
0.0012
0.011


II-5F-55a

0.0019
0.061


II-6A-55a
0.047
0.026
0.1


II-7A-31a

0.082
0.027


II-7A-47a

0.0038
0.059


II-7A-55a
0.0062
0.0042
0.057


II-7A-55e

0.019
0.19


II-7A-59a

0.040
0.042


II-7A-143a

0.037
0.019


II-7I-55a
0.0018
0.0023
0.063


II-7I-59a

0.015
0.015


II-7I-126a

0.102
0.013


II-7I-239a

0.046
0.042


II-7I-270a

0.0006
0.032


II-7I-343a

0.0041
0.079


II-7M-1a

0.0012
0.054


II-7M-1e

0.011
0.12


II-7M-1k

0.020
0.02


II-7M-31a

0.047
0.033


II-7M-47a
0.024
0.0018
0.073


II-7M-55a
0.0013
0.0022
0.013


II-7M-59a

0.027
0.021


II-7M-88a

0.122
0.014


II-7M-126a

0.119
0.026


II-7M-197a

0.012
0.019


II-7M-239a

0.055
0.028


II-7M-270a

0.0006
0.034


II-7M-307a

0.077
0.021


II-7M-332a

0.0017
0.067


II-7M-343a

0.0045
0.075


II-7N-55a
0.0065
0.0025
0.02


II-7P-55a

0.0084
0.047


II-7R-55a

0.0036
0.013


II-7R-270a

0.015
0.023


II-7U-55a

0.021
0.077



















TABLE 70






Binding activity
Binding activity
Inhibitory



to PGD2 receptor
to TXA2 receptor
activity for the



in human platelet
in human platelet
increase of cAMP



membrane
membrane
caused by PGD2



fraction
fraction
in human platelet


Compd. No..
IC50(μM)
IC50(μM)
IC50(μM)







I-1
0.0043
0.003
0.0013


I-10
0.0016
0.092
0.0018


I-31
0.0082
0.130
0.0057


I-47
0.0041
0.0062
0.007


I-59
0.00041
0.016
0.0046


I-66
0.0046
0.034
0.044


I-79
0.00042
0.015
0.024


I-80
0.0066
0.0052
0.039


I-82
0.032
0.0018
0.053


I-88
0.0076
0.078
0.0047


I-93
0.0070
0.072
0.0084


I-94
0.001
0.083
0.01


I-104
0.0001
0.039
0.0016


I-106
0.013
0.013
0.0093


I-117
0.0091
0.0038
0.047


I-128
0.020
0.048
0.01


I-129
0.011
0.052
0.022


I-131
0.044
0.019
0.041


I-132
0.032
0.012
0.043


I-136
0.023
0.016
0.015


I-143
0.0027
0.028
0.0019


I-146
0.044
0.019
0.073


I-160
0.028
0.02
0.085


I-168
0.00046
0.034
0.029


I-169
0.00061
0.032
0.026


I-170
0.00092
0.027
0.017


I-182
0.061
0.028
0.011.



















TABLE 71






Binding activity
Binding activity
Inhibitory



to PGD2 receptor
to TXA2 receptor
activity for the



in human platelet
in human platelet
increase of cAMP



membrane
membrane
caused by PGD2



fraction
fraction
in human platelet


Compd. No..
IC50(μM)
IC50(μM)
IC50(μM)







II-1
0.002
0.012
0.011


II-18
0.0079
0.030
0.0003


II-37
0.026
0.0043
0.035


II-47
0.00096
0.0036
0.004


II-55
0.0015
0.0044
0.0039


II-59
0.0001
0.014
0.024


II-101
0.072
0.0040
0.045


II-117
0.022
0.0026
0.024


II-126
0.0046
0.045
0.004


II-138
0.032
0.072
0.025









Experiment 4 Change of Plasma Concentration of Drug in Rat

Compound (0.5 to 2 mg/kg) was administered intravenously to Jcl-SD male rats. The concentration of the unchanged compound was measured at 2, 5, 15, 30, 60, 120, and 240 min after the administration by the use of HPLC (determination limit; 0.05 μg/ml) and LC/MS/MS (determination limit; 0.001 μg/ml) and the half life of the disappearance was calculated.










TABLE 72








half life of the




disappearance



Compd. No..
(min)



















Reference Compd.I-1
9.4



I-7M-1a
26.3



Reference Compd.I-143
4.7



I-7M-143a
38.4



Reference Compd.II-59
11.0



II-7I-59a
67.0



II-7M-59a
92.6










A half-life of the disappearance of a compound of the present invention was observed to be about 3 to 8 times as long as that of the compound of reference and the metabolic stability was confirmed.
Experiments for comparing the present compound having a dual antagonistic activity against PGD2/TXA2 receptors (e.g., II-7I-55a, II-7M-55a) with a PGD2 receptor antagonist (e.g., B-1, B-2) and a TXA2 antagonist (e.g., A) are shown below.




The experiments were carried out in accordance with the above Experiment 1–3 for the purpose of comparing the compound having a dual antagonistic activity against PGD2/TXA2 receptor with a PGD2 receptor antagonist and a TXA2 receptor antagonist.










TABLE 73






Experiment 1
Experiment 2
Experiment 3



Antagonistic
Antagonistic
Antagonistic



activity
activity
activity



against PGD2
against TXA2
against PGD2



receptor
receptor
receptor


Compd.
IC50 (μM)
IC50 (μM)
IC50 (μM)


















Compound
0.0018
0.0023
0.063


(II-7I-55a)


Compound
0.0013
0.0022
0.013


(II-7M-55a)


TXA2 receptor
>10
0.0038
>10


antagonist (A)


PGD2 receptor
0.022
0.37
0.030


antagonist


(B-1)









Comparative Experiment 2

Antigen-Induced Bronchial Hyperresponsiveness

Male Hartley guinea pigs were actively sensitized to ovalbumin (OVA) by inhalation of aerosolized solution of 1% ovalbumin twice at a week interval. One week after the second sensitization, the animals were treated with antihistamine, diphenhydramine (10 mg/kg, i.p.), and then challenged with 1% OVA aerosol for 5 min. Twenty four hours later, acetylcholine at doses at 3.13, 6.25, 12.5, 25, 50 and 100 micro g/kg was sequentially injected into the animals which were anesthetized with pentobarbital (30 mg/kg, i.p.). The bronchoconstriction induced by each dose of acetylcholine was monitored by the modified method of Konzett-Rössler technique, and made a dose-response curve of acetylcholine. Using the dose-response curve, the dose required for 200% increase in bronchoconstriction from baseline (PD200) was calculated in each animal and used as an indication of bronchial responsiveness. Compounds were orally administered 1 hour before antigen challenge. **: P<0.01 vs Vehicle(Dunnett's test), ##: P<0.01 vs Vehicle(Student's t test).









TABLE 74







Log PD200



















Vehicle
1.033 ± 0.053



Compound (II-7I-55a)10 mg/kg
1.442 ± 0.055**



Compound (II-7M-55a)10 mg/kg
1.485 ± 0.119**



Negative control
1.517 ± 0.067##



















TABLE 75







Log PD200



















Vehicle
1.125 ± 0.023



Compound (B-2)10 mg/kg
1.237 ± 0.052



Negative control
1.465 ± 0.074##



















TABLE 76







Log PD200



















Vehicle
1.11 ± 0.06



Compound (A)1 mg/kg
1.29 ± 0.04



Compound (A)10 mg/kg
1.61 ± 0.09**



Negative control
1.69 ± 0.06##










As shown in Table 74 to Table 76, a PGD2 receptor antagonist (B-2) did not inhibit the induction of bronchial hyperresponsiveness, but TXA2 receptor antagonist (A) and PGD2/TXA2 dual receptor antagonist, (e.g., II-71-55a, II-7M-55a) suppressed it, indicating that TXA2 receptor antagonism is necessary for improvement of bronchial hyperresponsiveness.
Comparative Experiment 3
Antigen-Induced Increase in the Eosinophil Number in Bronchoalveolar Lavage Fluid.
Bronchoalveolar lavage was performed with 10 mL of saline, after the animals were sensitized and challenged with antigen. The number of total cells in the recovered fluid was stained with Türk and counted using hemocytometer. *: P<0.05, **:P<0.01 vs Vehicle(Dunnett's test), ##: P<0.01 vs Vehicle(Student's t test). ( ): inhibition %.









TABLE 77







Total cells (× 106cells/animal)



















Vehicle
23.36 ± 2.33



Compound (II-7I-55a) 10 mg/kg
12.26 ± 1.54**(80%)



Compound (II-7M-55a) 10 mg/kg
18.29 ± 1.46 (36%)



Negative control
 9.43 ± 0.78##



















TABLE 78







Total cells (× 106 cells/animal)



















Vehicle
17.12 ± 2.20



Compound (B-2) 10 mg/kg
 9.72 ± 2.32* (53%)



Negative control
 3.20 ± 0.52##



















TABLE 79







Total cells (× 106 cells/animal)



















Vehicle
13.89 ± 2.42



Compound (A) 10 mg/kg
15.20 ± 2.20 (−12%)



Negative control
2.98 ± 0.28##










As shown in Table 77 to Table 79, PGD2 receptor antagonist (B-2) and PGD2/TXA2 dual receptor antagonist (II-71-55a, II-7M55a) significantly suppressed the eosinophil infiltration. But a TXA2 receptor antagonist (A) did not show any inhibitory actions. These results indicate that PGD2 receptor antagonism is necessary for suppression of inflammatory cell infiltration.
Comparative Experiment 4
Acceleration of Vascular Permeability of Conjunctiva Induced by PGD2 and U-46619
Using male Hartley guinea pigs, PGD2- and TxA2 receptor-mediated increase in conjunctival vascular permeability was produced by instillation of each 10 μl solution of either 0.1% PGD2 or U-46619 (TXA2 receptor agonist) to the both eyes without anesthetization. Immediately after that, Evans blue dye (20 mg/kg) was intravenously injected. 30 min after the challenge, guinea pigs were sacrificed by bleeding under anesthesia with Pentobarbital (30 mg/kg, i.p.) and the tissue of conjunctiva was removed. The dye leaked into the tissue was extracted in formamide 3 ml at 60° C. for more than 24 h, and then centrifuged. The absorbance of the supernatant was measured at 620 nm. The amount of dye was calculated from the calibration curve of Evans blue dye. Each compound was suspended in 0.5% methyl-cellulose and administrated orally at 1 h before the challenge. The antagonistic activity was evaluated by the inhibition ratio against the dye leaked into conjunctiva caused by PGD2 or U-46619 at each dose and then a 50% effective dose of inhibition (ED50 value) of each compound was calculated.











TABLE 80








ED50 (mg/kg)




Compound
PGD2
TXA2 (U-46619)




















II-7I-55a
0.33
0.030



II-7M-55a
0.043
0.083



PGD2 receptor antagonist
0.099
>10



(B-2)



TXA2 receptor antagonist
>30
0.017



(A)










As shown in Table 80, a PGD2 receptor antagonist (B-2) inhibited the increase in vascular permeability in conjunctiva by the stimulation with PGD2 but did not inhibit that caused by U-46619, viceversa, a TXA2 receptor antagonist (A) suppressed only U-46619-induced response. PGD2/TXA2 dual receptor antagonist (e.g., II-7I-55a, II-7M-55a) showed both responses. Thus, the inhibition of both receptor-mediated responses was ascertained in vivo.
Formulation Example
It is to be noted that the following Formulation Examples 1 to 8 are mere illustration, but not intended to limit the scope of the invention. The term “Active ingredient” means a compound of the present invention, the prodrug thereof, their pharmaceutically acceptable salt, or their hydrate.
Formulation Example 1
Hard gelatin capsules are prepared using the following ingredients:













Dose



(mg/capsule)



















Active ingredient
250



Starch, dried
200



Magnesium stearate
 10



Total
460 mg










Formulation Example 2
Tablet are prepared using the following ingredients:













Dose



(mg/tablet)



















Active ingredient
250



Cellulose, microcrystals
400



Silicon dioxide, fumed
 10



Stearic acid
 5



Total
665 mg










The ingredients are blended and compressed to form tablets each weighing 665 mg.
Formulation Example 3
An aerosol solution is prepared containing the following components:













Weight



















Active ingredient
0.25



Ethanol
25.75



Propellant 22 (chlorodifluoromethane)
74.00



Total
100.00










The active ingredient is mixed with ethanol and the admixture added to a portion of the propellant 22, cooled to −30° C. and transferred to a filling device. The required amount is then fed to a stainless steel container and diluted with the reminder of the propellant. The valve units are then fitted to the container.
Formulation Example 4
Tablets, each containing 60 mg of active ingredient, are made as follows.

















Active ingredient
60
mg



Starch
45
mg



Microcrystals cellulose
35
mg



Polyvinylpyrrolidone (as 10% solution in
4
mg



water)



Sodium carboxymethyl starch
4.5
mg



Magnesium stearate
0.5
mg



Talc
1
mg



Total
150
mg










The active ingredient, starch, and cellulose are passed through a No. 45 mesh U.S. sieve, and the mixed thoroughly. The aqueous solution containing polyvinylpyrrolidone is mixed with the resultant powder, and the admixture then is passed through a No. 14 mesh U.S. sieve. The granules so produced are dried at 50° C. and passed through a No. 18 mesh U.S. sieve. The sodium carboxymethyl starch, magnesium stearate, and talc, previously passed through No. 60 mesh U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 150 mg.
Formulation Example 5
Capsules, each containing 80 mg of active ingredient, are made as follows:

















Active ingredient
80
mg



Starch
59
mg



Microcrystals cellulose
59
mg



Magnesium stearate
2
mg



Total
200
mg










The active ingredient, cellulose, starch, and magnesium stearate are blended, passed through a No. 45 mesh U.S. sieve, and filled into hard gelatin capsules in 200 mg quantities.
Formulation Example 6
Suppositories, each containing 225 mg of active ingredient, are made as follows:
















Active ingredient
 225 mg



Saturated fatty acid glycerides
2000 mg



Total
2225 mg










The active ingredient; is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimum heat necessary. The mixture is then poured into a suppository mold of nominal 2 g capacity and allowed to cool.
Formulation Example 7
Suspensions, each containing 50 mg of active ingredient per 5 ml dose, are made as follows:

















Active ingredient
50
mg



Sodium carboxymethyl cellulose
50
mg



Syrup
1.25
ml



Benzoic acid solution
0.10
ml



Flavor
q.v.



Color
q.v.



Purified water to total
5
ml










The active ingredient is passed through a No. 45 U.S. sieve, and mixed with the sodium carboxymethyl cellulose and syrup to form a smooth paste. The benzoic acid solution, flavor and color are diluted with a portion of the water and added, with stirring. Sufficient water is then added to produce the required volume.
Formulation Example 8
An intravenous formulation may be prepared as follows:
















Active ingredient
 100 mg



Isotonic saline
1000 ml










The solution of the above ingredients is generally administered intravenously to a subject at a rate of 1 ml per minute.
INDUSTRIAL APPLICABILITY
The pharmacological effect of the compound of the present invention is compared with that of TXA2 receptor antagonist and PGD2 receptor antagonist in the following table.











TABLE 81







TXA2 receptor
PGD2 receptor




antagonist
antagonist
Compound (I)



















Bronchial asthma





Eosinophilic
x
⊚
⊚


infiltration


Advance of respiratory
⊚
x
⊚


anaphylaxis


Respiratory
⊚
x
⊚


contraction









In bronchial asthma, a TXA2 receptor antagonist itself can inhibit advance of respiratory anaphylaxis and respiratory contraction, but has no effect for eosinophilic infiltration. A PGD2 receptor antagonist itself can inhibit eosinophilic infiltration, but has no effect for advance of respiratory anaphylaxis and respiratory contraction. On the other hand, a compound having a dual antagonistic activity against PGD2/TXA2 receptors like the compound (I) is efficient for all of eosinophilic infiltration, advance of respiratory anaphylaxis and respiratory contraction.
A TXA2 receptor antagonist has no effect for eosinophilic infiltration but was ascertained to increase the inhibitory effect for eosinophilic infiltration caused by a PGD2 receptor antagonist. That is, a TXA2 receptor antagonist and a PGD2 receptor antagonist were ascertained to show a synergistic effect. Then, a compound having a dual antagonistic activity against PGD2/TXA2 receptors like the compound (I) is very efficient.
The compound having a dual antagonistic activity against PGD2/TXA2 receptors is useful for treating systemic mastocytosis and disorder of systemic mast cell activation as well as tracheal contraction, asthma, allergic rhinitis, allergic conjunctivitis, urticaria, itching, atopic dermatitis, alimentary allergy, ischemic reperfusion injury, cerebrovascular disorder, and inflammation, and effective for treating or improving condition of diseases such as arteriosclerosis, myocardial infarction, acute myocardial ischemia angina, cardiovascular shock or preventing unexpected death and the like, especially asthma or nasal blockage.
With a dual antagonistic activity against both a TXA2 receptor and a PGD2 receptor, the present compound can overcome some problems such as that due to the metabolic rate difference of each compound, which occur upon simultaneous administration of both a TXA2 receptor antagonist and a PGD2 receptor antagonist.

## Claims

1. A compound of the formula (I):



A is alkylene optionally intervened with a heteroatom, optionally having an oxo group, optionally substituted with halogen and/or optionally having an unsaturated bond;
R is —C(═O)—R1, —CH2—R1, or tetrazolyl;
R1 is hydroxy, alkyloxy, or optionally substituted amino;
m is 0 or 1;
provided that combinations wherein m is 1, A is —CH═CH—CH2—CH2—CH2— and R is —C(═O)—R1 (R1 is hydroxy or alkyloxy) or wherein A is —CH2—CH═CH—CH2—CH2—CH2— and R is —C(═O)—R1 wherein R1 is hydroxy or alkyloxy are excluded,
p is 0 or 1, provided that when p=0,




X1 and X3 are each independently optionally substituted aryl, optionally substituted heteroaryl or optionally substituted non-aromatic heterocyclyl;
X2 is a bond, —CH2—, —CH2—CH2—, —C(═O)—, —O—, —S—, —SO—, —SO2—, —NH—, —N(CH3)—, —C(═N—O—CH3)—, —N═N—, —CH═CH—, —(C═O)—NH—, —NH—(C═O)—, —CH2—NH—, —NH—CH2—, —CH2—O—, —O—CH2—, —CH2—S, —S—CH2—, —CH2—SO2—, —SO2—CH2—, —SO2—NH—, —NH—SO2—, —C(═CH2)—, —SO2N(Me)—, —CH2NHSO2—, —CH2NH—(C═O)—, —NH—C(═O)—NH or —NH—C(═O)—N(Me)—;
X4 is —CH2—, —CH2—CH2—, —C(═O)—, —SO—, —SO2—, —(C═O)—NH—, —NH—(C═O)—, —CH2—NH—, —NH—CH2—, —CH2—O—, —O—CH2—, —CH2—S—, —S—CH2—, —CH2—SO2—, —SO2—CH2—, —SO2—NH— or —NH—SO2—,

provided that a combination wherein



A is —CH═CH—CH2—CH2—CH2—, R is —COOH, m is 1, p is 0, X1 and X3 are phenyl, and X2 is —N═N—, is excluded

and provided that when



X1 and X3 are phenyl, X2 is —CH═CH—, —O—, or —S—, m is 0, and p is 0, a compound wherein
A is —CH═CH—CH2—CH2—CH2—C(CH3)2— and R is COOH,
A is —CH2—CH═CH—CH2—CH2—C(CH3)2— and R is COOH,
A is —CH2—C(═O)—CH2—CH2—CH2—CH2— and R is COOH,
A is —CH2—CH2—CH2—CH2—CH2— and R is —COOH,
A is —CH2—CH2—CH2—CH2—CH2—CH2— and R is —COOH,
A is —CH2—CH═CH—CH2—CH2—CH2— and R is —CH2OH, or
A is —CH═CH—CH2—CH2—CH2— and R is —CH2OH,

is excluded,
a pharmaceutically acceptable salt or a solvate thereof.

2. A compound as described in claim 1 wherein A is alkylene optionally intervened with a heteroatom, optionally having an oxo group, optionally substituted with halogen and/or optionally having an unsaturated bond;
R is —C(═O)—R1, —CH2—R1, or tetrazolyl;
R1 is hydroxy, alkyloxy, or optionally substituted amino;
provided that compounds wherein A is —CH═CH—CH2—CH2—CH2— and R is —C(═O)—R1 (R1 is hydroxy or alkyloxy), or A is —CH2—CH═CH—CH2—CH2—CH2— and R is —C(═O)—R1 wherein R1 is hydroxy or alkyloxy are excluded,

a pharmaceutically acceptable salt or a solvate thereof.

3. A compound as described in claim 1, wherein A is alkylene intervened with a heteroatom, optionally having an oxo group, optionally substituted with halogen and/or optionally having an unsaturated bond,
a pharmaceutically acceptable salt, or a solvate thereof.

4. A compound as described in claim 1, wherein A is C1 to C4 or C7 to C9 alkylene optionally intervened with a heteroatom, optionally having an oxo group, optionally substituted with halogen and/or optionally having an unsaturated bond, a pharmaceutically acceptable salt, or a solvate thereof.

5. A compound as described in claim 1, wherein A is —CH2—CH2—CH2—, —CH2—CH2—CH(F)—, —CH2CH═CH—, —CH2—O—CH2—, —CH2CH═C(F)—, —CH2—CH2—CH2—CH2—, —CH2CH═CH—CH2—, —CH2—CH2—CH═CH—, —CH═CH—CH2—CH2—, —CH2—CH2—O—CH2—, —CH2—CH2—S—CH2—, —CH2—CO—NH—CH2—, —CH2—CH2—CH2—CH2—CH2—, CH2CH═CH—CH2—CH2—, —CH2—CH2—CH2—CH═CH—, —CH2—CH2—CH2—O—CH2—, —CH2—CH2—CH2—S—CH2—, —CH2—CH2—CO—NH—CH2—, —CH2—CH2—CH2—CH2—CH2—CH2—, —CH2—CH2—CH2—CH2—CH2—CH(Me)—, —CH2—CH2—CH2—CH2—CH2—C(Me)2—, —CH2—CH2—CH2—CH2—CH2—CH(F)—, —CH2—CH═CH—CH2—CH2—CH(Me)—, —CH2—CH═CH—CH2—CH2—C(Me)2—, —CH2—CH═CH—CH2—CH2—CH(F)—, —CH2—CH2—CH2—CH2—CH═CH—, —CH2—CH2—CH2—CH2—CH═C(Me)—, —CH2—CH2—CH2—CH2—C(Me)═CH—, —CH2—CH2—CH2—CH2—CH═C(F)—, —CH2—CH2—CH2—CH2—O—CH2—, —CH2—CH═CH—CH2—O—CH2—, —CH2—CH═CH—CH2—S—CH2—, —CH2—CH═C(F)—CH2—O—CH2—, —CH2—CH2—O—CH2—CH═CH—, —CH2—CH2—CH2—CH2—S—CH2—, —CH2—CH2—CH2—CO—NH—CH2—, —CH2—CH2—CH═N—O—CH2—, —CH2—CH2—S—CH2—CH2—CH2—, —CH2—CH2—CH2—CH2—CH2—CH2—CH2—, —CH2—CH═CH—CH2—CH2—CH2—CH2—, —CH2—CH2—CH2—CH2—CH2—O—CH2—, —CH2—CH2—CH2—CH2—CH2—CH2—CH2—CH2—, or —CH2—CH═CH—CH2—CH2—CH2—CH2—CH2—,
a pharmaceutically acceptable salt, or a solvate thereof.

6. A compound as described in claim 5, wherein A is —CH2—CH2—CH2—CH2—, —CH2—CH2—CH2—CH2—CH═CH—, —CH2—CH2—CH2—CH2—O—CH2—, —CH2—CH═CH—CH2—O—CH2—, —CH2—CH═CH—CH2—S—CH2—, or —CH2—CH2—CH2—CH2—S—CH2—,
a pharmaceutically acceptable salt, or a solvate thereof.

7. A compound as described in claim 6, wherein A is —CH2—CH2—CH2—CH2—O—CH2—,
a pharmaceutically acceptable salt, or a solvate thereof.

8. A compound as described in claim 1, wherein X1 and X3 are each independently optionally substituted aryl or optionally substituted heteroaryl,
a pharmaceutically acceptable salt, or a solvate thereof.

9. A compound as described in claim 8, wherein at least one of X1 and X3 is optionally substituted heteroaryl,
a pharmaceutically acceptable salt, or a solvate thereof.

10. A compound as described in claim 9, wherein X1 and X3 are each independently optionally substituted heteroaryl,
a pharmaceutically acceptable salt, or a solvate thereof.

11. A compound as described in claim 9, wherein at least one of X1 and X3 is optionally substituted thienyl or optionally substituted benzothienyl,
a pharmaceutically acceptable salt, or a solvate thereof.

12. A compound as described in claim 1, wherein X2 is a bond, —CH2—, —S—, —SO2—, —CH2—O—, —O—CH2—, —CH2—S—, —S—CH2—, or —NH—C(═O)—NH—,
a pharmaceutically acceptable salt, or a solvate thereof.

13. A compound as described in claim 1, wherein m is 0 and p is 0,
a pharmaceutically acceptable salt, or a solvate thereof.

14. A compound as described in claim 1, wherein R is —C(═O)—R1 and R1 is hydroxy, alkyloxy, or optionally substituted amino,
a pharmaceutically acceptable salt, or a solvate thereof.

15. A pharmaceutical composition containing a compound, a pharmaceutically acceptable salt, or a solvate thereof as described in claim 1, together with a pharmaceutically acceptable carrier, excipient, solvent or base.

16. A pharmaceutical composition having a dual antagonistic activity against PGD2/TXA2 receptors as described in claim 15.

17. A pharmaceutical composition as described in claim 15, which is used for the treatment of asthma.

18. A pharmaceutical composition as described in claim 15, which is used for the treatment of nasal blockage.

19. A pharmaceutical composition as described in claim 15, which is used for the treatment of allergic conjunctivitis.

20. A pharmaceutical composition as described in claim 15, which is used for the treatment of allergic rhinitis.

21. A method for preparing a pharmaceutical composition for treating asthma, nasal blockage, allergic conjunctivitis or allergic rhinitis, which comprises mixing a compound according to claim 1 together with a pharmaceutically acceptable carrier, excipient, solvent or base.

22. A method for treating nasal blockage, allergic conjunctivitis or allergic rhinitis, which comprises administrating a compound as described in claim 1 to a patient in need thereof.

23. A compound as described in claim 1, wherein A is —CH2—CH2—CH(F)—, —CH2—O—CH2—, —CH2CH═C(F)—, —CH2—CH2—S—CH2—, —CH2—CH2—CH2—CH2—CH2—CH(Me)—, —CH2—CH═CH—CH2—CH2—CH(Me)—, —CH2—CH═CH—CH2—CH2—C(Me)2—, CH2—CH2—CH2—CH2—CH═C(Me)—, —CH2—CH2—CH2—CH2—C(Me)═CH—, —CH2—CH2—CH2—CH2—CH═C(F)—, —CH2—CH2—CH2—CH2—O—CH2—, —CH2—CH═CH—CH2—O—CH2—, —CH2—CH═CH—CH2—S—CH2—, —CH2—CH═C(F)—CH2—O—CH2—, —CH2—CH2—O—CH2—CH═CH—, —CH2—CH2—CH2—CO—NH—CH2—, —CH2—CH2—CH═N—O—CH2—, —CH2—CH2—CH2—CH2—CH2—O—CH2—, or —CH2—CH═CH—CH2—CH2—CH2—CH2—CH2—,
or pharmaceutically acceptable salt, or a solvate thereof.

24. A compound as described in claim 1, wherein p is 1,
a pharmaceutically acceptable salt, or a solvate thereof.